Skip to content
§Insights

The data behind the atlas

Twenty-five views of anti-cancer nephrotoxicity, drawn from the citation-grounded catalog: a phenotype-similarity map, the growing evidence base, onset timing, FAERS reporting signals, renal anatomy, several clinical cross-tabs, the field's co-authorship structure, the regimen pairs that compound kidney risk, and a browsable explorer of any agent's nearest phenotype analogs.

Phenotype & similarity

What kind of kidney injury each agent causes, and which agents resemble each other.

Every anti-cancer agent placed so that nearness means a similar kidney-injury phenotype — computed from the full set of kidney injuries each agent carries, nephron segments, severity, drug class, and a small approval-era term that keeps identical fingerprints apart. Neighborhoods emerge on their own: platinum tubular injury, anti-VEGF glomerular disease, checkpoint-inhibitor interstitial nephritis. Dot size scales with FAERS reporting volume. Filter by injury; tap a profiled agent to open it.

  • Acute Tubular Necrosis: Actinium 225 PSMA, BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib), Binimetinib, Carboplatin, Cisplatin, Cobimetinib, Datopotamab deruxtecan (Dato-DXd), Disitamab vedotin, Encorafenib, Enfortumab vedotin, Gallium nitrate, Ibandronate, Iobenguane I-131, Lenalidomide, Lurbinectedin, Melphalan flufenamide (melflufen), Nedaplatin, Pentostatin, Plicamycin (mithramycin), Procarbazine, Raltitrexed, Samarium-153 lexidronam, Sonidegib, Telisotuzumab vedotin (Teliso-V), Trabectedin, Trastuzumab deruxtecan, Vemurafenib, Zoledronic acid
  • Acute Interstitial Nephritis: Atezolizumab, Avelumab, Bicalutamide, Cadonilimab, Cemiplimab, Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab), Cosibelimab, Dabrafenib, Dostarlimab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Penpulimab, Relatlimab, Retifanlimab, Sugemalimab, Tislelizumab, Toripalimab
  • Thrombotic Microangiopathy: 5-Fluorouracil, Bortezomib, Busulfan, Carfilzomib, Carmofur (HCFU), Doxifluridine, Gemcitabine, Ixazomib, Mitomycin C, Moxetumomab pasudotox, Oxaliplatin, Tegafur-uracil (UFT), Trastuzumab emtansine (T-DM1), promacta
  • Glomerular Injury / Proteinuria: Belantamab mafodotin, Bevacizumab, Dasatinib, Doxorubicin, Erlotinib, Everolimus, Gefitinib, Interferon-α, Ivonescimab, Olverembatinib, Pamidronate, Pazopanib, Sirolimus, Temsirolimus, mTOR inhibitors (everolimus · temsirolimus)
  • Electrolyte Disturbance: Abiraterone, Amivantamab, Amsacrine, Avutometinib, Cetuximab, Dactinomycin (actinomycin D), Darolutamide, Defactinib, Denosumab, Erdafitinib, Fedratinib, Furmonertinib, Futibatinib, Gedatolisib, Imatinib, Inavolisib, Infigratinib, Lanreotide, Mechlorethamine, Mitotane, Necitumumab, Nirogacestat, Octreotide, Panitumumab, Pemigatinib, Relacorilant, Strontium-89 chloride, Sunvozertinib, Teniposide, Vinflunine
  • Fanconi Syndrome: Azacitidine, Ifosfamide, Streptozocin
  • Crystal / Obstructive Nephropathy: Bendamustine, Cladribine, Cytarabine, Decitabine, Etoposide, Fludarabine, Hydroxyurea, Idarubicin, Methotrexate (high-dose), Mitoxantrone, Nelarabine, Obinutuzumab, Odronextamab, Pirtobrutinib, Pralatrexate, Rituximab, Sonrotoclax, Venetoclax
  • Hypertension: Acalabrutinib, Asciminib, Axitinib, Cabozantinib, Copanlisib, Enzalutamide, Fruquintinib, Ibrutinib, Lenvatinib, Leuprolide, Nintedanib, Niraparib, Ponatinib, Pralsetinib, Ramucirumab, Regorafenib, Ripretinib, Selpercatinib, Sorafenib, Sunitinib, Tivozanib, VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib), Vandetanib, Ziv-aflibercept
  • Prerenal / Hemodynamic AKI: Adagrasib, Afamitresgene autoleucel (Afami-cel), Afatinib, Alpelisib, Altretamine (hexamethylmelamine), Anitocabtagene autoleucel, Arsenic trioxide, Asparaginase, Avapritinib, Belzutifan, Bleomycin, Blinatumomab, Brentuximab vedotin, CAR-T cell therapy, Cabazitaxel, Camizestrant, Capecitabine, Capivasertib, Casdatifan, Catumaxomab, Ceritinib, Ciltacabtagene autoleucel, Clofarabine, Dacarbazine, Daratumumab, Daraxonrasib, Denileukin diftitox, Dinutuximab, Docetaxel, Dordaviprone, Duvelisib, Elacestrant, Elotuzumab, Elranatamab, Enasidenib, Epcoritamab, Eribulin, Estramustine, Gemtuzumab ozogamicin, Gilteritinib, Glasdegib, Glofitamab, Iberdomide, Ibritumomab tiuxetan, Idecabtagene vicleucel, Idelalisib, Imetelstat, Inotuzumab ozogamicin, Interleukin-2 (high-dose), Irinotecan, Isatuximab, Ivosidenib, Lifileucel, Linvoseltamab, Lisocabtagene maraleucel, Loncastuximab tesirine, Midostaurin, Mirdametinib, Mirvetuximab soravtansine, Mobocertinib, Mogamulizumab, Mosunetuzumab, Naxitamab, Neratinib, Nilotinib, Obecabtagene autoleucel (Obe-cel), Olutasidenib, Paclitaxel, Pacritinib, Pegaspargase, Pexidartinib, Pivekimab sunirine, Polatuzumab vedotin, Pomalidomide, Quizartinib, Radium-223 dichloride, Revumenib, Ruxolitinib, Sacituzumab govitecan, Selumetinib, Sevabertinib, Sotorasib, Tafasitamab, Tagraxofusp, Talquetamab, Tarlatamab, Tasonermin, Tazemetostat, Tebentafusp, Teclistamab, Thalidomide, Tisotumab vedotin, Topotecan, Tovorafenib, Trametinib, Tretinoin (ATRA), Trifluridine/tipiracil, Vepdegestrant, Zanidatamab, Zanubrutinib, Zenocutuzumab, Zidesamtinib, Ziftomenib, Zolbetuximab
  • SIADH / Hyponatremia: Chlorambucil, Cyclophosphamide, Lazertinib, Melphalan, Osimertinib, Selinexor, Tamoxifen, Temozolomide, Vinblastine, Vincristine, Vinorelbine, Vismodegib
  • Hemorrhagic Cystitis: Thiotepa
  • Pseudo-AKI: Abemaciclib, Alectinib, Bosutinib, Brigatinib, Capmatinib, Ensartinib, Entrectinib, Imlunestrant, Larotrectinib, Lorlatinib, Momelotinib, Olaparib, Palbociclib, Repotrectinib, Ribociclib, Rucaparib, Talazoparib, Taletrectinib, Tepotinib, Tucatinib, Vimseltinib, Vorasidenib, Zongertinib, saruparib
  • Renal Cysts: Crizotinib
  • Chronic Interstitial Nephropathy: Carmustine (BCNU), Fotemustine, Lomustine (CCNU), Lutetium-177 Dotatate, Lutetium-177 PSMA-617 (vipivotide), Nimustine (ACNU), Pemetrexed
Cisplatin · Acute Tubular Necrosis · Platinum agentsCarboplatin · Acute Tubular Necrosis · Platinum agentsOxaliplatin · Thrombotic Microangiopathy · Platinum agentsNedaplatin · Acute Tubular Necrosis · Platinum agentsIfosfamide · Fanconi Syndrome · Alkylating agentsCyclophosphamide · SIADH / Hyponatremia · Alkylating agentsStreptozocin · Fanconi Syndrome · Alkylating agentsCarmustine (BCNU) · Chronic Interstitial Nephropathy · Alkylating agentsLomustine (CCNU) · Chronic Interstitial Nephropathy · Alkylating agentsBendamustine · Crystal / Obstructive Nephropathy · Alkylating agentsMelphalan · SIADH / Hyponatremia · Alkylating agentsBusulfan · Thrombotic Microangiopathy · Alkylating agentsTemozolomide · SIADH / Hyponatremia · Alkylating agentsDacarbazine · Prerenal / Hemodynamic AKI · Alkylating agentsThiotepa · Hemorrhagic Cystitis · Alkylating agentsMethotrexate (high-dose) · Crystal / Obstructive Nephropathy · AntimetabolitesPemetrexed · Chronic Interstitial Nephropathy · AntimetabolitesGemcitabine · Thrombotic Microangiopathy · AntimetabolitesPralatrexate · Crystal / Obstructive Nephropathy · Antimetabolites5-Fluorouracil · Thrombotic Microangiopathy · AntimetabolitesCapecitabine · Prerenal / Hemodynamic AKI · AntimetabolitesCytarabine · Crystal / Obstructive Nephropathy · AntimetabolitesFludarabine · Crystal / Obstructive Nephropathy · AntimetabolitesClofarabine · Prerenal / Hemodynamic AKI · AntimetabolitesAzacitidine · Fanconi Syndrome · AntimetabolitesDecitabine · Crystal / Obstructive Nephropathy · AntimetabolitesHydroxyurea · Crystal / Obstructive Nephropathy · AntimetabolitesNelarabine · Crystal / Obstructive Nephropathy · AntimetabolitesMitomycin C · Thrombotic Microangiopathy · Antitumor antibioticsDoxorubicin · Glomerular Injury / Proteinuria · Antitumor antibioticsPlicamycin (mithramycin) · Acute Tubular Necrosis · Antitumor antibioticsBevacizumab · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)Ramucirumab · Hypertension · Anti-angiogenic (VEGF)Ziv-aflibercept · Hypertension · Anti-angiogenic (VEGF)VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib) · Hypertension · Anti-angiogenic (VEGF)Lenvatinib · Hypertension · Anti-angiogenic (VEGF)Cabozantinib · Hypertension · Anti-angiogenic (VEGF)Regorafenib · Hypertension · Anti-angiogenic (VEGF)Vandetanib · Hypertension · Anti-angiogenic (VEGF)Tivozanib · Hypertension · Anti-angiogenic (VEGF)Nintedanib · Hypertension · Anti-angiogenic (VEGF)mTOR inhibitors (everolimus · temsirolimus) · Glomerular Injury / Proteinuria · mTOR inhibitorsSirolimus · Glomerular Injury / Proteinuria · mTOR inhibitorsCetuximab · Electrolyte Disturbance · Monoclonal antibodies (other)Panitumumab · Electrolyte Disturbance · Monoclonal antibodies (other)Necitumumab · Electrolyte Disturbance · Monoclonal antibodies (other)Osimertinib · SIADH / Hyponatremia · EGFR / HER2 inhibitorsErlotinib · Glomerular Injury / Proteinuria · EGFR / HER2 inhibitorsGefitinib · Glomerular Injury / Proteinuria · EGFR / HER2 inhibitorsAfatinib · Prerenal / Hemodynamic AKI · EGFR / HER2 inhibitorsCheckpoint inhibitors (pembrolizumab · nivolumab · ipilimumab) · Acute Interstitial Nephritis · Checkpoint inhibitorsAtezolizumab · Acute Interstitial Nephritis · Checkpoint inhibitorsDurvalumab · Acute Interstitial Nephritis · Checkpoint inhibitorsAvelumab · Acute Interstitial Nephritis · Checkpoint inhibitorsCemiplimab · Acute Interstitial Nephritis · Checkpoint inhibitorsDostarlimab · Acute Interstitial Nephritis · Checkpoint inhibitorsCAR-T cell therapy · Prerenal / Hemodynamic AKI · CAR-T cell therapyBlinatumomab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersTeclistamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersTalquetamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersElranatamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersMosunetuzumab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersEpcoritamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersGlofitamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersEnfortumab vedotin · Acute Tubular Necrosis · Antibody-drug conjugatesSacituzumab govitecan · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesTrastuzumab deruxtecan · Acute Tubular Necrosis · Antibody-drug conjugatesTrastuzumab emtansine (T-DM1) · Thrombotic Microangiopathy · Antibody-drug conjugatesBrentuximab vedotin · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesPolatuzumab vedotin · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesBelantamab mafodotin · Glomerular Injury / Proteinuria · Antibody-drug conjugatesMirvetuximab soravtansine · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesTisotumab vedotin · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesTebentafusp · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersZolbetuximab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Elacestrant · Prerenal / Hemodynamic AKI · Hormonal / endocrineImlunestrant · Pseudo-AKI · Hormonal / endocrineCamizestrant · Prerenal / Hemodynamic AKI · Hormonal / endocrineVepdegestrant · Prerenal / Hemodynamic AKI · Hormonal / endocrineRelatlimab · Acute Interstitial Nephritis · Checkpoint inhibitorsGemtuzumab ozogamicin · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesInotuzumab ozogamicin · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesCarfilzomib · Thrombotic Microangiopathy · Other targeted agentsBortezomib · Thrombotic Microangiopathy · Other targeted agentsIxazomib · Thrombotic Microangiopathy · Other targeted agentsLenalidomide · Acute Tubular Necrosis · Other targeted agentsPomalidomide · Prerenal / Hemodynamic AKI · Other targeted agentsThalidomide · Prerenal / Hemodynamic AKI · Other targeted agentsIberdomide · Prerenal / Hemodynamic AKI · Other targeted agentsImatinib · Electrolyte Disturbance · BCR-ABL inhibitorsDasatinib · Glomerular Injury / Proteinuria · BCR-ABL inhibitorsNilotinib · Prerenal / Hemodynamic AKI · BCR-ABL inhibitorsPonatinib · Hypertension · BCR-ABL inhibitorsBosutinib · Pseudo-AKI · BCR-ABL inhibitorsCrizotinib · Renal Cysts · ALK / ROS1 / MET / TRK inhibitorsAlectinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsBrigatinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsLorlatinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsCeritinib · Prerenal / Hemodynamic AKI · ALK / ROS1 / MET / TRK inhibitorsOlaparib · Pseudo-AKI · Other targeted agentsNiraparib · Hypertension · Other targeted agentsRucaparib · Pseudo-AKI · Other targeted agentsTalazoparib · Pseudo-AKI · Other targeted agentsBRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib) · Acute Tubular Necrosis · BRAF / MEK inhibitorsEncorafenib · Acute Tubular Necrosis · BRAF / MEK inhibitorsCobimetinib · Acute Tubular Necrosis · BRAF / MEK inhibitorsBinimetinib · Acute Tubular Necrosis · BRAF / MEK inhibitorsSelumetinib · Prerenal / Hemodynamic AKI · BRAF / MEK inhibitorsErdafitinib · Electrolyte Disturbance · FGFR inhibitorsPemigatinib · Electrolyte Disturbance · FGFR inhibitorsFutibatinib · Electrolyte Disturbance · FGFR inhibitorsSelpercatinib · Hypertension · Other kinase inhibitorsPralsetinib · Hypertension · Other kinase inhibitorsCapmatinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsTepotinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsIvosidenib · Prerenal / Hemodynamic AKI · Other targeted agentsEnasidenib · Prerenal / Hemodynamic AKI · Other targeted agentsSotorasib · Prerenal / Hemodynamic AKI · Other targeted agentsAdagrasib · Prerenal / Hemodynamic AKI · Other targeted agentsDaraxonrasib · Prerenal / Hemodynamic AKI · Other targeted agentsBelzutifan · Prerenal / Hemodynamic AKI · Other targeted agentsIbrutinib · Hypertension · BTK inhibitorsAcalabrutinib · Hypertension · BTK inhibitorsZanubrutinib · Prerenal / Hemodynamic AKI · BTK inhibitorsVenetoclax · Crystal / Obstructive Nephropathy · Other targeted agentsSonrotoclax · Crystal / Obstructive Nephropathy · Other targeted agentsTretinoin (ATRA) · Prerenal / Hemodynamic AKI · Other targeted agentsArsenic trioxide · Prerenal / Hemodynamic AKI · Other targeted agentsRituximab · Crystal / Obstructive Nephropathy · Monoclonal antibodies (other)Obinutuzumab · Crystal / Obstructive Nephropathy · Monoclonal antibodies (other)Daratumumab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Isatuximab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Abemaciclib · Pseudo-AKI · CDK4/6 inhibitorsPalbociclib · Pseudo-AKI · CDK4/6 inhibitorsRibociclib · Pseudo-AKI · CDK4/6 inhibitorsTagraxofusp · Prerenal / Hemodynamic AKI · Other targeted agentsPivekimab sunirine · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesIrinotecan · Prerenal / Hemodynamic AKI · Topoisomerase inhibitorsTopotecan · Prerenal / Hemodynamic AKI · Topoisomerase inhibitorsEtoposide · Crystal / Obstructive Nephropathy · Topoisomerase inhibitorsVincristine · SIADH / Hyponatremia · Microtubule inhibitorsVinblastine · SIADH / Hyponatremia · Microtubule inhibitorsVinorelbine · SIADH / Hyponatremia · Microtubule inhibitorsPaclitaxel · Prerenal / Hemodynamic AKI · Microtubule inhibitorsDocetaxel · Prerenal / Hemodynamic AKI · Microtubule inhibitorsCabazitaxel · Prerenal / Hemodynamic AKI · Microtubule inhibitorsEribulin · Prerenal / Hemodynamic AKI · Microtubule inhibitorsAsparaginase · Prerenal / Hemodynamic AKI · Cytokines & enzymesInterferon-α · Glomerular Injury / Proteinuria · Cytokines & enzymesInterleukin-2 (high-dose) · Prerenal / Hemodynamic AKI · Cytokines & enzymesZoledronic acid · Acute Tubular Necrosis · Bisphosphonates & bonePamidronate · Glomerular Injury / Proteinuria · Bisphosphonates & boneDenosumab · Electrolyte Disturbance · Bisphosphonates & boneIbandronate · Acute Tubular Necrosis · Bisphosphonates & boneAbiraterone · Electrolyte Disturbance · Hormonal / endocrineEnzalutamide · Hypertension · Hormonal / endocrineRelacorilant · Electrolyte Disturbance · Other targeted agentsTamoxifen · SIADH / Hyponatremia · Hormonal / endocrineLeuprolide · Hypertension · Hormonal / endocrineAmivantamab · Electrolyte Disturbance · Monoclonal antibodies (other)Zenocutuzumab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Datopotamab deruxtecan (Dato-DXd) · Acute Tubular Necrosis · Antibody-drug conjugatesTarlatamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersRevumenib · Prerenal / Hemodynamic AKI · Other targeted agentsFruquintinib · Hypertension · Anti-angiogenic (VEGF)Pirtobrutinib · Crystal / Obstructive Nephropathy · BTK inhibitorsCapivasertib · Prerenal / Hemodynamic AKI · PI3K / AKT inhibitorsNirogacestat · Electrolyte Disturbance · Other targeted agentsLazertinib · SIADH / Hyponatremia · EGFR / HER2 inhibitorsRepotrectinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsZanidatamab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Lifileucel · Prerenal / Hemodynamic AKI · Other targeted agentsTovorafenib · Prerenal / Hemodynamic AKI · BRAF / MEK inhibitorsImetelstat · Prerenal / Hemodynamic AKI · Other targeted agentsMirdametinib · Prerenal / Hemodynamic AKI · BRAF / MEK inhibitorsSunvozertinib · Electrolyte Disturbance · EGFR / HER2 inhibitorsTucatinib · Pseudo-AKI · EGFR / HER2 inhibitorsRuxolitinib · Prerenal / Hemodynamic AKI · Other kinase inhibitorsMomelotinib · Pseudo-AKI · Other kinase inhibitorsEntrectinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsQuizartinib · Prerenal / Hemodynamic AKI · Other kinase inhibitorsZiftomenib · Prerenal / Hemodynamic AKI · Other targeted agentsCasdatifan · Prerenal / Hemodynamic AKI · Other targeted agentsZongertinib · Pseudo-AKI · EGFR / HER2 inhibitorsSevabertinib · Prerenal / Hemodynamic AKI · EGFR / HER2 inhibitorsDordaviprone · Prerenal / Hemodynamic AKI · Other targeted agentsLutetium-177 Dotatate · Chronic Interstitial Nephropathy · RadiopharmaceuticalsLutetium-177 PSMA-617 (vipivotide) · Chronic Interstitial Nephropathy · RadiopharmaceuticalsIbritumomab tiuxetan · Prerenal / Hemodynamic AKI · RadiopharmaceuticalsRadium-223 dichloride · Prerenal / Hemodynamic AKI · RadiopharmaceuticalsTrabectedin · Acute Tubular Necrosis · Alkylating agentsLurbinectedin · Acute Tubular Necrosis · Alkylating agentsMoxetumomab pasudotox · Thrombotic Microangiopathy · Other targeted agentsDenileukin diftitox · Prerenal / Hemodynamic AKI · Other targeted agentsSelinexor · SIADH / Hyponatremia · Other targeted agentsCladribine · Crystal / Obstructive Nephropathy · AntimetabolitesPentostatin · Acute Tubular Necrosis · AntimetabolitesPegaspargase · Prerenal / Hemodynamic AKI · Cytokines & enzymesInfigratinib · Electrolyte Disturbance · FGFR inhibitorsMobocertinib · Prerenal / Hemodynamic AKI · EGFR / HER2 inhibitorsLarotrectinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsIdecabtagene vicleucel · Prerenal / Hemodynamic AKI · CAR-T cell therapyCiltacabtagene autoleucel · Prerenal / Hemodynamic AKI · CAR-T cell therapyMitoxantrone · Crystal / Obstructive Nephropathy · Antitumor antibioticsIdarubicin · Crystal / Obstructive Nephropathy · Antitumor antibioticsEstramustine · Prerenal / Hemodynamic AKI · Alkylating agentsAlpelisib · Prerenal / Hemodynamic AKI · PI3K / AKT inhibitorsIdelalisib · Prerenal / Hemodynamic AKI · PI3K / AKT inhibitorsDuvelisib · Prerenal / Hemodynamic AKI · PI3K / AKT inhibitorsCopanlisib · Hypertension · PI3K / AKT inhibitorsGedatolisib · Electrolyte Disturbance · PI3K / AKT inhibitorsVismodegib · SIADH / Hyponatremia · Other targeted agentsSonidegib · Acute Tubular Necrosis · Other targeted agentsGlasdegib · Prerenal / Hemodynamic AKI · Other targeted agentsGilteritinib · Prerenal / Hemodynamic AKI · Other kinase inhibitorsMidostaurin · Prerenal / Hemodynamic AKI · Other kinase inhibitorsAsciminib · Hypertension · BCR-ABL inhibitorsAvapritinib · Prerenal / Hemodynamic AKI · Other kinase inhibitorsRipretinib · Hypertension · Other kinase inhibitorsPexidartinib · Prerenal / Hemodynamic AKI · Other kinase inhibitorsTazemetostat · Prerenal / Hemodynamic AKI · Other targeted agentsNeratinib · Prerenal / Hemodynamic AKI · EGFR / HER2 inhibitorsOlutasidenib · Prerenal / Hemodynamic AKI · Other targeted agentsLoncastuximab tesirine · Prerenal / Hemodynamic AKI · Antibody-drug conjugatesTafasitamab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Mogamulizumab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Dinutuximab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Raltitrexed · Acute Tubular Necrosis · AntimetabolitesTrifluridine/tipiracil · Prerenal / Hemodynamic AKI · AntimetabolitesElotuzumab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Melphalan flufenamide (melflufen) · Acute Tubular Necrosis · Alkylating agentsProcarbazine · Acute Tubular Necrosis · Alkylating agentsCatumaxomab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersBleomycin · Prerenal / Hemodynamic AKI · Antitumor antibioticsVinflunine · Electrolyte Disturbance · Microtubule inhibitorsFotemustine · Chronic Interstitial Nephropathy · Alkylating agentsNimustine (ACNU) · Chronic Interstitial Nephropathy · Alkylating agentsTeniposide · Electrolyte Disturbance · Topoisomerase inhibitorsDactinomycin (actinomycin D) · Electrolyte Disturbance · Antitumor antibioticsMechlorethamine · Electrolyte Disturbance · Alkylating agentsChlorambucil · SIADH / Hyponatremia · Alkylating agentsAmsacrine · Electrolyte Disturbance · Topoisomerase inhibitorsAltretamine (hexamethylmelamine) · Prerenal / Hemodynamic AKI · Alkylating agentsTegafur-uracil (UFT) · Thrombotic Microangiopathy · AntimetabolitesDoxifluridine · Thrombotic Microangiopathy · AntimetabolitesCarmofur (HCFU) · Thrombotic Microangiopathy · AntimetabolitesSamarium-153 lexidronam · Acute Tubular Necrosis · RadiopharmaceuticalsBicalutamide · Acute Interstitial Nephritis · Hormonal / endocrineOctreotide · Electrolyte Disturbance · Hormonal / endocrineLanreotide · Electrolyte Disturbance · Hormonal / endocrineMitotane · Electrolyte Disturbance · Hormonal / endocrineDarolutamide · Electrolyte Disturbance · Hormonal / endocrineStrontium-89 chloride · Electrolyte Disturbance · RadiopharmaceuticalsTislelizumab · Acute Interstitial Nephritis · Checkpoint inhibitorsToripalimab · Acute Interstitial Nephritis · Checkpoint inhibitorsRetifanlimab · Acute Interstitial Nephritis · Checkpoint inhibitorsCosibelimab · Acute Interstitial Nephritis · Checkpoint inhibitorsIvonescimab · Glomerular Injury / Proteinuria · Checkpoint inhibitorsLinvoseltamab · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagersOlverembatinib · Glomerular Injury / Proteinuria · BCR-ABL inhibitorsVorasidenib · Pseudo-AKI · Other targeted agentsVimseltinib · Pseudo-AKI · Other kinase inhibitorsPenpulimab · Acute Interstitial Nephritis · Checkpoint inhibitorsSugemalimab · Acute Interstitial Nephritis · Checkpoint inhibitorsTaletrectinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsZidesamtinib · Prerenal / Hemodynamic AKI · ALK / ROS1 / MET / TRK inhibitorsEnsartinib · Pseudo-AKI · ALK / ROS1 / MET / TRK inhibitorsInavolisib · Electrolyte Disturbance · PI3K / AKT inhibitorsTelisotuzumab vedotin (Teliso-V) · Acute Tubular Necrosis · Antibody-drug conjugatesAfamitresgene autoleucel (Afami-cel) · Prerenal / Hemodynamic AKI · Other targeted agentsObecabtagene autoleucel (Obe-cel) · Prerenal / Hemodynamic AKI · CAR-T cell therapySunitinib · Hypertension · Anti-angiogenic (VEGF)Axitinib · Hypertension · Anti-angiogenic (VEGF)Pazopanib · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)Ipilimumab · Acute Interstitial Nephritis · Checkpoint inhibitorsNivolumab · Acute Interstitial Nephritis · Checkpoint inhibitorsPembrolizumab · Acute Interstitial Nephritis · Checkpoint inhibitorsVemurafenib · Acute Tubular Necrosis · BRAF / MEK inhibitorsDabrafenib · Acute Interstitial Nephritis · BRAF / MEK inhibitorsTrametinib · Prerenal / Hemodynamic AKI · BRAF / MEK inhibitorsEverolimus · Glomerular Injury / Proteinuria · mTOR inhibitorsTemsirolimus · Glomerular Injury / Proteinuria · mTOR inhibitorsSorafenib · Hypertension · Anti-angiogenic (VEGF)Pacritinib · Prerenal / Hemodynamic AKI · Other kinase inhibitorsAvutometinib · Electrolyte Disturbance · BRAF / MEK inhibitorsFedratinib · Electrolyte Disturbance · Other kinase inhibitorsOdronextamab · Crystal / Obstructive Nephropathy · Bispecifics / T-cell engagersNaxitamab · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)Iobenguane I-131 · Acute Tubular Necrosis · RadiopharmaceuticalsLisocabtagene maraleucel · Prerenal / Hemodynamic AKI · CAR-T cell therapyGallium nitrate · Acute Tubular Necrosis · Other targeted agentsTasonermin · Prerenal / Hemodynamic AKI · Cytokines & enzymespromacta · Thrombotic Microangiopathy · Other targeted agentssaruparib · Pseudo-AKI · Other targeted agentsDisitamab vedotin · Acute Tubular Necrosis · Antibody-drug conjugatesAnitocabtagene autoleucel · Prerenal / Hemodynamic AKI · Other targeted agentsActinium 225 PSMA · Acute Tubular Necrosis · RadiopharmaceuticalsFurmonertinib · Electrolyte Disturbance · Other kinase inhibitorsDefactinib · Electrolyte Disturbance · Other targeted agentsCadonilimab · Acute Interstitial Nephritis · Checkpoint inhibitors

300 agents · dot size = FAERS reporting volume, for the 283 agents openFDA returns reports for. The remaining 17 are drawn as hollow rings: every static-catalog agent is queried, so a ring means openFDA came back empty — a withdrawn drug, a non-US approval, a 2025 launch, or a catalog entry that names a whole class and has no generic name to query; a recently added agent may simply lack a stored lookup yet. Position = clinical-toxicity similarity (2-D MDS). A small deterministic jitter keeps agents with identical fingerprints from stacking — treat fine nearest-neighbor ordering as approximate.

Figure 1·Anti-cancer agents embedded so proximity encodes a shared kidney-injury phenotype (2-D MDS over each agent's injury set, nephron targets, severity, class, and a small approval-era tie-break).

The focused companion to the map (fig 1): pick an agent and see the six agents whose kidney-injury phenotype sits closest — nearer the center means a tighter match. The chips name why each pair pulls together: a shared signature injury, nephron segment, class family, or severity band.

or:
Nivolumab, 70 percent match — Same signature · Acute Interstitial Nephritis; Shares Interstitium, Distal Tubule / Collecting Duct, Glomerulus; Same class · Checkpoint inhibitors; Same severity · ModerateNivolumabToripalimab, 68 percent match — Same signature · Acute Interstitial Nephritis; Shares Interstitium, Glomerulus; Same class · Checkpoint inhibitors; Same severity · ModerateToripalimabCosibelimab, 67 percent match — Same signature · Acute Interstitial Nephritis; Shares Interstitium, Glomerulus; Same class · Checkpoint inhibitors; Same severity · ModerateCosibelimabSugemalimab, 66 percent match — Same signature · Acute Interstitial Nephritis; Shares Interstitium, Distal Tubule / Collecting Duct, Glomerulus; Same class · Checkpoint inhibitors; Same severity · ModerateSugemalimabPenpulimab, 66 percent match — Same signature · Acute Interstitial Nephritis; Shares Interstitium, Distal Tubule / Collecting Duct, Glomerulus; Same class · Checkpoint inhibitors; Same severity · ModeratePenpulimabTislelizumab, 64 percent match — Same signature · Acute Interstitial Nephritis; Shares Interstitium, Glomerulus; Same class · Checkpoint inhibitors; Same severity · ModerateTislelizumabPembrolizum…

Nearest analogs of Pembrolizumab

Open Pembrolizumab →

Acute Interstitial Nephritis · Checkpoint inhibitors · Moderate

  1. Nivolumab70%
    Same signature · Acute Interstitial NephritisShares Interstitium, Distal Tubule / Collecting Duct, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
  2. Toripalimab68%
    Same signature · Acute Interstitial NephritisShares Interstitium, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
  3. Cosibelimab67%
    Same signature · Acute Interstitial NephritisShares Interstitium, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
  4. Sugemalimab66%
    Same signature · Acute Interstitial NephritisShares Interstitium, Distal Tubule / Collecting Duct, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
  5. Penpulimab66%
    Same signature · Acute Interstitial NephritisShares Interstitium, Distal Tubule / Collecting Duct, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate
  6. Tislelizumab64%
    Same signature · Acute Interstitial NephritisShares Interstitium, GlomerulusSame class · Checkpoint inhibitorsSame severity · Moderate

Distance from the center = phenotype similarity (closer is a tighter match), ranked by the exact clinical-fingerprint distance the map's 2-D MDS approximates — injury signature (weight 0.48), nephron target (0.23), severity (0.11), class family (0.11), and a 0.07 approval-era term that breaks ties between otherwise-identical fingerprints. That last term is small but not nothing: it decides which neighbors appear when several agents share a signature, anatomy, severity and class. Click a neighbor to recenter and walk the neighborhood; the list links to each profile. Similarity is a phenotype resemblance, not a shared mechanism or an interchangeability claim.

Figure 2·The interactive, browsable companion to the map (fig 1): pick any agent and its six nearest kidney-toxicity analogs appear as a radial constellation, each placed at a radius set by the exact phenotype-distance metric the map's 2-D MDS approximates — injury signature (0.48), nephron target (0.23), severity (0.11), class family (0.11), and a 0.07 approval-era term that separates otherwise-identical fingerprints. The chips make the resemblance explicit (shared signature injury, nephron segment, class family, or severity); click a neighbor to recenter and walk the neighborhood. A phenotype resemblance, not a shared mechanism or interchangeability claim.

The kidney-injury combinations that strike the same agent, ranked by how many agents carry each exact set. The dot column under each bar shows which injuries are in that combination — the multi-way overlaps a pairwise chord can only hint at. A set-size bar to the left of each injury row totals how often that injury appears across these combinations, for comparison against any single set.

  • 32 agents: Electrolyte Disturbance + Prerenal / Hemodynamic AKI
  • 22 agents: Electrolyte Disturbance + Crystal / Obstructive Nephropathy + Prerenal / Hemodynamic AKI
  • 11 agents: Acute Tubular Necrosis + Electrolyte Disturbance + Prerenal / Hemodynamic AKI
  • 11 agents: Prerenal / Hemodynamic AKI + Pseudo-AKI
  • 9 agents: Thrombotic Microangiopathy + Glomerular Injury / Proteinuria + Hypertension
  • 9 agents: Acute Tubular Necrosis + Prerenal / Hemodynamic AKI
  • 8 agents: Electrolyte Disturbance + SIADH / Hyponatremia
  • 8 agents: Acute Tubular Necrosis + Electrolyte Disturbance + Crystal / Obstructive Nephropathy + Prerenal / Hemodynamic AKI
  • 5 agents: Electrolyte Disturbance + Prerenal / Hemodynamic AKI + SIADH / Hyponatremia
  • 5 agents: Acute Tubular Necrosis + Electrolyte Disturbance
  • 5 agents: Thrombotic Microangiopathy + Electrolyte Disturbance + Prerenal / Hemodynamic AKI
  • 4 agents: Glomerular Injury / Proteinuria + Hypertension
  • 4 agents: Acute Interstitial Nephritis + Glomerular Injury / Proteinuria
  • 3 agents: Acute Tubular Necrosis + Crystal / Obstructive Nephropathy
  • Acute Tubular Necrosis: 36 agents across the shown combinations
  • Acute Interstitial Nephritis: 4 agents across the shown combinations
  • Thrombotic Microangiopathy: 14 agents across the shown combinations
  • Glomerular Injury / Proteinuria: 17 agents across the shown combinations
  • Electrolyte Disturbance: 96 agents across the shown combinations
  • Crystal / Obstructive Nephropathy: 33 agents across the shown combinations
  • Hypertension: 13 agents across the shown combinations
  • Prerenal / Hemodynamic AKI: 103 agents across the shown combinations
  • SIADH / Hyponatremia: 13 agents across the shown combinations
  • Pseudo-AKI: 11 agents across the shown combinations
322211119988555443set sizeAcute Tubular Necrosis36Acute Interstitial Nephritis4Thrombotic Microangiopathy14Glomerular Injury / Proteinuria17Electrolyte Disturbance96Crystal / Obstructive Nephropathy33Hypertension13Prerenal / Hemodynamic AKI103SIADH / Hyponatremia13Pseudo-AKI11

Top 14 injury combinations among profiled agents · top bar = agents with exactly that set · connected dots = injuries in the combination · left set-size bar = total agents across these combinations carrying that injury (each agent counted once).

Figure 3·The 14 most frequent of the 87 exact multi-injury combinations profiled agents carry, covering 136 of the 238 agents with more than one injury — the intersection logic a pairwise chord cannot show.

Every profiled agent as a row; the 14 kidney injuries as columns. A colored tick means the agent carries that injury. Rows are grouped by drug class, so agents in a family light up the same injury columns. Tap a column header to isolate an injury.

Profiled anti-cancer agents (rows) by the kidney injuries they carry (columns). A colored tick marks a present injury; the agent's signature injury is outlined.
Agent
Other targeted agents · 45
AdagrasibGlomerular Injury / ProteinuriaPrerenal / Hemodynamic AKI (signature)Pseudo-AKI
Afamitresgene autoleucel (Afami-cel)Electrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
Anitocabtagene autoleucelPrerenal / Hemodynamic AKI (signature)
Arsenic trioxideAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
BelzutifanPrerenal / Hemodynamic AKI (signature)
BortezomibThrombotic Microangiopathy (signature)Glomerular Injury / Proteinuria
CarfilzomibAcute Tubular NecrosisThrombotic Microangiopathy (signature)Glomerular Injury / ProteinuriaHypertension
CasdatifanPrerenal / Hemodynamic AKI (signature)
DaraxonrasibThrombotic MicroangiopathyElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
DefactinibElectrolyte Disturbance (signature)
Denileukin diftitoxPrerenal / Hemodynamic AKI (signature)
DordavipronePrerenal / Hemodynamic AKI (signature)
EnasidenibAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
Gallium nitrateAcute Tubular Necrosis (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKI
GlasdegibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
IberdomidePrerenal / Hemodynamic AKI (signature)
ImetelstatElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
IvosidenibAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
IxazomibThrombotic Microangiopathy (signature)
LenalidomideAcute Tubular Necrosis (signature)Thrombotic MicroangiopathyFanconi Syndrome
LifileucelAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
Moxetumomab pasudotoxThrombotic Microangiopathy (signature)Prerenal / Hemodynamic AKI
NiraparibHypertension (signature)Pseudo-AKI
NirogacestatElectrolyte Disturbance (signature)Fanconi Syndrome
OlaparibThrombotic MicroangiopathyPseudo-AKI (signature)
OlutasidenibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
PomalidomideElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
promactaThrombotic Microangiopathy (signature)
RelacorilantElectrolyte Disturbance (signature)Hypertension
RevumenibElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
RucaparibPseudo-AKI (signature)
saruparibPseudo-AKI (signature)
SelinexorElectrolyte DisturbancePrerenal / Hemodynamic AKISIADH / Hyponatremia (signature)
SonidegibAcute Tubular Necrosis (signature)
SonrotoclaxElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
SotorasibAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
TagraxofuspAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
TalazoparibPseudo-AKI (signature)
TazemetostatElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
ThalidomideElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Tretinoin (ATRA)Acute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
VenetoclaxAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
VismodegibElectrolyte DisturbanceSIADH / Hyponatremia (signature)
VorasidenibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
ZiftomenibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
Alkylating agents · 21
Altretamine (hexamethylmelamine)Prerenal / Hemodynamic AKI (signature)
BendamustineThrombotic MicroangiopathyElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)
BusulfanThrombotic Microangiopathy (signature)
Carmustine (BCNU)Thrombotic MicroangiopathyChronic Interstitial Nephropathy (signature)
ChlorambucilElectrolyte DisturbanceSIADH / Hyponatremia (signature)
CyclophosphamideSIADH / Hyponatremia (signature)Hemorrhagic Cystitis
DacarbazinePrerenal / Hemodynamic AKI (signature)
EstramustinePrerenal / Hemodynamic AKI (signature)
FotemustineAcute Tubular NecrosisElectrolyte DisturbanceChronic Interstitial Nephropathy (signature)
IfosfamideAcute Tubular NecrosisElectrolyte DisturbanceFanconi Syndrome (signature)Hemorrhagic Cystitis
Lomustine (CCNU)Chronic Interstitial Nephropathy (signature)
LurbinectedinAcute Tubular Necrosis (signature)Electrolyte DisturbanceCrystal / Obstructive Nephropathy
MechlorethamineElectrolyte Disturbance (signature)Crystal / Obstructive Nephropathy
MelphalanElectrolyte DisturbanceSIADH / Hyponatremia (signature)
Melphalan flufenamide (melflufen)Acute Tubular Necrosis (signature)Electrolyte Disturbance
Nimustine (ACNU)Acute Tubular NecrosisElectrolyte DisturbanceChronic Interstitial Nephropathy (signature)
ProcarbazineAcute Tubular Necrosis (signature)Acute Interstitial Nephritis
StreptozocinAcute Tubular NecrosisElectrolyte DisturbanceFanconi Syndrome (signature)
TemozolomideElectrolyte DisturbanceSIADH / Hyponatremia (signature)
ThiotepaHemorrhagic Cystitis (signature)
TrabectedinAcute Tubular Necrosis (signature)Electrolyte Disturbance
Antimetabolites · 20
5-FluorouracilThrombotic Microangiopathy (signature)Prerenal / Hemodynamic AKI
AzacitidineAcute Tubular NecrosisElectrolyte DisturbanceFanconi Syndrome (signature)Pseudo-AKI
CapecitabineThrombotic MicroangiopathyPrerenal / Hemodynamic AKI (signature)
Carmofur (HCFU)Thrombotic Microangiopathy (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKI
CladribineElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
ClofarabineAcute Tubular NecrosisGlomerular Injury / ProteinuriaCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
CytarabineElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKISIADH / Hyponatremia
DecitabineThrombotic MicroangiopathyElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
DoxifluridineThrombotic Microangiopathy (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKI
FludarabineElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
GemcitabineThrombotic Microangiopathy (signature)Glomerular Injury / ProteinuriaHypertensionHemorrhagic Cystitis
HydroxyureaElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
Methotrexate (high-dose)Acute Tubular NecrosisCrystal / Obstructive Nephropathy (signature)
NelarabineElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
PemetrexedAcute Tubular NecrosisElectrolyte DisturbanceSIADH / HyponatremiaChronic Interstitial Nephropathy (signature)
PentostatinAcute Tubular Necrosis (signature)Electrolyte DisturbanceSIADH / Hyponatremia
PralatrexateAcute Tubular NecrosisCrystal / Obstructive Nephropathy (signature)
RaltitrexedAcute Tubular Necrosis (signature)Crystal / Obstructive Nephropathy
Tegafur-uracil (UFT)Thrombotic Microangiopathy (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKI
Trifluridine/tipiracilPrerenal / Hemodynamic AKI (signature)
Checkpoint inhibitors · 18
AtezolizumabAcute Interstitial Nephritis (signature)Glomerular Injury / ProteinuriaSIADH / HyponatremiaHemorrhagic Cystitis
AvelumabAcute Interstitial Nephritis (signature)Glomerular Injury / Proteinuria
CadonilimabAcute Interstitial Nephritis (signature)
CemiplimabAcute Interstitial Nephritis (signature)Glomerular Injury / Proteinuria
Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)Acute Interstitial Nephritis (signature)Glomerular Injury / ProteinuriaElectrolyte Disturbance
CosibelimabAcute Interstitial Nephritis (signature)Glomerular Injury / ProteinuriaElectrolyte Disturbance
DostarlimabAcute Interstitial Nephritis (signature)Glomerular Injury / Proteinuria
DurvalumabAcute Interstitial Nephritis (signature)Glomerular Injury / Proteinuria
IpilimumabAcute Interstitial Nephritis (signature)Thrombotic MicroangiopathyGlomerular Injury / ProteinuriaPrerenal / Hemodynamic AKIChronic Interstitial Nephropathy
IvonescimabAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)HypertensionPrerenal / Hemodynamic AKI
NivolumabAcute Tubular NecrosisAcute Interstitial Nephritis (signature)Thrombotic MicroangiopathyGlomerular Injury / ProteinuriaSIADH / HyponatremiaChronic Interstitial Nephropathy
PembrolizumabAcute Interstitial Nephritis (signature)Thrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceHemorrhagic CystitisChronic Interstitial Nephropathy
PenpulimabAcute Tubular NecrosisAcute Interstitial Nephritis (signature)Glomerular Injury / ProteinuriaElectrolyte Disturbance
RelatlimabAcute Interstitial Nephritis (signature)
RetifanlimabAcute Interstitial Nephritis (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKI
SugemalimabAcute Tubular NecrosisAcute Interstitial Nephritis (signature)Glomerular Injury / ProteinuriaElectrolyte Disturbance
TislelizumabAcute Interstitial Nephritis (signature)Thrombotic MicroangiopathyGlomerular Injury / ProteinuriaPrerenal / Hemodynamic AKI
ToripalimabAcute Interstitial Nephritis (signature)Glomerular Injury / ProteinuriaElectrolyte Disturbance
Monoclonal antibodies (other) · 16
AmivantamabAcute Interstitial NephritisElectrolyte Disturbance (signature)
CetuximabGlomerular Injury / ProteinuriaElectrolyte Disturbance (signature)
DaratumumabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
DinutuximabThrombotic MicroangiopathyHypertensionPrerenal / Hemodynamic AKI (signature)
ElotuzumabPrerenal / Hemodynamic AKI (signature)
IsatuximabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
MogamulizumabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
NaxitamabHypertensionPrerenal / Hemodynamic AKI (signature)
NecitumumabElectrolyte Disturbance (signature)
ObinutuzumabAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
PanitumumabGlomerular Injury / ProteinuriaElectrolyte Disturbance (signature)
RituximabAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
TafasitamabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
ZanidatamabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
ZenocutuzumabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
ZolbetuximabPrerenal / Hemodynamic AKI (signature)
Antibody-drug conjugates · 16
Belantamab mafodotinGlomerular Injury / Proteinuria (signature)
Brentuximab vedotinElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Datopotamab deruxtecan (Dato-DXd)Acute Tubular Necrosis (signature)Glomerular Injury / Proteinuria
Disitamab vedotinAcute Tubular Necrosis (signature)
Enfortumab vedotinAcute Tubular Necrosis (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKI
Gemtuzumab ozogamicinElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Inotuzumab ozogamicinElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Loncastuximab tesirineElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
Mirvetuximab soravtansinePrerenal / Hemodynamic AKI (signature)
Pivekimab sunirineAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Polatuzumab vedotinElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Sacituzumab govitecanAcute Tubular NecrosisAcute Interstitial NephritisPrerenal / Hemodynamic AKI (signature)
Telisotuzumab vedotin (Teliso-V)Acute Tubular Necrosis (signature)Electrolyte Disturbance
Tisotumab vedotinPrerenal / Hemodynamic AKI (signature)
Trastuzumab deruxtecanAcute Tubular Necrosis (signature)Electrolyte DisturbanceFanconi Syndrome
Trastuzumab emtansine (T-DM1)Thrombotic Microangiopathy (signature)Glomerular Injury / ProteinuriaHypertension
Anti-angiogenic (VEGF) · 15
AxitinibThrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)
BevacizumabThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)Hypertension
CabozantinibGlomerular Injury / ProteinuriaHypertension (signature)
FruquintinibThrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)
LenvatinibGlomerular Injury / ProteinuriaHypertension (signature)
NintedanibThrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)
PazopanibThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)Hypertension
RamucirumabThrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)
RegorafenibGlomerular Injury / ProteinuriaHypertension (signature)
SorafenibThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceHypertension (signature)
SunitinibThrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)Prerenal / Hemodynamic AKI
TivozanibGlomerular Injury / ProteinuriaHypertension (signature)
VandetanibGlomerular Injury / ProteinuriaElectrolyte DisturbanceHypertension (signature)
VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)Thrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)
Ziv-afliberceptThrombotic MicroangiopathyGlomerular Injury / ProteinuriaHypertension (signature)
Other kinase inhibitors · 14
AvapritinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
FedratinibElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
FurmonertinibElectrolyte Disturbance (signature)
GilteritinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
MidostaurinElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
MomelotinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
PacritinibAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
PexidartinibPrerenal / Hemodynamic AKI (signature)
PralsetinibHypertension (signature)Prerenal / Hemodynamic AKIPseudo-AKI
QuizartinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
RipretinibHypertension (signature)
RuxolitinibThrombotic MicroangiopathyElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
SelpercatinibGlomerular Injury / ProteinuriaHypertension (signature)Prerenal / Hemodynamic AKISIADH / HyponatremiaPseudo-AKI
VimseltinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
ALK / ROS1 / MET / TRK inhibitors · 13
AlectinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
BrigatinibHypertensionPrerenal / Hemodynamic AKIPseudo-AKI (signature)
CapmatinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
CeritinibPrerenal / Hemodynamic AKI (signature)Pseudo-AKI
CrizotinibElectrolyte DisturbancePseudo-AKIRenal Cysts (signature)
EnsartinibElectrolyte DisturbancePseudo-AKI (signature)Renal Cysts
EntrectinibPseudo-AKI (signature)
LarotrectinibPseudo-AKI (signature)
LorlatinibGlomerular Injury / ProteinuriaPrerenal / Hemodynamic AKIPseudo-AKI (signature)
RepotrectinibPseudo-AKI (signature)
TaletrectinibPseudo-AKI (signature)
TepotinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
ZidesamtinibPrerenal / Hemodynamic AKI (signature)
Hormonal / endocrine · 13
AbirateroneElectrolyte Disturbance (signature)Hypertension
BicalutamideAcute Interstitial Nephritis (signature)
CamizestrantPrerenal / Hemodynamic AKI (signature)
DarolutamideElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
ElacestrantPrerenal / Hemodynamic AKI (signature)
EnzalutamideElectrolyte DisturbanceHypertension (signature)
ImlunestrantPrerenal / Hemodynamic AKIPseudo-AKI (signature)
LanreotideElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
LeuprolideHypertension (signature)
MitotaneElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
OctreotideElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
TamoxifenElectrolyte DisturbancePrerenal / Hemodynamic AKISIADH / Hyponatremia (signature)
VepdegestrantPrerenal / Hemodynamic AKI (signature)
Bispecifics / T-cell engagers · 12
BlinatumomabAcute Tubular NecrosisCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
CatumaxomabElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
ElranatamabAcute Tubular NecrosisCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
EpcoritamabElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
GlofitamabElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
LinvoseltamabElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
MosunetuzumabElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
OdronextamabAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
TalquetamabAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
TarlatamabAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
TebentafuspPrerenal / Hemodynamic AKI (signature)
TeclistamabAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
BRAF / MEK inhibitors · 11
AvutometinibAcute Tubular NecrosisElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
BinimetinibAcute Tubular Necrosis (signature)Prerenal / Hemodynamic AKI
BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib)Acute Tubular Necrosis (signature)Acute Interstitial NephritisElectrolyte DisturbanceFanconi SyndromePseudo-AKI
CobimetinibAcute Tubular Necrosis (signature)Acute Interstitial Nephritis
DabrafenibAcute Tubular NecrosisAcute Interstitial Nephritis (signature)Electrolyte DisturbancePrerenal / Hemodynamic AKISIADH / Hyponatremia
EncorafenibAcute Tubular Necrosis (signature)Acute Interstitial Nephritis
MirdametinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
SelumetinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
TovorafenibPrerenal / Hemodynamic AKI (signature)
TrametinibAcute Interstitial NephritisGlomerular Injury / ProteinuriaHypertensionPrerenal / Hemodynamic AKI (signature)
VemurafenibAcute Tubular Necrosis (signature)Electrolyte DisturbanceFanconi SyndromeChronic Interstitial Nephropathy
EGFR / HER2 inhibitors · 11
AfatinibAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
ErlotinibAcute Tubular NecrosisThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)Prerenal / Hemodynamic AKI
GefitinibAcute Interstitial NephritisGlomerular Injury / Proteinuria (signature)Hemorrhagic Cystitis
LazertinibElectrolyte DisturbanceSIADH / Hyponatremia (signature)
MobocertinibAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
NeratinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
OsimertinibElectrolyte DisturbanceSIADH / Hyponatremia (signature)Pseudo-AKI
SevabertinibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
SunvozertinibElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKISIADH / Hyponatremia
TucatinibPseudo-AKI (signature)
ZongertinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
Microtubule inhibitors · 8
CabazitaxelPrerenal / Hemodynamic AKI (signature)Hemorrhagic Cystitis
DocetaxelThrombotic MicroangiopathyPrerenal / Hemodynamic AKI (signature)Hemorrhagic Cystitis
EribulinPrerenal / Hemodynamic AKI (signature)
PaclitaxelGlomerular Injury / ProteinuriaPrerenal / Hemodynamic AKI (signature)Hemorrhagic Cystitis
VinblastineElectrolyte DisturbanceSIADH / Hyponatremia (signature)
VincristineElectrolyte DisturbanceSIADH / Hyponatremia (signature)
VinflunineElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKISIADH / Hyponatremia
VinorelbineElectrolyte DisturbanceSIADH / Hyponatremia (signature)
Radiopharmaceuticals · 8
Actinium 225 PSMAAcute Tubular Necrosis (signature)
Ibritumomab tiuxetanElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Iobenguane I-131Acute Tubular Necrosis (signature)Glomerular Injury / ProteinuriaHypertensionChronic Interstitial Nephropathy
Lutetium-177 DotatateThrombotic MicroangiopathyChronic Interstitial Nephropathy (signature)
Lutetium-177 PSMA-617 (vipivotide)Electrolyte DisturbanceChronic Interstitial Nephropathy (signature)
Radium-223 dichloridePrerenal / Hemodynamic AKI (signature)
Samarium-153 lexidronamAcute Tubular Necrosis (signature)
Strontium-89 chlorideElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
Antitumor antibiotics · 7
BleomycinPrerenal / Hemodynamic AKI (signature)
Dactinomycin (actinomycin D)Electrolyte Disturbance (signature)Crystal / Obstructive NephropathyPrerenal / Hemodynamic AKI
DoxorubicinThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)Hemorrhagic Cystitis
IdarubicinElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
Mitomycin CThrombotic Microangiopathy (signature)Glomerular Injury / ProteinuriaHemorrhagic Cystitis
MitoxantroneElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKIHemorrhagic Cystitis
Plicamycin (mithramycin)Acute Tubular Necrosis (signature)Electrolyte Disturbance
BCR-ABL inhibitors · 7
AsciminibHypertension (signature)Prerenal / Hemodynamic AKI
BosutinibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
DasatinibGlomerular Injury / Proteinuria (signature)
ImatinibAcute Tubular NecrosisElectrolyte Disturbance (signature)Fanconi Syndrome
NilotinibPrerenal / Hemodynamic AKI (signature)
OlverembatinibGlomerular Injury / Proteinuria (signature)HypertensionPrerenal / Hemodynamic AKIPseudo-AKI
PonatinibThrombotic MicroangiopathyHypertension (signature)Prerenal / Hemodynamic AKI
PI3K / AKT inhibitors · 7
AlpelisibAcute Tubular NecrosisElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
CapivasertibElectrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
CopanlisibHypertension (signature)
DuvelisibAcute Interstitial NephritisPrerenal / Hemodynamic AKI (signature)
GedatolisibElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
IdelalisibAcute Interstitial NephritisPrerenal / Hemodynamic AKI (signature)
InavolisibElectrolyte Disturbance (signature)
CAR-T cell therapy · 5
CAR-T cell therapyAcute Tubular NecrosisCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Ciltacabtagene autoleucelAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Idecabtagene vicleucelAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Lisocabtagene maraleucelAcute Tubular NecrosisElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
Obecabtagene autoleucel (Obe-cel)Electrolyte DisturbancePrerenal / Hemodynamic AKI (signature)
Cytokines & enzymes · 5
AsparaginasePrerenal / Hemodynamic AKI (signature)
Interferon-αThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)
Interleukin-2 (high-dose)Electrolyte DisturbancePrerenal / Hemodynamic AKI (signature)SIADH / Hyponatremia
PegaspargaseAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
TasonerminAcute Tubular NecrosisPrerenal / Hemodynamic AKI (signature)
Topoisomerase inhibitors · 5
AmsacrineElectrolyte Disturbance (signature)Crystal / Obstructive Nephropathy
EtoposideElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
IrinotecanPrerenal / Hemodynamic AKI (signature)
TeniposideElectrolyte Disturbance (signature)Prerenal / Hemodynamic AKI
TopotecanPrerenal / Hemodynamic AKI (signature)
Platinum agents · 4
CarboplatinAcute Tubular Necrosis (signature)Electrolyte DisturbanceSIADH / HyponatremiaHemorrhagic Cystitis
CisplatinAcute Tubular Necrosis (signature)Electrolyte DisturbanceFanconi SyndromePrerenal / Hemodynamic AKISIADH / HyponatremiaHemorrhagic Cystitis
NedaplatinAcute Tubular Necrosis (signature)Electrolyte Disturbance
OxaliplatinAcute Tubular NecrosisThrombotic Microangiopathy (signature)
mTOR inhibitors · 4
EverolimusThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)Electrolyte Disturbance
mTOR inhibitors (everolimus · temsirolimus)Acute Tubular NecrosisThrombotic MicroangiopathyGlomerular Injury / Proteinuria (signature)
SirolimusAcute Tubular NecrosisGlomerular Injury / Proteinuria (signature)
TemsirolimusGlomerular Injury / Proteinuria (signature)Electrolyte Disturbance
Bisphosphonates & bone · 4
DenosumabElectrolyte Disturbance (signature)
IbandronateAcute Tubular Necrosis (signature)Glomerular Injury / ProteinuriaElectrolyte Disturbance
PamidronateGlomerular Injury / Proteinuria (signature)
Zoledronic acidAcute Tubular Necrosis (signature)Fanconi Syndrome
FGFR inhibitors · 4
ErdafitinibElectrolyte Disturbance (signature)
FutibatinibElectrolyte Disturbance (signature)
InfigratinibElectrolyte Disturbance (signature)Crystal / Obstructive Nephropathy
PemigatinibElectrolyte Disturbance (signature)
BTK inhibitors · 4
AcalabrutinibCrystal / Obstructive NephropathyHypertension (signature)Prerenal / Hemodynamic AKI
IbrutinibAcute Tubular NecrosisAcute Interstitial NephritisGlomerular Injury / ProteinuriaHypertension (signature)Prerenal / Hemodynamic AKI
PirtobrutinibElectrolyte DisturbanceCrystal / Obstructive Nephropathy (signature)Prerenal / Hemodynamic AKI
ZanubrutinibElectrolyte DisturbanceCrystal / Obstructive NephropathyPrerenal / Hemodynamic AKI (signature)
CDK4/6 inhibitors · 3
AbemaciclibPrerenal / Hemodynamic AKIPseudo-AKI (signature)
PalbociclibElectrolyte DisturbancePrerenal / Hemodynamic AKIPseudo-AKI (signature)
RibociclibElectrolyte DisturbancePrerenal / Hemodynamic AKIPseudo-AKI (signature)

300 profiled agents × 14 injuries · tick = injury present · outlined tick = the agent's signature injury.

Figure 4·Every profiled agent as a row and the 14 kidney injuries as columns, grouped by class so each family's shared injury signature is visible.

Agents by their worst-case severity against whether the injury reverses. The severe × often-irreversible cell is the highest-stakes group.

Show:
raw agent counts, shaded across the whole grid
Number of profiled agents at each worst-case renal severity (rows) and reversibility outcome (columns).
Severity
Reversiblecolumn total: 204
Partially reversiblecolumn total: 39
Often irreversiblecolumn total: 6
Variablecolumn total: 43
Severe, row total 13
Severe, Reversible: 1 agent (8% of row)
Severe, Partially reversible: 5 agents (38% of row)
Severe, Often irreversible: 3 agents (23% of row)
Severe, Variable: 4 agents (31% of row)
Moderate, row total 136
Moderate, Reversible: 75 agents (55% of row)
Moderate, Partially reversible: 33 agents (24% of row)
Moderate, Often irreversible: 3 agents (2% of row)
Moderate, Variable: 25 agents (18% of row)
Mild, row total 143
Mild, Reversible: 128 agents (90% of row)
Mild, Partially reversible: 1 agent (1% of row)
Mild, Often irreversible: 0 agents (0% of row)
Mild, Variable: 14 agents (10% of row)

Agent counts per severity × reversibility · color depth scales within the grid · column totals above each outcome.

Figure 5·Every profiled agent cross-tabulated by worst-case renal severity (rows) and how the injury resolves (columns); the count fill scales within the grid.

For the agents carrying a specific renal dose action: which class family forces it, and whether the action is a CrCl-banded reduction or an outright avoid. The antimetabolites lead the reduce-by-CrCl column; radiopharmaceuticals and antibody-drug conjugates sit only under avoid.

Show:
raw agent counts, shaded across the whole grid
Agents needing a renal dose change, by class family (rows) and the prescribing action (columns).
Class family
Reduce dose by kidney functioncolumn total: 52
Avoid or contraindicated in impairmentcolumn total: 17
Dose calculated from GFRcolumn total: 1
Caution — no defined thresholdcolumn total: 6
Antimetabolites, row total 15
Antimetabolites, Reduce dose by kidney function: 10 agents (67% of row)
Antimetabolites, Avoid or contraindicated in impairment: 2 agents (13% of row)
Antimetabolites, Dose calculated from GFR: 0 agents (0% of row)
Antimetabolites, Caution — no defined threshold: 3 agents (20% of row)
Other targeted agents, row total 10
Other targeted agents, Reduce dose by kidney function: 6 agents (60% of row)
Other targeted agents, Avoid or contraindicated in impairment: 1 agent (10% of row)
Other targeted agents, Dose calculated from GFR: 0 agents (0% of row)
Other targeted agents, Caution — no defined threshold: 3 agents (30% of row)
Alkylating agents, row total 8
Alkylating agents, Reduce dose by kidney function: 5 agents (63% of row)
Alkylating agents, Avoid or contraindicated in impairment: 3 agents (38% of row)
Alkylating agents, Dose calculated from GFR: 0 agents (0% of row)
Alkylating agents, Caution — no defined threshold: 0 agents (0% of row)
Antitumor antibiotics, row total 4
Antitumor antibiotics, Reduce dose by kidney function: 2 agents (50% of row)
Antitumor antibiotics, Avoid or contraindicated in impairment: 2 agents (50% of row)
Antitumor antibiotics, Dose calculated from GFR: 0 agents (0% of row)
Antitumor antibiotics, Caution — no defined threshold: 0 agents (0% of row)
Hormonal / endocrine, row total 4
Hormonal / endocrine, Reduce dose by kidney function: 3 agents (75% of row)
Hormonal / endocrine, Avoid or contraindicated in impairment: 1 agent (25% of row)
Hormonal / endocrine, Dose calculated from GFR: 0 agents (0% of row)
Hormonal / endocrine, Caution — no defined threshold: 0 agents (0% of row)
Other kinase inhibitors, row total 4
Other kinase inhibitors, Reduce dose by kidney function: 3 agents (75% of row)
Other kinase inhibitors, Avoid or contraindicated in impairment: 1 agent (25% of row)
Other kinase inhibitors, Dose calculated from GFR: 0 agents (0% of row)
Other kinase inhibitors, Caution — no defined threshold: 0 agents (0% of row)
Platinum agents, row total 4
Platinum agents, Reduce dose by kidney function: 3 agents (75% of row)
Platinum agents, Avoid or contraindicated in impairment: 0 agents (0% of row)
Platinum agents, Dose calculated from GFR: 1 agent (25% of row)
Platinum agents, Caution — no defined threshold: 0 agents (0% of row)
Topoisomerase inhibitors, row total 4
Topoisomerase inhibitors, Reduce dose by kidney function: 3 agents (75% of row)
Topoisomerase inhibitors, Avoid or contraindicated in impairment: 1 agent (25% of row)
Topoisomerase inhibitors, Dose calculated from GFR: 0 agents (0% of row)
Topoisomerase inhibitors, Caution — no defined threshold: 0 agents (0% of row)
ALK / ROS1 / MET / TRK inhibitors, row total 3
ALK / ROS1 / MET / TRK inhibitors, Reduce dose by kidney function: 3 agents (100% of row)
ALK / ROS1 / MET / TRK inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
ALK / ROS1 / MET / TRK inhibitors, Dose calculated from GFR: 0 agents (0% of row)
ALK / ROS1 / MET / TRK inhibitors, Caution — no defined threshold: 0 agents (0% of row)
Bisphosphonates & bone, row total 3
Bisphosphonates & bone, Reduce dose by kidney function: 2 agents (67% of row)
Bisphosphonates & bone, Avoid or contraindicated in impairment: 1 agent (33% of row)
Bisphosphonates & bone, Dose calculated from GFR: 0 agents (0% of row)
Bisphosphonates & bone, Caution — no defined threshold: 0 agents (0% of row)
Anti-angiogenic (VEGF), row total 2
Anti-angiogenic (VEGF), Reduce dose by kidney function: 2 agents (100% of row)
Anti-angiogenic (VEGF), Avoid or contraindicated in impairment: 0 agents (0% of row)
Anti-angiogenic (VEGF), Dose calculated from GFR: 0 agents (0% of row)
Anti-angiogenic (VEGF), Caution — no defined threshold: 0 agents (0% of row)
BCR-ABL inhibitors, row total 2
BCR-ABL inhibitors, Reduce dose by kidney function: 2 agents (100% of row)
BCR-ABL inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
BCR-ABL inhibitors, Dose calculated from GFR: 0 agents (0% of row)
BCR-ABL inhibitors, Caution — no defined threshold: 0 agents (0% of row)
Cytokines & enzymes, row total 2
Cytokines & enzymes, Reduce dose by kidney function: 1 agent (50% of row)
Cytokines & enzymes, Avoid or contraindicated in impairment: 1 agent (50% of row)
Cytokines & enzymes, Dose calculated from GFR: 0 agents (0% of row)
Cytokines & enzymes, Caution — no defined threshold: 0 agents (0% of row)
EGFR / HER2 inhibitors, row total 2
EGFR / HER2 inhibitors, Reduce dose by kidney function: 1 agent (50% of row)
EGFR / HER2 inhibitors, Avoid or contraindicated in impairment: 1 agent (50% of row)
EGFR / HER2 inhibitors, Dose calculated from GFR: 0 agents (0% of row)
EGFR / HER2 inhibitors, Caution — no defined threshold: 0 agents (0% of row)
Microtubule inhibitors, row total 2
Microtubule inhibitors, Reduce dose by kidney function: 2 agents (100% of row)
Microtubule inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
Microtubule inhibitors, Dose calculated from GFR: 0 agents (0% of row)
Microtubule inhibitors, Caution — no defined threshold: 0 agents (0% of row)
Radiopharmaceuticals, row total 2
Radiopharmaceuticals, Reduce dose by kidney function: 0 agents (0% of row)
Radiopharmaceuticals, Avoid or contraindicated in impairment: 2 agents (100% of row)
Radiopharmaceuticals, Dose calculated from GFR: 0 agents (0% of row)
Radiopharmaceuticals, Caution — no defined threshold: 0 agents (0% of row)
Antibody-drug conjugates, row total 1
Antibody-drug conjugates, Reduce dose by kidney function: 0 agents (0% of row)
Antibody-drug conjugates, Avoid or contraindicated in impairment: 1 agent (100% of row)
Antibody-drug conjugates, Dose calculated from GFR: 0 agents (0% of row)
Antibody-drug conjugates, Caution — no defined threshold: 0 agents (0% of row)
BTK inhibitors, row total 1
BTK inhibitors, Reduce dose by kidney function: 1 agent (100% of row)
BTK inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
BTK inhibitors, Dose calculated from GFR: 0 agents (0% of row)
BTK inhibitors, Caution — no defined threshold: 0 agents (0% of row)
CDK4/6 inhibitors, row total 1
CDK4/6 inhibitors, Reduce dose by kidney function: 1 agent (100% of row)
CDK4/6 inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
CDK4/6 inhibitors, Dose calculated from GFR: 0 agents (0% of row)
CDK4/6 inhibitors, Caution — no defined threshold: 0 agents (0% of row)
FGFR inhibitors, row total 1
FGFR inhibitors, Reduce dose by kidney function: 1 agent (100% of row)
FGFR inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
FGFR inhibitors, Dose calculated from GFR: 0 agents (0% of row)
FGFR inhibitors, Caution — no defined threshold: 0 agents (0% of row)
PI3K / AKT inhibitors, row total 1
PI3K / AKT inhibitors, Reduce dose by kidney function: 1 agent (100% of row)
PI3K / AKT inhibitors, Avoid or contraindicated in impairment: 0 agents (0% of row)
PI3K / AKT inhibitors, Dose calculated from GFR: 0 agents (0% of row)
PI3K / AKT inhibitors, Caution — no defined threshold: 0 agents (0% of row)

Counts the agents FLAGGED as needing a renal change (not all 292) · each agent carries exactly one action and one family, so it lands in one cell · color depth scales within the grid · column totals above each action. Source: renal-dose-adjustments, verified against FDA labels.

Figure 6·For the agents flagged as needing a renal dose change, which drug-class families most often force which prescribing action in reduced kidney function.

Anatomy & mechanism

Where in the nephron the damage lands.

Where each drug class strikes the nephron. Rows are class families, columns are nephron segments; a cell's depth of color is how many agents in that class the catalog files under that segment (each agent is bucketed into one primary segment). Most agents whose signature is prerenal or hemodynamic AKI, which injures no segment structurally, are filed under the vasculature, so that column mixes endothelial injury with perfusion risk. Read down a column for the agents filed under one structure, across a row for a class's anatomical footprint.

Number of anti-cancer agents in each drug-class family (rows) filed under each nephron segment (columns) — the catalog's primary segment; most prerenal agents are filed under the vasculature.
Drug class family
Glomeruluscolumn total: 25
Vasculature / Endotheliumcolumn total: 137
Proximal Tubulecolumn total: 60
Distal Tubule / Collecting Ductcolumn total: 28
Interstitiumcolumn total: 23
Tubular Lumencolumn total: 18
Bladder / Urotheliumcolumn total: 1
Other targeted agents
Other targeted agents, Glomerulus: 0 agents
Other targeted agents, Vasculature / Endothelium: 27 agents
Other targeted agents, Proximal Tubule: 9 agents
Other targeted agents, Distal Tubule / Collecting Duct: 3 agents
Other targeted agents, Interstitium: 0 agents
Other targeted agents, Tubular Lumen: 2 agents
Other targeted agents, Bladder / Urothelium: 0 agents
Alkylating agents
Alkylating agents, Glomerulus: 0 agents
Alkylating agents, Vasculature / Endothelium: 4 agents
Alkylating agents, Proximal Tubule: 7 agents
Alkylating agents, Distal Tubule / Collecting Duct: 4 agents
Alkylating agents, Interstitium: 4 agents
Alkylating agents, Tubular Lumen: 1 agent
Alkylating agents, Bladder / Urothelium: 1 agent
Antimetabolites
Antimetabolites, Glomerulus: 0 agents
Antimetabolites, Vasculature / Endothelium: 9 agents
Antimetabolites, Proximal Tubule: 3 agents
Antimetabolites, Distal Tubule / Collecting Duct: 0 agents
Antimetabolites, Interstitium: 1 agent
Antimetabolites, Tubular Lumen: 7 agents
Antimetabolites, Bladder / Urothelium: 0 agents
Checkpoint inhibitors
Checkpoint inhibitors, Glomerulus: 1 agent
Checkpoint inhibitors, Vasculature / Endothelium: 0 agents
Checkpoint inhibitors, Proximal Tubule: 0 agents
Checkpoint inhibitors, Distal Tubule / Collecting Duct: 0 agents
Checkpoint inhibitors, Interstitium: 16 agents
Checkpoint inhibitors, Tubular Lumen: 0 agents
Checkpoint inhibitors, Bladder / Urothelium: 0 agents
Monoclonal antibodies (other)
Monoclonal antibodies (other), Glomerulus: 0 agents
Monoclonal antibodies (other), Vasculature / Endothelium: 10 agents
Monoclonal antibodies (other), Proximal Tubule: 0 agents
Monoclonal antibodies (other), Distal Tubule / Collecting Duct: 4 agents
Monoclonal antibodies (other), Interstitium: 0 agents
Monoclonal antibodies (other), Tubular Lumen: 2 agents
Monoclonal antibodies (other), Bladder / Urothelium: 0 agents
Anti-angiogenic (VEGF)
Anti-angiogenic (VEGF), Glomerulus: 11 agents
Anti-angiogenic (VEGF), Vasculature / Endothelium: 4 agents
Anti-angiogenic (VEGF), Proximal Tubule: 0 agents
Anti-angiogenic (VEGF), Distal Tubule / Collecting Duct: 0 agents
Anti-angiogenic (VEGF), Interstitium: 0 agents
Anti-angiogenic (VEGF), Tubular Lumen: 0 agents
Anti-angiogenic (VEGF), Bladder / Urothelium: 0 agents
Antibody-drug conjugates
Antibody-drug conjugates, Glomerulus: 1 agent
Antibody-drug conjugates, Vasculature / Endothelium: 10 agents
Antibody-drug conjugates, Proximal Tubule: 4 agents
Antibody-drug conjugates, Distal Tubule / Collecting Duct: 0 agents
Antibody-drug conjugates, Interstitium: 0 agents
Antibody-drug conjugates, Tubular Lumen: 0 agents
Antibody-drug conjugates, Bladder / Urothelium: 0 agents
Hormonal / endocrine
Hormonal / endocrine, Glomerulus: 0 agents
Hormonal / endocrine, Vasculature / Endothelium: 5 agents
Hormonal / endocrine, Proximal Tubule: 1 agent
Hormonal / endocrine, Distal Tubule / Collecting Duct: 6 agents
Hormonal / endocrine, Interstitium: 1 agent
Hormonal / endocrine, Tubular Lumen: 0 agents
Hormonal / endocrine, Bladder / Urothelium: 0 agents
ALK / ROS1 / MET / TRK inhibitors
ALK / ROS1 / MET / TRK inhibitors, Glomerulus: 0 agents
ALK / ROS1 / MET / TRK inhibitors, Vasculature / Endothelium: 5 agents
ALK / ROS1 / MET / TRK inhibitors, Proximal Tubule: 8 agents
ALK / ROS1 / MET / TRK inhibitors, Distal Tubule / Collecting Duct: 0 agents
ALK / ROS1 / MET / TRK inhibitors, Interstitium: 0 agents
ALK / ROS1 / MET / TRK inhibitors, Tubular Lumen: 0 agents
ALK / ROS1 / MET / TRK inhibitors, Bladder / Urothelium: 0 agents
Other kinase inhibitors
Other kinase inhibitors, Glomerulus: 0 agents
Other kinase inhibitors, Vasculature / Endothelium: 11 agents
Other kinase inhibitors, Proximal Tubule: 1 agent
Other kinase inhibitors, Distal Tubule / Collecting Duct: 1 agent
Other kinase inhibitors, Interstitium: 0 agents
Other kinase inhibitors, Tubular Lumen: 0 agents
Other kinase inhibitors, Bladder / Urothelium: 0 agents
Bispecifics / T-cell engagers
Bispecifics / T-cell engagers, Glomerulus: 0 agents
Bispecifics / T-cell engagers, Vasculature / Endothelium: 11 agents
Bispecifics / T-cell engagers, Proximal Tubule: 0 agents
Bispecifics / T-cell engagers, Distal Tubule / Collecting Duct: 0 agents
Bispecifics / T-cell engagers, Interstitium: 0 agents
Bispecifics / T-cell engagers, Tubular Lumen: 1 agent
Bispecifics / T-cell engagers, Bladder / Urothelium: 0 agents
EGFR / HER2 inhibitors
EGFR / HER2 inhibitors, Glomerulus: 2 agents
EGFR / HER2 inhibitors, Vasculature / Endothelium: 4 agents
EGFR / HER2 inhibitors, Proximal Tubule: 2 agents
EGFR / HER2 inhibitors, Distal Tubule / Collecting Duct: 3 agents
EGFR / HER2 inhibitors, Interstitium: 0 agents
EGFR / HER2 inhibitors, Tubular Lumen: 0 agents
EGFR / HER2 inhibitors, Bladder / Urothelium: 0 agents
BRAF / MEK inhibitors
BRAF / MEK inhibitors, Glomerulus: 0 agents
BRAF / MEK inhibitors, Vasculature / Endothelium: 4 agents
BRAF / MEK inhibitors, Proximal Tubule: 6 agents
BRAF / MEK inhibitors, Distal Tubule / Collecting Duct: 0 agents
BRAF / MEK inhibitors, Interstitium: 1 agent
BRAF / MEK inhibitors, Tubular Lumen: 0 agents
BRAF / MEK inhibitors, Bladder / Urothelium: 0 agents
Microtubule inhibitors
Microtubule inhibitors, Glomerulus: 0 agents
Microtubule inhibitors, Vasculature / Endothelium: 4 agents
Microtubule inhibitors, Proximal Tubule: 0 agents
Microtubule inhibitors, Distal Tubule / Collecting Duct: 4 agents
Microtubule inhibitors, Interstitium: 0 agents
Microtubule inhibitors, Tubular Lumen: 0 agents
Microtubule inhibitors, Bladder / Urothelium: 0 agents
Antitumor antibiotics
Antitumor antibiotics, Glomerulus: 1 agent
Antitumor antibiotics, Vasculature / Endothelium: 1 agent
Antitumor antibiotics, Proximal Tubule: 2 agents
Antitumor antibiotics, Distal Tubule / Collecting Duct: 0 agents
Antitumor antibiotics, Interstitium: 0 agents
Antitumor antibiotics, Tubular Lumen: 3 agents
Antitumor antibiotics, Bladder / Urothelium: 0 agents
BCR-ABL inhibitors
BCR-ABL inhibitors, Glomerulus: 2 agents
BCR-ABL inhibitors, Vasculature / Endothelium: 4 agents
BCR-ABL inhibitors, Proximal Tubule: 1 agent
BCR-ABL inhibitors, Distal Tubule / Collecting Duct: 0 agents
BCR-ABL inhibitors, Interstitium: 0 agents
BCR-ABL inhibitors, Tubular Lumen: 0 agents
BCR-ABL inhibitors, Bladder / Urothelium: 0 agents
PI3K / AKT inhibitors
PI3K / AKT inhibitors, Glomerulus: 0 agents
PI3K / AKT inhibitors, Vasculature / Endothelium: 5 agents
PI3K / AKT inhibitors, Proximal Tubule: 0 agents
PI3K / AKT inhibitors, Distal Tubule / Collecting Duct: 2 agents
PI3K / AKT inhibitors, Interstitium: 0 agents
PI3K / AKT inhibitors, Tubular Lumen: 0 agents
PI3K / AKT inhibitors, Bladder / Urothelium: 0 agents
Radiopharmaceuticals
Radiopharmaceuticals, Glomerulus: 1 agent
Radiopharmaceuticals, Vasculature / Endothelium: 3 agents
Radiopharmaceuticals, Proximal Tubule: 3 agents
Radiopharmaceuticals, Distal Tubule / Collecting Duct: 0 agents
Radiopharmaceuticals, Interstitium: 0 agents
Radiopharmaceuticals, Tubular Lumen: 0 agents
Radiopharmaceuticals, Bladder / Urothelium: 0 agents
CAR-T cell therapy
CAR-T cell therapy, Glomerulus: 0 agents
CAR-T cell therapy, Vasculature / Endothelium: 5 agents
CAR-T cell therapy, Proximal Tubule: 0 agents
CAR-T cell therapy, Distal Tubule / Collecting Duct: 0 agents
CAR-T cell therapy, Interstitium: 0 agents
CAR-T cell therapy, Tubular Lumen: 0 agents
CAR-T cell therapy, Bladder / Urothelium: 0 agents
Topoisomerase inhibitors
Topoisomerase inhibitors, Glomerulus: 0 agents
Topoisomerase inhibitors, Vasculature / Endothelium: 2 agents
Topoisomerase inhibitors, Proximal Tubule: 1 agent
Topoisomerase inhibitors, Distal Tubule / Collecting Duct: 0 agents
Topoisomerase inhibitors, Interstitium: 0 agents
Topoisomerase inhibitors, Tubular Lumen: 2 agents
Topoisomerase inhibitors, Bladder / Urothelium: 0 agents
Cytokines & enzymes
Cytokines & enzymes, Glomerulus: 1 agent
Cytokines & enzymes, Vasculature / Endothelium: 4 agents
Cytokines & enzymes, Proximal Tubule: 0 agents
Cytokines & enzymes, Distal Tubule / Collecting Duct: 0 agents
Cytokines & enzymes, Interstitium: 0 agents
Cytokines & enzymes, Tubular Lumen: 0 agents
Cytokines & enzymes, Bladder / Urothelium: 0 agents
Platinum agents
Platinum agents, Glomerulus: 0 agents
Platinum agents, Vasculature / Endothelium: 0 agents
Platinum agents, Proximal Tubule: 4 agents
Platinum agents, Distal Tubule / Collecting Duct: 0 agents
Platinum agents, Interstitium: 0 agents
Platinum agents, Tubular Lumen: 0 agents
Platinum agents, Bladder / Urothelium: 0 agents
mTOR inhibitors
mTOR inhibitors, Glomerulus: 4 agents
mTOR inhibitors, Vasculature / Endothelium: 0 agents
mTOR inhibitors, Proximal Tubule: 0 agents
mTOR inhibitors, Distal Tubule / Collecting Duct: 0 agents
mTOR inhibitors, Interstitium: 0 agents
mTOR inhibitors, Tubular Lumen: 0 agents
mTOR inhibitors, Bladder / Urothelium: 0 agents
FGFR inhibitors
FGFR inhibitors, Glomerulus: 0 agents
FGFR inhibitors, Vasculature / Endothelium: 0 agents
FGFR inhibitors, Proximal Tubule: 4 agents
FGFR inhibitors, Distal Tubule / Collecting Duct: 0 agents
FGFR inhibitors, Interstitium: 0 agents
FGFR inhibitors, Tubular Lumen: 0 agents
FGFR inhibitors, Bladder / Urothelium: 0 agents
BTK inhibitors
BTK inhibitors, Glomerulus: 0 agents
BTK inhibitors, Vasculature / Endothelium: 4 agents
BTK inhibitors, Proximal Tubule: 0 agents
BTK inhibitors, Distal Tubule / Collecting Duct: 0 agents
BTK inhibitors, Interstitium: 0 agents
BTK inhibitors, Tubular Lumen: 0 agents
BTK inhibitors, Bladder / Urothelium: 0 agents
Bisphosphonates & bone
Bisphosphonates & bone, Glomerulus: 1 agent
Bisphosphonates & bone, Vasculature / Endothelium: 0 agents
Bisphosphonates & bone, Proximal Tubule: 2 agents
Bisphosphonates & bone, Distal Tubule / Collecting Duct: 1 agent
Bisphosphonates & bone, Interstitium: 0 agents
Bisphosphonates & bone, Tubular Lumen: 0 agents
Bisphosphonates & bone, Bladder / Urothelium: 0 agents
CDK4/6 inhibitors
CDK4/6 inhibitors, Glomerulus: 0 agents
CDK4/6 inhibitors, Vasculature / Endothelium: 1 agent
CDK4/6 inhibitors, Proximal Tubule: 2 agents
CDK4/6 inhibitors, Distal Tubule / Collecting Duct: 0 agents
CDK4/6 inhibitors, Interstitium: 0 agents
CDK4/6 inhibitors, Tubular Lumen: 0 agents
CDK4/6 inhibitors, Bladder / Urothelium: 0 agents

Cell depth scales to the per-grid maximum; column totals sum each segment.

Figure 7·Agent counts per drug-class family × nephron segment — the anatomy of class-level renal risk in one grid.

Which nephron structures absorb the most damage. Each ribbon groups agents by their signature injury (left) and carries them to every nephron segment those agents strike (right); ribbon width = agent count. The tallest right-hand nodes are the structures the catalog injures most — hover or tap a node to isolate its flows. A ribbon links an agent group to an anatomy, not a lesion to a segment: an agent's segments cover all of its injuries, so ifosfamide's cystitis reaches the bladder under its Fanconi signature.

  • Acute Tubular Necrosis → Glomerulus: 1 agents
  • Acute Tubular Necrosis → Vasculature / Endothelium: 3 agents
  • Acute Tubular Necrosis → Proximal Tubule: 26 agents
  • Acute Tubular Necrosis → Distal Tubule / Collecting Duct: 2 agents
  • Acute Tubular Necrosis → Interstitium: 8 agents
  • Acute Tubular Necrosis → Tubular Lumen: 6 agents
  • Acute Interstitial Nephritis → Glomerulus: 13 agents
  • Acute Interstitial Nephritis → Vasculature / Endothelium: 1 agents
  • Acute Interstitial Nephritis → Proximal Tubule: 4 agents
  • Acute Interstitial Nephritis → Distal Tubule / Collecting Duct: 6 agents
  • Acute Interstitial Nephritis → Interstitium: 18 agents
  • Thrombotic Microangiopathy → Glomerulus: 7 agents
  • Thrombotic Microangiopathy → Vasculature / Endothelium: 13 agents
  • Thrombotic Microangiopathy → Proximal Tubule: 1 agents
  • Glomerular Injury / Proteinuria → Glomerulus: 15 agents
  • Glomerular Injury / Proteinuria → Vasculature / Endothelium: 6 agents
  • Glomerular Injury / Proteinuria → Proximal Tubule: 5 agents
  • Glomerular Injury / Proteinuria → Interstitium: 1 agents
  • Electrolyte Disturbance → Vasculature / Endothelium: 10 agents
  • Electrolyte Disturbance → Proximal Tubule: 10 agents
  • Electrolyte Disturbance → Distal Tubule / Collecting Duct: 18 agents
  • Electrolyte Disturbance → Tubular Lumen: 4 agents
  • Fanconi Syndrome → Proximal Tubule: 3 agents
  • Fanconi Syndrome → Distal Tubule / Collecting Duct: 1 agents
  • Fanconi Syndrome → Bladder / Urothelium: 1 agents
  • Crystal / Obstructive Nephropathy → Vasculature / Endothelium: 14 agents
  • Crystal / Obstructive Nephropathy → Proximal Tubule: 6 agents
  • Crystal / Obstructive Nephropathy → Distal Tubule / Collecting Duct: 2 agents
  • Crystal / Obstructive Nephropathy → Tubular Lumen: 18 agents
  • Hypertension → Glomerulus: 14 agents
  • Hypertension → Vasculature / Endothelium: 23 agents
  • Hypertension → Proximal Tubule: 3 agents
  • Hypertension → Interstitium: 1 agents
  • Prerenal / Hemodynamic AKI → Glomerulus: 6 agents
  • Prerenal / Hemodynamic AKI → Vasculature / Endothelium: 101 agents
  • Prerenal / Hemodynamic AKI → Proximal Tubule: 23 agents
  • Prerenal / Hemodynamic AKI → Distal Tubule / Collecting Duct: 6 agents
  • Prerenal / Hemodynamic AKI → Interstitium: 3 agents
  • Prerenal / Hemodynamic AKI → Tubular Lumen: 16 agents
  • SIADH / Hyponatremia → Vasculature / Endothelium: 1 agents
  • SIADH / Hyponatremia → Proximal Tubule: 1 agents
  • SIADH / Hyponatremia → Distal Tubule / Collecting Duct: 12 agents
  • SIADH / Hyponatremia → Bladder / Urothelium: 1 agents
  • Hemorrhagic Cystitis → Bladder / Urothelium: 1 agents
  • Pseudo-AKI → Vasculature / Endothelium: 11 agents
  • Pseudo-AKI → Proximal Tubule: 23 agents
  • Renal Cysts → Proximal Tubule: 1 agents
  • Chronic Interstitial Nephropathy → Glomerulus: 1 agents
  • Chronic Interstitial Nephropathy → Vasculature / Endothelium: 1 agents
  • Chronic Interstitial Nephropathy → Proximal Tubule: 5 agents
  • Chronic Interstitial Nephropathy → Interstitium: 7 agents
Acute Tubular Necrosis → Proximal Tubule: 26 agentsAcute Tubular Necrosis → Distal Tubule / Collecting Duct: 2 agentsAcute Tubular Necrosis → Vasculature / Endothelium: 3 agentsAcute Tubular Necrosis → Interstitium: 8 agentsAcute Tubular Necrosis → Tubular Lumen: 6 agentsAcute Tubular Necrosis → Glomerulus: 1 agentsAcute Interstitial Nephritis → Interstitium: 18 agentsAcute Interstitial Nephritis → Glomerulus: 13 agentsAcute Interstitial Nephritis → Distal Tubule / Collecting Duct: 6 agentsAcute Interstitial Nephritis → Proximal Tubule: 4 agentsAcute Interstitial Nephritis → Vasculature / Endothelium: 1 agentsThrombotic Microangiopathy → Vasculature / Endothelium: 13 agentsThrombotic Microangiopathy → Proximal Tubule: 1 agentsThrombotic Microangiopathy → Glomerulus: 7 agentsGlomerular Injury / Proteinuria → Glomerulus: 15 agentsGlomerular Injury / Proteinuria → Vasculature / Endothelium: 6 agentsGlomerular Injury / Proteinuria → Proximal Tubule: 5 agentsGlomerular Injury / Proteinuria → Interstitium: 1 agentsElectrolyte Disturbance → Distal Tubule / Collecting Duct: 18 agentsElectrolyte Disturbance → Proximal Tubule: 10 agentsElectrolyte Disturbance → Vasculature / Endothelium: 10 agentsElectrolyte Disturbance → Tubular Lumen: 4 agentsFanconi Syndrome → Proximal Tubule: 3 agentsFanconi Syndrome → Distal Tubule / Collecting Duct: 1 agentsFanconi Syndrome → Bladder / Urothelium: 1 agentsCrystal / Obstructive Nephropathy → Proximal Tubule: 6 agentsCrystal / Obstructive Nephropathy → Tubular Lumen: 18 agentsCrystal / Obstructive Nephropathy → Vasculature / Endothelium: 14 agentsCrystal / Obstructive Nephropathy → Distal Tubule / Collecting Duct: 2 agentsHypertension → Glomerulus: 14 agentsHypertension → Vasculature / Endothelium: 23 agentsHypertension → Proximal Tubule: 3 agentsHypertension → Interstitium: 1 agentsPrerenal / Hemodynamic AKI → Vasculature / Endothelium: 101 agentsPrerenal / Hemodynamic AKI → Proximal Tubule: 23 agentsPrerenal / Hemodynamic AKI → Tubular Lumen: 16 agentsPrerenal / Hemodynamic AKI → Glomerulus: 6 agentsPrerenal / Hemodynamic AKI → Distal Tubule / Collecting Duct: 6 agentsPrerenal / Hemodynamic AKI → Interstitium: 3 agentsSIADH / Hyponatremia → Distal Tubule / Collecting Duct: 12 agentsSIADH / Hyponatremia → Bladder / Urothelium: 1 agentsSIADH / Hyponatremia → Proximal Tubule: 1 agentsSIADH / Hyponatremia → Vasculature / Endothelium: 1 agentsHemorrhagic Cystitis → Bladder / Urothelium: 1 agentsPseudo-AKI → Vasculature / Endothelium: 11 agentsPseudo-AKI → Proximal Tubule: 23 agentsRenal Cysts → Proximal Tubule: 1 agentsChronic Interstitial Nephropathy → Proximal Tubule: 5 agentsChronic Interstitial Nephropathy → Interstitium: 7 agentsChronic Interstitial Nephropathy → Vasculature / Endothelium: 1 agentsChronic Interstitial Nephropathy → Glomerulus: 1 agentsAcute Tubular NecrosisAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceFanconi SyndromeCrystal / Obstructive NephropathyHypertensionPrerenal / Hemodynamic AKISIADH / HyponatremiaHemorrhagic CystitisPseudo-AKIRenal CystsChronic Interstitial NephropathyGlomerulusVasculature / EndotheliumProximal TubuleDistal Tubule / Collecting DuctInterstitiumTubular LumenBladder / Urothelium

Ribbon width = agents whose signature injury strikes that segment · left node height = agent-incidences per injury (an agent striking several segments counts in each) · right node height = total agent-incidences per segment.

Figure 8·Agents grouped by signature kidney injury (left), flowing to every nephron segment those agents strike (right); ribbon width is the number of agents. The tallest right-hand nodes are the structures the catalog injures most — the vasculature/endothelium leads, then the proximal tubule, with the glomerulus third. A ribbon is an agent-level association: an agent's segments span all of its injuries, not only its signature.

Evidence & literature

How the evidence base grew, how deep it runs, and who built it.

Every citation record placed by its publication year and its citing drug's signature kidney injury — a reference shared across agents counts once per agent. Band composition shows the field's focus shifting: platinum tubular injury, then anti-VEGF vascular disease, then checkpoint-inhibitor interstitial nephritis. Hover a year; click a band to isolate an injury.

Hemorrhagic CystitisFanconi SyndromeSIADH / HyponatremiaGlomerular Injury / ProteinuriaPseudo-AKIElectrolyte DisturbanceAcute Tubular NecrosisPrerenal / Hemodynamic AKIHypertensionAcute Interstitial NephritisCrystal / Obstructive NephropathyThrombotic MicroangiopathyChronic Interstitial NephropathyRenal Cysts19801990200020102020

53 years · each citation counted once per citing agent · band thickness = citation records that year

  • 1974: 1 citation records
  • 1975: 0 citation records
  • 1976: 0 citation records
  • 1977: 2 citation records
  • 1978: 0 citation records
  • 1979: 2 citation records
  • 1980: 3 citation records
  • 1981: 4 citation records
  • 1982: 2 citation records
  • 1983: 7 citation records
  • 1984: 2 citation records
  • 1985: 9 citation records
  • 1986: 3 citation records
  • 1987: 5 citation records
  • 1988: 6 citation records
  • 1989: 6 citation records
  • 1990: 5 citation records
  • 1991: 12 citation records
  • 1992: 5 citation records
  • 1993: 10 citation records
  • 1994: 5 citation records
  • 1995: 12 citation records
  • 1996: 7 citation records
  • 1997: 7 citation records
  • 1998: 14 citation records
  • 1999: 10 citation records
  • 2000: 4 citation records
  • 2001: 29 citation records
  • 2002: 17 citation records
  • 2003: 17 citation records
  • 2004: 11 citation records
  • 2005: 21 citation records
  • 2006: 13 citation records
  • 2007: 21 citation records
  • 2008: 35 citation records
  • 2009: 19 citation records
  • 2010: 37 citation records
  • 2011: 40 citation records
  • 2012: 17 citation records
  • 2013: 35 citation records
  • 2014: 49 citation records
  • 2015: 84 citation records
  • 2016: 71 citation records
  • 2017: 104 citation records
  • 2018: 95 citation records
  • 2019: 88 citation records
  • 2020: 157 citation records
  • 2021: 221 citation records
  • 2022: 166 citation records
  • 2023: 165 citation records
  • 2024: 223 citation records
  • 2025: 207 citation records
  • 2026: 85 citation records
Figure 9·Evidence over CALENDAR time: citation records per publication year (a reference shared across agents counts once per agent), stacked by the citing drug's signature injury — the volume and shifting focus of what the literature is paying attention to (the era alluvial is the complementary agent-count view by drug era).

From approval (hollow) to the earliest reference the atlas cites (filled). The bar is how far the curated evidence trails approval, not when the kidney signal first appeared: the atlas favors recent trials and reviews, so an agent whose nephrotoxicity was known at approval can still draw a long bar.

19501960197019801990200020102020MechlorethamineMechlorethamine: approved 1949, first atlas citation 2011 (62-yr lag) · Electrolyte Disturbance · Alkylating agents62yMethotrexate…Methotrexate (high-dose)Methotrexate (high-dose): approved 1953, first atlas citation 2010 (57-yr lag) · Crystal / Obstructive Nephropathy · Antimetabolites57yBusulfanBusulfan: approved 1954, first atlas citation 2001 (47-yr lag) · Thrombotic Microangiopathy · Alkylating agents47yMitotaneMitotane: approved 1970, first atlas citation 2017 (47-yr lag) · Electrolyte Disturbance · Hormonal / endocrine47yChlorambucilChlorambucil: approved 1957, first atlas citation 1999 (42-yr lag) · SIADH / Hyponatremia · Alkylating agents42yThiotepaThiotepa: approved 1959, first atlas citation 1998 (39-yr lag) · Hemorrhagic Cystitis · Alkylating agents39yVincristineVincristine: approved 1963, first atlas citation 2002 (39-yr lag) · SIADH / Hyponatremia · Microtubule inhibitors39yHydroxyureaHydroxyurea: approved 1967, first atlas citation 2003 (36-yr lag) · Crystal / Obstructive Nephropathy · Antimetabolites36yDactinomycin…Dactinomycin (actinomycin D)Dactinomycin (actinomycin D): approved 1964, first atlas citation 1996 (32-yr lag) · Electrolyte Disturbance · Antitumor antibiotics32yTamoxifenTamoxifen: approved 1977, first atlas citation 2006 (29-yr lag) · SIADH / Hyponatremia · Hormonal / endocrine29y5-Fluorouracil5-Fluorouracil: approved 1962, first atlas citation 1987 (25-yr lag) · Thrombotic Microangiopathy · Antimetabolites25yIrinotecanIrinotecan: approved 1996, first atlas citation 2020 (24-yr lag) · Prerenal / Hemodynamic AKI · Topoisomerase inhibitors24yPaclitaxelPaclitaxel: approved 1992, first atlas citation 2015 (23-yr lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors23yLeuprolideLeuprolide: approved 1985, first atlas citation 2007 (22-yr lag) · Hypertension · Hormonal / endocrine22yMelphalanMelphalan: approved 1964, first atlas citation 1985 (21-yr lag) · SIADH / Hyponatremia · Alkylating agents21yCisplatinCisplatin: approved 1978, first atlas citation 1998 (20-yr lag) · Acute Tubular Necrosis · Platinum agents20yTopotecanTopotecan: approved 1996, first atlas citation 2015 (19-yr lag) · Prerenal / Hemodynamic AKI · Topoisomerase inhibitors19yDoxorubicinDoxorubicin: approved 1974, first atlas citation 1991 (17-yr lag) · Glomerular Injury / Proteinuria · Antitumor antibiotics17yCyclophosphamideCyclophosphamide: approved 1959, first atlas citation 1974 (15-yr lag) · SIADH / Hyponatremia · Alkylating agents15yDacarbazineDacarbazine: approved 1975, first atlas citation 1990 (15-yr lag) · Prerenal / Hemodynamic AKI · Alkylating agents15yVinblastineVinblastine: approved 1965, first atlas citation 1980 (15-yr lag) · SIADH / Hyponatremia · Microtubule inhibitors15yDocetaxelDocetaxel: approved 1996, first atlas citation 2010 (14-yr lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors14yProcarbazineProcarbazine: approved 1969, first atlas citation 1983 (14-yr lag) · Acute Tubular Necrosis · Alkylating agents14yPlicamycin…Plicamycin (mithramycin)Plicamycin (mithramycin): approved 1970, first atlas citation 1983 (13-yr lag) · Acute Tubular Necrosis · Antitumor antibiotics13yVinorelbineVinorelbine: approved 1994, first atlas citation 2007 (13-yr lag) · SIADH / Hyponatremia · Microtubule inhibitors13yBortezomibBortezomib: approved 2003, first atlas citation 2015 (12-yr lag) · Thrombotic Microangiopathy · Other targeted agents12yEtoposideEtoposide: approved 1983, first atlas citation 1995 (12-yr lag) · Crystal / Obstructive Nephropathy · Topoisomerase inhibitors12yIdarubicinIdarubicin: approved 1990, first atlas citation 2002 (12-yr lag) · Crystal / Obstructive Nephropathy · Antitumor antibiotics12yNimustine (ACNU)Nimustine (ACNU): approved 1979, first atlas citation 1991 (12-yr lag) · Chronic Interstitial Nephropathy · Alkylating agents12yArsenic trioxideArsenic trioxide: approved 2000, first atlas citation 2011 (11-yr lag) · Prerenal / Hemodynamic AKI · Other targeted agents11yRituximabRituximab: approved 1997, first atlas citation 2008 (11-yr lag) · Crystal / Obstructive Nephropathy · Monoclonal antibodies (other)11yInterferon-αInterferon-α: approved 1986, first atlas citation 1997 (11-yr lag) · Glomerular Injury / Proteinuria · Cytokines & enzymes11yCytarabineCytarabine: approved 1969, first atlas citation 1979 (10-yr lag) · Crystal / Obstructive Nephropathy · Antimetabolites10yMitomycin CMitomycin C: approved 1974, first atlas citation 1984 (10-yr lag) · Thrombotic Microangiopathy · Antitumor antibiotics10yPamidronatePamidronate: approved 1991, first atlas citation 2001 (10-yr lag) · Glomerular Injury / Proteinuria · Bisphosphonates & bone10yStrontium-89…Strontium-89 chlorideStrontium-89 chloride: approved 1993, first atlas citation 2003 (10-yr lag) · Electrolyte Disturbance · Radiopharmaceuticals10yPegaspargasePegaspargase: approved 1994, first atlas citation 2003 (9-yr lag) · Prerenal / Hemodynamic AKI · Cytokines & enzymes9yNilotinibNilotinib: approved 2007, first atlas citation 2015 (8-yr lag) · Prerenal / Hemodynamic AKI · BCR-ABL inhibitors8yDasatinibDasatinib: approved 2006, first atlas citation 2013 (7-yr lag) · Glomerular Injury / Proteinuria · BCR-ABL inhibitors7yAbemaciclibAbemaciclib: approved 2017, first atlas citation 2024 (7-yr lag) · Pseudo-AKI · CDK4/6 inhibitors7yPazopanibPazopanib: approved 2009, first atlas citation 2016 (7-yr lag) · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)7yMitoxantroneMitoxantrone: approved 1987, first atlas citation 1993 (6-yr lag) · Crystal / Obstructive Nephropathy · Antitumor antibiotics6yTegafur-uracil (UFT)Tegafur-uracil (UFT): approved 1984, first atlas citation 1990 (6-yr lag) · Thrombotic Microangiopathy · Antimetabolites6ySamarium-153…Samarium-153 lexidronamSamarium-153 lexidronam: approved 1997, first atlas citation 2003 (6-yr lag) · Acute Tubular Necrosis · Radiopharmaceuticals6yNelarabineNelarabine: approved 2005, first atlas citation 2010 (5-yr lag) · Crystal / Obstructive Nephropathy · Antimetabolites5yDaratumumabDaratumumab: approved 2015, first atlas citation 2020 (5-yr lag) · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)5yOctreotideOctreotide: approved 1988, first atlas citation 1993 (5-yr lag) · Electrolyte Disturbance · Hormonal / endocrine5yIpilimumabIpilimumab: approved 2011, first atlas citation 2016 (5-yr lag) · Acute Interstitial Nephritis · Checkpoint inhibitors5yCarmustine (BCNU)Carmustine (BCNU): approved 1977, first atlas citation 1981 (4-yr lag) · Chronic Interstitial Nephropathy · Alkylating agents4yDecitabineDecitabine: approved 2006, first atlas citation 2010 (4-yr lag) · Crystal / Obstructive Nephropathy · Antimetabolites4yBevacizumabBevacizumab: approved 2004, first atlas citation 2008 (4-yr lag) · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)4yCrizotinibCrizotinib: approved 2011, first atlas citation 2015 (4-yr lag) · Renal Cysts · ALK / ROS1 / MET / TRK inhibitors4yRibociclibRibociclib: approved 2017, first atlas citation 2021 (4-yr lag) · Pseudo-AKI · CDK4/6 inhibitors4yCabazitaxelCabazitaxel: approved 2010, first atlas citation 2014 (4-yr lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors4yAsparaginaseAsparaginase: approved 1978, first atlas citation 1982 (4-yr lag) · Prerenal / Hemodynamic AKI · Cytokines & enzymes4yDenosumabDenosumab: approved 2010, first atlas citation 2014 (4-yr lag) · Electrolyte Disturbance · Bisphosphonates & bone4yRuxolitinibRuxolitinib: approved 2011, first atlas citation 2015 (4-yr lag) · Prerenal / Hemodynamic AKI · Other kinase inhibitors4yBleomycinBleomycin: approved 1973, first atlas citation 1977 (4-yr lag) · Prerenal / Hemodynamic AKI · Antitumor antibiotics4yCarmofur (HCFU)Carmofur (HCFU): approved 1981, first atlas citation 1985 (4-yr lag) · Thrombotic Microangiopathy · Antimetabolites4yOxaliplatinOxaliplatin: approved 2002, first atlas citation 2005 (3-yr lag) · Thrombotic Microangiopathy · Platinum agents3yIfosfamideIfosfamide: approved 1988, first atlas citation 1991 (3-yr lag) · Fanconi Syndrome · Alkylating agents3yLomustine (CCNU)Lomustine (CCNU): approved 1976, first atlas citation 1979 (3-yr lag) · Chronic Interstitial Nephropathy · Alkylating agents3yGemcitabineGemcitabine: approved 1996, first atlas citation 1999 (3-yr lag) · Thrombotic Microangiopathy · Antimetabolites3yCapecitabineCapecitabine: approved 1998, first atlas citation 2001 (3-yr lag) · Prerenal / Hemodynamic AKI · Antimetabolites3yLenvatinibLenvatinib: approved 2015, first atlas citation 2018 (3-yr lag) · Hypertension · Anti-angiogenic (VEGF)3ySirolimusSirolimus: approved 1999, first atlas citation 2002 (3-yr lag) · Glomerular Injury / Proteinuria · mTOR inhibitors3yCetuximabCetuximab: approved 2004, first atlas citation 2007 (3-yr lag) · Electrolyte Disturbance · Monoclonal antibodies (other)3yErlotinibErlotinib: approved 2004, first atlas citation 2007 (3-yr lag) · Glomerular Injury / Proteinuria · EGFR / HER2 inhibitors3yCAR-T cell therapyCAR-T cell therapy: approved 2017, first atlas citation 2020 (3-yr lag) · Prerenal / Hemodynamic AKI · CAR-T cell therapy3yPonatinibPonatinib: approved 2012, first atlas citation 2015 (3-yr lag) · Hypertension · BCR-ABL inhibitors3yBosutinibBosutinib: approved 2012, first atlas citation 2015 (3-yr lag) · Pseudo-AKI · BCR-ABL inhibitors3yNiraparibNiraparib: approved 2017, first atlas citation 2020 (3-yr lag) · Hypertension · Other targeted agents3yPalbociclibPalbociclib: approved 2015, first atlas citation 2018 (3-yr lag) · Pseudo-AKI · CDK4/6 inhibitors3yCatumaxomabCatumaxomab: approved 2009, first atlas citation 2012 (3-yr lag) · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagers3ySorafenibSorafenib: approved 2005, first atlas citation 2008 (3-yr lag) · Hypertension · Anti-angiogenic (VEGF)3yPemetrexedPemetrexed: approved 2004, first atlas citation 2006 (2-yr lag) · Chronic Interstitial Nephropathy · Antimetabolites2yVEGFR TKIs…VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib): approved 2006, first atlas citation 2008 (2-yr lag) · Hypertension · Anti-angiogenic (VEGF)2yCheckpoint…Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab): approved 2014, first atlas citation 2016 (2-yr lag) · Acute Interstitial Nephritis · Checkpoint inhibitors2yTrastuzumab…Trastuzumab emtansine (T-DM1)Trastuzumab emtansine (T-DM1): approved 2013, first atlas citation 2015 (2-yr lag) · Thrombotic Microangiopathy · Antibody-drug conjugates2yBrentuximab vedotinBrentuximab vedotin: approved 2011, first atlas citation 2013 (2-yr lag) · Prerenal / Hemodynamic AKI · Antibody-drug conjugates2yCarfilzomibCarfilzomib: approved 2012, first atlas citation 2014 (2-yr lag) · Thrombotic Microangiopathy · Other targeted agents2yIxazomibIxazomib: approved 2015, first atlas citation 2017 (2-yr lag) · Thrombotic Microangiopathy · Other targeted agents2yLenalidomideLenalidomide: approved 2005, first atlas citation 2007 (2-yr lag) · Acute Tubular Necrosis · Other targeted agents2yThalidomideThalidomide: approved 2006, first atlas citation 2008 (2-yr lag) · Prerenal / Hemodynamic AKI · Other targeted agents2yImatinibImatinib: approved 2001, first atlas citation 2003 (2-yr lag) · Electrolyte Disturbance · BCR-ABL inhibitors2yBRAF / MEK…BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib)BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib): approved 2011, first atlas citation 2013 (2-yr lag) · Acute Tubular Necrosis · BRAF / MEK inhibitors2yIbrutinibIbrutinib: approved 2013, first atlas citation 2015 (2-yr lag) · Hypertension · BTK inhibitors2yTretinoin (ATRA)Tretinoin (ATRA): approved 1995, first atlas citation 1997 (2-yr lag) · Prerenal / Hemodynamic AKI · Other targeted agents2yTagraxofuspTagraxofusp: approved 2018, first atlas citation 2020 (2-yr lag) · Prerenal / Hemodynamic AKI · Other targeted agents2yZoledronic acidZoledronic acid: approved 2001, first atlas citation 2003 (2-yr lag) · Acute Tubular Necrosis · Bisphosphonates & bone2y
  • Mechlorethamine: approved 1949, first atlas citation 2011 (62-year lag) · Electrolyte Disturbance · Alkylating agents
  • Methotrexate (high-dose): approved 1953, first atlas citation 2010 (57-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
  • Busulfan: approved 1954, first atlas citation 2001 (47-year lag) · Thrombotic Microangiopathy · Alkylating agents
  • Mitotane: approved 1970, first atlas citation 2017 (47-year lag) · Electrolyte Disturbance · Hormonal / endocrine
  • Chlorambucil: approved 1957, first atlas citation 1999 (42-year lag) · SIADH / Hyponatremia · Alkylating agents
  • Thiotepa: approved 1959, first atlas citation 1998 (39-year lag) · Hemorrhagic Cystitis · Alkylating agents
  • Vincristine: approved 1963, first atlas citation 2002 (39-year lag) · SIADH / Hyponatremia · Microtubule inhibitors
  • Hydroxyurea: approved 1967, first atlas citation 2003 (36-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
  • Dactinomycin (actinomycin D): approved 1964, first atlas citation 1996 (32-year lag) · Electrolyte Disturbance · Antitumor antibiotics
  • Tamoxifen: approved 1977, first atlas citation 2006 (29-year lag) · SIADH / Hyponatremia · Hormonal / endocrine
  • 5-Fluorouracil: approved 1962, first atlas citation 1987 (25-year lag) · Thrombotic Microangiopathy · Antimetabolites
  • Irinotecan: approved 1996, first atlas citation 2020 (24-year lag) · Prerenal / Hemodynamic AKI · Topoisomerase inhibitors
  • Paclitaxel: approved 1992, first atlas citation 2015 (23-year lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors
  • Leuprolide: approved 1985, first atlas citation 2007 (22-year lag) · Hypertension · Hormonal / endocrine
  • Melphalan: approved 1964, first atlas citation 1985 (21-year lag) · SIADH / Hyponatremia · Alkylating agents
  • Cisplatin: approved 1978, first atlas citation 1998 (20-year lag) · Acute Tubular Necrosis · Platinum agents
  • Topotecan: approved 1996, first atlas citation 2015 (19-year lag) · Prerenal / Hemodynamic AKI · Topoisomerase inhibitors
  • Doxorubicin: approved 1974, first atlas citation 1991 (17-year lag) · Glomerular Injury / Proteinuria · Antitumor antibiotics
  • Cyclophosphamide: approved 1959, first atlas citation 1974 (15-year lag) · SIADH / Hyponatremia · Alkylating agents
  • Dacarbazine: approved 1975, first atlas citation 1990 (15-year lag) · Prerenal / Hemodynamic AKI · Alkylating agents
  • Vinblastine: approved 1965, first atlas citation 1980 (15-year lag) · SIADH / Hyponatremia · Microtubule inhibitors
  • Docetaxel: approved 1996, first atlas citation 2010 (14-year lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors
  • Procarbazine: approved 1969, first atlas citation 1983 (14-year lag) · Acute Tubular Necrosis · Alkylating agents
  • Plicamycin (mithramycin): approved 1970, first atlas citation 1983 (13-year lag) · Acute Tubular Necrosis · Antitumor antibiotics
  • Vinorelbine: approved 1994, first atlas citation 2007 (13-year lag) · SIADH / Hyponatremia · Microtubule inhibitors
  • Bortezomib: approved 2003, first atlas citation 2015 (12-year lag) · Thrombotic Microangiopathy · Other targeted agents
  • Etoposide: approved 1983, first atlas citation 1995 (12-year lag) · Crystal / Obstructive Nephropathy · Topoisomerase inhibitors
  • Idarubicin: approved 1990, first atlas citation 2002 (12-year lag) · Crystal / Obstructive Nephropathy · Antitumor antibiotics
  • Nimustine (ACNU): approved 1979, first atlas citation 1991 (12-year lag) · Chronic Interstitial Nephropathy · Alkylating agents
  • Arsenic trioxide: approved 2000, first atlas citation 2011 (11-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
  • Rituximab: approved 1997, first atlas citation 2008 (11-year lag) · Crystal / Obstructive Nephropathy · Monoclonal antibodies (other)
  • Interferon-α: approved 1986, first atlas citation 1997 (11-year lag) · Glomerular Injury / Proteinuria · Cytokines & enzymes
  • Cytarabine: approved 1969, first atlas citation 1979 (10-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
  • Mitomycin C: approved 1974, first atlas citation 1984 (10-year lag) · Thrombotic Microangiopathy · Antitumor antibiotics
  • Pamidronate: approved 1991, first atlas citation 2001 (10-year lag) · Glomerular Injury / Proteinuria · Bisphosphonates & bone
  • Strontium-89 chloride: approved 1993, first atlas citation 2003 (10-year lag) · Electrolyte Disturbance · Radiopharmaceuticals
  • Pegaspargase: approved 1994, first atlas citation 2003 (9-year lag) · Prerenal / Hemodynamic AKI · Cytokines & enzymes
  • Nilotinib: approved 2007, first atlas citation 2015 (8-year lag) · Prerenal / Hemodynamic AKI · BCR-ABL inhibitors
  • Dasatinib: approved 2006, first atlas citation 2013 (7-year lag) · Glomerular Injury / Proteinuria · BCR-ABL inhibitors
  • Abemaciclib: approved 2017, first atlas citation 2024 (7-year lag) · Pseudo-AKI · CDK4/6 inhibitors
  • Pazopanib: approved 2009, first atlas citation 2016 (7-year lag) · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)
  • Mitoxantrone: approved 1987, first atlas citation 1993 (6-year lag) · Crystal / Obstructive Nephropathy · Antitumor antibiotics
  • Tegafur-uracil (UFT): approved 1984, first atlas citation 1990 (6-year lag) · Thrombotic Microangiopathy · Antimetabolites
  • Samarium-153 lexidronam: approved 1997, first atlas citation 2003 (6-year lag) · Acute Tubular Necrosis · Radiopharmaceuticals
  • Nelarabine: approved 2005, first atlas citation 2010 (5-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
  • Daratumumab: approved 2015, first atlas citation 2020 (5-year lag) · Prerenal / Hemodynamic AKI · Monoclonal antibodies (other)
  • Octreotide: approved 1988, first atlas citation 1993 (5-year lag) · Electrolyte Disturbance · Hormonal / endocrine
  • Ipilimumab: approved 2011, first atlas citation 2016 (5-year lag) · Acute Interstitial Nephritis · Checkpoint inhibitors
  • Carmustine (BCNU): approved 1977, first atlas citation 1981 (4-year lag) · Chronic Interstitial Nephropathy · Alkylating agents
  • Decitabine: approved 2006, first atlas citation 2010 (4-year lag) · Crystal / Obstructive Nephropathy · Antimetabolites
  • Bevacizumab: approved 2004, first atlas citation 2008 (4-year lag) · Glomerular Injury / Proteinuria · Anti-angiogenic (VEGF)
  • Crizotinib: approved 2011, first atlas citation 2015 (4-year lag) · Renal Cysts · ALK / ROS1 / MET / TRK inhibitors
  • Ribociclib: approved 2017, first atlas citation 2021 (4-year lag) · Pseudo-AKI · CDK4/6 inhibitors
  • Cabazitaxel: approved 2010, first atlas citation 2014 (4-year lag) · Prerenal / Hemodynamic AKI · Microtubule inhibitors
  • Asparaginase: approved 1978, first atlas citation 1982 (4-year lag) · Prerenal / Hemodynamic AKI · Cytokines & enzymes
  • Denosumab: approved 2010, first atlas citation 2014 (4-year lag) · Electrolyte Disturbance · Bisphosphonates & bone
  • Ruxolitinib: approved 2011, first atlas citation 2015 (4-year lag) · Prerenal / Hemodynamic AKI · Other kinase inhibitors
  • Bleomycin: approved 1973, first atlas citation 1977 (4-year lag) · Prerenal / Hemodynamic AKI · Antitumor antibiotics
  • Carmofur (HCFU): approved 1981, first atlas citation 1985 (4-year lag) · Thrombotic Microangiopathy · Antimetabolites
  • Oxaliplatin: approved 2002, first atlas citation 2005 (3-year lag) · Thrombotic Microangiopathy · Platinum agents
  • Ifosfamide: approved 1988, first atlas citation 1991 (3-year lag) · Fanconi Syndrome · Alkylating agents
  • Lomustine (CCNU): approved 1976, first atlas citation 1979 (3-year lag) · Chronic Interstitial Nephropathy · Alkylating agents
  • Gemcitabine: approved 1996, first atlas citation 1999 (3-year lag) · Thrombotic Microangiopathy · Antimetabolites
  • Capecitabine: approved 1998, first atlas citation 2001 (3-year lag) · Prerenal / Hemodynamic AKI · Antimetabolites
  • Lenvatinib: approved 2015, first atlas citation 2018 (3-year lag) · Hypertension · Anti-angiogenic (VEGF)
  • Sirolimus: approved 1999, first atlas citation 2002 (3-year lag) · Glomerular Injury / Proteinuria · mTOR inhibitors
  • Cetuximab: approved 2004, first atlas citation 2007 (3-year lag) · Electrolyte Disturbance · Monoclonal antibodies (other)
  • Erlotinib: approved 2004, first atlas citation 2007 (3-year lag) · Glomerular Injury / Proteinuria · EGFR / HER2 inhibitors
  • CAR-T cell therapy: approved 2017, first atlas citation 2020 (3-year lag) · Prerenal / Hemodynamic AKI · CAR-T cell therapy
  • Ponatinib: approved 2012, first atlas citation 2015 (3-year lag) · Hypertension · BCR-ABL inhibitors
  • Bosutinib: approved 2012, first atlas citation 2015 (3-year lag) · Pseudo-AKI · BCR-ABL inhibitors
  • Niraparib: approved 2017, first atlas citation 2020 (3-year lag) · Hypertension · Other targeted agents
  • Palbociclib: approved 2015, first atlas citation 2018 (3-year lag) · Pseudo-AKI · CDK4/6 inhibitors
  • Catumaxomab: approved 2009, first atlas citation 2012 (3-year lag) · Prerenal / Hemodynamic AKI · Bispecifics / T-cell engagers
  • Sorafenib: approved 2005, first atlas citation 2008 (3-year lag) · Hypertension · Anti-angiogenic (VEGF)
  • Pemetrexed: approved 2004, first atlas citation 2006 (2-year lag) · Chronic Interstitial Nephropathy · Antimetabolites
  • VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib): approved 2006, first atlas citation 2008 (2-year lag) · Hypertension · Anti-angiogenic (VEGF)
  • Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab): approved 2014, first atlas citation 2016 (2-year lag) · Acute Interstitial Nephritis · Checkpoint inhibitors
  • Trastuzumab emtansine (T-DM1): approved 2013, first atlas citation 2015 (2-year lag) · Thrombotic Microangiopathy · Antibody-drug conjugates
  • Brentuximab vedotin: approved 2011, first atlas citation 2013 (2-year lag) · Prerenal / Hemodynamic AKI · Antibody-drug conjugates
  • Carfilzomib: approved 2012, first atlas citation 2014 (2-year lag) · Thrombotic Microangiopathy · Other targeted agents
  • Ixazomib: approved 2015, first atlas citation 2017 (2-year lag) · Thrombotic Microangiopathy · Other targeted agents
  • Lenalidomide: approved 2005, first atlas citation 2007 (2-year lag) · Acute Tubular Necrosis · Other targeted agents
  • Thalidomide: approved 2006, first atlas citation 2008 (2-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
  • Imatinib: approved 2001, first atlas citation 2003 (2-year lag) · Electrolyte Disturbance · BCR-ABL inhibitors
  • BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib): approved 2011, first atlas citation 2013 (2-year lag) · Acute Tubular Necrosis · BRAF / MEK inhibitors
  • Ibrutinib: approved 2013, first atlas citation 2015 (2-year lag) · Hypertension · BTK inhibitors
  • Tretinoin (ATRA): approved 1995, first atlas citation 1997 (2-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
  • Tagraxofusp: approved 2018, first atlas citation 2020 (2-year lag) · Prerenal / Hemodynamic AKI · Other targeted agents
  • Zoledronic acid: approved 2001, first atlas citation 2003 (2-year lag) · Acute Tubular Necrosis · Bisphosphonates & bone

The 90 longest-lag agents (of those with both an approval year and a dated citation) · hollow = approval · filled = first atlas citation · bar = years to first dated citation · color = signature injury.

Acute Tubular NecrosisAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceFanconi SyndromeCrystal / Obstructive NephropathyHypertensionPrerenal / Hemodynamic AKISIADH / HyponatremiaHemorrhagic CystitisPseudo-AKIRenal CystsChronic Interstitial Nephropathy
Figure 10·From approval to the first dated atlas citation, which shows how far the curated evidence trails approval (not when the kidney signal first appeared), for the 90 longest-gap agents (those whose earliest citation post-dates approval).

Every catalog agent with citation evidence by evidence depth (citations, horizontal) and recency (newest reference, vertical). The crosshairs are the medians — the upper-left quadrant is the frontier (fresh but thin), the lower-right is deep but aging.

emerging · fresh & thinmaintained · deep & freshcontent gap · thin & agingestablished · deep & aging1351020200020052010201520202025citations (log)Cisplatin — 21 citations, newest 2025, Acute Tubular NecrosisCarboplatin — 12 citations, newest 2024, Acute Tubular NecrosisOxaliplatin — 10 citations, newest 2026, Thrombotic MicroangiopathyIfosfamide — 16 citations, newest 2026, Fanconi SyndromeCyclophosphamide — 8 citations, newest 2023, SIADH / HyponatremiaMethotrexate (high-dose) — 10 citations, newest 2025, Crystal / Obstructive NephropathyPemetrexed — 10 citations, newest 2026, Chronic Interstitial NephropathyGemcitabine — 14 citations, newest 2026, Thrombotic MicroangiopathyMitomycin C — 13 citations, newest 2025, Thrombotic MicroangiopathyBevacizumab — 9 citations, newest 2019, Glomerular Injury / ProteinuriaVEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib) — 8 citations, newest 2024, HypertensionmTOR inhibitors (everolimus · temsirolimus) — 8 citations, newest 2019, Glomerular Injury / ProteinuriaCheckpoint inhibitors (pembrolizumab · nivolumab · ipilimumab) — 8 citations, newest 2023, Acute Interstitial NephritisCAR-T cell therapy — 9 citations, newest 2025, Prerenal / Hemodynamic AKIInterferon-α — 8 citations, newest 2025, Glomerular Injury / ProteinuriaInterleukin-2 (high-dose) — 10 citations, newest 2011, Prerenal / Hemodynamic AKIZoledronic acid — 11 citations, newest 2026, Acute Tubular NecrosisPamidronate — 6 citations, newest 2011, Glomerular Injury / ProteinuriaBRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib) — 8 citations, newest 2022, Acute Tubular NecrosisNedaplatin — 11 citations, newest 2023, Acute Tubular NecrosisStreptozocin — 10 citations, newest 2026, Fanconi SyndromeCarmustine (BCNU) — 7 citations, newest 2012, Chronic Interstitial NephropathyLomustine (CCNU) — 9 citations, newest 2019, Chronic Interstitial NephropathyBendamustine — 10 citations, newest 2026, Crystal / Obstructive NephropathyMelphalan — 8 citations, newest 2025, SIADH / HyponatremiaBusulfan — 8 citations, newest 2019, Thrombotic MicroangiopathyTemozolomide — 9 citations, newest 2025, SIADH / HyponatremiaDacarbazine — 2 citations, newest 2001, Prerenal / Hemodynamic AKIThiotepa — 8 citations, newest 2024, Hemorrhagic CystitisPralatrexate — 8 citations, newest 2022, Crystal / Obstructive Nephropathy5-Fluorouracil — 9 citations, newest 2024, Thrombotic MicroangiopathyCapecitabine — 9 citations, newest 2025, Prerenal / Hemodynamic AKICytarabine — 9 citations, newest 2023, Crystal / Obstructive NephropathyFludarabine — 11 citations, newest 2017, Crystal / Obstructive NephropathyClofarabine — 10 citations, newest 2020, Prerenal / Hemodynamic AKIAzacitidine — 8 citations, newest 2024, Fanconi SyndromeDecitabine — 6 citations, newest 2023, Crystal / Obstructive NephropathyHydroxyurea — 7 citations, newest 2020, Crystal / Obstructive NephropathyNelarabine — 6 citations, newest 2020, Crystal / Obstructive NephropathyDoxorubicin — 12 citations, newest 2026, Glomerular Injury / ProteinuriaPlicamycin (mithramycin) — 9 citations, newest 2017, Acute Tubular NecrosisRamucirumab — 11 citations, newest 2025, HypertensionZiv-aflibercept — 8 citations, newest 2022, HypertensionLenvatinib — 13 citations, newest 2026, HypertensionCabozantinib — 10 citations, newest 2026, HypertensionRegorafenib — 10 citations, newest 2025, HypertensionVandetanib — 6 citations, newest 2023, HypertensionTivozanib — 5 citations, newest 2021, HypertensionNintedanib — 9 citations, newest 2026, HypertensionSirolimus — 13 citations, newest 2019, Glomerular Injury / ProteinuriaNecitumumab — 9 citations, newest 2021, Electrolyte DisturbanceOsimertinib — 9 citations, newest 2026, SIADH / HyponatremiaErlotinib — 9 citations, newest 2024, Glomerular Injury / ProteinuriaGefitinib — 12 citations, newest 2018, Glomerular Injury / ProteinuriaAfatinib — 8 citations, newest 2024, Prerenal / Hemodynamic AKIAtezolizumab — 15 citations, newest 2025, Acute Interstitial NephritisDurvalumab — 11 citations, newest 2026, Acute Interstitial NephritisAvelumab — 9 citations, newest 2026, Acute Interstitial NephritisCemiplimab — 11 citations, newest 2026, Acute Interstitial NephritisDostarlimab — 9 citations, newest 2025, Acute Interstitial NephritisBlinatumomab — 8 citations, newest 2022, Prerenal / Hemodynamic AKITeclistamab — 9 citations, newest 2026, Prerenal / Hemodynamic AKITalquetamab — 7 citations, newest 2026, Prerenal / Hemodynamic AKIElranatamab — 10 citations, newest 2026, Prerenal / Hemodynamic AKIMosunetuzumab — 8 citations, newest 2024, Prerenal / Hemodynamic AKIEpcoritamab — 9 citations, newest 2026, Prerenal / Hemodynamic AKIGlofitamab — 6 citations, newest 2024, Prerenal / Hemodynamic AKIEnfortumab vedotin — 10 citations, newest 2025, Acute Tubular NecrosisSacituzumab govitecan — 5 citations, newest 2026, Prerenal / Hemodynamic AKITrastuzumab deruxtecan — 6 citations, newest 2026, Acute Tubular NecrosisTrastuzumab emtansine (T-DM1) — 7 citations, newest 2026, Thrombotic MicroangiopathyBrentuximab vedotin — 5 citations, newest 2024, Prerenal / Hemodynamic AKIPolatuzumab vedotin — 4 citations, newest 2024, Prerenal / Hemodynamic AKIBelantamab mafodotin — 6 citations, newest 2026, Glomerular Injury / ProteinuriaMirvetuximab soravtansine — 4 citations, newest 2024, Prerenal / Hemodynamic AKIGemtuzumab ozogamicin — 4 citations, newest 2020, Prerenal / Hemodynamic AKIInotuzumab ozogamicin — 4 citations, newest 2023, Prerenal / Hemodynamic AKICarfilzomib — 13 citations, newest 2025, Thrombotic MicroangiopathyBortezomib — 7 citations, newest 2025, Thrombotic MicroangiopathyIxazomib — 8 citations, newest 2025, Thrombotic MicroangiopathyLenalidomide — 9 citations, newest 2025, Acute Tubular NecrosisPomalidomide — 7 citations, newest 2025, Prerenal / Hemodynamic AKIThalidomide — 6 citations, newest 2017, Prerenal / Hemodynamic AKIImatinib — 9 citations, newest 2024, Electrolyte DisturbanceDasatinib — 9 citations, newest 2025, Glomerular Injury / ProteinuriaNilotinib — 8 citations, newest 2025, Prerenal / Hemodynamic AKIPonatinib — 9 citations, newest 2025, HypertensionBosutinib — 9 citations, newest 2025, Pseudo-AKICrizotinib — 10 citations, newest 2025, Renal CystsAlectinib — 9 citations, newest 2026, Pseudo-AKIBrigatinib — 9 citations, newest 2025, Pseudo-AKILorlatinib — 8 citations, newest 2025, Pseudo-AKICeritinib — 6 citations, newest 2025, Prerenal / Hemodynamic AKIOlaparib — 8 citations, newest 2026, Pseudo-AKINiraparib — 8 citations, newest 2026, HypertensionRucaparib — 7 citations, newest 2026, Pseudo-AKITalazoparib — 6 citations, newest 2026, Pseudo-AKIEncorafenib — 9 citations, newest 2022, Acute Tubular NecrosisCobimetinib — 7 citations, newest 2022, Acute Tubular NecrosisBinimetinib — 9 citations, newest 2022, Acute Tubular NecrosisSelumetinib — 6 citations, newest 2023, Prerenal / Hemodynamic AKIErdafitinib — 7 citations, newest 2024, Electrolyte DisturbancePemigatinib — 9 citations, newest 2025, Electrolyte DisturbanceFutibatinib — 6 citations, newest 2024, Electrolyte DisturbanceSelpercatinib — 11 citations, newest 2026, HypertensionPralsetinib — 6 citations, newest 2025, HypertensionCapmatinib — 8 citations, newest 2025, Pseudo-AKITepotinib — 8 citations, newest 2025, Pseudo-AKIIvosidenib — 6 citations, newest 2024, Prerenal / Hemodynamic AKIEnasidenib — 8 citations, newest 2025, Prerenal / Hemodynamic AKISotorasib — 6 citations, newest 2025, Prerenal / Hemodynamic AKIAdagrasib — 6 citations, newest 2025, Prerenal / Hemodynamic AKIBelzutifan — 7 citations, newest 2025, Prerenal / Hemodynamic AKIIbrutinib — 9 citations, newest 2025, HypertensionAcalabrutinib — 8 citations, newest 2025, HypertensionZanubrutinib — 7 citations, newest 2024, Prerenal / Hemodynamic AKIVenetoclax — 12 citations, newest 2025, Crystal / Obstructive NephropathyTretinoin (ATRA) — 10 citations, newest 2025, Prerenal / Hemodynamic AKIArsenic trioxide — 9 citations, newest 2025, Prerenal / Hemodynamic AKIRituximab — 8 citations, newest 2024, Crystal / Obstructive NephropathyObinutuzumab — 8 citations, newest 2025, Crystal / Obstructive NephropathyDaratumumab — 9 citations, newest 2025, Prerenal / Hemodynamic AKIIsatuximab — 7 citations, newest 2025, Prerenal / Hemodynamic AKIAbemaciclib — 8 citations, newest 2026, Pseudo-AKIPalbociclib — 8 citations, newest 2026, Pseudo-AKIRibociclib — 9 citations, newest 2026, Pseudo-AKITagraxofusp — 7 citations, newest 2026, Prerenal / Hemodynamic AKIIrinotecan — 5 citations, newest 2024, Prerenal / Hemodynamic AKITopotecan — 4 citations, newest 2022, Prerenal / Hemodynamic AKIEtoposide — 9 citations, newest 2021, Crystal / Obstructive NephropathyVincristine — 9 citations, newest 2024, SIADH / HyponatremiaVinblastine — 8 citations, newest 2024, SIADH / HyponatremiaVinorelbine — 7 citations, newest 2024, SIADH / HyponatremiaPaclitaxel — 9 citations, newest 2024, Prerenal / Hemodynamic AKIDocetaxel — 10 citations, newest 2025, Prerenal / Hemodynamic AKICabazitaxel — 9 citations, newest 2025, Prerenal / Hemodynamic AKIEribulin — 6 citations, newest 2022, Prerenal / Hemodynamic AKIAsparaginase — 6 citations, newest 2025, Prerenal / Hemodynamic AKIDenosumab — 10 citations, newest 2025, Electrolyte DisturbanceIbandronate — 9 citations, newest 2024, Acute Tubular NecrosisAbiraterone — 11 citations, newest 2025, Electrolyte DisturbanceEnzalutamide — 9 citations, newest 2024, HypertensionTamoxifen — 6 citations, newest 2023, SIADH / HyponatremiaLeuprolide — 8 citations, newest 2024, HypertensionAmivantamab — 7 citations, newest 2025, Electrolyte DisturbanceDatopotamab deruxtecan (Dato-DXd) — 6 citations, newest 2025, Acute Tubular NecrosisTarlatamab — 8 citations, newest 2026, Prerenal / Hemodynamic AKIRevumenib — 6 citations, newest 2024, Prerenal / Hemodynamic AKIFruquintinib — 10 citations, newest 2025, HypertensionPirtobrutinib — 6 citations, newest 2024, Crystal / Obstructive NephropathyCapivasertib — 8 citations, newest 2026, Prerenal / Hemodynamic AKINirogacestat — 7 citations, newest 2024, Electrolyte DisturbanceLazertinib — 6 citations, newest 2024, SIADH / HyponatremiaRepotrectinib — 6 citations, newest 2025, Pseudo-AKIZanidatamab — 5 citations, newest 2025, Prerenal / Hemodynamic AKILifileucel — 6 citations, newest 2025, Prerenal / Hemodynamic AKITovorafenib — 4 citations, newest 2024, Prerenal / Hemodynamic AKIImetelstat — 5 citations, newest 2024, Prerenal / Hemodynamic AKIMirdametinib — 4 citations, newest 2024, Prerenal / Hemodynamic AKISunvozertinib — 4 citations, newest 2024, Electrolyte DisturbanceTucatinib — 4 citations, newest 2024, Pseudo-AKIRuxolitinib — 7 citations, newest 2026, Prerenal / Hemodynamic AKIMomelotinib — 7 citations, newest 2026, Pseudo-AKIEntrectinib — 7 citations, newest 2024, Pseudo-AKIQuizartinib — 6 citations, newest 2025, Prerenal / Hemodynamic AKIZiftomenib — 5 citations, newest 2026, Prerenal / Hemodynamic AKICasdatifan — 4 citations, newest 2026, Prerenal / Hemodynamic AKIZongertinib — 4 citations, newest 2025, Pseudo-AKILutetium-177 Dotatate — 19 citations, newest 2025, Chronic Interstitial NephropathyLutetium-177 PSMA-617 (vipivotide) — 12 citations, newest 2026, Chronic Interstitial NephropathyIbritumomab tiuxetan — 6 citations, newest 2004, Prerenal / Hemodynamic AKIRadium-223 dichloride — 8 citations, newest 2022, Prerenal / Hemodynamic AKITrabectedin — 10 citations, newest 2019, Acute Tubular NecrosisLurbinectedin — 8 citations, newest 2025, Acute Tubular NecrosisMoxetumomab pasudotox — 8 citations, newest 2020, Thrombotic MicroangiopathyDenileukin diftitox — 8 citations, newest 2025, Prerenal / Hemodynamic AKISelinexor — 10 citations, newest 2024, SIADH / HyponatremiaCladribine — 10 citations, newest 2023, Crystal / Obstructive NephropathyPentostatin — 11 citations, newest 2013, Acute Tubular NecrosisPegaspargase — 8 citations, newest 2020, Prerenal / Hemodynamic AKIInfigratinib — 7 citations, newest 2025, Electrolyte DisturbanceMobocertinib — 7 citations, newest 2025, Prerenal / Hemodynamic AKILarotrectinib — 7 citations, newest 2020, Pseudo-AKIIdecabtagene vicleucel — 9 citations, newest 2026, Prerenal / Hemodynamic AKICiltacabtagene autoleucel — 10 citations, newest 2026, Prerenal / Hemodynamic AKIMitoxantrone — 9 citations, newest 2016, Crystal / Obstructive NephropathyIdarubicin — 8 citations, newest 2023, Crystal / Obstructive NephropathyEstramustine — 7 citations, newest 2015, Prerenal / Hemodynamic AKIAlpelisib — 7 citations, newest 2024, Prerenal / Hemodynamic AKIIdelalisib — 6 citations, newest 2021, Prerenal / Hemodynamic AKIDuvelisib — 7 citations, newest 2025, Prerenal / Hemodynamic AKICopanlisib — 6 citations, newest 2021, HypertensionVismodegib — 6 citations, newest 2023, SIADH / HyponatremiaSonidegib — 6 citations, newest 2023, Acute Tubular NecrosisGlasdegib — 6 citations, newest 2023, Prerenal / Hemodynamic AKIGilteritinib — 7 citations, newest 2026, Prerenal / Hemodynamic AKIMidostaurin — 7 citations, newest 2023, Prerenal / Hemodynamic AKIAsciminib — 7 citations, newest 2026, HypertensionAvapritinib — 5 citations, newest 2021, Prerenal / Hemodynamic AKIRipretinib — 7 citations, newest 2026, HypertensionPexidartinib — 5 citations, newest 2023, Prerenal / Hemodynamic AKITazemetostat — 7 citations, newest 2022, Prerenal / Hemodynamic AKINeratinib — 6 citations, newest 2022, Prerenal / Hemodynamic AKIOlutasidenib — 6 citations, newest 2025, Prerenal / Hemodynamic AKILoncastuximab tesirine — 5 citations, newest 2024, Prerenal / Hemodynamic AKITafasitamab — 6 citations, newest 2024, Prerenal / Hemodynamic AKIMogamulizumab — 6 citations, newest 2021, Prerenal / Hemodynamic AKIDinutuximab — 7 citations, newest 2025, Prerenal / Hemodynamic AKITisotumab vedotin — 4 citations, newest 2024, Prerenal / Hemodynamic AKITebentafusp — 4 citations, newest 2023, Prerenal / Hemodynamic AKIZolbetuximab — 4 citations, newest 2025, Prerenal / Hemodynamic AKIElacestrant — 4 citations, newest 2024, Prerenal / Hemodynamic AKIRelatlimab — 7 citations, newest 2026, Acute Interstitial NephritisRaltitrexed — 4 citations, newest 2021, Acute Tubular NecrosisTrifluridine/tipiracil — 7 citations, newest 2025, Prerenal / Hemodynamic AKIElotuzumab — 4 citations, newest 2017, Prerenal / Hemodynamic AKIMelphalan flufenamide (melflufen) — 4 citations, newest 2026, Acute Tubular NecrosisProcarbazine — 4 citations, newest 2021, Acute Tubular NecrosisCatumaxomab — 4 citations, newest 2017, Prerenal / Hemodynamic AKIBleomycin — 7 citations, newest 2021, Prerenal / Hemodynamic AKIVinflunine — 5 citations, newest 2019, Electrolyte DisturbanceFotemustine — 4 citations, newest 2015, Chronic Interstitial NephropathyNimustine (ACNU) — 4 citations, newest 2023, Chronic Interstitial NephropathyTeniposide — 5 citations, newest 2021, Electrolyte DisturbanceDactinomycin (actinomycin D) — 4 citations, newest 2017, Electrolyte DisturbanceMechlorethamine — 4 citations, newest 2021, Electrolyte DisturbanceChlorambucil — 3 citations, newest 2021, SIADH / HyponatremiaAmsacrine — 4 citations, newest 2017, Electrolyte DisturbanceAltretamine (hexamethylmelamine) — 3 citations, newest 2017, Prerenal / Hemodynamic AKITegafur-uracil (UFT) — 4 citations, newest 2021, Thrombotic MicroangiopathyDoxifluridine — 4 citations, newest 2021, Thrombotic MicroangiopathyCarmofur (HCFU) — 3 citations, newest 2021, Thrombotic MicroangiopathySamarium-153 lexidronam — 4 citations, newest 2014, Acute Tubular NecrosisBicalutamide — 4 citations, newest 2020, Acute Interstitial NephritisOctreotide — 7 citations, newest 2024, Electrolyte DisturbanceLanreotide — 6 citations, newest 2018, Electrolyte DisturbanceMitotane — 6 citations, newest 2025, Electrolyte DisturbanceDarolutamide — 5 citations, newest 2025, Electrolyte DisturbanceStrontium-89 chloride — 4 citations, newest 2021, Electrolyte DisturbanceTislelizumab — 8 citations, newest 2026, Acute Interstitial NephritisToripalimab — 7 citations, newest 2024, Acute Interstitial NephritisRetifanlimab — 6 citations, newest 2025, Acute Interstitial NephritisCosibelimab — 5 citations, newest 2025, Acute Interstitial NephritisIvonescimab — 5 citations, newest 2025, Glomerular Injury / ProteinuriaLinvoseltamab — 6 citations, newest 2025, Prerenal / Hemodynamic AKIOlverembatinib — 5 citations, newest 2026, Glomerular Injury / ProteinuriaVorasidenib — 4 citations, newest 2026, Pseudo-AKIVimseltinib — 5 citations, newest 2025, Pseudo-AKIPenpulimab — 5 citations, newest 2026, Acute Interstitial NephritisSugemalimab — 5 citations, newest 2024, Acute Interstitial NephritisTaletrectinib — 4 citations, newest 2026, Pseudo-AKIEnsartinib — 5 citations, newest 2025, Pseudo-AKIInavolisib — 4 citations, newest 2024, Electrolyte DisturbanceTelisotuzumab vedotin (Teliso-V) — 3 citations, newest 2025, Acute Tubular NecrosisAfamitresgene autoleucel (Afami-cel) — 4 citations, newest 2025, Prerenal / Hemodynamic AKIObecabtagene autoleucel (Obe-cel) — 5 citations, newest 2025, Prerenal / Hemodynamic AKISunitinib — 8 citations, newest 2026, HypertensionAxitinib — 7 citations, newest 2023, HypertensionPazopanib — 9 citations, newest 2024, Glomerular Injury / ProteinuriaIpilimumab — 13 citations, newest 2026, Acute Interstitial NephritisNivolumab — 10 citations, newest 2026, Acute Interstitial NephritisPembrolizumab — 15 citations, newest 2026, Acute Interstitial NephritisCetuximab — 13 citations, newest 2022, Electrolyte DisturbancePanitumumab — 10 citations, newest 2026, Electrolyte DisturbanceVemurafenib — 9 citations, newest 2021, Acute Tubular NecrosisDabrafenib — 9 citations, newest 2022, Acute Interstitial NephritisTrametinib — 10 citations, newest 2024, Prerenal / Hemodynamic AKIEverolimus — 12 citations, newest 2025, Glomerular Injury / ProteinuriaTemsirolimus — 10 citations, newest 2016, Glomerular Injury / ProteinuriaSorafenib — 11 citations, newest 2021, HypertensionPacritinib — 7 citations, newest 2025, Prerenal / Hemodynamic AKIAvutometinib — 7 citations, newest 2025, Electrolyte DisturbanceFedratinib — 7 citations, newest 2020, Electrolyte DisturbanceOdronextamab — 7 citations, newest 2025, Crystal / Obstructive NephropathyNaxitamab — 8 citations, newest 2025, Prerenal / Hemodynamic AKIIobenguane I-131 — 9 citations, newest 2025, Acute Tubular NecrosisLisocabtagene maraleucel — 8 citations, newest 2025, Prerenal / Hemodynamic AKIGallium nitrate — 8 citations, newest 2003, Acute Tubular NecrosisTasonermin — 8 citations, newest 2000, Prerenal / Hemodynamic AKISonrotoclax — 7 citations, newest 2026, Crystal / Obstructive NephropathyPivekimab sunirine — 6 citations, newest 2024, Prerenal / Hemodynamic AKIRelacorilant — 3 citations, newest 2025, Electrolyte DisturbanceSevabertinib — 3 citations, newest 2026, Prerenal / Hemodynamic AKIImlunestrant — 2 citations, newest 2025, Pseudo-AKIVepdegestrant — 2 citations, newest 2025, Prerenal / Hemodynamic AKIDordaviprone — 2 citations, newest 2025, Prerenal / Hemodynamic AKIZenocutuzumab — 2 citations, newest 2025, Prerenal / Hemodynamic AKIGedatolisib — 3 citations, newest 2026, Electrolyte DisturbanceZidesamtinib — 4 citations, newest 2026, Prerenal / Hemodynamic AKIIberdomide — 7 citations, newest 2025, Prerenal / Hemodynamic AKICamizestrant — 10 citations, newest 2026, Prerenal / Hemodynamic AKIDaraxonrasib — 7 citations, newest 2026, Prerenal / Hemodynamic AKIpromacta — 1 citations, newest 2010, Thrombotic Microangiopathysaruparib — 1 citations, newest 2026, Pseudo-AKIDisitamab vedotin — 8 citations, newest 2026, Acute Tubular NecrosisAnitocabtagene autoleucel — 8 citations, newest 2026, Prerenal / Hemodynamic AKIActinium 225 PSMA — 2 citations, newest 2025, Acute Tubular NecrosisFurmonertinib — 2 citations, newest 2026, Electrolyte DisturbanceDefactinib — 2 citations, newest 2023, Electrolyte DisturbanceCadonilimab — 5 citations, newest 2026, Acute Interstitial Nephritis
Acute Tubular NecrosisAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceFanconi SyndromeCrystal / Obstructive NephropathyHypertensionPrerenal / Hemodynamic AKISIADH / HyponatremiaHemorrhagic CystitisPseudo-AKIRenal CystsChronic Interstitial Nephropathy

300 agents · x = citation count (log) · y = newest citation year · crosshair = medians.

  • Cisplatin — 21 citations, newest 2025, Acute Tubular Necrosis
  • Lutetium-177 Dotatate — 19 citations, newest 2025, Chronic Interstitial Nephropathy
  • Ifosfamide — 16 citations, newest 2026, Fanconi Syndrome
  • Atezolizumab — 15 citations, newest 2025, Acute Interstitial Nephritis
  • Pembrolizumab — 15 citations, newest 2026, Acute Interstitial Nephritis
  • Gemcitabine — 14 citations, newest 2026, Thrombotic Microangiopathy
  • Mitomycin C — 13 citations, newest 2025, Thrombotic Microangiopathy
  • Lenvatinib — 13 citations, newest 2026, Hypertension
  • Sirolimus — 13 citations, newest 2019, Glomerular Injury / Proteinuria
  • Carfilzomib — 13 citations, newest 2025, Thrombotic Microangiopathy
  • Ipilimumab — 13 citations, newest 2026, Acute Interstitial Nephritis
  • Cetuximab — 13 citations, newest 2022, Electrolyte Disturbance
  • Carboplatin — 12 citations, newest 2024, Acute Tubular Necrosis
  • Doxorubicin — 12 citations, newest 2026, Glomerular Injury / Proteinuria
  • Gefitinib — 12 citations, newest 2018, Glomerular Injury / Proteinuria
  • Venetoclax — 12 citations, newest 2025, Crystal / Obstructive Nephropathy
  • Lutetium-177 PSMA-617 (vipivotide) — 12 citations, newest 2026, Chronic Interstitial Nephropathy
  • Everolimus — 12 citations, newest 2025, Glomerular Injury / Proteinuria
  • Zoledronic acid — 11 citations, newest 2026, Acute Tubular Necrosis
  • Nedaplatin — 11 citations, newest 2023, Acute Tubular Necrosis
  • Fludarabine — 11 citations, newest 2017, Crystal / Obstructive Nephropathy
  • Ramucirumab — 11 citations, newest 2025, Hypertension
  • Durvalumab — 11 citations, newest 2026, Acute Interstitial Nephritis
  • Cemiplimab — 11 citations, newest 2026, Acute Interstitial Nephritis
  • Selpercatinib — 11 citations, newest 2026, Hypertension
  • Abiraterone — 11 citations, newest 2025, Electrolyte Disturbance
  • Pentostatin — 11 citations, newest 2013, Acute Tubular Necrosis
  • Sorafenib — 11 citations, newest 2021, Hypertension
  • Oxaliplatin — 10 citations, newest 2026, Thrombotic Microangiopathy
  • Methotrexate (high-dose) — 10 citations, newest 2025, Crystal / Obstructive Nephropathy
  • Pemetrexed — 10 citations, newest 2026, Chronic Interstitial Nephropathy
  • Interleukin-2 (high-dose) — 10 citations, newest 2011, Prerenal / Hemodynamic AKI
  • Streptozocin — 10 citations, newest 2026, Fanconi Syndrome
  • Bendamustine — 10 citations, newest 2026, Crystal / Obstructive Nephropathy
  • Clofarabine — 10 citations, newest 2020, Prerenal / Hemodynamic AKI
  • Cabozantinib — 10 citations, newest 2026, Hypertension
  • Regorafenib — 10 citations, newest 2025, Hypertension
  • Elranatamab — 10 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Enfortumab vedotin — 10 citations, newest 2025, Acute Tubular Necrosis
  • Crizotinib — 10 citations, newest 2025, Renal Cysts
  • Tretinoin (ATRA) — 10 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Docetaxel — 10 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Denosumab — 10 citations, newest 2025, Electrolyte Disturbance
  • Fruquintinib — 10 citations, newest 2025, Hypertension
  • Trabectedin — 10 citations, newest 2019, Acute Tubular Necrosis
  • Selinexor — 10 citations, newest 2024, SIADH / Hyponatremia
  • Cladribine — 10 citations, newest 2023, Crystal / Obstructive Nephropathy
  • Ciltacabtagene autoleucel — 10 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Nivolumab — 10 citations, newest 2026, Acute Interstitial Nephritis
  • Panitumumab — 10 citations, newest 2026, Electrolyte Disturbance
  • Trametinib — 10 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Temsirolimus — 10 citations, newest 2016, Glomerular Injury / Proteinuria
  • Camizestrant — 10 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Bevacizumab — 9 citations, newest 2019, Glomerular Injury / Proteinuria
  • CAR-T cell therapy — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Lomustine (CCNU) — 9 citations, newest 2019, Chronic Interstitial Nephropathy
  • Temozolomide — 9 citations, newest 2025, SIADH / Hyponatremia
  • 5-Fluorouracil — 9 citations, newest 2024, Thrombotic Microangiopathy
  • Capecitabine — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Cytarabine — 9 citations, newest 2023, Crystal / Obstructive Nephropathy
  • Plicamycin (mithramycin) — 9 citations, newest 2017, Acute Tubular Necrosis
  • Nintedanib — 9 citations, newest 2026, Hypertension
  • Necitumumab — 9 citations, newest 2021, Electrolyte Disturbance
  • Osimertinib — 9 citations, newest 2026, SIADH / Hyponatremia
  • Erlotinib — 9 citations, newest 2024, Glomerular Injury / Proteinuria
  • Avelumab — 9 citations, newest 2026, Acute Interstitial Nephritis
  • Dostarlimab — 9 citations, newest 2025, Acute Interstitial Nephritis
  • Teclistamab — 9 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Epcoritamab — 9 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Lenalidomide — 9 citations, newest 2025, Acute Tubular Necrosis
  • Imatinib — 9 citations, newest 2024, Electrolyte Disturbance
  • Dasatinib — 9 citations, newest 2025, Glomerular Injury / Proteinuria
  • Ponatinib — 9 citations, newest 2025, Hypertension
  • Bosutinib — 9 citations, newest 2025, Pseudo-AKI
  • Alectinib — 9 citations, newest 2026, Pseudo-AKI
  • Brigatinib — 9 citations, newest 2025, Pseudo-AKI
  • Encorafenib — 9 citations, newest 2022, Acute Tubular Necrosis
  • Binimetinib — 9 citations, newest 2022, Acute Tubular Necrosis
  • Pemigatinib — 9 citations, newest 2025, Electrolyte Disturbance
  • Ibrutinib — 9 citations, newest 2025, Hypertension
  • Arsenic trioxide — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Daratumumab — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Ribociclib — 9 citations, newest 2026, Pseudo-AKI
  • Etoposide — 9 citations, newest 2021, Crystal / Obstructive Nephropathy
  • Vincristine — 9 citations, newest 2024, SIADH / Hyponatremia
  • Paclitaxel — 9 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Cabazitaxel — 9 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Ibandronate — 9 citations, newest 2024, Acute Tubular Necrosis
  • Enzalutamide — 9 citations, newest 2024, Hypertension
  • Idecabtagene vicleucel — 9 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Mitoxantrone — 9 citations, newest 2016, Crystal / Obstructive Nephropathy
  • Pazopanib — 9 citations, newest 2024, Glomerular Injury / Proteinuria
  • Vemurafenib — 9 citations, newest 2021, Acute Tubular Necrosis
  • Dabrafenib — 9 citations, newest 2022, Acute Interstitial Nephritis
  • Iobenguane I-131 — 9 citations, newest 2025, Acute Tubular Necrosis
  • Cyclophosphamide — 8 citations, newest 2023, SIADH / Hyponatremia
  • VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib) — 8 citations, newest 2024, Hypertension
  • mTOR inhibitors (everolimus · temsirolimus) — 8 citations, newest 2019, Glomerular Injury / Proteinuria
  • Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab) — 8 citations, newest 2023, Acute Interstitial Nephritis
  • Interferon-α — 8 citations, newest 2025, Glomerular Injury / Proteinuria
  • BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib) — 8 citations, newest 2022, Acute Tubular Necrosis
  • Melphalan — 8 citations, newest 2025, SIADH / Hyponatremia
  • Busulfan — 8 citations, newest 2019, Thrombotic Microangiopathy
  • Thiotepa — 8 citations, newest 2024, Hemorrhagic Cystitis
  • Pralatrexate — 8 citations, newest 2022, Crystal / Obstructive Nephropathy
  • Azacitidine — 8 citations, newest 2024, Fanconi Syndrome
  • Ziv-aflibercept — 8 citations, newest 2022, Hypertension
  • Afatinib — 8 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Blinatumomab — 8 citations, newest 2022, Prerenal / Hemodynamic AKI
  • Mosunetuzumab — 8 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Ixazomib — 8 citations, newest 2025, Thrombotic Microangiopathy
  • Nilotinib — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Lorlatinib — 8 citations, newest 2025, Pseudo-AKI
  • Olaparib — 8 citations, newest 2026, Pseudo-AKI
  • Niraparib — 8 citations, newest 2026, Hypertension
  • Capmatinib — 8 citations, newest 2025, Pseudo-AKI
  • Tepotinib — 8 citations, newest 2025, Pseudo-AKI
  • Enasidenib — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Acalabrutinib — 8 citations, newest 2025, Hypertension
  • Rituximab — 8 citations, newest 2024, Crystal / Obstructive Nephropathy
  • Obinutuzumab — 8 citations, newest 2025, Crystal / Obstructive Nephropathy
  • Abemaciclib — 8 citations, newest 2026, Pseudo-AKI
  • Palbociclib — 8 citations, newest 2026, Pseudo-AKI
  • Vinblastine — 8 citations, newest 2024, SIADH / Hyponatremia
  • Leuprolide — 8 citations, newest 2024, Hypertension
  • Tarlatamab — 8 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Capivasertib — 8 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Radium-223 dichloride — 8 citations, newest 2022, Prerenal / Hemodynamic AKI
  • Lurbinectedin — 8 citations, newest 2025, Acute Tubular Necrosis
  • Moxetumomab pasudotox — 8 citations, newest 2020, Thrombotic Microangiopathy
  • Denileukin diftitox — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Pegaspargase — 8 citations, newest 2020, Prerenal / Hemodynamic AKI
  • Idarubicin — 8 citations, newest 2023, Crystal / Obstructive Nephropathy
  • Tislelizumab — 8 citations, newest 2026, Acute Interstitial Nephritis
  • Sunitinib — 8 citations, newest 2026, Hypertension
  • Naxitamab — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Lisocabtagene maraleucel — 8 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Gallium nitrate — 8 citations, newest 2003, Acute Tubular Necrosis
  • Tasonermin — 8 citations, newest 2000, Prerenal / Hemodynamic AKI
  • Disitamab vedotin — 8 citations, newest 2026, Acute Tubular Necrosis
  • Anitocabtagene autoleucel — 8 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Carmustine (BCNU) — 7 citations, newest 2012, Chronic Interstitial Nephropathy
  • Hydroxyurea — 7 citations, newest 2020, Crystal / Obstructive Nephropathy
  • Talquetamab — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Trastuzumab emtansine (T-DM1) — 7 citations, newest 2026, Thrombotic Microangiopathy
  • Bortezomib — 7 citations, newest 2025, Thrombotic Microangiopathy
  • Pomalidomide — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Rucaparib — 7 citations, newest 2026, Pseudo-AKI
  • Cobimetinib — 7 citations, newest 2022, Acute Tubular Necrosis
  • Erdafitinib — 7 citations, newest 2024, Electrolyte Disturbance
  • Belzutifan — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Zanubrutinib — 7 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Isatuximab — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Tagraxofusp — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Vinorelbine — 7 citations, newest 2024, SIADH / Hyponatremia
  • Amivantamab — 7 citations, newest 2025, Electrolyte Disturbance
  • Nirogacestat — 7 citations, newest 2024, Electrolyte Disturbance
  • Ruxolitinib — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Momelotinib — 7 citations, newest 2026, Pseudo-AKI
  • Entrectinib — 7 citations, newest 2024, Pseudo-AKI
  • Infigratinib — 7 citations, newest 2025, Electrolyte Disturbance
  • Mobocertinib — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Larotrectinib — 7 citations, newest 2020, Pseudo-AKI
  • Estramustine — 7 citations, newest 2015, Prerenal / Hemodynamic AKI
  • Alpelisib — 7 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Duvelisib — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Gilteritinib — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Midostaurin — 7 citations, newest 2023, Prerenal / Hemodynamic AKI
  • Asciminib — 7 citations, newest 2026, Hypertension
  • Ripretinib — 7 citations, newest 2026, Hypertension
  • Tazemetostat — 7 citations, newest 2022, Prerenal / Hemodynamic AKI
  • Dinutuximab — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Relatlimab — 7 citations, newest 2026, Acute Interstitial Nephritis
  • Trifluridine/tipiracil — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Bleomycin — 7 citations, newest 2021, Prerenal / Hemodynamic AKI
  • Octreotide — 7 citations, newest 2024, Electrolyte Disturbance
  • Toripalimab — 7 citations, newest 2024, Acute Interstitial Nephritis
  • Axitinib — 7 citations, newest 2023, Hypertension
  • Pacritinib — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Avutometinib — 7 citations, newest 2025, Electrolyte Disturbance
  • Fedratinib — 7 citations, newest 2020, Electrolyte Disturbance
  • Odronextamab — 7 citations, newest 2025, Crystal / Obstructive Nephropathy
  • Sonrotoclax — 7 citations, newest 2026, Crystal / Obstructive Nephropathy
  • Iberdomide — 7 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Daraxonrasib — 7 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Pamidronate — 6 citations, newest 2011, Glomerular Injury / Proteinuria
  • Decitabine — 6 citations, newest 2023, Crystal / Obstructive Nephropathy
  • Nelarabine — 6 citations, newest 2020, Crystal / Obstructive Nephropathy
  • Vandetanib — 6 citations, newest 2023, Hypertension
  • Glofitamab — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Trastuzumab deruxtecan — 6 citations, newest 2026, Acute Tubular Necrosis
  • Belantamab mafodotin — 6 citations, newest 2026, Glomerular Injury / Proteinuria
  • Thalidomide — 6 citations, newest 2017, Prerenal / Hemodynamic AKI
  • Ceritinib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Talazoparib — 6 citations, newest 2026, Pseudo-AKI
  • Selumetinib — 6 citations, newest 2023, Prerenal / Hemodynamic AKI
  • Futibatinib — 6 citations, newest 2024, Electrolyte Disturbance
  • Pralsetinib — 6 citations, newest 2025, Hypertension
  • Ivosidenib — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Sotorasib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Adagrasib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Eribulin — 6 citations, newest 2022, Prerenal / Hemodynamic AKI
  • Asparaginase — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Tamoxifen — 6 citations, newest 2023, SIADH / Hyponatremia
  • Datopotamab deruxtecan (Dato-DXd) — 6 citations, newest 2025, Acute Tubular Necrosis
  • Revumenib — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Pirtobrutinib — 6 citations, newest 2024, Crystal / Obstructive Nephropathy
  • Lazertinib — 6 citations, newest 2024, SIADH / Hyponatremia
  • Repotrectinib — 6 citations, newest 2025, Pseudo-AKI
  • Lifileucel — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Quizartinib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Ibritumomab tiuxetan — 6 citations, newest 2004, Prerenal / Hemodynamic AKI
  • Idelalisib — 6 citations, newest 2021, Prerenal / Hemodynamic AKI
  • Copanlisib — 6 citations, newest 2021, Hypertension
  • Vismodegib — 6 citations, newest 2023, SIADH / Hyponatremia
  • Sonidegib — 6 citations, newest 2023, Acute Tubular Necrosis
  • Glasdegib — 6 citations, newest 2023, Prerenal / Hemodynamic AKI
  • Neratinib — 6 citations, newest 2022, Prerenal / Hemodynamic AKI
  • Olutasidenib — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Tafasitamab — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Mogamulizumab — 6 citations, newest 2021, Prerenal / Hemodynamic AKI
  • Lanreotide — 6 citations, newest 2018, Electrolyte Disturbance
  • Mitotane — 6 citations, newest 2025, Electrolyte Disturbance
  • Retifanlimab — 6 citations, newest 2025, Acute Interstitial Nephritis
  • Linvoseltamab — 6 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Pivekimab sunirine — 6 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Tivozanib — 5 citations, newest 2021, Hypertension
  • Sacituzumab govitecan — 5 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Brentuximab vedotin — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Irinotecan — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Zanidatamab — 5 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Imetelstat — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Ziftomenib — 5 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Avapritinib — 5 citations, newest 2021, Prerenal / Hemodynamic AKI
  • Pexidartinib — 5 citations, newest 2023, Prerenal / Hemodynamic AKI
  • Loncastuximab tesirine — 5 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Vinflunine — 5 citations, newest 2019, Electrolyte Disturbance
  • Teniposide — 5 citations, newest 2021, Electrolyte Disturbance
  • Darolutamide — 5 citations, newest 2025, Electrolyte Disturbance
  • Cosibelimab — 5 citations, newest 2025, Acute Interstitial Nephritis
  • Ivonescimab — 5 citations, newest 2025, Glomerular Injury / Proteinuria
  • Olverembatinib — 5 citations, newest 2026, Glomerular Injury / Proteinuria
  • Vimseltinib — 5 citations, newest 2025, Pseudo-AKI
  • Penpulimab — 5 citations, newest 2026, Acute Interstitial Nephritis
  • Sugemalimab — 5 citations, newest 2024, Acute Interstitial Nephritis
  • Ensartinib — 5 citations, newest 2025, Pseudo-AKI
  • Obecabtagene autoleucel (Obe-cel) — 5 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Cadonilimab — 5 citations, newest 2026, Acute Interstitial Nephritis
  • Polatuzumab vedotin — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Mirvetuximab soravtansine — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Gemtuzumab ozogamicin — 4 citations, newest 2020, Prerenal / Hemodynamic AKI
  • Inotuzumab ozogamicin — 4 citations, newest 2023, Prerenal / Hemodynamic AKI
  • Topotecan — 4 citations, newest 2022, Prerenal / Hemodynamic AKI
  • Tovorafenib — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Mirdametinib — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Sunvozertinib — 4 citations, newest 2024, Electrolyte Disturbance
  • Tucatinib — 4 citations, newest 2024, Pseudo-AKI
  • Casdatifan — 4 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Zongertinib — 4 citations, newest 2025, Pseudo-AKI
  • Tisotumab vedotin — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Tebentafusp — 4 citations, newest 2023, Prerenal / Hemodynamic AKI
  • Zolbetuximab — 4 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Elacestrant — 4 citations, newest 2024, Prerenal / Hemodynamic AKI
  • Raltitrexed — 4 citations, newest 2021, Acute Tubular Necrosis
  • Elotuzumab — 4 citations, newest 2017, Prerenal / Hemodynamic AKI
  • Melphalan flufenamide (melflufen) — 4 citations, newest 2026, Acute Tubular Necrosis
  • Procarbazine — 4 citations, newest 2021, Acute Tubular Necrosis
  • Catumaxomab — 4 citations, newest 2017, Prerenal / Hemodynamic AKI
  • Fotemustine — 4 citations, newest 2015, Chronic Interstitial Nephropathy
  • Nimustine (ACNU) — 4 citations, newest 2023, Chronic Interstitial Nephropathy
  • Dactinomycin (actinomycin D) — 4 citations, newest 2017, Electrolyte Disturbance
  • Mechlorethamine — 4 citations, newest 2021, Electrolyte Disturbance
  • Amsacrine — 4 citations, newest 2017, Electrolyte Disturbance
  • Tegafur-uracil (UFT) — 4 citations, newest 2021, Thrombotic Microangiopathy
  • Doxifluridine — 4 citations, newest 2021, Thrombotic Microangiopathy
  • Samarium-153 lexidronam — 4 citations, newest 2014, Acute Tubular Necrosis
  • Bicalutamide — 4 citations, newest 2020, Acute Interstitial Nephritis
  • Strontium-89 chloride — 4 citations, newest 2021, Electrolyte Disturbance
  • Vorasidenib — 4 citations, newest 2026, Pseudo-AKI
  • Taletrectinib — 4 citations, newest 2026, Pseudo-AKI
  • Inavolisib — 4 citations, newest 2024, Electrolyte Disturbance
  • Afamitresgene autoleucel (Afami-cel) — 4 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Zidesamtinib — 4 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Chlorambucil — 3 citations, newest 2021, SIADH / Hyponatremia
  • Altretamine (hexamethylmelamine) — 3 citations, newest 2017, Prerenal / Hemodynamic AKI
  • Carmofur (HCFU) — 3 citations, newest 2021, Thrombotic Microangiopathy
  • Telisotuzumab vedotin (Teliso-V) — 3 citations, newest 2025, Acute Tubular Necrosis
  • Relacorilant — 3 citations, newest 2025, Electrolyte Disturbance
  • Sevabertinib — 3 citations, newest 2026, Prerenal / Hemodynamic AKI
  • Gedatolisib — 3 citations, newest 2026, Electrolyte Disturbance
  • Dacarbazine — 2 citations, newest 2001, Prerenal / Hemodynamic AKI
  • Imlunestrant — 2 citations, newest 2025, Pseudo-AKI
  • Vepdegestrant — 2 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Dordaviprone — 2 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Zenocutuzumab — 2 citations, newest 2025, Prerenal / Hemodynamic AKI
  • Actinium 225 PSMA — 2 citations, newest 2025, Acute Tubular Necrosis
  • Furmonertinib — 2 citations, newest 2026, Electrolyte Disturbance
  • Defactinib — 2 citations, newest 2023, Electrolyte Disturbance
  • promacta — 1 citations, newest 2010, Thrombotic Microangiopathy
  • saruparib — 1 citations, newest 2026, Pseudo-AKI
Figure 11·Each profiled agent by citation depth (x) and newest-reference recency (y); the median crosshairs mark the frontier (fresh & thin, upper-left) and the established core (deep & aging, lower-right).

Published relative risks and odds ratios for kidney-injury associations in cancer therapy, on a log axis with the null line at 1.0. Right of the line is increased risk; left is protective. These are clinical effect sizes from trials and meta-analyses, the complement to the FAERS reporting signals in the section below.

0.250.5125102050100effect size — relative risk / odds ratio (log)PanitumumabGrade 3/4 hypomagnesemia, CRC vs chemo aloneRR 18.29 (7.29–48.41)Severe CRSCAR-T–associated AKIOR 16.4 (1.9–138.5)BevacizumabNephrotic syndromeRR 7.78 (1.8–33.62)Bevacizumab (high dose)HypertensionRR 7.5 (4.2–13.4)CetuximabGrade 3/4 hypomagnesemia, CRC vs chemo aloneRR 7.14 (3.13–16.27)Anti-EGFR mAbAny-grade hypomagnesemia, metastatic CRCOR 6.73 (3.84–11.82)BevacizumabHigh-grade hypertensionRR 5.28 (4.15–6.71)BevacizumabHigh-grade proteinuriaRR 4.79 (2.71–8.46)Bevacizumab (low dose)HypertensionRR 3 (2.2–4.2)Concurrent PPICheckpoint-inhibitor AKIOR 1.84 (1.16–2.9)Magnesium prophylaxisCisplatin AKIOR 0.24 (0.19–0.32) ↓

11 estimates · x = effect size (log), null at 1.0 · whisker = 95% CI · colored by the injury each estimate is for. Effect sizes as reported; heterogeneous designs (RCT meta-analyses, cohorts) — not directly comparable across rows.

Figure 12·Published relative risks and odds ratios for anti-cancer-drug kidney-injury associations, on a log axis with the null at 1.0 — the clinical-trial/meta-analysis complement to the FAERS reporting signals (fig 15). Right of the line is increased risk, left is protective (magnesium prophylaxis against cisplatin AKI); every estimate is quoted from a real PubMed record. Designs are heterogeneous (RCT meta-analyses, cohorts), so rows are not directly comparable.

The rise of onconephrology in the literature: each year's height stacks the clinical PubMed papers matching each of the eight subfield queries behind the contributor atlas — a paper matching two subfields adds to both bands, so the stacked total counts memberships, not distinct papers. The drug-toxicity base gives way to the myeloma/MGRS surge and the checkpoint-inhibitor era. Hover a year; click a band to isolate a subfield.

Onco-nephrology (general)Anticancer drug nephrotoxicityCheckpoint-inhibitor kidney injuryMGRS & paraprotein kidney diseaseMyeloma cast nephropathyAnti-VEGF / TKI renal effectsTumor lysis & electrolytesCellular therapy renal effects199019952000200520102015202020252026 incomplete →

38 years · a paper may match more than one subfield · band height = papers matching that subfield · 2026 is shaded because the corpus was harvested mid-year — its dip is incomplete indexing, not a decline

  • 1990: 165 subfield matches
  • 1991: 151 subfield matches
  • 1992: 144 subfield matches
  • 1993: 156 subfield matches
  • 1994: 164 subfield matches
  • 1995: 177 subfield matches
  • 1996: 176 subfield matches
  • 1997: 172 subfield matches
  • 1998: 168 subfield matches
  • 1999: 177 subfield matches
  • 2000: 174 subfield matches
  • 2001: 186 subfield matches
  • 2002: 164 subfield matches
  • 2003: 196 subfield matches
  • 2004: 203 subfield matches
  • 2005: 244 subfield matches
  • 2006: 204 subfield matches
  • 2007: 309 subfield matches
  • 2008: 284 subfield matches
  • 2009: 294 subfield matches
  • 2010: 374 subfield matches
  • 2011: 386 subfield matches
  • 2012: 452 subfield matches
  • 2013: 436 subfield matches
  • 2014: 523 subfield matches
  • 2015: 590 subfield matches
  • 2016: 621 subfield matches
  • 2017: 605 subfield matches
  • 2018: 682 subfield matches
  • 2019: 728 subfield matches
  • 2020: 997 subfield matches
  • 2021: 1,033 subfield matches
  • 2022: 976 subfield matches
  • 2023: 937 subfield matches
  • 2024: 1,061 subfield matches
  • 2025: 1,226 subfield matches
  • 2026: 1,321 subfield matches
  • 2027: 4 subfield matches
Figure 13·The growth of onconephrology itself: CLINICAL PubMed papers per year across the eight subfield queries behind the contributor atlas (/authors). Where the other figures count the catalog's agents and citations, this counts the field's human/clinical output — the drug-toxicity base giving way to the myeloma/MGRS surge and the checkpoint-inhibitor era.
  • Dispenzieri, Angela and Gertz, Morie A: 76 shared corpus papers
  • Dispenzieri, Angela and Leung, Nelson: 64 shared corpus papers
  • Dispenzieri, Angela and Lacy, Martha Q: 59 shared corpus papers
  • Gertz, Morie A and Lacy, Martha Q: 59 shared corpus papers
  • Leung, Nelson and Nasr, Samih H: 59 shared corpus papers
  • Dimopoulos, Meletios A and Terpos, Evangelos: 57 shared corpus papers
  • Gertz, Morie A and Leung, Nelson: 57 shared corpus papers
  • Dispenzieri, Angela and Kumar, Shaji K: 55 shared corpus papers
  • Gertz, Morie A and Kumar, Shaji K: 52 shared corpus papers
  • Dimopoulos, Meletios A and Kastritis, Efstathios: 50 shared corpus papers
  • Kumar, Shaji K and Leung, Nelson: 47 shared corpus papers
  • Lacy, Martha Q and Leung, Nelson: 44 shared corpus papers
  • Kumar, Shaji K and Lacy, Martha Q: 43 shared corpus papers
  • Dispenzieri, Angela and Kyle, Robert A: 42 shared corpus papers
  • Kastritis, Efstathios and Terpos, Evangelos: 39 shared corpus papers
  • Leung, Nelson and Sethi, Sanjeev: 39 shared corpus papers
  • Nasr, Samih H and Sethi, Sanjeev: 38 shared corpus papers
  • Fervenza, Fernando C and Sethi, Sanjeev: 37 shared corpus papers
  • Gertz, Morie A and Kyle, Robert A: 37 shared corpus papers
  • Kyle, Robert A and Leung, Nelson: 35 shared corpus papers
  • Kumar, Shaji K and Kyle, Robert A: 32 shared corpus papers
  • Kyle, Robert A and Lacy, Martha Q: 31 shared corpus papers
  • Fervenza, Fernando C and Leung, Nelson: 30 shared corpus papers
  • Merlini, Giampaolo and Palladini, Giovanni: 27 shared corpus papers
  • Bridoux, Frank and Leung, Nelson: 23 shared corpus papers
  • Cornell, Lynn D and Nasr, Samih H: 23 shared corpus papers
  • Fervenza, Fernando C and Nasr, Samih H: 23 shared corpus papers
  • Cornell, Lynn D and Leung, Nelson: 21 shared corpus papers
  • Cornell, Lynn D and Sethi, Sanjeev: 21 shared corpus papers
  • Anderson, Kenneth C and Richardson, Paul G: 19 shared corpus papers
  • Bridoux, Frank and Nasr, Samih H: 17 shared corpus papers
  • Dispenzieri, Angela and Nasr, Samih H: 17 shared corpus papers
  • Gupta, Shruti and Leaf, David E: 16 shared corpus papers
  • Herrmann, Sandra M and Leung, Nelson: 14 shared corpus papers
  • D'Agati, Vivette D and Nasr, Samih H: 13 shared corpus papers
  • Dispenzieri, Angela and Fervenza, Fernando C: 13 shared corpus papers
  • Gupta, Shruti and Sise, Meghan E: 13 shared corpus papers
  • Dimopoulos, Meletios A and Richardson, Paul G: 12 shared corpus papers
  • Fervenza, Fernando C and Gertz, Morie A: 12 shared corpus papers
  • D'Agati, Vivette D and Sethi, Sanjeev: 11 shared corpus papers
  • Dispenzieri, Angela and Sethi, Sanjeev: 11 shared corpus papers
  • Gertz, Morie A and Nasr, Samih H: 11 shared corpus papers
  • Kastritis, Efstathios and Merlini, Giampaolo: 11 shared corpus papers
  • Perazella, Mark A and Rosner, Mitchell H: 11 shared corpus papers
  • D'Agati, Vivette D and Leung, Nelson: 10 shared corpus papers
  • Fervenza, Fernando C and Kumar, Shaji K: 10 shared corpus papers
  • Fervenza, Fernando C and Lacy, Martha Q: 10 shared corpus papers
  • Kastritis, Efstathios and Leung, Nelson: 10 shared corpus papers
  • Cornell, Lynn D and Fervenza, Fernando C: 9 shared corpus papers
  • Gertz, Morie A and Sethi, Sanjeev: 9 shared corpus papers
  • Gupta, Shruti and Herrmann, Sandra M: 9 shared corpus papers
  • Gupta, Shruti and Jhaveri, Kenar D: 9 shared corpus papers
  • Herrmann, Sandra M and Kitchlu, Abhijat: 9 shared corpus papers
  • Kyle, Robert A and Nasr, Samih H: 9 shared corpus papers
  • Leaf, David E and Sise, Meghan E: 9 shared corpus papers
  • Abudayyeh, Ala and Gupta, Shruti: 8 shared corpus papers
  • Dimopoulos, Meletios A and Merlini, Giampaolo: 8 shared corpus papers
  • Dispenzieri, Angela and Merlini, Giampaolo: 8 shared corpus papers
  • Gupta, Shruti and Kitchlu, Abhijat: 8 shared corpus papers
  • Jhaveri, Kenar D and Perazella, Mark A: 8 shared corpus papers
  • Lacy, Martha Q and Nasr, Samih H: 8 shared corpus papers
  • Merlini, Giampaolo and Wechalekar, Ashutosh D: 8 shared corpus papers
  • Palladini, Giovanni and Wechalekar, Ashutosh D: 8 shared corpus papers
  • Bridoux, Frank and Dispenzieri, Angela: 7 shared corpus papers
  • Fervenza, Fernando C and Kyle, Robert A: 7 shared corpus papers
  • Herrmann, Sandra M and Sise, Meghan E: 7 shared corpus papers
  • Izzedine, Hassan and Perazella, Mark A: 7 shared corpus papers
  • Kastritis, Efstathios and Palladini, Giovanni: 7 shared corpus papers
  • Kumar, Shaji K and Nasr, Samih H: 7 shared corpus papers
  • Kumar, Shaji K and Sethi, Sanjeev: 7 shared corpus papers
  • Leung, Nelson and Merlini, Giampaolo: 7 shared corpus papers
  • Abudayyeh, Ala and Herrmann, Sandra M: 6 shared corpus papers
  • Abudayyeh, Ala and Kitchlu, Abhijat: 6 shared corpus papers
  • Abudayyeh, Ala and Leaf, David E: 6 shared corpus papers
  • Cornell, Lynn D and D'Agati, Vivette D: 6 shared corpus papers
  • Dimopoulos, Meletios A and Leung, Nelson: 6 shared corpus papers
  • Dispenzieri, Angela and Kastritis, Efstathios: 6 shared corpus papers
  • Gertz, Morie A and Merlini, Giampaolo: 6 shared corpus papers
  • Herrmann, Sandra M and Leaf, David E: 6 shared corpus papers
  • Izzedine, Hassan and Jhaveri, Kenar D: 6 shared corpus papers
  • Jhaveri, Kenar D and Rosner, Mitchell H: 6 shared corpus papers
  • Kastritis, Efstathios and Wechalekar, Ashutosh D: 6 shared corpus papers
  • Kyle, Robert A and Sethi, Sanjeev: 6 shared corpus papers
  • Azoulay, Elie and Zafrani, Lara: 5 shared corpus papers
  • Bridoux, Frank and Kastritis, Efstathios: 5 shared corpus papers
  • Bridoux, Frank and Sethi, Sanjeev: 5 shared corpus papers
  • Bridoux, Frank and Merlini, Giampaolo: 5 shared corpus papers
  • Hutchison, Colin A and Leung, Nelson: 5 shared corpus papers
  • Jhaveri, Kenar D and Sise, Meghan E: 5 shared corpus papers
  • Kastritis, Efstathios and Kyle, Robert A: 5 shared corpus papers
  • Kitchlu, Abhijat and Leaf, David E: 5 shared corpus papers
  • Kyle, Robert A and Merlini, Giampaolo: 5 shared corpus papers
  • Lacy, Martha Q and Sethi, Sanjeev: 5 shared corpus papers
  • Merlini, Giampaolo and Terpos, Evangelos: 5 shared corpus papers
  • Richardson, Paul G and Terpos, Evangelos: 5 shared corpus papers
  • Abudayyeh, Ala and Jhaveri, Kenar D: 4 shared corpus papers
  • Abudayyeh, Ala and Sise, Meghan E: 4 shared corpus papers
  • Bridoux, Frank and D'Agati, Vivette D: 4 shared corpus papers
  • Bridoux, Frank and Kyle, Robert A: 4 shared corpus papers
  • Bridoux, Frank and Hutchison, Colin A: 4 shared corpus papers
  • Cornell, Lynn D and Dispenzieri, Angela: 4 shared corpus papers
  • Cornell, Lynn D and Gertz, Morie A: 4 shared corpus papers
  • D'Agati, Vivette D and Fervenza, Fernando C: 4 shared corpus papers
  • Dimopoulos, Meletios A and Palladini, Giovanni: 4 shared corpus papers
  • Dispenzieri, Angela and Palladini, Giovanni: 4 shared corpus papers
  • Dispenzieri, Angela and Hutchison, Colin A: 4 shared corpus papers
  • Fervenza, Fernando C and Herrmann, Sandra M: 4 shared corpus papers
  • Gertz, Morie A and Palladini, Giovanni: 4 shared corpus papers
  • Gratama, Jan W and Lamers, Cor H J: 4 shared corpus papers
  • Gupta, Shruti and Rosner, Mitchell H: 4 shared corpus papers
  • Herrmann, Sandra M and Rosner, Mitchell H: 4 shared corpus papers
  • Herrmann, Sandra M and Jhaveri, Kenar D: 4 shared corpus papers
  • Hutchison, Colin A and Kyle, Robert A: 4 shared corpus papers
  • Jhaveri, Kenar D and Leaf, David E: 4 shared corpus papers
  • Kastritis, Efstathios and Richardson, Paul G: 4 shared corpus papers
  • Kitchlu, Abhijat and Sise, Meghan E: 4 shared corpus papers
  • Leung, Nelson and Terpos, Evangelos: 4 shared corpus papers
  • Leung, Nelson and Wechalekar, Ashutosh D: 4 shared corpus papers
  • Abudayyeh, Ala and Rosner, Mitchell H: 3 shared corpus papers
  • Anderson, Kenneth C and Dimopoulos, Meletios A: 3 shared corpus papers
  • Anderson, Kenneth C and Kumar, Shaji K: 3 shared corpus papers
  • Anderson, Kenneth C and Kyle, Robert A: 3 shared corpus papers
  • Bridoux, Frank and Dimopoulos, Meletios A: 3 shared corpus papers
  • Bridoux, Frank and Wechalekar, Ashutosh D: 3 shared corpus papers
  • Dimopoulos, Meletios A and Dispenzieri, Angela: 3 shared corpus papers
  • Dimopoulos, Meletios A and Kumar, Shaji K: 3 shared corpus papers
  • Dispenzieri, Angela and Wechalekar, Ashutosh D: 3 shared corpus papers
  • Gupta, Shruti and Perazella, Mark A: 3 shared corpus papers
  • Herrmann, Sandra M and Sethi, Sanjeev: 3 shared corpus papers
  • Kastritis, Efstathios and Kumar, Shaji K: 3 shared corpus papers
  • Kitchlu, Abhijat and Leung, Nelson: 3 shared corpus papers
  • Kitchlu, Abhijat and Rosner, Mitchell H: 3 shared corpus papers
  • Kumar, Shaji K and Merlini, Giampaolo: 3 shared corpus papers
  • Kumar, Shaji K and Wechalekar, Ashutosh D: 3 shared corpus papers
  • Leung, Nelson and Rosner, Mitchell H: 3 shared corpus papers
  • Leung, Nelson and Richardson, Paul G: 3 shared corpus papers
  • Marasco, Wayne A and Suarez, Eloah Rabello: 3 shared corpus papers
  • Merlini, Giampaolo and Nasr, Samih H: 3 shared corpus papers
  • Merlini, Giampaolo and Sethi, Sanjeev: 3 shared corpus papers
  • Merlini, Giampaolo and Richardson, Paul G: 3 shared corpus papers
  • Abudayyeh, Ala and Leung, Nelson: 2 shared corpus papers
  • Anderson, Kenneth C and Terpos, Evangelos: 2 shared corpus papers
  • Bridoux, Frank and Jhaveri, Kenar D: 2 shared corpus papers
  • Bridoux, Frank and Terpos, Evangelos: 2 shared corpus papers
  • Bridoux, Frank and Cornell, Lynn D: 2 shared corpus papers
  • Bridoux, Frank and Palladini, Giovanni: 2 shared corpus papers
  • Bridoux, Frank and Fervenza, Fernando C: 2 shared corpus papers
  • Chen, Helen X and Rini, Brian I: 2 shared corpus papers
  • Cornell, Lynn D and Lacy, Martha Q: 2 shared corpus papers
  • D'Agati, Vivette D and Wechalekar, Ashutosh D: 2 shared corpus papers
  • Dimopoulos, Meletios A and Wechalekar, Ashutosh D: 2 shared corpus papers
  • Dimopoulos, Meletios A and Gertz, Morie A: 2 shared corpus papers
  • Dispenzieri, Angela and Herrmann, Sandra M: 2 shared corpus papers
  • Fervenza, Fernando C and Kastritis, Efstathios: 2 shared corpus papers
  • Fervenza, Fernando C and Merlini, Giampaolo: 2 shared corpus papers
  • Fervenza, Fernando C and Wechalekar, Ashutosh D: 2 shared corpus papers
  • Gertz, Morie A and Kastritis, Efstathios: 2 shared corpus papers
  • Gertz, Morie A and Wechalekar, Ashutosh D: 2 shared corpus papers
  • Gertz, Morie A and Herrmann, Sandra M: 2 shared corpus papers
  • Gupta, Shruti and Leung, Nelson: 2 shared corpus papers
  • Herrmann, Sandra M and Nasr, Samih H: 2 shared corpus papers
  • Herrmann, Sandra M and Kumar, Shaji K: 2 shared corpus papers
  • Herrmann, Sandra M and Perazella, Mark A: 2 shared corpus papers
  • Herrmann, Sandra M and Lacy, Martha Q: 2 shared corpus papers
  • Hutchison, Colin A and Nasr, Samih H: 2 shared corpus papers
  • Hutchison, Colin A and Kastritis, Efstathios: 2 shared corpus papers
  • Jhaveri, Kenar D and Leung, Nelson: 2 shared corpus papers
  • Jhaveri, Kenar D and Kitchlu, Abhijat: 2 shared corpus papers
  • Kastritis, Efstathios and Nasr, Samih H: 2 shared corpus papers
  • Kastritis, Efstathios and Sethi, Sanjeev: 2 shared corpus papers
  • Kumar, Shaji K and Palladini, Giovanni: 2 shared corpus papers
  • Kumar, Shaji K and Richardson, Paul G: 2 shared corpus papers
  • Leaf, David E and Perazella, Mark A: 2 shared corpus papers
  • Leaf, David E and Rosner, Mitchell H: 2 shared corpus papers
  • Leung, Nelson and Palladini, Giovanni: 2 shared corpus papers
  • Nasr, Samih H and Wechalekar, Ashutosh D: 2 shared corpus papers
  • Sethi, Sanjeev and Wechalekar, Ashutosh D: 2 shared corpus papers
  • Anderson, Kenneth C and Leung, Nelson: 1 shared corpus paper
  • Anderson, Kenneth C and Dispenzieri, Angela: 1 shared corpus paper
  • Anderson, Kenneth C and Kastritis, Efstathios: 1 shared corpus paper
  • Anderson, Kenneth C and Merlini, Giampaolo: 1 shared corpus paper
  • Anderson, Kenneth C and Gupta, Shruti: 1 shared corpus paper
  • Bridoux, Frank and Richardson, Paul G: 1 shared corpus paper
  • Cornell, Lynn D and Kumar, Shaji K: 1 shared corpus paper
  • Cornell, Lynn D and Kyle, Robert A: 1 shared corpus paper
  • Cornell, Lynn D and Herrmann, Sandra M: 1 shared corpus paper
  • Cornell, Lynn D and Gupta, Shruti: 1 shared corpus paper
  • Cornell, Lynn D and Sise, Meghan E: 1 shared corpus paper
  • Cornell, Lynn D and Leaf, David E: 1 shared corpus paper
  • D'Agati, Vivette D and Dispenzieri, Angela: 1 shared corpus paper
  • D'Agati, Vivette D and Kumar, Shaji K: 1 shared corpus paper
  • D'Agati, Vivette D and Kyle, Robert A: 1 shared corpus paper
  • D'Agati, Vivette D and Kastritis, Efstathios: 1 shared corpus paper
  • D'Agati, Vivette D and Merlini, Giampaolo: 1 shared corpus paper
  • Dimopoulos, Meletios A and Jhaveri, Kenar D: 1 shared corpus paper
  • Dimopoulos, Meletios A and Lacy, Martha Q: 1 shared corpus paper
  • Dimopoulos, Meletios A and Kyle, Robert A: 1 shared corpus paper
  • Dispenzieri, Angela and Richardson, Paul G: 1 shared corpus paper
  • Dispenzieri, Angela and Terpos, Evangelos: 1 shared corpus paper
  • Fervenza, Fernando C and Hutchison, Colin A: 1 shared corpus paper
  • Gertz, Morie A and Hutchison, Colin A: 1 shared corpus paper
  • Herrmann, Sandra M and Kyle, Robert A: 1 shared corpus paper
  • Hutchison, Colin A and Sethi, Sanjeev: 1 shared corpus paper
  • Hutchison, Colin A and Kumar, Shaji K: 1 shared corpus paper
  • Hutchison, Colin A and Merlini, Giampaolo: 1 shared corpus paper
  • Jhaveri, Kenar D and Nasr, Samih H: 1 shared corpus paper
  • Jhaveri, Kenar D and Terpos, Evangelos: 1 shared corpus paper
  • Jhaveri, Kenar D and Kastritis, Efstathios: 1 shared corpus paper
  • Kitchlu, Abhijat and Perazella, Mark A: 1 shared corpus paper
  • Kumar, Shaji K and Terpos, Evangelos: 1 shared corpus paper
  • Kyle, Robert A and Terpos, Evangelos: 1 shared corpus paper
  • Kyle, Robert A and Wechalekar, Ashutosh D: 1 shared corpus paper
  • Kyle, Robert A and Palladini, Giovanni: 1 shared corpus paper
  • Kyle, Robert A and Richardson, Paul G: 1 shared corpus paper
  • Palladini, Giovanni and Terpos, Evangelos: 1 shared corpus paper
Jhaveri, Kenar DIzzedine, HassanRosner, Mitchell HPerazella, Mark AHerrmann, Sandra MGupta, ShrutiAbudayyeh, AlaDong, ZhengSise, Meghan EKitchlu, AbhijatLeaf, David ELeung, NelsonDispenzieri, AngelaGertz, Morie ANasr, Samih HBridoux, FrankKumar, Shaji KSethi, SanjeevKyle, Robert ALacy, Martha QFervenza, Fernando CMerlini, GiampaoloWechalekar, Ashutosh DPalladini, GiovanniCornell, Lynn DD'Agati, Vivette DDimopoulos, Meletios ATerpos, EvangelosKastritis, EfstathiosAnderson, Kenneth CRichardson, Paul GHutchison, Colin AChen, Helen XRini, Brian IPazdur, RichardKumada, HiromitsuAzoulay, ElieZafrani, LaraJohnson, Richard JMalaguarnera, MarianoMirrakhimov, Aibek EZheng, JunnianLamers, Cor H JMarasco, Wayne ASuarez, Eloah RabelloGratama, Jan W
  • Onco-nephrology (general)
  • Anticancer drug nephrotoxicity
  • MGRS & paraprotein kidney disease
  • Myeloma cast nephropathy
  • Anti-VEGF / TKI renal effects
  • Tumor lysis & electrolytes
  • Cellular therapy renal effects

Hover, tap, or focus a node to trace its co-authorship links and reach the contributor page.

Arcs and co-author counts are drawn only between recognized contributors, and papers with more than 40 authors are left out of the pair tally — a lower bound on the full collaboration graph, not a complete count.

Figure 14·The onconephrology co-authorship structure: each recognized contributor (/authors) sits on the ring inside their primary-subfield sector, and an arc joins two contributors who share corpus papers, weighted by shared-paper count — the dense myeloma/MGRS core, the smaller tumor-lysis and cellular-therapy clusters, and the few names that bridge subfields.

FAERS & real-world signals

What spontaneous reporting shows — disproportionate reporting, never incidence.

Each agent's acute-kidney-injury reporting odds ratio (horizontal, log) against its AKI report count (vertical, log). A dot right of the ROR = 1 line has a point estimate above 1; it reports AKI disproportionately only when its whisker clears the line too (filled). Size = total report volume.

ROR = 10.1×0.25×0.5×1×2×4×8×16×1101001000AKI reporting odds ratio (log)AKI reports (log)Lifileucel (Prerenal / Hemodynamic AKI): ROR 8.22 (95% CI 5.37–12.58), 23 AKI reports of 285 total — signal; IC025 2.09Clofarabine (Prerenal / Hemodynamic AKI): ROR 5.51 (95% CI 4.60–6.58), 127 AKI reports of 2,287 total — signal; IC025 2.11Interleukin-2 (high-dose) (Prerenal / Hemodynamic AKI): ROR 5.41 (95% CI 4.24–6.90), 69 AKI reports of 1,263 total — signal; IC025 1.97Trabectedin (Acute Tubular Necrosis): ROR 4.69 (95% CI 3.88–5.67), 112 AKI reports of 2,350 total — signal; IC025 1.87Tagraxofusp (Prerenal / Hemodynamic AKI): ROR 4.37 (95% CI 2.90–6.58), 24 AKI reports of 538 total — signal; IC025 1.35Streptozocin (Fanconi Syndrome): ROR 4.04 (95% CI 2.08–7.87), 9 AKI reports of 245 total — signal; IC025 0.67Pemetrexed (Chronic Interstitial Nephropathy): ROR 3.88 (95% CI 3.69–4.08), 1,547 AKI reports of 39,105 total — signal; IC025 1.83Idecabtagene vicleucel (Prerenal / Hemodynamic AKI): ROR 3.77 (95% CI 2.82–5.03), 48 AKI reports of 1,241 total — signal; IC025 1.40Sirolimus (Glomerular Injury / Proteinuria): ROR 3.65 (95% CI 3.34–3.98), 512 AKI reports of 13,673 total — signal; IC025 1.69Adagrasib (Prerenal / Hemodynamic AKI): ROR 3.48 (95% CI 2.49–4.84), 36 AKI reports of 1,134 total — signal; IC025 1.21Cisplatin (Acute Tubular Necrosis): ROR 3.43 (95% CI 3.30–3.56), 2,766 AKI reports of 79,025 total — signal; IC025 1.67Retifanlimab (Acute Interstitial Nephritis): ROR 3.40 (95% CI 1.51–7.67), 6 AKI reports of 193 total — signal; IC025 0.12Pamidronate (Glomerular Injury / Proteinuria): ROR 3.16 (95% CI 2.65–3.77), 127 AKI reports of 4,390 total — signal; IC025 1.36Carfilzomib (Thrombotic Microangiopathy): ROR 3.11 (95% CI 2.91–3.32), 909 AKI reports of 28,379 total — signal; IC025 1.50Cobimetinib (Acute Tubular Necrosis): ROR 3.05 (95% CI 2.58–3.61), 140 AKI reports of 4,436 total — signal; IC025 1.32Inavolisib (Electrolyte Disturbance): ROR 3.03 (95% CI 1.96–4.68), 21 AKI reports of 670 total — signal; IC025 0.82Melphalan (SIADH / Hyponatremia): ROR 2.94 (95% CI 2.73–3.16), 768 AKI reports of 25,290 total — signal; IC025 1.42Gemtuzumab ozogamicin (Prerenal / Hemodynamic AKI): ROR 2.82 (95% CI 2.32–3.41), 107 AKI reports of 3,665 total — signal; IC025 1.17Lurbinectedin (Acute Tubular Necrosis): ROR 2.78 (95% CI 1.93–3.99), 30 AKI reports of 1,175 total — signal; IC025 0.85Fludarabine (Crystal / Obstructive Nephropathy): ROR 2.66 (95% CI 2.51–2.83), 1,098 AKI reports of 39,838 total — signal; IC025 1.29Pembrolizumab (Acute Interstitial Nephritis): ROR 2.59 (95% CI 2.49–2.69), 2,572 AKI reports of 109,044 total — signal; IC025 1.28Isatuximab (Prerenal / Hemodynamic AKI): ROR 2.58 (95% CI 2.20–3.02), 157 AKI reports of 5,853 total — signal; IC025 1.10Cytarabine (Crystal / Obstructive Nephropathy): ROR 2.57 (95% CI 2.45–2.70), 1,679 AKI reports of 63,055 total — signal; IC025 1.26Ifosfamide (Fanconi Syndrome): ROR 2.50 (95% CI 2.29–2.72), 557 AKI reports of 21,470 total — signal; IC025 1.17Avelumab (Acute Interstitial Nephritis): ROR 2.42 (95% CI 1.97–2.97), 93 AKI reports of 4,169 total — signal; IC025 0.94Carboplatin (Acute Tubular Necrosis): ROR 2.41 (95% CI 2.33–2.50), 3,233 AKI reports of 130,075 total — signal; IC025 1.18Carmustine (BCNU) (Chronic Interstitial Nephropathy): ROR 2.38 (95% CI 1.98–2.86), 117 AKI reports of 4,718 total — signal; IC025 0.95; 14 of the AKI reports look like one case filed repeatedlyGemcitabine (Thrombotic Microangiopathy): ROR 2.36 (95% CI 2.24–2.50), 1,326 AKI reports of 54,066 total — signal; IC025 1.13Zanidatamab (Prerenal / Hemodynamic AKI): ROR 2.34 (95% CI 0.57–9.52), 2 AKI reports of 82 total; IC025 −1.72Etoposide (Crystal / Obstructive Nephropathy): ROR 2.33 (95% CI 2.23–2.45), 1,814 AKI reports of 74,949 total — signal; IC025 1.13Epcoritamab (Prerenal / Hemodynamic AKI): ROR 2.27 (95% CI 1.81–2.83), 79 AKI reports of 3,771 total — signal; IC025 0.82; 10 of the AKI reports look like one case filed repeatedlyThiotepa (Hemorrhagic Cystitis): ROR 2.27 (95% CI 1.99–2.59), 231 AKI reports of 9,762 total — signal; IC025 0.97Binimetinib (Acute Tubular Necrosis): ROR 2.23 (95% CI 1.93–2.58), 185 AKI reports of 7,953 total — signal; IC025 0.92Encorafenib (Acute Tubular Necrosis): ROR 2.23 (95% CI 1.96–2.54), 237 AKI reports of 10,191 total — signal; IC025 0.94Bendamustine (Crystal / Obstructive Nephropathy): ROR 2.19 (95% CI 2.01–2.38), 550 AKI reports of 24,082 total — signal; IC025 0.99Zoledronic acid (Acute Tubular Necrosis): ROR 2.13 (95% CI 2.02–2.25), 1,314 AKI reports of 66,922 total — signal; IC025 0.99Mogamulizumab (Prerenal / Hemodynamic AKI): ROR 2.10 (95% CI 1.51–2.90), 37 AKI reports of 1,908 total — signal; IC025 0.53Busulfan (Thrombotic Microangiopathy): ROR 2.09 (95% CI 1.88–2.32), 347 AKI reports of 15,927 total — signal; IC025 0.89Pirtobrutinib (Crystal / Obstructive Nephropathy): ROR 2.09 (95% CI 1.33–3.30), 19 AKI reports of 981 total — signal; IC025 0.29Ipilimumab (Acute Interstitial Nephritis): ROR 2.08 (95% CI 1.95–2.22), 951 AKI reports of 43,846 total — signal; IC025 0.94Temsirolimus (Glomerular Injury / Proteinuria): ROR 2.08 (95% CI 1.70–2.54), 98 AKI reports of 4,507 total — signal; IC025 0.73Enfortumab vedotin (Acute Tubular Necrosis): ROR 2.07 (95% CI 1.78–2.41), 170 AKI reports of 7,851 total — signal; IC025 0.80Vinorelbine (SIADH / Hyponatremia): ROR 2.05 (95% CI 1.74–2.41), 149 AKI reports of 6,966 total — signal; IC025 0.77Linvoseltamab (Prerenal / Hemodynamic AKI): ROR 2.04 (95% CI 0.28–14.74), 1 AKI reports of 53 total; IC025 −3.21Atezolizumab (Acute Interstitial Nephritis): ROR 2.03 (95% CI 1.89–2.19), 752 AKI reports of 40,046 total — signal; IC025 0.90Vemurafenib (Acute Tubular Necrosis): ROR 2.01 (95% CI 1.77–2.28), 252 AKI reports of 11,991 total — signal; IC025 0.80Oxaliplatin (Thrombotic Microangiopathy): ROR 2.00 (95% CI 1.90–2.10), 1,579 AKI reports of 75,953 total — signal; IC025 0.90Pegaspargase (Prerenal / Hemodynamic AKI): ROR 1.99 (95% CI 1.76–2.26), 258 AKI reports of 12,377 total — signal; IC025 0.80Inotuzumab ozogamicin (Prerenal / Hemodynamic AKI): ROR 1.98 (95% CI 1.54–2.55), 62 AKI reports of 2,992 total — signal; IC025 0.585-Fluorouracil (Thrombotic Microangiopathy): ROR 1.96 (95% CI 1.86–2.06), 1,607 AKI reports of 78,755 total — signal; IC025 0.88Nelarabine (Crystal / Obstructive Nephropathy): ROR 1.96 (95% CI 1.26–3.06), 20 AKI reports of 974 total — signal; IC025 0.22Capivasertib (Prerenal / Hemodynamic AKI): ROR 1.94 (95% CI 1.48–2.53), 55 AKI reports of 3,064 total — signal; IC025 0.52Pentostatin (Acute Tubular Necrosis): ROR 1.94 (95% CI 1.04–3.63), 10 AKI reports of 555 total — signal; IC025 −0.15, which does not clear 0Raltitrexed (Acute Tubular Necrosis): ROR 1.93 (95% CI 1.09–3.41), 12 AKI reports of 672 total — signal; IC025 −0.05, which does not clear 0Relacorilant (Electrolyte Disturbance): ROR 1.93 (95% CI 0.48–7.83), 2 AKI reports of 99 total; IC025 −1.90Procarbazine (Acute Tubular Necrosis): ROR 1.92 (95% CI 1.61–2.28), 130 AKI reports of 7,315 total — signal; IC025 0.66Brentuximab vedotin (Prerenal / Hemodynamic AKI): ROR 1.91 (95% CI 1.67–2.19), 208 AKI reports of 10,402 total — signal; IC025 0.71Elotuzumab (Prerenal / Hemodynamic AKI): ROR 1.90 (95% CI 1.56–2.31), 103 AKI reports of 5,171 total — signal; IC025 0.62Vincristine (SIADH / Hyponatremia): ROR 1.90 (95% CI 1.75–2.07), 588 AKI reports of 29,521 total — signal; IC025 0.79Nivolumab (Acute Interstitial Nephritis): ROR 1.88 (95% CI 1.80–1.97), 1,935 AKI reports of 98,547 total — signal; IC025 0.83Idelalisib (Prerenal / Hemodynamic AKI): ROR 1.87 (95% CI 1.57–2.24), 124 AKI reports of 7,144 total — signal; IC025 0.62Amsacrine (Electrolyte Disturbance): ROR 1.80 (95% CI 0.93–3.48), 9 AKI reports of 538 total; IC025 −0.31Cyclophosphamide (SIADH / Hyponatremia): ROR 1.80 (95% CI 1.74–1.87), 3,364 AKI reports of 179,391 total — signal; IC025 0.78Denileukin diftitox (Prerenal / Hemodynamic AKI): ROR 1.80 (95% CI 0.25–12.96), 1 AKI reports of 60 total; IC025 −3.30Bortezomib (Thrombotic Microangiopathy): ROR 1.78 (95% CI 1.69–1.86), 1,669 AKI reports of 89,993 total — signal; IC025 0.74Tisotumab vedotin (Prerenal / Hemodynamic AKI): ROR 1.78 (95% CI 1.08–2.91), 16 AKI reports of 971 total — signal; IC025 −0.01, which does not clear 0Gilteritinib (Prerenal / Hemodynamic AKI): ROR 1.77 (95% CI 1.42–2.22), 78 AKI reports of 4,738 total — signal; IC025 0.47Neratinib (Prerenal / Hemodynamic AKI): ROR 1.77 (95% CI 1.31–2.39), 43 AKI reports of 2,319 total — signal; IC025 0.33; 13 of the AKI reports look like one case filed repeatedly, and without them the ratio does not clear 1Lisocabtagene maraleucel (Prerenal / Hemodynamic AKI): ROR 1.74 (95% CI 1.06–2.85), 16 AKI reports of 876 total — signal; IC025 −0.04, which does not clear 0Arsenic trioxide (Prerenal / Hemodynamic AKI): ROR 1.70 (95% CI 1.34–2.14), 72 AKI reports of 4,043 total — signal; IC025 0.39Bicalutamide (Acute Interstitial Nephritis): ROR 1.69 (95% CI 1.50–1.90), 271 AKI reports of 15,311 total — signal; IC025 0.56Everolimus (Glomerular Injury / Proteinuria): ROR 1.69 (95% CI 1.58–1.81), 881 AKI reports of 49,667 total — signal; IC025 0.65Lenvatinib (Hypertension): ROR 1.69 (95% CI 1.56–1.83), 622 AKI reports of 39,694 total — signal; IC025 0.63Cabazitaxel (Prerenal / Hemodynamic AKI): ROR 1.68 (95% CI 1.31–2.16), 62 AKI reports of 3,517 total — signal; IC025 0.35Doxorubicin (Glomerular Injury / Proteinuria): ROR 1.68 (95% CI 1.60–1.76), 1,704 AKI reports of 97,231 total — signal; IC025 0.66Relatlimab (Acute Interstitial Nephritis): ROR 1.66 (95% CI 0.86–3.22), 9 AKI reports of 515 total; IC025 −0.42Tafasitamab (Prerenal / Hemodynamic AKI): ROR 1.65 (95% CI 1.21–2.25), 41 AKI reports of 2,675 total — signal; IC025 0.23Vinblastine (SIADH / Hyponatremia): ROR 1.65 (95% CI 1.18–2.32), 34 AKI reports of 1,961 total — signal; IC025 0.17Abemaciclib (Pseudo-AKI): ROR 1.63 (95% CI 1.47–1.82), 325 AKI reports of 21,412 total — signal; IC025 0.54Mitoxantrone (Crystal / Obstructive Nephropathy): ROR 1.60 (95% CI 1.32–1.95), 106 AKI reports of 6,289 total — signal; IC025 0.38Hydroxyurea (Crystal / Obstructive Nephropathy): ROR 1.58 (95% CI 1.42–1.75), 353 AKI reports of 21,340 total — signal; IC025 0.49Infigratinib (Electrolyte Disturbance): ROR 1.58 (95% CI 0.22–11.39), 1 AKI reports of 68 total; IC025 −3.40Daratumumab (Prerenal / Hemodynamic AKI): ROR 1.57 (95% CI 1.45–1.69), 655 AKI reports of 44,998 total — signal; IC025 0.53Decitabine (Crystal / Obstructive Nephropathy): ROR 1.57 (95% CI 1.27–1.94), 88 AKI reports of 5,334 total — signal; IC025 0.32Belantamab mafodotin (Glomerular Injury / Proteinuria): ROR 1.52 (95% CI 1.13–2.05), 44 AKI reports of 3,110 total — signal; IC025 0.13Paclitaxel (Prerenal / Hemodynamic AKI): ROR 1.52 (95% CI 1.45–1.60), 1,618 AKI reports of 101,259 total — signal; IC025 0.52Cemiplimab (Acute Interstitial Nephritis): ROR 1.51 (95% CI 1.07–2.13), 33 AKI reports of 2,083 total — signal; IC025 0.04Vandetanib (Hypertension): ROR 1.50 (95% CI 0.94–2.40), 18 AKI reports of 1,286 total; IC025 −0.18Irinotecan (Prerenal / Hemodynamic AKI): ROR 1.48 (95% CI 1.29–1.70), 205 AKI reports of 13,147 total — signal; IC025 0.35Momelotinib (Pseudo-AKI): ROR 1.48 (95% CI 0.98–2.23), 23 AKI reports of 1,481 total; IC025 −0.11Asparaginase (Prerenal / Hemodynamic AKI): ROR 1.47 (95% CI 0.96–2.26), 21 AKI reports of 1,533 total; IC025 −0.15Afatinib (Prerenal / Hemodynamic AKI): ROR 1.45 (95% CI 1.19–1.76), 101 AKI reports of 6,622 total — signal; IC025 0.23Necitumumab (Electrolyte Disturbance): ROR 1.43 (95% CI 0.64–3.21), 6 AKI reports of 450 total; IC025 −0.91Bleomycin (Prerenal / Hemodynamic AKI): ROR 1.42 (95% CI 1.21–1.67), 155 AKI reports of 10,369 total — signal; IC025 0.26Entrectinib (Pseudo-AKI): ROR 1.40 (95% CI 0.92–2.13), 22 AKI reports of 1,691 total; IC025 −0.20Glasdegib (Prerenal / Hemodynamic AKI): ROR 1.40 (95% CI 0.67–2.96), 7 AKI reports of 474 total; IC025 −0.82Rituximab (Crystal / Obstructive Nephropathy): ROR 1.38 (95% CI 1.34–1.43), 3,173 AKI reports of 218,782 total — signal; IC025 0.41Azacitidine (Fanconi Syndrome): ROR 1.37 (95% CI 1.25–1.51), 436 AKI reports of 30,141 total — signal; IC025 0.31Ibritumomab tiuxetan (Prerenal / Hemodynamic AKI): ROR 1.37 (95% CI 0.90–2.09), 22 AKI reports of 1,524 total; IC025 −0.23Tucatinib (Pseudo-AKI): ROR 1.37 (95% CI 1.12–1.69), 91 AKI reports of 7,112 total — signal; IC025 0.14Obecabtagene autoleucel (Obe-cel) (Prerenal / Hemodynamic AKI): ROR 1.34 (95% CI 0.19–9.63), 1 AKI reports of 71 total; IC025 −3.53Copanlisib (Hypertension): ROR 1.33 (95% CI 0.55–3.22), 5 AKI reports of 403 total; IC025 −1.16Dinutuximab (Prerenal / Hemodynamic AKI): ROR 1.33 (95% CI 0.75–2.34), 12 AKI reports of 859 total; IC025 −0.55Cetuximab (Electrolyte Disturbance): ROR 1.32 (95% CI 1.20–1.45), 440 AKI reports of 31,704 total — signal; IC025 0.25Ceritinib (Prerenal / Hemodynamic AKI): ROR 1.31 (95% CI 0.94–1.82), 36 AKI reports of 2,947 total; IC025 −0.13Talquetamab (Prerenal / Hemodynamic AKI): ROR 1.31 (95% CI 0.90–1.90), 28 AKI reports of 2,290 total; IC025 −0.20Abiraterone (Electrolyte Disturbance): ROR 1.29 (95% CI 1.19–1.40), 559 AKI reports of 41,137 total — signal; IC025 0.24Iberdomide (Prerenal / Hemodynamic AKI): ROR 1.27 (95% CI 0.32–5.14), 2 AKI reports of 149 total; IC025 −2.32Temozolomide (SIADH / Hyponatremia): ROR 1.26 (95% CI 1.12–1.42), 283 AKI reports of 21,320 total — signal; IC025 0.15Obinutuzumab (Crystal / Obstructive Nephropathy): ROR 1.24 (95% CI 1.08–1.43), 206 AKI reports of 17,772 total — signal; IC025 0.11Panitumumab (Electrolyte Disturbance): ROR 1.24 (95% CI 1.08–1.42), 210 AKI reports of 16,107 total — signal; IC025 0.10Zolbetuximab (Prerenal / Hemodynamic AKI): ROR 1.24 (95% CI 0.80–1.93), 20 AKI reports of 1,525 total; IC025 −0.40Docetaxel (Prerenal / Hemodynamic AKI): ROR 1.19 (95% CI 1.12–1.28), 858 AKI reports of 68,125 total — signal; IC025 0.15Tretinoin (ATRA) (Prerenal / Hemodynamic AKI): ROR 1.18 (95% CI 0.97–1.42), 111 AKI reports of 8,951 total; IC025 −0.05Bevacizumab (Glomerular Injury / Proteinuria): ROR 1.18 (95% CI 1.13–1.24), 1,630 AKI reports of 130,956 total — signal; IC025 0.16Ixazomib (Thrombotic Microangiopathy): ROR 1.17 (95% CI 1.05–1.30), 354 AKI reports of 28,726 total — signal; IC025 0.07Mobocertinib (Prerenal / Hemodynamic AKI): ROR 1.17 (95% CI 0.58–2.34), 8 AKI reports of 735 total; IC025 −0.96Chlorambucil (SIADH / Hyponatremia): ROR 1.16 (95% CI 0.87–1.54), 48 AKI reports of 3,932 total; IC025 −0.23Imlunestrant (Pseudo-AKI): ROR 1.16 (95% CI 0.16–8.36), 1 AKI reports of 92 total; IC025 −3.66Selpercatinib (Hypertension): ROR 1.15 (95% CI 0.69–1.92), 15 AKI reports of 1,396 total; IC025 −0.63Idarubicin (Crystal / Obstructive Nephropathy): ROR 1.14 (95% CI 0.68–1.94), 14 AKI reports of 1,159 total; IC025 −0.67Polatuzumab vedotin (Prerenal / Hemodynamic AKI): ROR 1.14 (95% CI 0.96–1.36), 123 AKI reports of 10,202 total; IC025 −0.08Glofitamab (Prerenal / Hemodynamic AKI): ROR 1.12 (95% CI 0.79–1.58), 32 AKI reports of 2,709 total; IC025 −0.39Ponatinib (Hypertension): ROR 1.12 (95% CI 0.93–1.34), 119 AKI reports of 11,399 total; IC025 −0.11Dostarlimab (Acute Interstitial Nephritis): ROR 1.11 (95% CI 0.76–1.64), 26 AKI reports of 2,502 total; IC025 −0.46Tepotinib (Pseudo-AKI): ROR 1.10 (95% CI 0.55–2.20), 8 AKI reports of 691 total; IC025 −1.05Dabrafenib (Acute Interstitial Nephritis): ROR 1.08 (95% CI 0.95–1.23), 241 AKI reports of 21,157 total; IC025 −0.08Dacarbazine (Prerenal / Hemodynamic AKI): ROR 1.08 (95% CI 0.87–1.33), 86 AKI reports of 7,561 total; IC025 −0.22Selinexor (SIADH / Hyponatremia): ROR 1.08 (95% CI 0.89–1.32), 100 AKI reports of 8,763 total; IC025 −0.19Tamoxifen (SIADH / Hyponatremia): ROR 1.08 (95% CI 0.85–1.38), 66 AKI reports of 5,782 total; IC025 −0.26Axitinib (Hypertension): ROR 1.07 (95% CI 0.94–1.22), 221 AKI reports of 19,550 total; IC025 −0.10Dactinomycin (actinomycin D) (Electrolyte Disturbance): ROR 1.07 (95% CI 0.72–1.59), 25 AKI reports of 2,211 total; IC025 −0.53Methotrexate (high-dose) (Crystal / Obstructive Nephropathy): ROR 1.07 (95% CI 1.04–1.10), 5,575 AKI reports of 494,382 total — signal; IC025 0.05Thalidomide (Prerenal / Hemodynamic AKI): ROR 1.05 (95% CI 0.91–1.21), 194 AKI reports of 19,824 total; IC025 −0.14Ribociclib (Pseudo-AKI): ROR 1.04 (95% CI 0.94–1.15), 359 AKI reports of 32,716 total; IC025 −0.10Capecitabine (Prerenal / Hemodynamic AKI): ROR 1.03 (95% CI 0.96–1.09), 999 AKI reports of 92,086 total; IC025 −0.05Belzutifan (Prerenal / Hemodynamic AKI): ROR 1.02 (95% CI 0.64–1.65), 17 AKI reports of 1,777 total; IC025 −0.73Crizotinib (Renal Cysts): ROR 1.02 (95% CI 0.84–1.24), 103 AKI reports of 10,760 total; IC025 −0.26Sorafenib (Hypertension): ROR 1.02 (95% CI 0.89–1.16), 223 AKI reports of 20,700 total; IC025 −0.17Topotecan (Prerenal / Hemodynamic AKI): ROR 1.01 (95% CI 0.80–1.27), 74 AKI reports of 6,940 total; IC025 −0.34Duvelisib (Prerenal / Hemodynamic AKI): ROR 1.00 (95% CI 0.52–1.93), 9 AKI reports of 853 total; IC025 −1.10Elranatamab (Prerenal / Hemodynamic AKI): ROR 0.98 (95% CI 0.65–1.50), 22 AKI reports of 2,391 total; IC025 −0.69Mitotane (Electrolyte Disturbance): ROR 0.98 (95% CI 0.63–1.54), 19 AKI reports of 1,830 total; IC025 −0.75Durvalumab (Acute Interstitial Nephritis): ROR 0.96 (95% CI 0.84–1.10), 220 AKI reports of 21,581 total; IC025 −0.25Trametinib (Prerenal / Hemodynamic AKI): ROR 0.94 (95% CI 0.83–1.07), 243 AKI reports of 24,319 total; IC025 −0.27Regorafenib (Hypertension): ROR 0.93 (95% CI 0.77–1.12), 114 AKI reports of 11,611 total; IC025 −0.38Imatinib (Electrolyte Disturbance): ROR 0.92 (95% CI 0.84–1.02), 408 AKI reports of 47,183 total; IC025 −0.26Loncastuximab tesirine (Prerenal / Hemodynamic AKI): ROR 0.92 (95% CI 0.34–2.47), 4 AKI reports of 410 total; IC025 −1.84Fedratinib (Electrolyte Disturbance): ROR 0.91 (95% CI 0.53–1.57), 13 AKI reports of 1,349 total; IC025 −1.02Melphalan flufenamide (melflufen) (Acute Tubular Necrosis): ROR 0.91 (95% CI 0.13–6.54), 1 AKI reports of 117 total; IC025 −3.88Taletrectinib (Pseudo-AKI): ROR 0.89 (95% CI 0.12–6.38), 1 AKI reports of 120 total; IC025 −3.91Eribulin (Prerenal / Hemodynamic AKI): ROR 0.88 (95% CI 0.63–1.23), 35 AKI reports of 3,739 total; IC025 −0.69Ramucirumab (Hypertension): ROR 0.88 (95% CI 0.68–1.14), 59 AKI reports of 6,320 total; IC025 −0.57Bosutinib (Pseudo-AKI): ROR 0.87 (95% CI 0.70–1.08), 83 AKI reports of 8,981 total; IC025 −0.52Lazertinib (SIADH / Hyponatremia): ROR 0.87 (95% CI 0.43–1.75), 8 AKI reports of 865 total; IC025 −1.35Sunitinib (Hypertension): ROR 0.87 (95% CI 0.78–0.96), 360 AKI reports of 39,148 total; IC025 −0.35Zanubrutinib (Prerenal / Hemodynamic AKI): ROR 0.86 (95% CI 0.62–1.19), 37 AKI reports of 4,598 total; IC025 −0.72Futibatinib (Electrolyte Disturbance): ROR 0.85 (95% CI 0.21–3.42), 2 AKI reports of 222 total; IC025 −2.78Octreotide (Electrolyte Disturbance): ROR 0.85 (95% CI 0.76–0.96), 279 AKI reports of 31,000 total; IC025 −0.41Mitomycin C (Thrombotic Microangiopathy): ROR 0.83 (95% CI 0.58–1.17), 32 AKI reports of 3,659 total; IC025 −0.81Venetoclax (Crystal / Obstructive Nephropathy): ROR 0.83 (95% CI 0.76–0.90), 551 AKI reports of 62,878 total; IC025 −0.39Pralatrexate (Crystal / Obstructive Nephropathy): ROR 0.81 (95% CI 0.30–2.16), 4 AKI reports of 529 total; IC025 −2.01Trifluridine/tipiracil (Prerenal / Hemodynamic AKI): ROR 0.81 (95% CI 0.67–0.99), 97 AKI reports of 11,253 total; IC025 −0.59Sacituzumab govitecan (Prerenal / Hemodynamic AKI): ROR 0.80 (95% CI 0.59–1.09), 41 AKI reports of 4,834 total; IC025 −0.79Blinatumomab (Prerenal / Hemodynamic AKI): ROR 0.79 (95% CI 0.64–0.97), 90 AKI reports of 10,722 total; IC025 −0.64Sonidegib (Acute Tubular Necrosis): ROR 0.79 (95% CI 0.47–1.33), 14 AKI reports of 1,679 total; IC025 −1.19Teniposide (Electrolyte Disturbance): ROR 0.79 (95% CI 0.25–2.46), 3 AKI reports of 405 total; IC025 −2.34Nedaplatin (Acute Tubular Necrosis): ROR 0.78 (95% CI 0.39–1.56), 8 AKI reports of 1,100 total; IC025 −1.51Tebentafusp (Prerenal / Hemodynamic AKI): ROR 0.78 (95% CI 0.33–1.89), 5 AKI reports of 602 total; IC025 −1.85Erdafitinib (Electrolyte Disturbance): ROR 0.76 (95% CI 0.41–1.41), 10 AKI reports of 1,247 total; IC025 −1.41Naxitamab (Prerenal / Hemodynamic AKI): ROR 0.75 (95% CI 0.19–3.04), 2 AKI reports of 250 total; IC025 −2.92Pazopanib (Glomerular Injury / Proteinuria): ROR 0.75 (95% CI 0.66–0.86), 215 AKI reports of 26,971 total; IC025 −0.61Teclistamab (Prerenal / Hemodynamic AKI): ROR 0.75 (95% CI 0.48–1.18), 19 AKI reports of 2,379 total; IC025 −1.12Capmatinib (Pseudo-AKI): ROR 0.74 (95% CI 0.46–1.20), 17 AKI reports of 2,444 total; IC025 −1.18Ivosidenib (Prerenal / Hemodynamic AKI): ROR 0.74 (95% CI 0.46–1.19), 17 AKI reports of 2,178 total; IC025 −1.19Larotrectinib (Pseudo-AKI): ROR 0.74 (95% CI 0.35–1.55), 7 AKI reports of 896 total; IC025 −1.67Rucaparib (Pseudo-AKI): ROR 0.74 (95% CI 0.57–0.95), 61 AKI reports of 8,832 total; IC025 −0.82Alpelisib (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.57–0.93), 62 AKI reports of 9,106 total; IC025 −0.84Asciminib (Hypertension): ROR 0.73 (95% CI 0.49–1.09), 24 AKI reports of 3,514 total; IC025 −1.08Ciltacabtagene autoleucel (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.56–0.96), 51 AKI reports of 6,566 total; IC025 −0.86Estramustine (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.23–2.28), 3 AKI reports of 437 total; IC025 −2.44Midostaurin (Prerenal / Hemodynamic AKI): ROR 0.72 (95% CI 0.43–1.20), 15 AKI reports of 1,957 total; IC025 −1.27Tarlatamab (Prerenal / Hemodynamic AKI): ROR 0.72 (95% CI 0.42–1.25), 13 AKI reports of 1,917 total; IC025 −1.34Gefitinib (Glomerular Injury / Proteinuria): ROR 0.70 (95% CI 0.55–0.89), 67 AKI reports of 8,990 total; IC025 −0.87Ibrutinib (Hypertension): ROR 0.70 (95% CI 0.65–0.76), 605 AKI reports of 80,997 total; IC025 −0.62Lenalidomide (Acute Tubular Necrosis): ROR 0.69 (95% CI 0.67–0.72), 3,147 AKI reports of 425,916 total; IC025 −0.57Repotrectinib (Pseudo-AKI): ROR 0.69 (95% CI 0.17–2.77), 2 AKI reports of 274 total; IC025 −3.03Ibandronate (Acute Tubular Necrosis): ROR 0.66 (95% CI 0.54–0.82), 92 AKI reports of 14,757 total; IC025 −0.89Pemigatinib (Electrolyte Disturbance): ROR 0.66 (95% CI 0.30–1.48), 6 AKI reports of 853 total; IC025 −1.93Pomalidomide (Prerenal / Hemodynamic AKI): ROR 0.66 (95% CI 0.61–0.71), 725 AKI reports of 103,640 total; IC025 −0.70Dasatinib (Glomerular Injury / Proteinuria): ROR 0.62 (95% CI 0.54–0.72), 191 AKI reports of 32,694 total; IC025 −0.89Lutetium-177 Dotatate (Chronic Interstitial Nephropathy): ROR 0.62 (95% CI 0.45–0.85), 38 AKI reports of 5,819 total; IC025 −1.18Darolutamide (Electrolyte Disturbance): ROR 0.61 (95% CI 0.44–0.86), 34 AKI reports of 5,924 total; IC025 −1.22Nirogacestat (Electrolyte Disturbance): ROR 0.61 (95% CI 0.27–1.37), 6 AKI reports of 923 total; IC025 −2.03Talazoparib (Pseudo-AKI): ROR 0.61 (95% CI 0.35–1.08), 12 AKI reports of 1,853 total; IC025 −1.61Tislelizumab (Acute Interstitial Nephritis): ROR 0.61 (95% CI 0.47–0.81), 51 AKI reports of 8,853 total; IC025 −1.12Mosunetuzumab (Prerenal / Hemodynamic AKI): ROR 0.60 (95% CI 0.28–1.25), 7 AKI reports of 1,107 total; IC025 −1.96Ruxolitinib (Prerenal / Hemodynamic AKI): ROR 0.58 (95% CI 0.53–0.63), 449 AKI reports of 73,257 total; IC025 −0.92Nintedanib (Hypertension): ROR 0.57 (95% CI 0.50–0.66), 199 AKI reports of 32,818 total; IC025 −1.01Zongertinib (Pseudo-AKI): ROR 0.56 (95% CI 0.08–4.03), 1 AKI reports of 167 total; IC025 −4.39Radium-223 dichloride (Prerenal / Hemodynamic AKI): ROR 0.54 (95% CI 0.38–0.78), 29 AKI reports of 5,055 total; IC025 −1.44Amivantamab (Electrolyte Disturbance): ROR 0.53 (95% CI 0.34–0.82), 20 AKI reports of 3,576 total; IC025 −1.60Erlotinib (Glomerular Injury / Proteinuria): ROR 0.53 (95% CI 0.44–0.64), 115 AKI reports of 22,936 total; IC025 −1.17Sotorasib (Prerenal / Hemodynamic AKI): ROR 0.52 (95% CI 0.33–0.81), 19 AKI reports of 3,470 total; IC025 −1.65Lomustine (CCNU) (Chronic Interstitial Nephropathy): ROR 0.51 (95% CI 0.30–0.86), 14 AKI reports of 2,597 total; IC025 −1.80Toripalimab (Acute Interstitial Nephritis): ROR 0.50 (95% CI 0.26–0.96), 9 AKI reports of 1,928 total; IC025 −2.06Acalabrutinib (Hypertension): ROR 0.49 (95% CI 0.38–0.62), 66 AKI reports of 12,744 total; IC025 −1.39Cabozantinib (Hypertension): ROR 0.49 (95% CI 0.43–0.55), 251 AKI reports of 48,250 total; IC025 −1.21Fruquintinib (Hypertension): ROR 0.48 (95% CI 0.31–0.74), 20 AKI reports of 3,941 total; IC025 −1.74Tivozanib (Hypertension): ROR 0.47 (95% CI 0.22–0.99), 7 AKI reports of 1,588 total; IC025 −2.29Brigatinib (Pseudo-AKI): ROR 0.46 (95% CI 0.29–0.74), 18 AKI reports of 3,655 total; IC025 −1.82Trastuzumab deruxtecan (Acute Tubular Necrosis): ROR 0.46 (95% CI 0.35–0.60), 53 AKI reports of 10,910 total; IC025 −1.53Trastuzumab emtansine (T-DM1) (Thrombotic Microangiopathy): ROR 0.44 (95% CI 0.33–0.61), 40 AKI reports of 8,459 total; IC025 −1.63Nilotinib (Prerenal / Hemodynamic AKI): ROR 0.43 (95% CI 0.36–0.50), 134 AKI reports of 29,571 total; IC025 −1.47Enzalutamide (Hypertension): ROR 0.42 (95% CI 0.37–0.47), 262 AKI reports of 58,866 total; IC025 −1.43Cladribine (Crystal / Obstructive Nephropathy): ROR 0.40 (95% CI 0.29–0.54), 42 AKI reports of 9,967 total; IC025 −1.79Denosumab (Electrolyte Disturbance): ROR 0.40 (95% CI 0.37–0.42), 864 AKI reports of 203,750 total; IC025 −1.42Lanreotide (Electrolyte Disturbance): ROR 0.39 (95% CI 0.28–0.55), 33 AKI reports of 7,953 total; IC025 −1.87Osimertinib (SIADH / Hyponatremia): ROR 0.39 (95% CI 0.33–0.47), 125 AKI reports of 33,803 total; IC025 −1.60Ziv-aflibercept (Hypertension): ROR 0.37 (95% CI 0.31–0.44), 130 AKI reports of 32,703 total; IC025 −1.67Palbociclib (Pseudo-AKI): ROR 0.36 (95% CI 0.33–0.40), 369 AKI reports of 95,562 total; IC025 −1.60Leuprolide (Hypertension): ROR 0.35 (95% CI 0.32–0.40), 300 AKI reports of 79,718 total; IC025 −1.66Lorlatinib (Pseudo-AKI): ROR 0.35 (95% CI 0.24–0.51), 28 AKI reports of 7,455 total; IC025 −2.06Alectinib (Pseudo-AKI): ROR 0.34 (95% CI 0.23–0.50), 27 AKI reports of 7,388 total; IC025 −2.11Selumetinib (Prerenal / Hemodynamic AKI): ROR 0.33 (95% CI 0.15–0.75), 6 AKI reports of 1,684 total; IC025 −2.87Fotemustine (Chronic Interstitial Nephropathy): ROR 0.32 (95% CI 0.04–2.29), 1 AKI reports of 331 total; IC025 −5.06Lutetium-177 PSMA-617 (vipivotide) (Chronic Interstitial Nephropathy): ROR 0.30 (95% CI 0.22–0.40), 44 AKI reports of 13,841 total; IC025 −2.18Olaparib (Pseudo-AKI): ROR 0.26 (95% CI 0.20–0.34), 60 AKI reports of 21,443 total; IC025 −2.30Vismodegib (SIADH / Hyponatremia): ROR 0.25 (95% CI 0.17–0.38), 24 AKI reports of 8,927 total; IC025 −2.59Niraparib (Hypertension): ROR 0.22 (95% CI 0.17–0.29), 53 AKI reports of 22,237 total; IC025 −2.55Pacritinib (Prerenal / Hemodynamic AKI): ROR 0.21 (95% CI 0.10–0.45), 7 AKI reports of 3,069 total; IC025 −3.40Pralsetinib (Hypertension): ROR 0.21 (95% CI 0.08–0.55), 4 AKI reports of 1,824 total; IC025 −3.87Enasidenib (Prerenal / Hemodynamic AKI): ROR 0.19 (95% CI 0.09–0.41), 7 AKI reports of 3,369 total; IC025 −3.53Tazemetostat (Prerenal / Hemodynamic AKI): ROR 0.17 (95% CI 0.06–0.54), 3 AKI reports of 1,622 total; IC025 −4.38Vorasidenib (Pseudo-AKI): ROR 0.17 (95% CI 0.02–1.23), 1 AKI reports of 612 total; IC025 −5.85Ripretinib (Hypertension): ROR 0.16 (95% CI 0.08–0.31), 9 AKI reports of 5,243 total; IC025 −3.65Pexidartinib (Prerenal / Hemodynamic AKI): ROR 0.13 (95% CI 0.02–0.93), 1 AKI reports of 717 total; IC025 −6.23Quizartinib (Prerenal / Hemodynamic AKI): ROR 0.13 (95% CI 0.02–0.95), 1 AKI reports of 702 total; IC025 −6.20Datopotamab deruxtecan (Dato-DXd) (Acute Tubular Necrosis): ROR 0.11 (95% CI 0.01–0.78), 1 AKI reports of 859 total; IC025 −6.47Mirvetuximab soravtansine (Prerenal / Hemodynamic AKI): ROR 0.10 (95% CI 0.03–0.41), 2 AKI reports of 1,814 total; IC025 −5.57Avapritinib (Prerenal / Hemodynamic AKI): ROR 0.09 (95% CI 0.05–0.17), 11 AKI reports of 12,654 total; IC025 −4.35Revumenib (Prerenal / Hemodynamic AKI): ROR 0.09 (95% CI 0.01–0.65), 1 AKI reports of 1,031 total; IC025 −6.72Avutometinib (Electrolyte Disturbance): ROR 0.08 (95% CI 0.01–0.59), 1 AKI reports of 1,125 total; IC025 −6.84Elacestrant (Prerenal / Hemodynamic AKI): ROR 0.07 (95% CI 0.03–0.16), 5 AKI reports of 7,181 total; IC025 −5.32Mechlorethamine (Electrolyte Disturbance): ROR 0.04 (95% CI 0.01–0.30), 1 AKI reports of 2,247 total; IC025 −7.81

Acute Tubular NecrosisAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceFanconi SyndromeCrystal / Obstructive NephropathyHypertensionPrerenal / Hemodynamic AKISIADH / HyponatremiaHemorrhagic CystitisPseudo-AKIRenal CystsChronic Interstitial Nephropathy

245 agents plotted — every ROR rests on at least 50 total reports (its AKI count, on the vertical axis, can still be 1 or 2 — hence the widest whiskers at the bottom) · whisker = ROR 95% CI · filled = significant renal signal (CI lower bound > 1 — whisker clears the ROR = 1 line) · faint = no signal · dashed ring = a signal whose IC025 does not clear 0 (4 of 95) · 3 of the signals rest in part on one case filed repeatedly (named in each mark's label; the drug page gives the ratio without it) · size = total FAERS reports · color = signature injury. Reporting, not incidence. 6 agents queried but not plotted — under 50 total reports the ratio's own denominator is too thin to divide. FAERS snapshot 2026-11-15.

  • Lifileucel (Prerenal / Hemodynamic AKI): ROR 8.22 (95% CI 5.37–12.58), 23 AKI reports of 285 total — signal; IC025 2.09
  • Clofarabine (Prerenal / Hemodynamic AKI): ROR 5.51 (95% CI 4.60–6.58), 127 AKI reports of 2,287 total — signal; IC025 2.11
  • Interleukin-2 (high-dose) (Prerenal / Hemodynamic AKI): ROR 5.41 (95% CI 4.24–6.90), 69 AKI reports of 1,263 total — signal; IC025 1.97
  • Trabectedin (Acute Tubular Necrosis): ROR 4.69 (95% CI 3.88–5.67), 112 AKI reports of 2,350 total — signal; IC025 1.87
  • Tagraxofusp (Prerenal / Hemodynamic AKI): ROR 4.37 (95% CI 2.90–6.58), 24 AKI reports of 538 total — signal; IC025 1.35
  • Streptozocin (Fanconi Syndrome): ROR 4.04 (95% CI 2.08–7.87), 9 AKI reports of 245 total — signal; IC025 0.67
  • Pemetrexed (Chronic Interstitial Nephropathy): ROR 3.88 (95% CI 3.69–4.08), 1,547 AKI reports of 39,105 total — signal; IC025 1.83
  • Idecabtagene vicleucel (Prerenal / Hemodynamic AKI): ROR 3.77 (95% CI 2.82–5.03), 48 AKI reports of 1,241 total — signal; IC025 1.40
  • Sirolimus (Glomerular Injury / Proteinuria): ROR 3.65 (95% CI 3.34–3.98), 512 AKI reports of 13,673 total — signal; IC025 1.69
  • Adagrasib (Prerenal / Hemodynamic AKI): ROR 3.48 (95% CI 2.49–4.84), 36 AKI reports of 1,134 total — signal; IC025 1.21
  • Cisplatin (Acute Tubular Necrosis): ROR 3.43 (95% CI 3.30–3.56), 2,766 AKI reports of 79,025 total — signal; IC025 1.67
  • Retifanlimab (Acute Interstitial Nephritis): ROR 3.40 (95% CI 1.51–7.67), 6 AKI reports of 193 total — signal; IC025 0.12
  • Pamidronate (Glomerular Injury / Proteinuria): ROR 3.16 (95% CI 2.65–3.77), 127 AKI reports of 4,390 total — signal; IC025 1.36
  • Carfilzomib (Thrombotic Microangiopathy): ROR 3.11 (95% CI 2.91–3.32), 909 AKI reports of 28,379 total — signal; IC025 1.50
  • Cobimetinib (Acute Tubular Necrosis): ROR 3.05 (95% CI 2.58–3.61), 140 AKI reports of 4,436 total — signal; IC025 1.32
  • Inavolisib (Electrolyte Disturbance): ROR 3.03 (95% CI 1.96–4.68), 21 AKI reports of 670 total — signal; IC025 0.82
  • Melphalan (SIADH / Hyponatremia): ROR 2.94 (95% CI 2.73–3.16), 768 AKI reports of 25,290 total — signal; IC025 1.42
  • Gemtuzumab ozogamicin (Prerenal / Hemodynamic AKI): ROR 2.82 (95% CI 2.32–3.41), 107 AKI reports of 3,665 total — signal; IC025 1.17
  • Lurbinectedin (Acute Tubular Necrosis): ROR 2.78 (95% CI 1.93–3.99), 30 AKI reports of 1,175 total — signal; IC025 0.85
  • Fludarabine (Crystal / Obstructive Nephropathy): ROR 2.66 (95% CI 2.51–2.83), 1,098 AKI reports of 39,838 total — signal; IC025 1.29
  • Pembrolizumab (Acute Interstitial Nephritis): ROR 2.59 (95% CI 2.49–2.69), 2,572 AKI reports of 109,044 total — signal; IC025 1.28
  • Isatuximab (Prerenal / Hemodynamic AKI): ROR 2.58 (95% CI 2.20–3.02), 157 AKI reports of 5,853 total — signal; IC025 1.10
  • Cytarabine (Crystal / Obstructive Nephropathy): ROR 2.57 (95% CI 2.45–2.70), 1,679 AKI reports of 63,055 total — signal; IC025 1.26
  • Ifosfamide (Fanconi Syndrome): ROR 2.50 (95% CI 2.29–2.72), 557 AKI reports of 21,470 total — signal; IC025 1.17
  • Avelumab (Acute Interstitial Nephritis): ROR 2.42 (95% CI 1.97–2.97), 93 AKI reports of 4,169 total — signal; IC025 0.94
  • Carboplatin (Acute Tubular Necrosis): ROR 2.41 (95% CI 2.33–2.50), 3,233 AKI reports of 130,075 total — signal; IC025 1.18
  • Carmustine (BCNU) (Chronic Interstitial Nephropathy): ROR 2.38 (95% CI 1.98–2.86), 117 AKI reports of 4,718 total — signal; IC025 0.95; 14 of the AKI reports look like one case filed repeatedly
  • Gemcitabine (Thrombotic Microangiopathy): ROR 2.36 (95% CI 2.24–2.50), 1,326 AKI reports of 54,066 total — signal; IC025 1.13
  • Zanidatamab (Prerenal / Hemodynamic AKI): ROR 2.34 (95% CI 0.57–9.52), 2 AKI reports of 82 total; IC025 −1.72
  • Etoposide (Crystal / Obstructive Nephropathy): ROR 2.33 (95% CI 2.23–2.45), 1,814 AKI reports of 74,949 total — signal; IC025 1.13
  • Epcoritamab (Prerenal / Hemodynamic AKI): ROR 2.27 (95% CI 1.81–2.83), 79 AKI reports of 3,771 total — signal; IC025 0.82; 10 of the AKI reports look like one case filed repeatedly
  • Thiotepa (Hemorrhagic Cystitis): ROR 2.27 (95% CI 1.99–2.59), 231 AKI reports of 9,762 total — signal; IC025 0.97
  • Binimetinib (Acute Tubular Necrosis): ROR 2.23 (95% CI 1.93–2.58), 185 AKI reports of 7,953 total — signal; IC025 0.92
  • Encorafenib (Acute Tubular Necrosis): ROR 2.23 (95% CI 1.96–2.54), 237 AKI reports of 10,191 total — signal; IC025 0.94
  • Bendamustine (Crystal / Obstructive Nephropathy): ROR 2.19 (95% CI 2.01–2.38), 550 AKI reports of 24,082 total — signal; IC025 0.99
  • Zoledronic acid (Acute Tubular Necrosis): ROR 2.13 (95% CI 2.02–2.25), 1,314 AKI reports of 66,922 total — signal; IC025 0.99
  • Mogamulizumab (Prerenal / Hemodynamic AKI): ROR 2.10 (95% CI 1.51–2.90), 37 AKI reports of 1,908 total — signal; IC025 0.53
  • Busulfan (Thrombotic Microangiopathy): ROR 2.09 (95% CI 1.88–2.32), 347 AKI reports of 15,927 total — signal; IC025 0.89
  • Pirtobrutinib (Crystal / Obstructive Nephropathy): ROR 2.09 (95% CI 1.33–3.30), 19 AKI reports of 981 total — signal; IC025 0.29
  • Ipilimumab (Acute Interstitial Nephritis): ROR 2.08 (95% CI 1.95–2.22), 951 AKI reports of 43,846 total — signal; IC025 0.94
  • Temsirolimus (Glomerular Injury / Proteinuria): ROR 2.08 (95% CI 1.70–2.54), 98 AKI reports of 4,507 total — signal; IC025 0.73
  • Enfortumab vedotin (Acute Tubular Necrosis): ROR 2.07 (95% CI 1.78–2.41), 170 AKI reports of 7,851 total — signal; IC025 0.80
  • Vinorelbine (SIADH / Hyponatremia): ROR 2.05 (95% CI 1.74–2.41), 149 AKI reports of 6,966 total — signal; IC025 0.77
  • Linvoseltamab (Prerenal / Hemodynamic AKI): ROR 2.04 (95% CI 0.28–14.74), 1 AKI reports of 53 total; IC025 −3.21
  • Atezolizumab (Acute Interstitial Nephritis): ROR 2.03 (95% CI 1.89–2.19), 752 AKI reports of 40,046 total — signal; IC025 0.90
  • Vemurafenib (Acute Tubular Necrosis): ROR 2.01 (95% CI 1.77–2.28), 252 AKI reports of 11,991 total — signal; IC025 0.80
  • Oxaliplatin (Thrombotic Microangiopathy): ROR 2.00 (95% CI 1.90–2.10), 1,579 AKI reports of 75,953 total — signal; IC025 0.90
  • Pegaspargase (Prerenal / Hemodynamic AKI): ROR 1.99 (95% CI 1.76–2.26), 258 AKI reports of 12,377 total — signal; IC025 0.80
  • Inotuzumab ozogamicin (Prerenal / Hemodynamic AKI): ROR 1.98 (95% CI 1.54–2.55), 62 AKI reports of 2,992 total — signal; IC025 0.58
  • 5-Fluorouracil (Thrombotic Microangiopathy): ROR 1.96 (95% CI 1.86–2.06), 1,607 AKI reports of 78,755 total — signal; IC025 0.88
  • Nelarabine (Crystal / Obstructive Nephropathy): ROR 1.96 (95% CI 1.26–3.06), 20 AKI reports of 974 total — signal; IC025 0.22
  • Capivasertib (Prerenal / Hemodynamic AKI): ROR 1.94 (95% CI 1.48–2.53), 55 AKI reports of 3,064 total — signal; IC025 0.52
  • Pentostatin (Acute Tubular Necrosis): ROR 1.94 (95% CI 1.04–3.63), 10 AKI reports of 555 total — signal; IC025 −0.15, which does not clear 0
  • Raltitrexed (Acute Tubular Necrosis): ROR 1.93 (95% CI 1.09–3.41), 12 AKI reports of 672 total — signal; IC025 −0.05, which does not clear 0
  • Relacorilant (Electrolyte Disturbance): ROR 1.93 (95% CI 0.48–7.83), 2 AKI reports of 99 total; IC025 −1.90
  • Procarbazine (Acute Tubular Necrosis): ROR 1.92 (95% CI 1.61–2.28), 130 AKI reports of 7,315 total — signal; IC025 0.66
  • Brentuximab vedotin (Prerenal / Hemodynamic AKI): ROR 1.91 (95% CI 1.67–2.19), 208 AKI reports of 10,402 total — signal; IC025 0.71
  • Elotuzumab (Prerenal / Hemodynamic AKI): ROR 1.90 (95% CI 1.56–2.31), 103 AKI reports of 5,171 total — signal; IC025 0.62
  • Vincristine (SIADH / Hyponatremia): ROR 1.90 (95% CI 1.75–2.07), 588 AKI reports of 29,521 total — signal; IC025 0.79
  • Nivolumab (Acute Interstitial Nephritis): ROR 1.88 (95% CI 1.80–1.97), 1,935 AKI reports of 98,547 total — signal; IC025 0.83
  • Idelalisib (Prerenal / Hemodynamic AKI): ROR 1.87 (95% CI 1.57–2.24), 124 AKI reports of 7,144 total — signal; IC025 0.62
  • Amsacrine (Electrolyte Disturbance): ROR 1.80 (95% CI 0.93–3.48), 9 AKI reports of 538 total; IC025 −0.31
  • Cyclophosphamide (SIADH / Hyponatremia): ROR 1.80 (95% CI 1.74–1.87), 3,364 AKI reports of 179,391 total — signal; IC025 0.78
  • Denileukin diftitox (Prerenal / Hemodynamic AKI): ROR 1.80 (95% CI 0.25–12.96), 1 AKI reports of 60 total; IC025 −3.30
  • Bortezomib (Thrombotic Microangiopathy): ROR 1.78 (95% CI 1.69–1.86), 1,669 AKI reports of 89,993 total — signal; IC025 0.74
  • Tisotumab vedotin (Prerenal / Hemodynamic AKI): ROR 1.78 (95% CI 1.08–2.91), 16 AKI reports of 971 total — signal; IC025 −0.01, which does not clear 0
  • Gilteritinib (Prerenal / Hemodynamic AKI): ROR 1.77 (95% CI 1.42–2.22), 78 AKI reports of 4,738 total — signal; IC025 0.47
  • Neratinib (Prerenal / Hemodynamic AKI): ROR 1.77 (95% CI 1.31–2.39), 43 AKI reports of 2,319 total — signal; IC025 0.33; 13 of the AKI reports look like one case filed repeatedly, and without them the ratio does not clear 1
  • Lisocabtagene maraleucel (Prerenal / Hemodynamic AKI): ROR 1.74 (95% CI 1.06–2.85), 16 AKI reports of 876 total — signal; IC025 −0.04, which does not clear 0
  • Arsenic trioxide (Prerenal / Hemodynamic AKI): ROR 1.70 (95% CI 1.34–2.14), 72 AKI reports of 4,043 total — signal; IC025 0.39
  • Bicalutamide (Acute Interstitial Nephritis): ROR 1.69 (95% CI 1.50–1.90), 271 AKI reports of 15,311 total — signal; IC025 0.56
  • Everolimus (Glomerular Injury / Proteinuria): ROR 1.69 (95% CI 1.58–1.81), 881 AKI reports of 49,667 total — signal; IC025 0.65
  • Lenvatinib (Hypertension): ROR 1.69 (95% CI 1.56–1.83), 622 AKI reports of 39,694 total — signal; IC025 0.63
  • Cabazitaxel (Prerenal / Hemodynamic AKI): ROR 1.68 (95% CI 1.31–2.16), 62 AKI reports of 3,517 total — signal; IC025 0.35
  • Doxorubicin (Glomerular Injury / Proteinuria): ROR 1.68 (95% CI 1.60–1.76), 1,704 AKI reports of 97,231 total — signal; IC025 0.66
  • Relatlimab (Acute Interstitial Nephritis): ROR 1.66 (95% CI 0.86–3.22), 9 AKI reports of 515 total; IC025 −0.42
  • Tafasitamab (Prerenal / Hemodynamic AKI): ROR 1.65 (95% CI 1.21–2.25), 41 AKI reports of 2,675 total — signal; IC025 0.23
  • Vinblastine (SIADH / Hyponatremia): ROR 1.65 (95% CI 1.18–2.32), 34 AKI reports of 1,961 total — signal; IC025 0.17
  • Abemaciclib (Pseudo-AKI): ROR 1.63 (95% CI 1.47–1.82), 325 AKI reports of 21,412 total — signal; IC025 0.54
  • Mitoxantrone (Crystal / Obstructive Nephropathy): ROR 1.60 (95% CI 1.32–1.95), 106 AKI reports of 6,289 total — signal; IC025 0.38
  • Hydroxyurea (Crystal / Obstructive Nephropathy): ROR 1.58 (95% CI 1.42–1.75), 353 AKI reports of 21,340 total — signal; IC025 0.49
  • Infigratinib (Electrolyte Disturbance): ROR 1.58 (95% CI 0.22–11.39), 1 AKI reports of 68 total; IC025 −3.40
  • Daratumumab (Prerenal / Hemodynamic AKI): ROR 1.57 (95% CI 1.45–1.69), 655 AKI reports of 44,998 total — signal; IC025 0.53
  • Decitabine (Crystal / Obstructive Nephropathy): ROR 1.57 (95% CI 1.27–1.94), 88 AKI reports of 5,334 total — signal; IC025 0.32
  • Belantamab mafodotin (Glomerular Injury / Proteinuria): ROR 1.52 (95% CI 1.13–2.05), 44 AKI reports of 3,110 total — signal; IC025 0.13
  • Paclitaxel (Prerenal / Hemodynamic AKI): ROR 1.52 (95% CI 1.45–1.60), 1,618 AKI reports of 101,259 total — signal; IC025 0.52
  • Cemiplimab (Acute Interstitial Nephritis): ROR 1.51 (95% CI 1.07–2.13), 33 AKI reports of 2,083 total — signal; IC025 0.04
  • Vandetanib (Hypertension): ROR 1.50 (95% CI 0.94–2.40), 18 AKI reports of 1,286 total; IC025 −0.18
  • Irinotecan (Prerenal / Hemodynamic AKI): ROR 1.48 (95% CI 1.29–1.70), 205 AKI reports of 13,147 total — signal; IC025 0.35
  • Momelotinib (Pseudo-AKI): ROR 1.48 (95% CI 0.98–2.23), 23 AKI reports of 1,481 total; IC025 −0.11
  • Asparaginase (Prerenal / Hemodynamic AKI): ROR 1.47 (95% CI 0.96–2.26), 21 AKI reports of 1,533 total; IC025 −0.15
  • Afatinib (Prerenal / Hemodynamic AKI): ROR 1.45 (95% CI 1.19–1.76), 101 AKI reports of 6,622 total — signal; IC025 0.23
  • Necitumumab (Electrolyte Disturbance): ROR 1.43 (95% CI 0.64–3.21), 6 AKI reports of 450 total; IC025 −0.91
  • Bleomycin (Prerenal / Hemodynamic AKI): ROR 1.42 (95% CI 1.21–1.67), 155 AKI reports of 10,369 total — signal; IC025 0.26
  • Entrectinib (Pseudo-AKI): ROR 1.40 (95% CI 0.92–2.13), 22 AKI reports of 1,691 total; IC025 −0.20
  • Glasdegib (Prerenal / Hemodynamic AKI): ROR 1.40 (95% CI 0.67–2.96), 7 AKI reports of 474 total; IC025 −0.82
  • Rituximab (Crystal / Obstructive Nephropathy): ROR 1.38 (95% CI 1.34–1.43), 3,173 AKI reports of 218,782 total — signal; IC025 0.41
  • Azacitidine (Fanconi Syndrome): ROR 1.37 (95% CI 1.25–1.51), 436 AKI reports of 30,141 total — signal; IC025 0.31
  • Ibritumomab tiuxetan (Prerenal / Hemodynamic AKI): ROR 1.37 (95% CI 0.90–2.09), 22 AKI reports of 1,524 total; IC025 −0.23
  • Tucatinib (Pseudo-AKI): ROR 1.37 (95% CI 1.12–1.69), 91 AKI reports of 7,112 total — signal; IC025 0.14
  • Obecabtagene autoleucel (Obe-cel) (Prerenal / Hemodynamic AKI): ROR 1.34 (95% CI 0.19–9.63), 1 AKI reports of 71 total; IC025 −3.53
  • Copanlisib (Hypertension): ROR 1.33 (95% CI 0.55–3.22), 5 AKI reports of 403 total; IC025 −1.16
  • Dinutuximab (Prerenal / Hemodynamic AKI): ROR 1.33 (95% CI 0.75–2.34), 12 AKI reports of 859 total; IC025 −0.55
  • Cetuximab (Electrolyte Disturbance): ROR 1.32 (95% CI 1.20–1.45), 440 AKI reports of 31,704 total — signal; IC025 0.25
  • Ceritinib (Prerenal / Hemodynamic AKI): ROR 1.31 (95% CI 0.94–1.82), 36 AKI reports of 2,947 total; IC025 −0.13
  • Talquetamab (Prerenal / Hemodynamic AKI): ROR 1.31 (95% CI 0.90–1.90), 28 AKI reports of 2,290 total; IC025 −0.20
  • Abiraterone (Electrolyte Disturbance): ROR 1.29 (95% CI 1.19–1.40), 559 AKI reports of 41,137 total — signal; IC025 0.24
  • Iberdomide (Prerenal / Hemodynamic AKI): ROR 1.27 (95% CI 0.32–5.14), 2 AKI reports of 149 total; IC025 −2.32
  • Temozolomide (SIADH / Hyponatremia): ROR 1.26 (95% CI 1.12–1.42), 283 AKI reports of 21,320 total — signal; IC025 0.15
  • Obinutuzumab (Crystal / Obstructive Nephropathy): ROR 1.24 (95% CI 1.08–1.43), 206 AKI reports of 17,772 total — signal; IC025 0.11
  • Panitumumab (Electrolyte Disturbance): ROR 1.24 (95% CI 1.08–1.42), 210 AKI reports of 16,107 total — signal; IC025 0.10
  • Zolbetuximab (Prerenal / Hemodynamic AKI): ROR 1.24 (95% CI 0.80–1.93), 20 AKI reports of 1,525 total; IC025 −0.40
  • Docetaxel (Prerenal / Hemodynamic AKI): ROR 1.19 (95% CI 1.12–1.28), 858 AKI reports of 68,125 total — signal; IC025 0.15
  • Tretinoin (ATRA) (Prerenal / Hemodynamic AKI): ROR 1.18 (95% CI 0.97–1.42), 111 AKI reports of 8,951 total; IC025 −0.05
  • Bevacizumab (Glomerular Injury / Proteinuria): ROR 1.18 (95% CI 1.13–1.24), 1,630 AKI reports of 130,956 total — signal; IC025 0.16
  • Ixazomib (Thrombotic Microangiopathy): ROR 1.17 (95% CI 1.05–1.30), 354 AKI reports of 28,726 total — signal; IC025 0.07
  • Mobocertinib (Prerenal / Hemodynamic AKI): ROR 1.17 (95% CI 0.58–2.34), 8 AKI reports of 735 total; IC025 −0.96
  • Chlorambucil (SIADH / Hyponatremia): ROR 1.16 (95% CI 0.87–1.54), 48 AKI reports of 3,932 total; IC025 −0.23
  • Imlunestrant (Pseudo-AKI): ROR 1.16 (95% CI 0.16–8.36), 1 AKI reports of 92 total; IC025 −3.66
  • Selpercatinib (Hypertension): ROR 1.15 (95% CI 0.69–1.92), 15 AKI reports of 1,396 total; IC025 −0.63
  • Idarubicin (Crystal / Obstructive Nephropathy): ROR 1.14 (95% CI 0.68–1.94), 14 AKI reports of 1,159 total; IC025 −0.67
  • Polatuzumab vedotin (Prerenal / Hemodynamic AKI): ROR 1.14 (95% CI 0.96–1.36), 123 AKI reports of 10,202 total; IC025 −0.08
  • Glofitamab (Prerenal / Hemodynamic AKI): ROR 1.12 (95% CI 0.79–1.58), 32 AKI reports of 2,709 total; IC025 −0.39
  • Ponatinib (Hypertension): ROR 1.12 (95% CI 0.93–1.34), 119 AKI reports of 11,399 total; IC025 −0.11
  • Dostarlimab (Acute Interstitial Nephritis): ROR 1.11 (95% CI 0.76–1.64), 26 AKI reports of 2,502 total; IC025 −0.46
  • Tepotinib (Pseudo-AKI): ROR 1.10 (95% CI 0.55–2.20), 8 AKI reports of 691 total; IC025 −1.05
  • Dabrafenib (Acute Interstitial Nephritis): ROR 1.08 (95% CI 0.95–1.23), 241 AKI reports of 21,157 total; IC025 −0.08
  • Dacarbazine (Prerenal / Hemodynamic AKI): ROR 1.08 (95% CI 0.87–1.33), 86 AKI reports of 7,561 total; IC025 −0.22
  • Selinexor (SIADH / Hyponatremia): ROR 1.08 (95% CI 0.89–1.32), 100 AKI reports of 8,763 total; IC025 −0.19
  • Tamoxifen (SIADH / Hyponatremia): ROR 1.08 (95% CI 0.85–1.38), 66 AKI reports of 5,782 total; IC025 −0.26
  • Axitinib (Hypertension): ROR 1.07 (95% CI 0.94–1.22), 221 AKI reports of 19,550 total; IC025 −0.10
  • Dactinomycin (actinomycin D) (Electrolyte Disturbance): ROR 1.07 (95% CI 0.72–1.59), 25 AKI reports of 2,211 total; IC025 −0.53
  • Methotrexate (high-dose) (Crystal / Obstructive Nephropathy): ROR 1.07 (95% CI 1.04–1.10), 5,575 AKI reports of 494,382 total — signal; IC025 0.05
  • Thalidomide (Prerenal / Hemodynamic AKI): ROR 1.05 (95% CI 0.91–1.21), 194 AKI reports of 19,824 total; IC025 −0.14
  • Ribociclib (Pseudo-AKI): ROR 1.04 (95% CI 0.94–1.15), 359 AKI reports of 32,716 total; IC025 −0.10
  • Capecitabine (Prerenal / Hemodynamic AKI): ROR 1.03 (95% CI 0.96–1.09), 999 AKI reports of 92,086 total; IC025 −0.05
  • Belzutifan (Prerenal / Hemodynamic AKI): ROR 1.02 (95% CI 0.64–1.65), 17 AKI reports of 1,777 total; IC025 −0.73
  • Crizotinib (Renal Cysts): ROR 1.02 (95% CI 0.84–1.24), 103 AKI reports of 10,760 total; IC025 −0.26
  • Sorafenib (Hypertension): ROR 1.02 (95% CI 0.89–1.16), 223 AKI reports of 20,700 total; IC025 −0.17
  • Topotecan (Prerenal / Hemodynamic AKI): ROR 1.01 (95% CI 0.80–1.27), 74 AKI reports of 6,940 total; IC025 −0.34
  • Duvelisib (Prerenal / Hemodynamic AKI): ROR 1.00 (95% CI 0.52–1.93), 9 AKI reports of 853 total; IC025 −1.10
  • Elranatamab (Prerenal / Hemodynamic AKI): ROR 0.98 (95% CI 0.65–1.50), 22 AKI reports of 2,391 total; IC025 −0.69
  • Mitotane (Electrolyte Disturbance): ROR 0.98 (95% CI 0.63–1.54), 19 AKI reports of 1,830 total; IC025 −0.75
  • Durvalumab (Acute Interstitial Nephritis): ROR 0.96 (95% CI 0.84–1.10), 220 AKI reports of 21,581 total; IC025 −0.25
  • Trametinib (Prerenal / Hemodynamic AKI): ROR 0.94 (95% CI 0.83–1.07), 243 AKI reports of 24,319 total; IC025 −0.27
  • Regorafenib (Hypertension): ROR 0.93 (95% CI 0.77–1.12), 114 AKI reports of 11,611 total; IC025 −0.38
  • Imatinib (Electrolyte Disturbance): ROR 0.92 (95% CI 0.84–1.02), 408 AKI reports of 47,183 total; IC025 −0.26
  • Loncastuximab tesirine (Prerenal / Hemodynamic AKI): ROR 0.92 (95% CI 0.34–2.47), 4 AKI reports of 410 total; IC025 −1.84
  • Fedratinib (Electrolyte Disturbance): ROR 0.91 (95% CI 0.53–1.57), 13 AKI reports of 1,349 total; IC025 −1.02
  • Melphalan flufenamide (melflufen) (Acute Tubular Necrosis): ROR 0.91 (95% CI 0.13–6.54), 1 AKI reports of 117 total; IC025 −3.88
  • Taletrectinib (Pseudo-AKI): ROR 0.89 (95% CI 0.12–6.38), 1 AKI reports of 120 total; IC025 −3.91
  • Eribulin (Prerenal / Hemodynamic AKI): ROR 0.88 (95% CI 0.63–1.23), 35 AKI reports of 3,739 total; IC025 −0.69
  • Ramucirumab (Hypertension): ROR 0.88 (95% CI 0.68–1.14), 59 AKI reports of 6,320 total; IC025 −0.57
  • Bosutinib (Pseudo-AKI): ROR 0.87 (95% CI 0.70–1.08), 83 AKI reports of 8,981 total; IC025 −0.52
  • Lazertinib (SIADH / Hyponatremia): ROR 0.87 (95% CI 0.43–1.75), 8 AKI reports of 865 total; IC025 −1.35
  • Sunitinib (Hypertension): ROR 0.87 (95% CI 0.78–0.96), 360 AKI reports of 39,148 total; IC025 −0.35
  • Zanubrutinib (Prerenal / Hemodynamic AKI): ROR 0.86 (95% CI 0.62–1.19), 37 AKI reports of 4,598 total; IC025 −0.72
  • Futibatinib (Electrolyte Disturbance): ROR 0.85 (95% CI 0.21–3.42), 2 AKI reports of 222 total; IC025 −2.78
  • Octreotide (Electrolyte Disturbance): ROR 0.85 (95% CI 0.76–0.96), 279 AKI reports of 31,000 total; IC025 −0.41
  • Mitomycin C (Thrombotic Microangiopathy): ROR 0.83 (95% CI 0.58–1.17), 32 AKI reports of 3,659 total; IC025 −0.81
  • Venetoclax (Crystal / Obstructive Nephropathy): ROR 0.83 (95% CI 0.76–0.90), 551 AKI reports of 62,878 total; IC025 −0.39
  • Pralatrexate (Crystal / Obstructive Nephropathy): ROR 0.81 (95% CI 0.30–2.16), 4 AKI reports of 529 total; IC025 −2.01
  • Trifluridine/tipiracil (Prerenal / Hemodynamic AKI): ROR 0.81 (95% CI 0.67–0.99), 97 AKI reports of 11,253 total; IC025 −0.59
  • Sacituzumab govitecan (Prerenal / Hemodynamic AKI): ROR 0.80 (95% CI 0.59–1.09), 41 AKI reports of 4,834 total; IC025 −0.79
  • Blinatumomab (Prerenal / Hemodynamic AKI): ROR 0.79 (95% CI 0.64–0.97), 90 AKI reports of 10,722 total; IC025 −0.64
  • Sonidegib (Acute Tubular Necrosis): ROR 0.79 (95% CI 0.47–1.33), 14 AKI reports of 1,679 total; IC025 −1.19
  • Teniposide (Electrolyte Disturbance): ROR 0.79 (95% CI 0.25–2.46), 3 AKI reports of 405 total; IC025 −2.34
  • Nedaplatin (Acute Tubular Necrosis): ROR 0.78 (95% CI 0.39–1.56), 8 AKI reports of 1,100 total; IC025 −1.51
  • Tebentafusp (Prerenal / Hemodynamic AKI): ROR 0.78 (95% CI 0.33–1.89), 5 AKI reports of 602 total; IC025 −1.85
  • Erdafitinib (Electrolyte Disturbance): ROR 0.76 (95% CI 0.41–1.41), 10 AKI reports of 1,247 total; IC025 −1.41
  • Naxitamab (Prerenal / Hemodynamic AKI): ROR 0.75 (95% CI 0.19–3.04), 2 AKI reports of 250 total; IC025 −2.92
  • Pazopanib (Glomerular Injury / Proteinuria): ROR 0.75 (95% CI 0.66–0.86), 215 AKI reports of 26,971 total; IC025 −0.61
  • Teclistamab (Prerenal / Hemodynamic AKI): ROR 0.75 (95% CI 0.48–1.18), 19 AKI reports of 2,379 total; IC025 −1.12
  • Capmatinib (Pseudo-AKI): ROR 0.74 (95% CI 0.46–1.20), 17 AKI reports of 2,444 total; IC025 −1.18
  • Ivosidenib (Prerenal / Hemodynamic AKI): ROR 0.74 (95% CI 0.46–1.19), 17 AKI reports of 2,178 total; IC025 −1.19
  • Larotrectinib (Pseudo-AKI): ROR 0.74 (95% CI 0.35–1.55), 7 AKI reports of 896 total; IC025 −1.67
  • Rucaparib (Pseudo-AKI): ROR 0.74 (95% CI 0.57–0.95), 61 AKI reports of 8,832 total; IC025 −0.82
  • Alpelisib (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.57–0.93), 62 AKI reports of 9,106 total; IC025 −0.84
  • Asciminib (Hypertension): ROR 0.73 (95% CI 0.49–1.09), 24 AKI reports of 3,514 total; IC025 −1.08
  • Ciltacabtagene autoleucel (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.56–0.96), 51 AKI reports of 6,566 total; IC025 −0.86
  • Estramustine (Prerenal / Hemodynamic AKI): ROR 0.73 (95% CI 0.23–2.28), 3 AKI reports of 437 total; IC025 −2.44
  • Midostaurin (Prerenal / Hemodynamic AKI): ROR 0.72 (95% CI 0.43–1.20), 15 AKI reports of 1,957 total; IC025 −1.27
  • Tarlatamab (Prerenal / Hemodynamic AKI): ROR 0.72 (95% CI 0.42–1.25), 13 AKI reports of 1,917 total; IC025 −1.34
  • Gefitinib (Glomerular Injury / Proteinuria): ROR 0.70 (95% CI 0.55–0.89), 67 AKI reports of 8,990 total; IC025 −0.87
  • Ibrutinib (Hypertension): ROR 0.70 (95% CI 0.65–0.76), 605 AKI reports of 80,997 total; IC025 −0.62
  • Lenalidomide (Acute Tubular Necrosis): ROR 0.69 (95% CI 0.67–0.72), 3,147 AKI reports of 425,916 total; IC025 −0.57
  • Repotrectinib (Pseudo-AKI): ROR 0.69 (95% CI 0.17–2.77), 2 AKI reports of 274 total; IC025 −3.03
  • Ibandronate (Acute Tubular Necrosis): ROR 0.66 (95% CI 0.54–0.82), 92 AKI reports of 14,757 total; IC025 −0.89
  • Pemigatinib (Electrolyte Disturbance): ROR 0.66 (95% CI 0.30–1.48), 6 AKI reports of 853 total; IC025 −1.93
  • Pomalidomide (Prerenal / Hemodynamic AKI): ROR 0.66 (95% CI 0.61–0.71), 725 AKI reports of 103,640 total; IC025 −0.70
  • Dasatinib (Glomerular Injury / Proteinuria): ROR 0.62 (95% CI 0.54–0.72), 191 AKI reports of 32,694 total; IC025 −0.89
  • Lutetium-177 Dotatate (Chronic Interstitial Nephropathy): ROR 0.62 (95% CI 0.45–0.85), 38 AKI reports of 5,819 total; IC025 −1.18
  • Darolutamide (Electrolyte Disturbance): ROR 0.61 (95% CI 0.44–0.86), 34 AKI reports of 5,924 total; IC025 −1.22
  • Nirogacestat (Electrolyte Disturbance): ROR 0.61 (95% CI 0.27–1.37), 6 AKI reports of 923 total; IC025 −2.03
  • Talazoparib (Pseudo-AKI): ROR 0.61 (95% CI 0.35–1.08), 12 AKI reports of 1,853 total; IC025 −1.61
  • Tislelizumab (Acute Interstitial Nephritis): ROR 0.61 (95% CI 0.47–0.81), 51 AKI reports of 8,853 total; IC025 −1.12
  • Mosunetuzumab (Prerenal / Hemodynamic AKI): ROR 0.60 (95% CI 0.28–1.25), 7 AKI reports of 1,107 total; IC025 −1.96
  • Ruxolitinib (Prerenal / Hemodynamic AKI): ROR 0.58 (95% CI 0.53–0.63), 449 AKI reports of 73,257 total; IC025 −0.92
  • Nintedanib (Hypertension): ROR 0.57 (95% CI 0.50–0.66), 199 AKI reports of 32,818 total; IC025 −1.01
  • Zongertinib (Pseudo-AKI): ROR 0.56 (95% CI 0.08–4.03), 1 AKI reports of 167 total; IC025 −4.39
  • Radium-223 dichloride (Prerenal / Hemodynamic AKI): ROR 0.54 (95% CI 0.38–0.78), 29 AKI reports of 5,055 total; IC025 −1.44
  • Amivantamab (Electrolyte Disturbance): ROR 0.53 (95% CI 0.34–0.82), 20 AKI reports of 3,576 total; IC025 −1.60
  • Erlotinib (Glomerular Injury / Proteinuria): ROR 0.53 (95% CI 0.44–0.64), 115 AKI reports of 22,936 total; IC025 −1.17
  • Sotorasib (Prerenal / Hemodynamic AKI): ROR 0.52 (95% CI 0.33–0.81), 19 AKI reports of 3,470 total; IC025 −1.65
  • Lomustine (CCNU) (Chronic Interstitial Nephropathy): ROR 0.51 (95% CI 0.30–0.86), 14 AKI reports of 2,597 total; IC025 −1.80
  • Toripalimab (Acute Interstitial Nephritis): ROR 0.50 (95% CI 0.26–0.96), 9 AKI reports of 1,928 total; IC025 −2.06
  • Acalabrutinib (Hypertension): ROR 0.49 (95% CI 0.38–0.62), 66 AKI reports of 12,744 total; IC025 −1.39
  • Cabozantinib (Hypertension): ROR 0.49 (95% CI 0.43–0.55), 251 AKI reports of 48,250 total; IC025 −1.21
  • Fruquintinib (Hypertension): ROR 0.48 (95% CI 0.31–0.74), 20 AKI reports of 3,941 total; IC025 −1.74
  • Tivozanib (Hypertension): ROR 0.47 (95% CI 0.22–0.99), 7 AKI reports of 1,588 total; IC025 −2.29
  • Brigatinib (Pseudo-AKI): ROR 0.46 (95% CI 0.29–0.74), 18 AKI reports of 3,655 total; IC025 −1.82
  • Trastuzumab deruxtecan (Acute Tubular Necrosis): ROR 0.46 (95% CI 0.35–0.60), 53 AKI reports of 10,910 total; IC025 −1.53
  • Trastuzumab emtansine (T-DM1) (Thrombotic Microangiopathy): ROR 0.44 (95% CI 0.33–0.61), 40 AKI reports of 8,459 total; IC025 −1.63
  • Nilotinib (Prerenal / Hemodynamic AKI): ROR 0.43 (95% CI 0.36–0.50), 134 AKI reports of 29,571 total; IC025 −1.47
  • Enzalutamide (Hypertension): ROR 0.42 (95% CI 0.37–0.47), 262 AKI reports of 58,866 total; IC025 −1.43
  • Cladribine (Crystal / Obstructive Nephropathy): ROR 0.40 (95% CI 0.29–0.54), 42 AKI reports of 9,967 total; IC025 −1.79
  • Denosumab (Electrolyte Disturbance): ROR 0.40 (95% CI 0.37–0.42), 864 AKI reports of 203,750 total; IC025 −1.42
  • Lanreotide (Electrolyte Disturbance): ROR 0.39 (95% CI 0.28–0.55), 33 AKI reports of 7,953 total; IC025 −1.87
  • Osimertinib (SIADH / Hyponatremia): ROR 0.39 (95% CI 0.33–0.47), 125 AKI reports of 33,803 total; IC025 −1.60
  • Ziv-aflibercept (Hypertension): ROR 0.37 (95% CI 0.31–0.44), 130 AKI reports of 32,703 total; IC025 −1.67
  • Palbociclib (Pseudo-AKI): ROR 0.36 (95% CI 0.33–0.40), 369 AKI reports of 95,562 total; IC025 −1.60
  • Leuprolide (Hypertension): ROR 0.35 (95% CI 0.32–0.40), 300 AKI reports of 79,718 total; IC025 −1.66
  • Lorlatinib (Pseudo-AKI): ROR 0.35 (95% CI 0.24–0.51), 28 AKI reports of 7,455 total; IC025 −2.06
  • Alectinib (Pseudo-AKI): ROR 0.34 (95% CI 0.23–0.50), 27 AKI reports of 7,388 total; IC025 −2.11
  • Selumetinib (Prerenal / Hemodynamic AKI): ROR 0.33 (95% CI 0.15–0.75), 6 AKI reports of 1,684 total; IC025 −2.87
  • Fotemustine (Chronic Interstitial Nephropathy): ROR 0.32 (95% CI 0.04–2.29), 1 AKI reports of 331 total; IC025 −5.06
  • Lutetium-177 PSMA-617 (vipivotide) (Chronic Interstitial Nephropathy): ROR 0.30 (95% CI 0.22–0.40), 44 AKI reports of 13,841 total; IC025 −2.18
  • Olaparib (Pseudo-AKI): ROR 0.26 (95% CI 0.20–0.34), 60 AKI reports of 21,443 total; IC025 −2.30
  • Vismodegib (SIADH / Hyponatremia): ROR 0.25 (95% CI 0.17–0.38), 24 AKI reports of 8,927 total; IC025 −2.59
  • Niraparib (Hypertension): ROR 0.22 (95% CI 0.17–0.29), 53 AKI reports of 22,237 total; IC025 −2.55
  • Pacritinib (Prerenal / Hemodynamic AKI): ROR 0.21 (95% CI 0.10–0.45), 7 AKI reports of 3,069 total; IC025 −3.40
  • Pralsetinib (Hypertension): ROR 0.21 (95% CI 0.08–0.55), 4 AKI reports of 1,824 total; IC025 −3.87
  • Enasidenib (Prerenal / Hemodynamic AKI): ROR 0.19 (95% CI 0.09–0.41), 7 AKI reports of 3,369 total; IC025 −3.53
  • Tazemetostat (Prerenal / Hemodynamic AKI): ROR 0.17 (95% CI 0.06–0.54), 3 AKI reports of 1,622 total; IC025 −4.38
  • Vorasidenib (Pseudo-AKI): ROR 0.17 (95% CI 0.02–1.23), 1 AKI reports of 612 total; IC025 −5.85
  • Ripretinib (Hypertension): ROR 0.16 (95% CI 0.08–0.31), 9 AKI reports of 5,243 total; IC025 −3.65
  • Pexidartinib (Prerenal / Hemodynamic AKI): ROR 0.13 (95% CI 0.02–0.93), 1 AKI reports of 717 total; IC025 −6.23
  • Quizartinib (Prerenal / Hemodynamic AKI): ROR 0.13 (95% CI 0.02–0.95), 1 AKI reports of 702 total; IC025 −6.20
  • Datopotamab deruxtecan (Dato-DXd) (Acute Tubular Necrosis): ROR 0.11 (95% CI 0.01–0.78), 1 AKI reports of 859 total; IC025 −6.47
  • Mirvetuximab soravtansine (Prerenal / Hemodynamic AKI): ROR 0.10 (95% CI 0.03–0.41), 2 AKI reports of 1,814 total; IC025 −5.57
  • Avapritinib (Prerenal / Hemodynamic AKI): ROR 0.09 (95% CI 0.05–0.17), 11 AKI reports of 12,654 total; IC025 −4.35
  • Revumenib (Prerenal / Hemodynamic AKI): ROR 0.09 (95% CI 0.01–0.65), 1 AKI reports of 1,031 total; IC025 −6.72
  • Avutometinib (Electrolyte Disturbance): ROR 0.08 (95% CI 0.01–0.59), 1 AKI reports of 1,125 total; IC025 −6.84
  • Elacestrant (Prerenal / Hemodynamic AKI): ROR 0.07 (95% CI 0.03–0.16), 5 AKI reports of 7,181 total; IC025 −5.32
  • Mechlorethamine (Electrolyte Disturbance): ROR 0.04 (95% CI 0.01–0.30), 1 AKI reports of 2,247 total; IC025 −7.81
Figure 15·FAERS acute-kidney-injury reporting odds ratio (x, log) vs AKI report count (y, log); right of the ROR = 1 line is a point estimate above 1 — filled dots, whose 95% CI also clears it, report AKI disproportionately.

Which kidney phenotypes each drug class actually gets reported for. A cell's depth of color counts agents with a significant FAERS signal (ROR 95% CI lower bound > 1, on at least 50 total reports) for that phenotype, out of the family's agents holding a FAERS matrix row — the number after each row label — so a deep cell in a 3-agent family is not the same claim as one in a 20-agent family. A reporting signal, not incidence or causation — and ATN/AIN undercount, since most true cases file as generic acute kidney injury. Where a phenotype's terms mix naming and merely-consistent ones (haematuria beside haemorrhagic cystitis; every crystal term), a cell also counts signals the naming terms alone do not carry — its readout says how many.

Number of anti-cancer agents in each drug-class family (rows) carrying a significant FAERS reporting signal for each kidney-injury signature (columns), out of that family's agents that have a FAERS matrix row.
Drug class family
ATNsignaling agents: 41
AINsignaling agents: 46
TMAsignaling agents: 80
GLOMsignaling agents: 83
LYTEsignaling agents: 161
FANCsignaling agents: 23
XTALsignaling agents: 48
HTNsignaling agents: 63
SIADHsignaling agents: 128
CYSTsignaling agents: 82
Antimetabolites — 20 agents in the FAERS matrix
Antimetabolites, Acute Tubular Necrosis: 7 agents — 5-Fluorouracil, Clofarabine, Cytarabine, Fludarabine, Gemcitabine, Hydroxyurea, Pemetrexed
Antimetabolites, Acute Interstitial Nephritis: 4 agents — Cytarabine, Fludarabine, Gemcitabine, Pemetrexed
Antimetabolites, Thrombotic Microangiopathy: 12 agents — 5-Fluorouracil, Azacitidine, Capecitabine, Cladribine, Clofarabine, Cytarabine, Decitabine, Fludarabine, Gemcitabine, Methotrexate (high-dose), Pemetrexed, Pentostatin
Antimetabolites, Glomerular Injury / Proteinuria: 10 agents (2 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Capecitabine, Cytarabine, Fludarabine, Gemcitabine, Pemetrexed, Pentostatin, Raltitrexed, Tegafur-uracil (UFT), Trifluridine/tipiracil
Antimetabolites, Electrolyte Disturbance: 14 agents (5 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Azacitidine, Capecitabine, Clofarabine, Cytarabine, Decitabine, Fludarabine, Gemcitabine, Hydroxyurea, Nelarabine, Pemetrexed, Pentostatin, Pralatrexate, Tegafur-uracil (UFT)
Antimetabolites, Fanconi Syndrome: 3 agents (1 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Azacitidine, Doxifluridine
Antimetabolites, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Cladribine, Hydroxyurea, Methotrexate (high-dose), Trifluridine/tipiracil
Antimetabolites, Hypertension: 3 agents — 5-Fluorouracil, Methotrexate (high-dose), Raltitrexed
Antimetabolites, SIADH / Hyponatremia: 10 agents (4 on terms only consistent with the lesion, not naming it) — 5-Fluorouracil, Azacitidine, Capecitabine, Cytarabine, Fludarabine, Gemcitabine, Hydroxyurea, Pemetrexed, Pentostatin, Pralatrexate
Antimetabolites, Hemorrhagic Cystitis: 10 agents — Azacitidine, Capecitabine, Clofarabine, Cytarabine, Fludarabine, Gemcitabine, Hydroxyurea, Methotrexate (high-dose), Nelarabine, Pentostatin
Alkylating agents — 21 agents in the FAERS matrix
Alkylating agents, Acute Tubular Necrosis: 6 agents — Bendamustine, Carmustine (BCNU), Cyclophosphamide, Ifosfamide, Melphalan, Trabectedin
Alkylating agents, Acute Interstitial Nephritis: 8 agents — Bendamustine, Busulfan, Carmustine (BCNU), Chlorambucil, Cyclophosphamide, Ifosfamide, Melphalan, Temozolomide
Alkylating agents, Thrombotic Microangiopathy: 9 agents — Bendamustine, Busulfan, Carmustine (BCNU), Cyclophosphamide, Dacarbazine, Ifosfamide, Melphalan, Thiotepa, Trabectedin
Alkylating agents, Glomerular Injury / Proteinuria: 11 agents (4 on terms only consistent with the lesion, not naming it) — Busulfan, Carmustine (BCNU), Chlorambucil, Cyclophosphamide, Fotemustine, Ifosfamide, Lomustine (CCNU), Melphalan, Streptozocin, Temozolomide, Thiotepa
Alkylating agents, Electrolyte Disturbance: 10 agents (5 on terms only consistent with the lesion, not naming it) — Bendamustine, Cyclophosphamide, Dacarbazine, Estramustine, Fotemustine, Ifosfamide, Melphalan, Streptozocin, Temozolomide, Trabectedin
Alkylating agents, Fanconi Syndrome: 4 agents — Busulfan, Cyclophosphamide, Ifosfamide, Melphalan
Alkylating agents, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Bendamustine
Alkylating agents, Hypertension: 1 agent — Busulfan
Alkylating agents, SIADH / Hyponatremia: 11 agents (4 on terms only consistent with the lesion, not naming it) — Busulfan, Cyclophosphamide, Dacarbazine, Ifosfamide, Lomustine (CCNU), Lurbinectedin, Melphalan, Nimustine (ACNU), Temozolomide, Thiotepa, Trabectedin
Alkylating agents, Hemorrhagic Cystitis: 8 agents (1 on terms only consistent with the lesion, not naming it) — Bendamustine, Busulfan, Carmustine (BCNU), Cyclophosphamide, Estramustine, Ifosfamide, Melphalan, Thiotepa
Anti-angiogenic (VEGF) — 14 agents in the FAERS matrix
Anti-angiogenic (VEGF), Acute Tubular Necrosis: no signal
Anti-angiogenic (VEGF), Acute Interstitial Nephritis: 1 agent — Axitinib
Anti-angiogenic (VEGF), Thrombotic Microangiopathy: 6 agents — Bevacizumab, Fruquintinib, Lenvatinib, Ramucirumab, Sorafenib, Sunitinib
Anti-angiogenic (VEGF), Glomerular Injury / Proteinuria: 14 agents (1 on terms only consistent with the lesion, not naming it) — Axitinib, Bevacizumab, Cabozantinib, Fruquintinib, Lenvatinib, Nintedanib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib, Ziv-aflibercept
Anti-angiogenic (VEGF), Electrolyte Disturbance: 11 agents (5 on terms only consistent with the lesion, not naming it) — Axitinib, Bevacizumab, Cabozantinib, Lenvatinib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib
Anti-angiogenic (VEGF), Fanconi Syndrome: no signal
Anti-angiogenic (VEGF), Crystal / Obstructive Nephropathy: 3 agents (3 on terms only consistent with the lesion, not naming it) — Bevacizumab, Nintedanib, Vandetanib
Anti-angiogenic (VEGF), Hypertension: 14 agents — Axitinib, Bevacizumab, Cabozantinib, Fruquintinib, Lenvatinib, Nintedanib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib, Ziv-aflibercept
Anti-angiogenic (VEGF), SIADH / Hyponatremia: 11 agents (9 on terms only consistent with the lesion, not naming it) — Axitinib, Bevacizumab, Cabozantinib, Lenvatinib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, Vandetanib
Anti-angiogenic (VEGF), Hemorrhagic Cystitis: 7 agents (5 on terms only consistent with the lesion, not naming it) — Bevacizumab, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Sorafenib, Sunitinib
Other targeted agents — 41 agents in the FAERS matrix
Other targeted agents, Acute Tubular Necrosis: 2 agents — Bortezomib, Thalidomide
Other targeted agents, Acute Interstitial Nephritis: 1 agent — Arsenic trioxide
Other targeted agents, Thrombotic Microangiopathy: 7 agents — Bortezomib, Carfilzomib, Denileukin diftitox, Ixazomib, Lifileucel, Moxetumomab pasudotox, Thalidomide
Other targeted agents, Glomerular Injury / Proteinuria: 3 agents (2 on terms only consistent with the lesion, not naming it) — Belzutifan, Bortezomib, Thalidomide
Other targeted agents, Electrolyte Disturbance: 20 agents (12 on terms only consistent with the lesion, not naming it) — Adagrasib, Arsenic trioxide, Belzutifan, Bortezomib, Carfilzomib, Denileukin diftitox, Glasdegib, Ivosidenib, Ixazomib, Lifileucel, Niraparib, Nirogacestat, Relacorilant, Selinexor, Sotorasib, Talazoparib, Thalidomide, Venetoclax, Vismodegib, Vorasidenib
Other targeted agents, Fanconi Syndrome: 1 agent — Tazemetostat
Other targeted agents, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Belzutifan, Niraparib, Relacorilant, Tretinoin (ATRA)
Other targeted agents, Hypertension: 4 agents (1 on terms only consistent with the lesion, not naming it) — Arsenic trioxide, Carfilzomib, Niraparib, Tretinoin (ATRA)
Other targeted agents, SIADH / Hyponatremia: 12 agents (10 on terms only consistent with the lesion, not naming it) — Belzutifan, Bortezomib, Denileukin diftitox, Glasdegib, Lifileucel, Niraparib, Relacorilant, Rucaparib, Selinexor, Talazoparib, Vismodegib, Vorasidenib
Other targeted agents, Hemorrhagic Cystitis: 5 agents (3 on terms only consistent with the lesion, not naming it) — Bortezomib, Niraparib, Sonidegib, Talazoparib, Thalidomide
Checkpoint inhibitors — 16 agents in the FAERS matrix
Checkpoint inhibitors, Acute Tubular Necrosis: 4 agents — Dostarlimab, Ipilimumab, Nivolumab, Pembrolizumab
Checkpoint inhibitors, Acute Interstitial Nephritis: 9 agents — Atezolizumab, Avelumab, Cemiplimab, Dostarlimab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Relatlimab
Checkpoint inhibitors, Thrombotic Microangiopathy: 4 agents — Atezolizumab, Dostarlimab, Durvalumab, Pembrolizumab
Checkpoint inhibitors, Glomerular Injury / Proteinuria: 9 agents (4 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Penpulimab, Tislelizumab, Toripalimab
Checkpoint inhibitors, Electrolyte Disturbance: 10 agents (4 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Dostarlimab, Ipilimumab, Nivolumab, Pembrolizumab, Penpulimab, Retifanlimab, Tislelizumab, Toripalimab
Checkpoint inhibitors, Fanconi Syndrome: 2 agents (2 on terms only consistent with the lesion, not naming it) — Nivolumab, Pembrolizumab
Checkpoint inhibitors, Crystal / Obstructive Nephropathy: no signal
Checkpoint inhibitors, Hypertension: 5 agents — Atezolizumab, Avelumab, Pembrolizumab, Penpulimab, Toripalimab
Checkpoint inhibitors, SIADH / Hyponatremia: 9 agents (2 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, Retifanlimab, Tislelizumab, Toripalimab
Checkpoint inhibitors, Hemorrhagic Cystitis: 4 agents (2 on terms only consistent with the lesion, not naming it) — Atezolizumab, Avelumab, Pembrolizumab, Penpulimab
Monoclonal antibodies (other) — 16 agents in the FAERS matrix
Monoclonal antibodies (other), Acute Tubular Necrosis: 4 agents — Amivantamab, Cetuximab, Necitumumab, Rituximab
Monoclonal antibodies (other), Acute Interstitial Nephritis: 2 agents — Amivantamab, Mogamulizumab
Monoclonal antibodies (other), Thrombotic Microangiopathy: 10 agents — Cetuximab, Daratumumab, Dinutuximab, Elotuzumab, Isatuximab, Mogamulizumab, Naxitamab, Obinutuzumab, Rituximab, Tafasitamab
Monoclonal antibodies (other), Glomerular Injury / Proteinuria: 7 agents (1 on terms only consistent with the lesion, not naming it) — Cetuximab, Daratumumab, Dinutuximab, Mogamulizumab, Obinutuzumab, Panitumumab, Rituximab
Monoclonal antibodies (other), Electrolyte Disturbance: 14 agents (7 on terms only consistent with the lesion, not naming it) — Amivantamab, Cetuximab, Daratumumab, Dinutuximab, Elotuzumab, Isatuximab, Mogamulizumab, Naxitamab, Necitumumab, Obinutuzumab, Panitumumab, Rituximab, Tafasitamab, Zolbetuximab
Monoclonal antibodies (other), Fanconi Syndrome: 1 agent — Zolbetuximab
Monoclonal antibodies (other), Crystal / Obstructive Nephropathy: 2 agents (2 on terms only consistent with the lesion, not naming it) — Naxitamab, Rituximab
Monoclonal antibodies (other), Hypertension: 5 agents — Dinutuximab, Isatuximab, Naxitamab, Obinutuzumab, Rituximab
Monoclonal antibodies (other), SIADH / Hyponatremia: 5 agents (5 on terms only consistent with the lesion, not naming it) — Cetuximab, Dinutuximab, Naxitamab, Necitumumab, Tafasitamab
Monoclonal antibodies (other), Hemorrhagic Cystitis: 2 agents (1 on terms only consistent with the lesion, not naming it) — Obinutuzumab, Rituximab
Hormonal / endocrine — 13 agents in the FAERS matrix
Hormonal / endocrine, Acute Tubular Necrosis: no signal
Hormonal / endocrine, Acute Interstitial Nephritis: no signal
Hormonal / endocrine, Thrombotic Microangiopathy: no signal
Hormonal / endocrine, Glomerular Injury / Proteinuria: 1 agent — Bicalutamide
Hormonal / endocrine, Electrolyte Disturbance: 7 agents (5 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Imlunestrant, Lanreotide, Mitotane, Octreotide, Tamoxifen
Hormonal / endocrine, Fanconi Syndrome: 1 agent — Bicalutamide
Hormonal / endocrine, Crystal / Obstructive Nephropathy: 8 agents (8 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Darolutamide, Enzalutamide, Lanreotide, Leuprolide, Octreotide, Tamoxifen
Hormonal / endocrine, Hypertension: 7 agents (1 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Darolutamide, Enzalutamide, Lanreotide, Octreotide, Tamoxifen
Hormonal / endocrine, SIADH / Hyponatremia: 7 agents (6 on terms only consistent with the lesion, not naming it) — Bicalutamide, Darolutamide, Imlunestrant, Lanreotide, Mitotane, Octreotide, Tamoxifen
Hormonal / endocrine, Hemorrhagic Cystitis: 7 agents (7 on terms only consistent with the lesion, not naming it) — Abiraterone, Bicalutamide, Darolutamide, Enzalutamide, Leuprolide, Octreotide, Tamoxifen
Antibody-drug conjugates — 15 agents in the FAERS matrix
Antibody-drug conjugates, Acute Tubular Necrosis: 1 agent — Tisotumab vedotin
Antibody-drug conjugates, Acute Interstitial Nephritis: 3 agents — Brentuximab vedotin, Enfortumab vedotin, Loncastuximab tesirine
Antibody-drug conjugates, Thrombotic Microangiopathy: 2 agents — Gemtuzumab ozogamicin, Inotuzumab ozogamicin
Antibody-drug conjugates, Glomerular Injury / Proteinuria: 1 agent (1 on terms only consistent with the lesion, not naming it) — Belantamab mafodotin
Antibody-drug conjugates, Electrolyte Disturbance: 10 agents (2 on terms only consistent with the lesion, not naming it) — Belantamab mafodotin, Brentuximab vedotin, Enfortumab vedotin, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Polatuzumab vedotin, Sacituzumab govitecan, Tisotumab vedotin, Trastuzumab deruxtecan, Trastuzumab emtansine (T-DM1)
Antibody-drug conjugates, Fanconi Syndrome: no signal
Antibody-drug conjugates, Crystal / Obstructive Nephropathy: 3 agents (3 on terms only consistent with the lesion, not naming it) — Enfortumab vedotin, Polatuzumab vedotin, Tisotumab vedotin
Antibody-drug conjugates, Hypertension: 1 agent — Trastuzumab emtansine (T-DM1)
Antibody-drug conjugates, SIADH / Hyponatremia: 8 agents (7 on terms only consistent with the lesion, not naming it) — Brentuximab vedotin, Enfortumab vedotin, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Polatuzumab vedotin, Tisotumab vedotin, Trastuzumab deruxtecan, Trastuzumab emtansine (T-DM1)
Antibody-drug conjugates, Hemorrhagic Cystitis: 5 agents (1 on terms only consistent with the lesion, not naming it) — Enfortumab vedotin, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Polatuzumab vedotin, Tisotumab vedotin
Microtubule inhibitors — 8 agents in the FAERS matrix
Microtubule inhibitors, Acute Tubular Necrosis: 2 agents — Paclitaxel, Vinblastine
Microtubule inhibitors, Acute Interstitial Nephritis: 2 agents — Paclitaxel, Vinorelbine
Microtubule inhibitors, Thrombotic Microangiopathy: 4 agents — Docetaxel, Paclitaxel, Vincristine, Vinorelbine
Microtubule inhibitors, Glomerular Injury / Proteinuria: 2 agents (1 on terms only consistent with the lesion, not naming it) — Docetaxel, Paclitaxel
Microtubule inhibitors, Electrolyte Disturbance: 7 agents (1 on terms only consistent with the lesion, not naming it) — Cabazitaxel, Docetaxel, Eribulin, Paclitaxel, Vinblastine, Vincristine, Vinorelbine
Microtubule inhibitors, Fanconi Syndrome: 1 agent — Vincristine
Microtubule inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Cabazitaxel
Microtubule inhibitors, Hypertension: 1 agent — Paclitaxel
Microtubule inhibitors, SIADH / Hyponatremia: 6 agents (1 on terms only consistent with the lesion, not naming it) — Cabazitaxel, Docetaxel, Paclitaxel, Vinblastine, Vincristine, Vinorelbine
Microtubule inhibitors, Hemorrhagic Cystitis: 4 agents — Cabazitaxel, Docetaxel, Paclitaxel, Vincristine
Platinum agents — 4 agents in the FAERS matrix
Platinum agents, Acute Tubular Necrosis: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
Platinum agents, Acute Interstitial Nephritis: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
Platinum agents, Thrombotic Microangiopathy: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
Platinum agents, Glomerular Injury / Proteinuria: 4 agents (2 on terms only consistent with the lesion, not naming it) — Carboplatin, Cisplatin, Nedaplatin, Oxaliplatin
Platinum agents, Electrolyte Disturbance: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
Platinum agents, Fanconi Syndrome: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
Platinum agents, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Cisplatin
Platinum agents, Hypertension: 1 agent — Oxaliplatin
Platinum agents, SIADH / Hyponatremia: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
Platinum agents, Hemorrhagic Cystitis: 3 agents — Carboplatin, Cisplatin, Oxaliplatin
BRAF / MEK inhibitors — 10 agents in the FAERS matrix
BRAF / MEK inhibitors, Acute Tubular Necrosis: 2 agents — Binimetinib, Cobimetinib
BRAF / MEK inhibitors, Acute Interstitial Nephritis: 5 agents — Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Trametinib
BRAF / MEK inhibitors, Thrombotic Microangiopathy: no signal
BRAF / MEK inhibitors, Glomerular Injury / Proteinuria: 3 agents (3 on terms only consistent with the lesion, not naming it) — Cobimetinib, Trametinib, Vemurafenib
BRAF / MEK inhibitors, Electrolyte Disturbance: 8 agents (6 on terms only consistent with the lesion, not naming it) — Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Mirdametinib, Tovorafenib, Trametinib, Vemurafenib
BRAF / MEK inhibitors, Fanconi Syndrome: no signal
BRAF / MEK inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Selumetinib
BRAF / MEK inhibitors, Hypertension: no signal
BRAF / MEK inhibitors, SIADH / Hyponatremia: 7 agents (7 on terms only consistent with the lesion, not naming it) — Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Tovorafenib, Trametinib, Vemurafenib
BRAF / MEK inhibitors, Hemorrhagic Cystitis: no signal
Antitumor antibiotics — 7 agents in the FAERS matrix
Antitumor antibiotics, Acute Tubular Necrosis: 1 agent — Bleomycin
Antitumor antibiotics, Acute Interstitial Nephritis: 2 agents — Dactinomycin (actinomycin D), Doxorubicin
Antitumor antibiotics, Thrombotic Microangiopathy: 6 agents — Bleomycin, Dactinomycin (actinomycin D), Doxorubicin, Idarubicin, Mitomycin C, Mitoxantrone
Antitumor antibiotics, Glomerular Injury / Proteinuria: 3 agents (2 on terms only consistent with the lesion, not naming it) — Dactinomycin (actinomycin D), Doxorubicin, Mitomycin C
Antitumor antibiotics, Electrolyte Disturbance: 4 agents (2 on terms only consistent with the lesion, not naming it) — Bleomycin, Doxorubicin, Idarubicin, Mitoxantrone
Antitumor antibiotics, Fanconi Syndrome: 2 agents — Dactinomycin (actinomycin D), Doxorubicin
Antitumor antibiotics, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Mitomycin C
Antitumor antibiotics, Hypertension: no signal
Antitumor antibiotics, SIADH / Hyponatremia: 2 agents — Bleomycin, Doxorubicin
Antitumor antibiotics, Hemorrhagic Cystitis: 4 agents — Dactinomycin (actinomycin D), Doxorubicin, Mitomycin C, Mitoxantrone
Bisphosphonates & bone — 4 agents in the FAERS matrix
Bisphosphonates & bone, Acute Tubular Necrosis: 1 agent — Zoledronic acid
Bisphosphonates & bone, Acute Interstitial Nephritis: 2 agents — Pamidronate, Zoledronic acid
Bisphosphonates & bone, Thrombotic Microangiopathy: no signal
Bisphosphonates & bone, Glomerular Injury / Proteinuria: 2 agents (1 on terms only consistent with the lesion, not naming it) — Pamidronate, Zoledronic acid
Bisphosphonates & bone, Electrolyte Disturbance: 4 agents — Denosumab, Ibandronate, Pamidronate, Zoledronic acid
Bisphosphonates & bone, Fanconi Syndrome: 2 agents — Ibandronate, Zoledronic acid
Bisphosphonates & bone, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Denosumab, Ibandronate, Pamidronate, Zoledronic acid
Bisphosphonates & bone, Hypertension: 3 agents — Ibandronate, Pamidronate, Zoledronic acid
Bisphosphonates & bone, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Pamidronate, Zoledronic acid
Bisphosphonates & bone, Hemorrhagic Cystitis: 4 agents (4 on terms only consistent with the lesion, not naming it) — Denosumab, Ibandronate, Pamidronate, Zoledronic acid
Topoisomerase inhibitors — 5 agents in the FAERS matrix
Topoisomerase inhibitors, Acute Tubular Necrosis: 2 agents — Etoposide, Topotecan
Topoisomerase inhibitors, Acute Interstitial Nephritis: 1 agent — Etoposide
Topoisomerase inhibitors, Thrombotic Microangiopathy: 3 agents — Amsacrine, Etoposide, Topotecan
Topoisomerase inhibitors, Glomerular Injury / Proteinuria: 4 agents (1 on terms only consistent with the lesion, not naming it) — Amsacrine, Etoposide, Irinotecan, Topotecan
Topoisomerase inhibitors, Electrolyte Disturbance: 3 agents — Etoposide, Irinotecan, Topotecan
Topoisomerase inhibitors, Fanconi Syndrome: 1 agent — Etoposide
Topoisomerase inhibitors, Crystal / Obstructive Nephropathy: 2 agents (2 on terms only consistent with the lesion, not naming it) — Irinotecan, Topotecan
Topoisomerase inhibitors, Hypertension: 1 agent — Irinotecan
Topoisomerase inhibitors, SIADH / Hyponatremia: 3 agents (1 on terms only consistent with the lesion, not naming it) — Etoposide, Irinotecan, Topotecan
Topoisomerase inhibitors, Hemorrhagic Cystitis: 3 agents — Etoposide, Teniposide, Topotecan
Other kinase inhibitors — 13 agents in the FAERS matrix
Other kinase inhibitors, Acute Tubular Necrosis: no signal
Other kinase inhibitors, Acute Interstitial Nephritis: no signal
Other kinase inhibitors, Thrombotic Microangiopathy: 3 agents — Gilteritinib, Ruxolitinib, Selpercatinib
Other kinase inhibitors, Glomerular Injury / Proteinuria: 1 agent — Selpercatinib
Other kinase inhibitors, Electrolyte Disturbance: 3 agents (1 on terms only consistent with the lesion, not naming it) — Gilteritinib, Pralsetinib, Selpercatinib
Other kinase inhibitors, Fanconi Syndrome: no signal
Other kinase inhibitors, Crystal / Obstructive Nephropathy: 4 agents (4 on terms only consistent with the lesion, not naming it) — Avapritinib, Pacritinib, Pexidartinib, Ruxolitinib
Other kinase inhibitors, Hypertension: 5 agents — Pexidartinib, Pralsetinib, Ripretinib, Selpercatinib, Vimseltinib
Other kinase inhibitors, SIADH / Hyponatremia: 3 agents (1 on terms only consistent with the lesion, not naming it) — Gilteritinib, Pralsetinib, Selpercatinib
Other kinase inhibitors, Hemorrhagic Cystitis: 3 agents (1 on terms only consistent with the lesion, not naming it) — Gilteritinib, Ruxolitinib, Selpercatinib
mTOR inhibitors — 3 agents in the FAERS matrix
mTOR inhibitors, Acute Tubular Necrosis: 3 agents — Everolimus, Sirolimus, Temsirolimus
mTOR inhibitors, Acute Interstitial Nephritis: 1 agent — Sirolimus
mTOR inhibitors, Thrombotic Microangiopathy: 2 agents — Everolimus, Sirolimus
mTOR inhibitors, Glomerular Injury / Proteinuria: 3 agents (1 on terms only consistent with the lesion, not naming it) — Everolimus, Sirolimus, Temsirolimus
mTOR inhibitors, Electrolyte Disturbance: 3 agents (1 on terms only consistent with the lesion, not naming it) — Everolimus, Sirolimus, Temsirolimus
mTOR inhibitors, Fanconi Syndrome: 1 agent — Everolimus
mTOR inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Everolimus
mTOR inhibitors, Hypertension: 2 agents — Everolimus, Temsirolimus
mTOR inhibitors, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Everolimus, Temsirolimus
mTOR inhibitors, Hemorrhagic Cystitis: 3 agents (1 on terms only consistent with the lesion, not naming it) — Everolimus, Sirolimus, Temsirolimus
EGFR / HER2 inhibitors — 11 agents in the FAERS matrix
EGFR / HER2 inhibitors, Acute Tubular Necrosis: 1 agent — Zongertinib
EGFR / HER2 inhibitors, Acute Interstitial Nephritis: no signal
EGFR / HER2 inhibitors, Thrombotic Microangiopathy: 1 agent — Erlotinib
EGFR / HER2 inhibitors, Glomerular Injury / Proteinuria: 2 agents (1 on terms only consistent with the lesion, not naming it) — Erlotinib, Gefitinib
EGFR / HER2 inhibitors, Electrolyte Disturbance: 6 agents (1 on terms only consistent with the lesion, not naming it) — Afatinib, Erlotinib, Gefitinib, Mobocertinib, Neratinib, Tucatinib
EGFR / HER2 inhibitors, Fanconi Syndrome: no signal
EGFR / HER2 inhibitors, Crystal / Obstructive Nephropathy: no signal
EGFR / HER2 inhibitors, Hypertension: no signal
EGFR / HER2 inhibitors, SIADH / Hyponatremia: 6 agents (5 on terms only consistent with the lesion, not naming it) — Afatinib, Erlotinib, Gefitinib, Mobocertinib, Osimertinib, Tucatinib
EGFR / HER2 inhibitors, Hemorrhagic Cystitis: 1 agent — Gefitinib
BTK inhibitors — 4 agents in the FAERS matrix
BTK inhibitors, Acute Tubular Necrosis: no signal
BTK inhibitors, Acute Interstitial Nephritis: no signal
BTK inhibitors, Thrombotic Microangiopathy: no signal
BTK inhibitors, Glomerular Injury / Proteinuria: no signal
BTK inhibitors, Electrolyte Disturbance: 3 agents (2 on terms only consistent with the lesion, not naming it) — Ibrutinib, Pirtobrutinib, Zanubrutinib
BTK inhibitors, Fanconi Syndrome: no signal
BTK inhibitors, Crystal / Obstructive Nephropathy: 3 agents (3 on terms only consistent with the lesion, not naming it) — Acalabrutinib, Ibrutinib, Zanubrutinib
BTK inhibitors, Hypertension: 2 agents — Ibrutinib, Zanubrutinib
BTK inhibitors, SIADH / Hyponatremia: 3 agents (3 on terms only consistent with the lesion, not naming it) — Acalabrutinib, Ibrutinib, Zanubrutinib
BTK inhibitors, Hemorrhagic Cystitis: 3 agents (2 on terms only consistent with the lesion, not naming it) — Ibrutinib, Pirtobrutinib, Zanubrutinib
BCR-ABL inhibitors — 7 agents in the FAERS matrix
BCR-ABL inhibitors, Acute Tubular Necrosis: 1 agent — Imatinib
BCR-ABL inhibitors, Acute Interstitial Nephritis: no signal
BCR-ABL inhibitors, Thrombotic Microangiopathy: 3 agents — Dasatinib, Imatinib, Ponatinib
BCR-ABL inhibitors, Glomerular Injury / Proteinuria: 2 agents — Dasatinib, Imatinib
BCR-ABL inhibitors, Electrolyte Disturbance: no signal
BCR-ABL inhibitors, Fanconi Syndrome: no signal
BCR-ABL inhibitors, Crystal / Obstructive Nephropathy: 2 agents (2 on terms only consistent with the lesion, not naming it) — Imatinib, Nilotinib
BCR-ABL inhibitors, Hypertension: 3 agents — Asciminib, Nilotinib, Ponatinib
BCR-ABL inhibitors, SIADH / Hyponatremia: no signal
BCR-ABL inhibitors, Hemorrhagic Cystitis: 2 agents (1 on terms only consistent with the lesion, not naming it) — Imatinib, Nilotinib
ALK / ROS1 / MET / TRK inhibitors — 13 agents in the FAERS matrix
ALK / ROS1 / MET / TRK inhibitors, Acute Tubular Necrosis: no signal
ALK / ROS1 / MET / TRK inhibitors, Acute Interstitial Nephritis: no signal
ALK / ROS1 / MET / TRK inhibitors, Thrombotic Microangiopathy: no signal
ALK / ROS1 / MET / TRK inhibitors, Glomerular Injury / Proteinuria: 1 agent — Lorlatinib
ALK / ROS1 / MET / TRK inhibitors, Electrolyte Disturbance: 3 agents (3 on terms only consistent with the lesion, not naming it) — Capmatinib, Ceritinib, Crizotinib
ALK / ROS1 / MET / TRK inhibitors, Fanconi Syndrome: no signal
ALK / ROS1 / MET / TRK inhibitors, Crystal / Obstructive Nephropathy: no signal
ALK / ROS1 / MET / TRK inhibitors, Hypertension: 2 agents (1 on terms only consistent with the lesion, not naming it) — Brigatinib, Lorlatinib
ALK / ROS1 / MET / TRK inhibitors, SIADH / Hyponatremia: 5 agents (4 on terms only consistent with the lesion, not naming it) — Capmatinib, Ceritinib, Crizotinib, Taletrectinib, Tepotinib
ALK / ROS1 / MET / TRK inhibitors, Hemorrhagic Cystitis: no signal
Bispecifics / T-cell engagers — 12 agents in the FAERS matrix
Bispecifics / T-cell engagers, Acute Tubular Necrosis: no signal
Bispecifics / T-cell engagers, Acute Interstitial Nephritis: 1 agent — Blinatumomab
Bispecifics / T-cell engagers, Thrombotic Microangiopathy: 2 agents — Blinatumomab, Epcoritamab
Bispecifics / T-cell engagers, Glomerular Injury / Proteinuria: no signal
Bispecifics / T-cell engagers, Electrolyte Disturbance: 5 agents (3 on terms only consistent with the lesion, not naming it) — Elranatamab, Epcoritamab, Glofitamab, Talquetamab, Tarlatamab
Bispecifics / T-cell engagers, Fanconi Syndrome: no signal
Bispecifics / T-cell engagers, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Epcoritamab
Bispecifics / T-cell engagers, Hypertension: no signal
Bispecifics / T-cell engagers, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Epcoritamab, Tarlatamab
Bispecifics / T-cell engagers, Hemorrhagic Cystitis: no signal
PI3K / AKT inhibitors — 7 agents in the FAERS matrix
PI3K / AKT inhibitors, Acute Tubular Necrosis: no signal
PI3K / AKT inhibitors, Acute Interstitial Nephritis: 1 agent — Copanlisib
PI3K / AKT inhibitors, Thrombotic Microangiopathy: no signal
PI3K / AKT inhibitors, Glomerular Injury / Proteinuria: no signal
PI3K / AKT inhibitors, Electrolyte Disturbance: 4 agents (4 on terms only consistent with the lesion, not naming it) — Alpelisib, Capivasertib, Copanlisib, Idelalisib
PI3K / AKT inhibitors, Fanconi Syndrome: no signal
PI3K / AKT inhibitors, Crystal / Obstructive Nephropathy: no signal
PI3K / AKT inhibitors, Hypertension: 1 agent — Copanlisib
PI3K / AKT inhibitors, SIADH / Hyponatremia: 3 agents (3 on terms only consistent with the lesion, not naming it) — Alpelisib, Capivasertib, Copanlisib
PI3K / AKT inhibitors, Hemorrhagic Cystitis: 1 agent — Capivasertib
Cytokines & enzymes — 4 agents in the FAERS matrix
Cytokines & enzymes, Acute Tubular Necrosis: no signal
Cytokines & enzymes, Acute Interstitial Nephritis: no signal
Cytokines & enzymes, Thrombotic Microangiopathy: 2 agents — Interleukin-2 (high-dose), Pegaspargase
Cytokines & enzymes, Glomerular Injury / Proteinuria: no signal
Cytokines & enzymes, Electrolyte Disturbance: 2 agents (1 on terms only consistent with the lesion, not naming it) — Interleukin-2 (high-dose), Pegaspargase
Cytokines & enzymes, Fanconi Syndrome: 1 agent (1 on terms only consistent with the lesion, not naming it) — Interleukin-2 (high-dose)
Cytokines & enzymes, Crystal / Obstructive Nephropathy: no signal
Cytokines & enzymes, Hypertension: 1 agent — Interleukin-2 (high-dose)
Cytokines & enzymes, SIADH / Hyponatremia: 2 agents — Interleukin-2 (high-dose), Pegaspargase
Cytokines & enzymes, Hemorrhagic Cystitis: 1 agent — Pegaspargase
CDK4/6 inhibitors — 3 agents in the FAERS matrix
CDK4/6 inhibitors, Acute Tubular Necrosis: 1 agent — Abemaciclib
CDK4/6 inhibitors, Acute Interstitial Nephritis: no signal
CDK4/6 inhibitors, Thrombotic Microangiopathy: no signal
CDK4/6 inhibitors, Glomerular Injury / Proteinuria: no signal
CDK4/6 inhibitors, Electrolyte Disturbance: 2 agents (2 on terms only consistent with the lesion, not naming it) — Abemaciclib, Ribociclib
CDK4/6 inhibitors, Fanconi Syndrome: no signal
CDK4/6 inhibitors, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Ribociclib
CDK4/6 inhibitors, Hypertension: 1 agent — Ribociclib
CDK4/6 inhibitors, SIADH / Hyponatremia: 2 agents (2 on terms only consistent with the lesion, not naming it) — Abemaciclib, Ribociclib
CDK4/6 inhibitors, Hemorrhagic Cystitis: 1 agent (1 on terms only consistent with the lesion, not naming it) — Ribociclib
FGFR inhibitors — 4 agents in the FAERS matrix
FGFR inhibitors, Acute Tubular Necrosis: no signal
FGFR inhibitors, Acute Interstitial Nephritis: no signal
FGFR inhibitors, Thrombotic Microangiopathy: no signal
FGFR inhibitors, Glomerular Injury / Proteinuria: no signal
FGFR inhibitors, Electrolyte Disturbance: 3 agents (2 on terms only consistent with the lesion, not naming it) — Futibatinib, Infigratinib, Pemigatinib
FGFR inhibitors, Fanconi Syndrome: no signal
FGFR inhibitors, Crystal / Obstructive Nephropathy: no signal
FGFR inhibitors, Hypertension: no signal
FGFR inhibitors, SIADH / Hyponatremia: 3 agents (2 on terms only consistent with the lesion, not naming it) — Erdafitinib, Futibatinib, Infigratinib
FGFR inhibitors, Hemorrhagic Cystitis: no signal
Radiopharmaceuticals — 4 agents in the FAERS matrix
Radiopharmaceuticals, Acute Tubular Necrosis: no signal
Radiopharmaceuticals, Acute Interstitial Nephritis: no signal
Radiopharmaceuticals, Thrombotic Microangiopathy: 1 agent — Ibritumomab tiuxetan
Radiopharmaceuticals, Glomerular Injury / Proteinuria: no signal
Radiopharmaceuticals, Electrolyte Disturbance: 2 agents (2 on terms only consistent with the lesion, not naming it) — Ibritumomab tiuxetan, Radium-223 dichloride
Radiopharmaceuticals, Fanconi Syndrome: no signal
Radiopharmaceuticals, Crystal / Obstructive Nephropathy: 1 agent (1 on terms only consistent with the lesion, not naming it) — Radium-223 dichloride
Radiopharmaceuticals, Hypertension: no signal
Radiopharmaceuticals, SIADH / Hyponatremia: 1 agent (1 on terms only consistent with the lesion, not naming it) — Ibritumomab tiuxetan
Radiopharmaceuticals, Hemorrhagic Cystitis: 1 agent (1 on terms only consistent with the lesion, not naming it) — Radium-223 dichloride
CAR-T cell therapy — 4 agents in the FAERS matrix
CAR-T cell therapy, Acute Tubular Necrosis: no signal
CAR-T cell therapy, Acute Interstitial Nephritis: no signal
CAR-T cell therapy, Thrombotic Microangiopathy: no signal
CAR-T cell therapy, Glomerular Injury / Proteinuria: no signal
CAR-T cell therapy, Electrolyte Disturbance: no signal
CAR-T cell therapy, Fanconi Syndrome: no signal
CAR-T cell therapy, Crystal / Obstructive Nephropathy: no signal
CAR-T cell therapy, Hypertension: no signal
CAR-T cell therapy, SIADH / Hyponatremia: no signal
CAR-T cell therapy, Hemorrhagic Cystitis: no signal
Figure 16·Drug-class family × kidney-injury signature, colored by how many agents in each class carry a significant FAERS signal (ROR 95% CI lower bound > 1, on at least 50 total reports) for that phenotype. A reporting signal, not incidence; ATN/AIN undercount.

Pick a kidney phenotype: of the 283 FAERS-covered agents, every one with a significant FAERS reporting signal for it on at least 50 total reports for the agent (a floor on the agent, not the phenotype: a row can still rest on one or two reports of the phenotype itself, which the dashed rows show), ranked by reporting odds ratio with its 95% CI and report count. Agents missing from that cohort are the class composites, which are never queried, and agents with no reports under either openFDA field the atlas asks — not checked and clean. A reporting signal, not incidence; every row clears significance (CI lower bound > 1) by construction. Dashed rows rest on fewer than 10 reports — a fragile signal. A * marks a signal carried only by terms consistent with the lesion, not naming it (haematuria rather than haemorrhagic cystitis).

Sort
1251020reporting odds ratio (log) — null at 1.0Necitumumab23.34 · n=74Pamidronate8.00 · n=277Panitumumab7.65 · n=1,157Infigratinib7.41 · n=4 *Futibatinib7.12 · n=15 *Dinutuximab6.98 · n=57Interleukin-2 (high-dose)6.82 · n=82Retifanlimab6.48 · n=10Denileukin diftitox6.24 · n=3 * †Vandetanib6.21 · n=64 * ‡Imlunestrant5.39 · n=4 *Relacorilant5.23 · n=5 *Mitotane5.14 · n=91 *Cisplatin4.87 · n=3,672Temsirolimus4.73 · n=207Selinexor4.65 · n=395Cetuximab4.55 · n=1,395Neratinib4.38 · n=99 ‡Copanlisib4.27 · n=14 *Penpulimab4.18 · n=4 * †Lifileucel3.94 · n=11 *Zoledronic acid3.70 · n=2,004Pralatrexate3.70 · n=16 *Irinotecan3.69 · n=475Zanubrutinib3.67 · n=138
  • Necitumumab: ROR 23.34 (95% CI 18.19–29.94), 74 reports; IC025 3.78.
  • Pamidronate: ROR 8.00 (95% CI 7.08–9.03), 277 reports; IC025 2.72.
  • Panitumumab: ROR 7.65 (95% CI 7.20–8.12), 1,157 reports; IC025 2.75.
  • Infigratinib: ROR 7.41 (95% CI 2.70–20.34), 4 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 0.34.
  • Futibatinib: ROR 7.12 (95% CI 4.21–12.02), 15 reports — rests on terms consistent with, not naming, the lesion; IC025 1.68.
  • Dinutuximab: ROR 6.98 (95% CI 5.34–9.14), 57 reports; IC025 2.25.
  • Interleukin-2 (high-dose): ROR 6.82 (95% CI 5.46–8.54), 82 reports; IC025 2.31.
  • Retifanlimab: ROR 6.48 (95% CI 3.43–12.24), 10 reports; IC025 1.28.
  • Denileukin diftitox: ROR 6.24 (95% CI 1.95–19.92), 3 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 −0.25, which does not clear 0.
  • Vandetanib: ROR 6.21 (95% CI 4.83–7.98), 64 reports — rests on terms consistent with, not naming, the lesion; IC025 2.14; 24 of the reports look like one case filed repeatedly.
  • Imlunestrant: ROR 5.39 (95% CI 1.98–14.67), 4 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 0.09.
  • Relacorilant: ROR 5.23 (95% CI 2.13–12.85), 5 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 0.35.
  • Mitotane: ROR 5.14 (95% CI 4.17–6.35), 91 reports — rests on terms consistent with, not naming, the lesion; IC025 1.96.
  • Cisplatin: ROR 4.87 (95% CI 4.71–5.04), 3,672 reports; IC025 2.16.
  • Temsirolimus: ROR 4.73 (95% CI 4.12–5.44), 207 reports; IC025 1.97.
  • Selinexor: ROR 4.65 (95% CI 4.20–5.14), 395 reports; IC025 2.01.
  • Cetuximab: ROR 4.55 (95% CI 4.31–4.80), 1,395 reports; IC025 2.05.
  • Neratinib: ROR 4.38 (95% CI 3.58–5.36), 99 reports; IC025 1.76; 15 of the reports look like one case filed repeatedly.
  • Copanlisib: ROR 4.27 (95% CI 2.50–7.27), 14 reports — rests on terms consistent with, not naming, the lesion; IC025 1.05.
  • Penpulimab: ROR 4.18 (95% CI 1.54–11.37), 4 reports — fragile, few reports — rests on terms consistent with, not naming, the lesion; IC025 −0.14, which does not clear 0.
  • Lifileucel: ROR 3.94 (95% CI 2.16–7.21), 11 reports — rests on terms consistent with, not naming, the lesion; IC025 0.79.
  • Zoledronic acid: ROR 3.70 (95% CI 3.54–3.87), 2,004 reports; IC025 1.77.
  • Pralatrexate: ROR 3.70 (95% CI 2.25–6.08), 16 reports — rests on terms consistent with, not naming, the lesion; IC025 0.95.
  • Irinotecan: ROR 3.69 (95% CI 3.37–4.04), 475 reports; IC025 1.71.
  • Zanubrutinib: ROR 3.67 (95% CI 3.10–4.35), 138 reports; IC025 1.58.

Electrolyte Disturbance: 161 of 283 FAERS-covered agents carry a significant signal, showing the 25 strongest by ROR · * 76 of 161 rest on terms consistent with, not naming, the lesion · † 8 of 161 have an IC025 that does not clear 0 (still signals) · ‡ 3 of 161 rest in part on one case filed repeatedly (the drug page gives the ratio without it) · whisker = 95% CI · n = reports carrying this phenotype for the agent (the ROR numerator) · reporting signal, not incidence · ATN/AIN undercount — most true cases file as generic AKI.

Figure 17·Per kidney phenotype FAERS can resolve: each agent's reporting odds ratio, 95% CI, and report count — the per-agent readout the AKI-only volcano (fig 15) and the class heatmap (fig 16) leave open. A reporting signal, not incidence.

Where the curated atlas and the FAERS record agree, and why they appear not to. The documented lesion is the atlas's assertion; FAERS corroborates it or is silent. A bar spans only the agents carrying that injury in either source, not all 283 with FAERS data.

The middle bands need reading before they count against either source. Documented, FAERS-silent: 99 of 213 are expected — naming ATN or AIN takes a biopsy, so reporters file generic acute kidney injury, and some agents have too few reports to divide — while the other 114 sit on a reportable term with enough reports, the one silence that does count against corroboration. Not attributable: a real reporting signal the lesion's own MedDRA terms do not carry — either no term names it (stones and obstruction are not crystal nephropathy), or the naming terms asked alone came back flat and the signal rests on the merely-consistent half: haematuria rather than haemorrhagic cystitis, hyponatraemia rather than SIADH. In the last band the naming term itself is disproportionate and no profile claims the lesion — mostly a class echo (a same-family agent documents it, so the signal is likelier real), some a histological term reachable without the biopsy it implies. The 2026-08 review adjudicated every cell of the residue those explanations leave — reporters naming the lesion with nothing in the class behind it: 33 documented associations entered the profiles, cells the review attributed to the population, co-therapy, or class-level literature sit in the middle band, and reviewed open leads stay here. What shows as unreviewed is the next worklist. Full reasoning on methods.

Corroborated— documented and reportedDocumented, FAERS-silent— partly a reporting blind spot (biopsy-defined term, too few reports), partly a reportable lesion FAERS does not flagNot attributable— the lesion's own terms do not carry the signal, or review attributed the reporting elsewhereReported by name, undocumented— the lesion's own term is disproportionate — a lead, not a lesion
For each kidney-injury signature, the number of agents (of 283 with FAERS data) whose documented lesion is corroborated by FAERS, is documented but FAERS-silent, carries a reporting signal the lesion's own MedDRA terms do not support or that adjudication attributed to the population, co-therapy, or class-level literature, or carries a signal on the naming term with nothing in the literature behind it.
Injury signatureConcordance breakdown
Electrolyte Disturbance
Electrolyte Disturbance, Corroborated: 45 agents — Amivantamab, Arsenic trioxide, Azacitidine, Bendamustine, Brentuximab vedotin, Carboplatin, Cetuximab, Cisplatin, Cytarabine, Daratumumab, Decitabine, Denosumab, +33 more
Electrolyte Disturbance, Documented, FAERS-silent: 61 agents — Afamitresgene autoleucel (Afami-cel), Amsacrine, Avapritinib, Avutometinib, Carmofur (HCFU), Catumaxomab, Chlorambucil, Ciltacabtagene autoleucel, Cladribine, Cosibelimab, Dactinomycin (actinomycin D), Daraxonrasib, Darolutamide, Doxifluridine, Enasidenib, Ensartinib, Enzalutamide, Erdafitinib, Gallium nitrate, Gedatolisib, Odronextamab, Pivekimab sunirine, Plicamycin (mithramycin), Sevabertinib, +37 more
Electrolyte Disturbance, Not attributable: 76 agents — Abemaciclib, Abiraterone, Afatinib, Alpelisib, Axitinib, Belzutifan, Bicalutamide, Capivasertib, Capmatinib, Ceritinib, Clofarabine, Cobimetinib, Copanlisib, Crizotinib, Dabrafenib, Dacarbazine, Denileukin diftitox, Dostarlimab, Epcoritamab, Fotemustine, Futibatinib, Glasdegib, Glofitamab, Ibritumomab tiuxetan, +52 more
Electrolyte Disturbance, Reported by name, undocumented: 40 agents — 5-Fluorouracil, Adagrasib, Atezolizumab, Avelumab, Belantamab mafodotin, Bevacizumab, Binimetinib, Bleomycin, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, +28 more
SIADH / Hyponatremia
SIADH / Hyponatremia, Corroborated: 14 agents — Atezolizumab, Carboplatin, Cisplatin, Cyclophosphamide, Cytarabine, Interleukin-2 (high-dose), Melphalan, Nivolumab, Osimertinib, Pemetrexed, Pentostatin, Selpercatinib, +2 more
SIADH / Hyponatremia, Documented, FAERS-silent: 4 agents — Chlorambucil, Lazertinib, Sunvozertinib, Vinflunine
SIADH / Hyponatremia, Not attributable: 90 agents — Abemaciclib, Acalabrutinib, Afatinib, Alpelisib, Axitinib, Azacitidine, Belzutifan, Bevacizumab, Bicalutamide, Binimetinib, Bleomycin, Brentuximab vedotin, Cabozantinib, Capecitabine, Capivasertib, Dabrafenib, Doxorubicin, Etoposide, Futibatinib, Selinexor, Tamoxifen, Temozolomide, Topotecan, Vinorelbine, Vismodegib, +65 more
SIADH / Hyponatremia, Reported by name, undocumented: 24 agents — 5-Fluorouracil, Avelumab, Bortezomib, Busulfan, Cabazitaxel, Dacarbazine, Darolutamide, Docetaxel, Durvalumab, Fludarabine, Gemcitabine, Gilteritinib, Lenvatinib, Taletrectinib, +10 more
Acute Tubular Necrosis
Acute Tubular Necrosis, Corroborated: 14 agents — Binimetinib, Carboplatin, Cisplatin, Clofarabine, Cobimetinib, Ifosfamide, Imatinib, Nivolumab, Oxaliplatin, Pemetrexed, Rituximab, Sirolimus, +2 more
Acute Tubular Necrosis, Documented, FAERS-silent: 56 agents — Afatinib, Alpelisib, Arsenic trioxide, Avutometinib, Azacitidine, Blinatumomab, Carfilzomib, Ciltacabtagene autoleucel, Dabrafenib, Datopotamab deruxtecan (Dato-DXd), Elranatamab, Enasidenib, +44 more
Acute Tubular Necrosis, Reported by name, undocumented: 27 agents — 5-Fluorouracil, Abemaciclib, Amivantamab, Bendamustine, Bleomycin, Bortezomib, Carmustine (BCNU), Cetuximab, Cyclophosphamide, Cytarabine, Dostarlimab, Etoposide, Everolimus, Fludarabine, Paclitaxel, Topotecan, Vinblastine, +10 more
Thrombotic Microangiopathy
Thrombotic Microangiopathy, Corroborated: 26 agents — 5-Fluorouracil, Bendamustine, Bevacizumab, Bortezomib, Busulfan, Capecitabine, Carfilzomib, Carmustine (BCNU), Decitabine, Dinutuximab, Docetaxel, Doxorubicin, +14 more
Thrombotic Microangiopathy, Documented, FAERS-silent: 16 agents — Axitinib, Carmofur (HCFU), Daraxonrasib, Doxifluridine, Ipilimumab, Ivonescimab, Lenalidomide, Lutetium-177 Dotatate, Nintedanib, Nivolumab, Olaparib, Pazopanib, Tegafur-uracil (UFT), Tislelizumab, Trastuzumab emtansine (T-DM1), +1 more
Thrombotic Microangiopathy, Not attributable: 3 agents — Blinatumomab, Etoposide, Topotecan
Thrombotic Microangiopathy, Reported by name, undocumented: 51 agents — Amsacrine, Atezolizumab, Azacitidine, Bleomycin, Carboplatin, Cetuximab, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin (actinomycin D), Epcoritamab, +37 more
Glomerular Injury / Proteinuria
Glomerular Injury / Proteinuria, Corroborated: 31 agents — Atezolizumab, Avelumab, Axitinib, Bevacizumab, Bortezomib, Cabozantinib, Cetuximab, Dasatinib, Everolimus, Fruquintinib, Gefitinib, Gemcitabine, +19 more
Glomerular Injury / Proteinuria, Documented, FAERS-silent: 13 agents — Adagrasib, Carfilzomib, Cemiplimab, Clofarabine, Cosibelimab, Datopotamab deruxtecan (Dato-DXd), Dostarlimab, Ibandronate, Ibrutinib, Ivonescimab, Olverembatinib, Sugemalimab, Trastuzumab emtansine (T-DM1)
Glomerular Injury / Proteinuria, Not attributable: 32 agents — Belantamab mafodotin, Belzutifan, Bicalutamide, Carboplatin, Chlorambucil, Cisplatin, Cobimetinib, Dactinomycin (actinomycin D), Dinutuximab, Docetaxel, Doxorubicin, Durvalumab, Erlotinib, Etoposide, Fotemustine, Irinotecan, Lomustine (CCNU), Nedaplatin, Oxaliplatin, Penpulimab, Pentostatin, Raltitrexed, Temsirolimus, Tislelizumab, Tivozanib, Toripalimab, Trametinib, +5 more
Glomerular Injury / Proteinuria, Reported by name, undocumented: 20 agents — 5-Fluorouracil, Amsacrine, Busulfan, Capecitabine, Carmustine (BCNU), Cyclophosphamide, Cytarabine, Daratumumab, Fludarabine, Ifosfamide, Imatinib, Melphalan, Mogamulizumab, Obinutuzumab, Pemetrexed, Rituximab, Tegafur-uracil (UFT), Temozolomide, Thiotepa, Trifluridine/tipiracil
Crystal / Obstructive Nephropathy
Crystal / Obstructive Nephropathy, Documented, FAERS-silent: 36 agents — Amsacrine, Blinatumomab, Brentuximab vedotin, Ciltacabtagene autoleucel, Clofarabine, Cytarabine, Dactinomycin (actinomycin D), Decitabine, Elranatamab, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Odronextamab, Pivekimab sunirine, Sonrotoclax, +21 more
Crystal / Obstructive Nephropathy, Not attributable: 48 agents — Abiraterone, Acalabrutinib, Avapritinib, Belzutifan, Bendamustine, Bevacizumab, Bicalutamide, Cabazitaxel, Cisplatin, Cladribine, Darolutamide, Denosumab, Enfortumab vedotin, Enzalutamide, Epcoritamab, Everolimus, Hydroxyurea, Methotrexate (high-dose), Polatuzumab vedotin, Rituximab, Zanubrutinib, +27 more
Hemorrhagic Cystitis
Hemorrhagic Cystitis, Corroborated: 15 agents — Atezolizumab, Cabazitaxel, Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Gefitinib, Gemcitabine, Ifosfamide, Mitomycin C, Mitoxantrone, +3 more
Hemorrhagic Cystitis, Not attributable: 49 agents — Abiraterone, Avelumab, Bevacizumab, Bicalutamide, Bortezomib, Capivasertib, Darolutamide, Denosumab, Enfortumab vedotin, Enzalutamide, Estramustine, Etoposide, Everolimus, Gemtuzumab ozogamicin, Ibandronate, Ibrutinib, Imatinib, Inotuzumab ozogamicin, Lenvatinib, Leuprolide, Nilotinib, Pegaspargase, Polatuzumab vedotin, Rituximab, +25 more
Hemorrhagic Cystitis, Reported by name, undocumented: 18 agents — Azacitidine, Bendamustine, Busulfan, Capecitabine, Carmustine (BCNU), Clofarabine, Cytarabine, Dactinomycin (actinomycin D), Fludarabine, Gilteritinib, Hydroxyurea, Melphalan, Methotrexate (high-dose), Teniposide, +4 more
Hypertension
Hypertension, Corroborated: 29 agents — Abiraterone, Asciminib, Axitinib, Bevacizumab, Brigatinib, Cabozantinib, Carfilzomib, Copanlisib, Dinutuximab, Enzalutamide, Fruquintinib, Ibrutinib, +17 more
Hypertension, Documented, FAERS-silent: 7 agents — Acalabrutinib, Gemcitabine, Ivonescimab, Leuprolide, Olverembatinib, Relacorilant, Trametinib
Hypertension, Not attributable: 14 agents — Arsenic trioxide, Busulfan, Darolutamide, Everolimus, Ibandronate, Interleukin-2 (high-dose), Irinotecan, Lorlatinib, Oxaliplatin, Paclitaxel, Pamidronate, Ribociclib, Temsirolimus, Zoledronic acid
Hypertension, Reported by name, undocumented: 20 agents — 5-Fluorouracil, Atezolizumab, Avelumab, Bicalutamide, Isatuximab, Lanreotide, Methotrexate (high-dose), Nilotinib, Obinutuzumab, Octreotide, Pembrolizumab, Penpulimab, +8 more
Acute Interstitial Nephritis
Acute Interstitial Nephritis, Corroborated: 14 agents — Amivantamab, Atezolizumab, Avelumab, Cemiplimab, Cobimetinib, Dabrafenib, Dostarlimab, Durvalumab, Encorafenib, Ipilimumab, Nivolumab, Pembrolizumab, +2 more
Acute Interstitial Nephritis, Documented, FAERS-silent: 14 agents — Bicalutamide, Cosibelimab, Duvelisib, Gefitinib, Ibrutinib, Idelalisib, Ivonescimab, Penpulimab, Procarbazine, Retifanlimab, Sacituzumab govitecan, Sugemalimab, +2 more
Acute Interstitial Nephritis, Reported by name, undocumented: 32 agents — Arsenic trioxide, Axitinib, Bendamustine, Binimetinib, Blinatumomab, Brentuximab vedotin, Busulfan, Carboplatin, Carmustine (BCNU), Chlorambucil, Cisplatin, Copanlisib, Cyclophosphamide, Cytarabine, Dactinomycin (actinomycin D), Doxorubicin, Enfortumab vedotin, Etoposide, Fludarabine, Gemcitabine, Ifosfamide, Loncastuximab tesirine, Melphalan, Oxaliplatin, +8 more
Fanconi Syndrome
Fanconi Syndrome, Corroborated: 3 agents — Cisplatin, Ifosfamide, Zoledronic acid
Fanconi Syndrome, Documented, FAERS-silent: 6 agents — Imatinib, Lenalidomide, Nirogacestat, Streptozocin, Trastuzumab deruxtecan, Vemurafenib
Fanconi Syndrome, Not attributable: 10 agents — Azacitidine, Bicalutamide, Dactinomycin (actinomycin D), Doxorubicin, Etoposide, Everolimus, Interleukin-2 (high-dose), Nivolumab, Pembrolizumab, Vincristine
Fanconi Syndrome, Reported by name, undocumented: 10 agents — 5-Fluorouracil, Busulfan, Carboplatin, Cyclophosphamide, Doxifluridine, Ibandronate, Melphalan, Oxaliplatin, Tazemetostat, Zolbetuximab
Figure 18·Curated profile vs FAERS record, for each injury FAERS can resolve, across agents with FAERS data. The documented lesion is the assertion; FAERS corroborates it, is silent (partly the ATN/AIN undercount, a reporting blind spot; partly a reportable lesion FAERS does not flag), reports something the lesion's own MedDRA terms cannot carry, or names the lesion with no literature behind it. Neither source is ground truth; a signal without literature is a lead, never a lesion.

Each agent's acute-kidney-injury reporting odds ratio (horizontal, log) against the share of its reports naming a death outcome (vertical). The upper-right quadrant holds agents right of ROR = 1 and above the cohort median death share; solid dots also clear the significance bar, faint ones do not. Both are REPORTING signals (notoriety, indication, reporting bias), not incidence or case fatality. Size = total report volume. 6 agents are queried but not plotted: under 50 reports a death share is noise and would move the median every other mark is read against.

ROR = 1median 18.1%0.5×1×2×4×8×0%10%20%30%40%AKI reporting odds ratio (log)Reports naming a death outcome (%)Lifileucel (Prerenal / Hemodynamic AKI): AKI ROR 8.22 — signal, 20.4% of reports name a death outcome, 285 reportsClofarabine (Prerenal / Hemodynamic AKI): AKI ROR 5.51 — signal, 39.6% of reports name a death outcome, 2,287 reportsInterleukin-2 (high-dose) (Prerenal / Hemodynamic AKI): AKI ROR 5.41 — signal, 16.8% of reports name a death outcome, 1,263 reportsTrabectedin (Acute Tubular Necrosis): AKI ROR 4.69 — signal, 19.7% of reports name a death outcome, 2,350 reportsTagraxofusp (Prerenal / Hemodynamic AKI): AKI ROR 4.37 — signal, 29.9% of reports name a death outcome, 538 reportsStreptozocin (Fanconi Syndrome): AKI ROR 4.04 — signal, 25.3% of reports name a death outcome, 245 reportsPemetrexed (Chronic Interstitial Nephropathy): AKI ROR 3.88 — signal, 18.8% of reports name a death outcome, 39,105 reportsIdecabtagene vicleucel (Prerenal / Hemodynamic AKI): AKI ROR 3.77 — signal, 14.2% of reports name a death outcome, 1,241 reportsSirolimus (Glomerular Injury / Proteinuria): AKI ROR 3.65 — signal, 15.9% of reports name a death outcome, 13,673 reportsAdagrasib (Prerenal / Hemodynamic AKI): AKI ROR 3.48 — signal, 30.8% of reports name a death outcome, 1,134 reportsCisplatin (Acute Tubular Necrosis): AKI ROR 3.43 — signal, 19.1% of reports name a death outcome, 79,025 reportsRetifanlimab (Acute Interstitial Nephritis): AKI ROR 3.40 — signal, 21.2% of reports name a death outcome, 193 reportsPamidronate (Glomerular Injury / Proteinuria): AKI ROR 3.16 — signal, 15.5% of reports name a death outcome, 4,390 reportsCarfilzomib (Thrombotic Microangiopathy): AKI ROR 3.11 — signal, 15.6% of reports name a death outcome, 28,379 reportsCobimetinib (Acute Tubular Necrosis): AKI ROR 3.05 — signal, 13.3% of reports name a death outcome, 4,436 reportsInavolisib (Electrolyte Disturbance): AKI ROR 3.03 — signal, 4.8% of reports name a death outcome, 670 reportsMelphalan (SIADH / Hyponatremia): AKI ROR 2.94 — signal, 23.7% of reports name a death outcome, 25,290 reportsGemtuzumab ozogamicin (Prerenal / Hemodynamic AKI): AKI ROR 2.82 — signal, 30.9% of reports name a death outcome, 3,665 reportsLurbinectedin (Acute Tubular Necrosis): AKI ROR 2.78 — signal, 24.6% of reports name a death outcome, 1,175 reportsFludarabine (Crystal / Obstructive Nephropathy): AKI ROR 2.66 — signal, 30.5% of reports name a death outcome, 39,838 reportsPembrolizumab (Acute Interstitial Nephritis): AKI ROR 2.59 — signal, 17.8% of reports name a death outcome, 109,044 reportsIsatuximab (Prerenal / Hemodynamic AKI): AKI ROR 2.58 — signal, 13.2% of reports name a death outcome, 5,853 reportsCytarabine (Crystal / Obstructive Nephropathy): AKI ROR 2.57 — signal, 23.1% of reports name a death outcome, 63,055 reportsIfosfamide (Fanconi Syndrome): AKI ROR 2.50 — signal, 20.1% of reports name a death outcome, 21,470 reportsAvelumab (Acute Interstitial Nephritis): AKI ROR 2.42 — signal, 22.9% of reports name a death outcome, 4,169 reportsCarboplatin (Acute Tubular Necrosis): AKI ROR 2.41 — signal, 15.7% of reports name a death outcome, 130,075 reportsCarmustine (BCNU) (Chronic Interstitial Nephropathy): AKI ROR 2.38 — signal, 25.8% of reports name a death outcome, 4,718 reportsGemcitabine (Thrombotic Microangiopathy): AKI ROR 2.36 — signal, 18.8% of reports name a death outcome, 54,066 reportsZanidatamab (Prerenal / Hemodynamic AKI): AKI ROR 2.34, 9.8% of reports name a death outcome, 82 reportsEtoposide (Crystal / Obstructive Nephropathy): AKI ROR 2.33 — signal, 24.1% of reports name a death outcome, 74,949 reportsEpcoritamab (Prerenal / Hemodynamic AKI): AKI ROR 2.27 — signal, 26.5% of reports name a death outcome, 3,771 reportsThiotepa (Hemorrhagic Cystitis): AKI ROR 2.27 — signal, 28% of reports name a death outcome, 9,762 reportsBinimetinib (Acute Tubular Necrosis): AKI ROR 2.23 — signal, 15.7% of reports name a death outcome, 7,953 reportsEncorafenib (Acute Tubular Necrosis): AKI ROR 2.23 — signal, 16.7% of reports name a death outcome, 10,191 reportsBendamustine (Crystal / Obstructive Nephropathy): AKI ROR 2.19 — signal, 20.5% of reports name a death outcome, 24,082 reportsZoledronic acid (Acute Tubular Necrosis): AKI ROR 2.13 — signal, 13.5% of reports name a death outcome, 66,922 reportsMogamulizumab (Prerenal / Hemodynamic AKI): AKI ROR 2.10 — signal, 18.1% of reports name a death outcome, 1,908 reportsBusulfan (Thrombotic Microangiopathy): AKI ROR 2.09 — signal, 29.3% of reports name a death outcome, 15,927 reportsPirtobrutinib (Crystal / Obstructive Nephropathy): AKI ROR 2.09 — signal, 23.6% of reports name a death outcome, 981 reportsIpilimumab (Acute Interstitial Nephritis): AKI ROR 2.08 — signal, 22.4% of reports name a death outcome, 43,846 reportsTemsirolimus (Glomerular Injury / Proteinuria): AKI ROR 2.08 — signal, 21.5% of reports name a death outcome, 4,507 reportsEnfortumab vedotin (Acute Tubular Necrosis): AKI ROR 2.07 — signal, 19.9% of reports name a death outcome, 7,851 reportsVinorelbine (SIADH / Hyponatremia): AKI ROR 2.05 — signal, 21.2% of reports name a death outcome, 6,966 reportsLinvoseltamab (Prerenal / Hemodynamic AKI): AKI ROR 2.04, 7.5% of reports name a death outcome, 53 reportsAtezolizumab (Acute Interstitial Nephritis): AKI ROR 2.03 — signal, 25.3% of reports name a death outcome, 40,046 reportsVemurafenib (Acute Tubular Necrosis): AKI ROR 2.01 — signal, 17.3% of reports name a death outcome, 11,991 reportsOxaliplatin (Thrombotic Microangiopathy): AKI ROR 2.00 — signal, 14.4% of reports name a death outcome, 75,953 reportsPegaspargase (Prerenal / Hemodynamic AKI): AKI ROR 1.99 — signal, 12.9% of reports name a death outcome, 12,377 reportsInotuzumab ozogamicin (Prerenal / Hemodynamic AKI): AKI ROR 1.98 — signal, 34% of reports name a death outcome, 2,992 reports5-Fluorouracil (Thrombotic Microangiopathy): AKI ROR 1.96 — signal, 14% of reports name a death outcome, 78,755 reportsNelarabine (Crystal / Obstructive Nephropathy): AKI ROR 1.96 — signal, 21.9% of reports name a death outcome, 974 reportsCapivasertib (Prerenal / Hemodynamic AKI): AKI ROR 1.94 — signal, 19.3% of reports name a death outcome, 3,064 reportsPentostatin (Acute Tubular Necrosis): AKI ROR 1.94 — signal, 25.2% of reports name a death outcome, 555 reportsRaltitrexed (Acute Tubular Necrosis): AKI ROR 1.93 — signal, 14.4% of reports name a death outcome, 672 reportsRelacorilant (Electrolyte Disturbance): AKI ROR 1.93, 22.2% of reports name a death outcome, 99 reportsProcarbazine (Acute Tubular Necrosis): AKI ROR 1.92 — signal, 13.2% of reports name a death outcome, 7,315 reportsBrentuximab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.91 — signal, 19.2% of reports name a death outcome, 10,402 reportsElotuzumab (Prerenal / Hemodynamic AKI): AKI ROR 1.90 — signal, 17.8% of reports name a death outcome, 5,171 reportsVincristine (SIADH / Hyponatremia): AKI ROR 1.90 — signal, 18.3% of reports name a death outcome, 29,521 reportsNivolumab (Acute Interstitial Nephritis): AKI ROR 1.88 — signal, 25.5% of reports name a death outcome, 98,547 reportsIdelalisib (Prerenal / Hemodynamic AKI): AKI ROR 1.87 — signal, 22.7% of reports name a death outcome, 7,144 reportsAmsacrine (Electrolyte Disturbance): AKI ROR 1.80, 37% of reports name a death outcome, 538 reportsCyclophosphamide (SIADH / Hyponatremia): AKI ROR 1.80 — signal, 20.2% of reports name a death outcome, 179,391 reportsDenileukin diftitox (Prerenal / Hemodynamic AKI): AKI ROR 1.80, 26.7% of reports name a death outcome, 60 reportsBortezomib (Thrombotic Microangiopathy): AKI ROR 1.78 — signal, 15.8% of reports name a death outcome, 89,993 reportsTisotumab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.78 — signal, 8.3% of reports name a death outcome, 971 reportsGilteritinib (Prerenal / Hemodynamic AKI): AKI ROR 1.77 — signal, 26.6% of reports name a death outcome, 4,738 reportsNeratinib (Prerenal / Hemodynamic AKI): AKI ROR 1.77 — signal, 15.7% of reports name a death outcome, 2,319 reportsLisocabtagene maraleucel (Prerenal / Hemodynamic AKI): AKI ROR 1.74 — signal, 17.6% of reports name a death outcome, 876 reportsArsenic trioxide (Prerenal / Hemodynamic AKI): AKI ROR 1.70 — signal, 6.6% of reports name a death outcome, 4,043 reportsBicalutamide (Acute Interstitial Nephritis): AKI ROR 1.69 — signal, 18% of reports name a death outcome, 15,311 reportsEverolimus (Glomerular Injury / Proteinuria): AKI ROR 1.69 — signal, 21.6% of reports name a death outcome, 49,667 reportsLenvatinib (Hypertension): AKI ROR 1.69 — signal, 13.5% of reports name a death outcome, 39,694 reportsCabazitaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.68 — signal, 20% of reports name a death outcome, 3,517 reportsDoxorubicin (Glomerular Injury / Proteinuria): AKI ROR 1.68 — signal, 18.7% of reports name a death outcome, 97,231 reportsRelatlimab (Acute Interstitial Nephritis): AKI ROR 1.66, 20.8% of reports name a death outcome, 515 reportsTafasitamab (Prerenal / Hemodynamic AKI): AKI ROR 1.65 — signal, 26.5% of reports name a death outcome, 2,675 reportsVinblastine (SIADH / Hyponatremia): AKI ROR 1.65 — signal, 14.1% of reports name a death outcome, 1,961 reportsAbemaciclib (Pseudo-AKI): AKI ROR 1.63 — signal, 7.1% of reports name a death outcome, 21,412 reportsMitoxantrone (Crystal / Obstructive Nephropathy): AKI ROR 1.60 — signal, 26.6% of reports name a death outcome, 6,289 reportsHydroxyurea (Crystal / Obstructive Nephropathy): AKI ROR 1.58 — signal, 14.9% of reports name a death outcome, 21,340 reportsInfigratinib (Electrolyte Disturbance): AKI ROR 1.58, 16.2% of reports name a death outcome, 68 reportsDaratumumab (Prerenal / Hemodynamic AKI): AKI ROR 1.57 — signal, 11.9% of reports name a death outcome, 44,998 reportsDecitabine (Crystal / Obstructive Nephropathy): AKI ROR 1.57 — signal, 25.4% of reports name a death outcome, 5,334 reportsBelantamab mafodotin (Glomerular Injury / Proteinuria): AKI ROR 1.52 — signal, 33.5% of reports name a death outcome, 3,110 reportsPaclitaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.52 — signal, 16.4% of reports name a death outcome, 101,259 reportsCemiplimab (Acute Interstitial Nephritis): AKI ROR 1.51 — signal, 21% of reports name a death outcome, 2,083 reportsVandetanib (Hypertension): AKI ROR 1.50, 7.8% of reports name a death outcome, 1,286 reportsIrinotecan (Prerenal / Hemodynamic AKI): AKI ROR 1.48 — signal, 20.6% of reports name a death outcome, 13,147 reportsMomelotinib (Pseudo-AKI): AKI ROR 1.48, 15.5% of reports name a death outcome, 1,481 reportsAsparaginase (Prerenal / Hemodynamic AKI): AKI ROR 1.47, 8.4% of reports name a death outcome, 1,533 reportsAfatinib (Prerenal / Hemodynamic AKI): AKI ROR 1.45 — signal, 22.3% of reports name a death outcome, 6,622 reportsNecitumumab (Electrolyte Disturbance): AKI ROR 1.43, 18.9% of reports name a death outcome, 450 reportsBleomycin (Prerenal / Hemodynamic AKI): AKI ROR 1.42 — signal, 23% of reports name a death outcome, 10,369 reportsEntrectinib (Pseudo-AKI): AKI ROR 1.40, 16.3% of reports name a death outcome, 1,691 reportsGlasdegib (Prerenal / Hemodynamic AKI): AKI ROR 1.40, 40.7% of reports name a death outcome, 474 reportsRituximab (Crystal / Obstructive Nephropathy): AKI ROR 1.38 — signal, 17.5% of reports name a death outcome, 218,782 reportsAzacitidine (Fanconi Syndrome): AKI ROR 1.37 — signal, 36.3% of reports name a death outcome, 30,141 reportsIbritumomab tiuxetan (Prerenal / Hemodynamic AKI): AKI ROR 1.37, 36.2% of reports name a death outcome, 1,524 reportsTucatinib (Pseudo-AKI): AKI ROR 1.37 — signal, 10.3% of reports name a death outcome, 7,112 reportsObecabtagene autoleucel (Obe-cel) (Prerenal / Hemodynamic AKI): AKI ROR 1.34, 31% of reports name a death outcome, 71 reportsCopanlisib (Hypertension): AKI ROR 1.33, 12.2% of reports name a death outcome, 403 reportsDinutuximab (Prerenal / Hemodynamic AKI): AKI ROR 1.33, 20.1% of reports name a death outcome, 859 reportsCetuximab (Electrolyte Disturbance): AKI ROR 1.32 — signal, 13.4% of reports name a death outcome, 31,704 reportsCeritinib (Prerenal / Hemodynamic AKI): AKI ROR 1.31, 28% of reports name a death outcome, 2,947 reportsTalquetamab (Prerenal / Hemodynamic AKI): AKI ROR 1.31, 11.4% of reports name a death outcome, 2,290 reportsAbiraterone (Electrolyte Disturbance): AKI ROR 1.29 — signal, 20.5% of reports name a death outcome, 41,137 reportsIberdomide (Prerenal / Hemodynamic AKI): AKI ROR 1.27, 8.1% of reports name a death outcome, 149 reportsTemozolomide (SIADH / Hyponatremia): AKI ROR 1.26 — signal, 21.1% of reports name a death outcome, 21,320 reportsObinutuzumab (Crystal / Obstructive Nephropathy): AKI ROR 1.24 — signal, 13.1% of reports name a death outcome, 17,772 reportsPanitumumab (Electrolyte Disturbance): AKI ROR 1.24 — signal, 17% of reports name a death outcome, 16,107 reportsZolbetuximab (Prerenal / Hemodynamic AKI): AKI ROR 1.24, 11.7% of reports name a death outcome, 1,525 reportsDocetaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.19 — signal, 13.2% of reports name a death outcome, 68,125 reportsTretinoin (ATRA) (Prerenal / Hemodynamic AKI): AKI ROR 1.18, 10% of reports name a death outcome, 8,951 reportsBevacizumab (Glomerular Injury / Proteinuria): AKI ROR 1.18 — signal, 22% of reports name a death outcome, 130,956 reportsIxazomib (Thrombotic Microangiopathy): AKI ROR 1.17 — signal, 18.4% of reports name a death outcome, 28,726 reportsMobocertinib (Prerenal / Hemodynamic AKI): AKI ROR 1.17, 44.8% of reports name a death outcome, 735 reportsChlorambucil (SIADH / Hyponatremia): AKI ROR 1.16, 23.7% of reports name a death outcome, 3,932 reportsImlunestrant (Pseudo-AKI): AKI ROR 1.16, 3.3% of reports name a death outcome, 92 reportsSelpercatinib (Hypertension): AKI ROR 1.15, 14.8% of reports name a death outcome, 1,396 reportsIdarubicin (Crystal / Obstructive Nephropathy): AKI ROR 1.14, 21.8% of reports name a death outcome, 1,159 reportsPolatuzumab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.14, 21.1% of reports name a death outcome, 10,202 reportsGlofitamab (Prerenal / Hemodynamic AKI): AKI ROR 1.12, 28.8% of reports name a death outcome, 2,709 reportsPonatinib (Hypertension): AKI ROR 1.12, 28.4% of reports name a death outcome, 11,399 reportsDostarlimab (Acute Interstitial Nephritis): AKI ROR 1.11, 11.9% of reports name a death outcome, 2,502 reportsTepotinib (Pseudo-AKI): AKI ROR 1.10, 23.6% of reports name a death outcome, 691 reportsDabrafenib (Acute Interstitial Nephritis): AKI ROR 1.08, 20.9% of reports name a death outcome, 21,157 reportsDacarbazine (Prerenal / Hemodynamic AKI): AKI ROR 1.08, 17.4% of reports name a death outcome, 7,561 reportsSelinexor (SIADH / Hyponatremia): AKI ROR 1.08, 17% of reports name a death outcome, 8,763 reportsTamoxifen (SIADH / Hyponatremia): AKI ROR 1.08, 8.2% of reports name a death outcome, 5,782 reportsAxitinib (Hypertension): AKI ROR 1.07, 20.2% of reports name a death outcome, 19,550 reportsDactinomycin (actinomycin D) (Electrolyte Disturbance): AKI ROR 1.07, 17.7% of reports name a death outcome, 2,211 reportsMethotrexate (high-dose) (Crystal / Obstructive Nephropathy): AKI ROR 1.07 — signal, 7.8% of reports name a death outcome, 494,382 reportsThalidomide (Prerenal / Hemodynamic AKI): AKI ROR 1.05, 17.6% of reports name a death outcome, 19,824 reportsRibociclib (Pseudo-AKI): AKI ROR 1.04, 14.3% of reports name a death outcome, 32,716 reportsCapecitabine (Prerenal / Hemodynamic AKI): AKI ROR 1.03, 20% of reports name a death outcome, 92,086 reportsBelzutifan (Prerenal / Hemodynamic AKI): AKI ROR 1.02, 9.4% of reports name a death outcome, 1,777 reportsCrizotinib (Renal Cysts): AKI ROR 1.02, 31.7% of reports name a death outcome, 10,760 reportsSorafenib (Hypertension): AKI ROR 1.02, 24.6% of reports name a death outcome, 20,700 reportsTopotecan (Prerenal / Hemodynamic AKI): AKI ROR 1.01, 23.8% of reports name a death outcome, 6,940 reportsDuvelisib (Prerenal / Hemodynamic AKI): AKI ROR 1.00, 21.2% of reports name a death outcome, 853 reportsElranatamab (Prerenal / Hemodynamic AKI): AKI ROR 0.98, 24.2% of reports name a death outcome, 2,391 reportsMitotane (Electrolyte Disturbance): AKI ROR 0.98, 13% of reports name a death outcome, 1,830 reportsDurvalumab (Acute Interstitial Nephritis): AKI ROR 0.96, 31.7% of reports name a death outcome, 21,581 reportsTrametinib (Prerenal / Hemodynamic AKI): AKI ROR 0.94, 21.3% of reports name a death outcome, 24,319 reportsRegorafenib (Hypertension): AKI ROR 0.93, 20.4% of reports name a death outcome, 11,611 reportsImatinib (Electrolyte Disturbance): AKI ROR 0.92, 31.1% of reports name a death outcome, 47,183 reportsLoncastuximab tesirine (Prerenal / Hemodynamic AKI): AKI ROR 0.92, 35.6% of reports name a death outcome, 410 reportsFedratinib (Electrolyte Disturbance): AKI ROR 0.91, 14.2% of reports name a death outcome, 1,349 reportsMelphalan flufenamide (melflufen) (Acute Tubular Necrosis): AKI ROR 0.91, 26.5% of reports name a death outcome, 117 reportsTaletrectinib (Pseudo-AKI): AKI ROR 0.89, 12.5% of reports name a death outcome, 120 reportsEribulin (Prerenal / Hemodynamic AKI): AKI ROR 0.88, 17.7% of reports name a death outcome, 3,739 reportsRamucirumab (Hypertension): AKI ROR 0.88, 26.8% of reports name a death outcome, 6,320 reportsBosutinib (Pseudo-AKI): AKI ROR 0.87, 8.9% of reports name a death outcome, 8,981 reportsLazertinib (SIADH / Hyponatremia): AKI ROR 0.87, 4% of reports name a death outcome, 865 reportsSunitinib (Hypertension): AKI ROR 0.87, 29.9% of reports name a death outcome, 39,148 reportsZanubrutinib (Prerenal / Hemodynamic AKI): AKI ROR 0.86, 11.1% of reports name a death outcome, 4,598 reportsFutibatinib (Electrolyte Disturbance): AKI ROR 0.85, 18.9% of reports name a death outcome, 222 reportsOctreotide (Electrolyte Disturbance): AKI ROR 0.85, 19.8% of reports name a death outcome, 31,000 reportsMitomycin C (Thrombotic Microangiopathy): AKI ROR 0.83, 10.9% of reports name a death outcome, 3,659 reportsVenetoclax (Crystal / Obstructive Nephropathy): AKI ROR 0.83, 28.1% of reports name a death outcome, 62,878 reportsPralatrexate (Crystal / Obstructive Nephropathy): AKI ROR 0.81, 25.1% of reports name a death outcome, 529 reportsTrifluridine/tipiracil (Prerenal / Hemodynamic AKI): AKI ROR 0.81, 38.2% of reports name a death outcome, 11,253 reportsSacituzumab govitecan (Prerenal / Hemodynamic AKI): AKI ROR 0.80, 21% of reports name a death outcome, 4,834 reportsBlinatumomab (Prerenal / Hemodynamic AKI): AKI ROR 0.79, 18% of reports name a death outcome, 10,722 reportsSonidegib (Acute Tubular Necrosis): AKI ROR 0.79, 9.4% of reports name a death outcome, 1,679 reportsTeniposide (Electrolyte Disturbance): AKI ROR 0.79, 21.7% of reports name a death outcome, 405 reportsNedaplatin (Acute Tubular Necrosis): AKI ROR 0.78, 11.6% of reports name a death outcome, 1,100 reportsTebentafusp (Prerenal / Hemodynamic AKI): AKI ROR 0.78, 17.8% of reports name a death outcome, 602 reportsErdafitinib (Electrolyte Disturbance): AKI ROR 0.76, 28% of reports name a death outcome, 1,247 reportsNaxitamab (Prerenal / Hemodynamic AKI): AKI ROR 0.75, 4.4% of reports name a death outcome, 250 reportsPazopanib (Glomerular Injury / Proteinuria): AKI ROR 0.75, 25.8% of reports name a death outcome, 26,971 reportsTeclistamab (Prerenal / Hemodynamic AKI): AKI ROR 0.75, 18.7% of reports name a death outcome, 2,379 reportsCapmatinib (Pseudo-AKI): AKI ROR 0.74, 24.9% of reports name a death outcome, 2,444 reportsIvosidenib (Prerenal / Hemodynamic AKI): AKI ROR 0.74, 10.5% of reports name a death outcome, 2,178 reportsLarotrectinib (Pseudo-AKI): AKI ROR 0.74, 18.2% of reports name a death outcome, 896 reportsRucaparib (Pseudo-AKI): AKI ROR 0.74, 5.9% of reports name a death outcome, 8,832 reportsAlpelisib (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 14.6% of reports name a death outcome, 9,106 reportsAsciminib (Hypertension): AKI ROR 0.73, 11.2% of reports name a death outcome, 3,514 reportsCiltacabtagene autoleucel (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 13.1% of reports name a death outcome, 6,566 reportsEstramustine (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 27.5% of reports name a death outcome, 437 reportsMidostaurin (Prerenal / Hemodynamic AKI): AKI ROR 0.72, 24.1% of reports name a death outcome, 1,957 reportsTarlatamab (Prerenal / Hemodynamic AKI): AKI ROR 0.72, 13.9% of reports name a death outcome, 1,917 reportsGefitinib (Glomerular Injury / Proteinuria): AKI ROR 0.70, 21.7% of reports name a death outcome, 8,990 reportsIbrutinib (Hypertension): AKI ROR 0.70, 17.1% of reports name a death outcome, 80,997 reportsLenalidomide (Acute Tubular Necrosis): AKI ROR 0.69, 12.7% of reports name a death outcome, 425,916 reportsRepotrectinib (Pseudo-AKI): AKI ROR 0.69, 13.1% of reports name a death outcome, 274 reportsIbandronate (Acute Tubular Necrosis): AKI ROR 0.66, 4% of reports name a death outcome, 14,757 reportsPemigatinib (Electrolyte Disturbance): AKI ROR 0.66, 17.6% of reports name a death outcome, 853 reportsPomalidomide (Prerenal / Hemodynamic AKI): AKI ROR 0.66, 13.7% of reports name a death outcome, 103,640 reportsDasatinib (Glomerular Injury / Proteinuria): AKI ROR 0.62, 9.2% of reports name a death outcome, 32,694 reportsLutetium-177 Dotatate (Chronic Interstitial Nephropathy): AKI ROR 0.62, 12.2% of reports name a death outcome, 5,819 reportsDarolutamide (Electrolyte Disturbance): AKI ROR 0.61, 12% of reports name a death outcome, 5,924 reportsNirogacestat (Electrolyte Disturbance): AKI ROR 0.61, 0.9% of reports name a death outcome, 923 reportsTalazoparib (Pseudo-AKI): AKI ROR 0.61, 18.5% of reports name a death outcome, 1,853 reportsTislelizumab (Acute Interstitial Nephritis): AKI ROR 0.61, 2.2% of reports name a death outcome, 8,853 reportsMosunetuzumab (Prerenal / Hemodynamic AKI): AKI ROR 0.60, 14.1% of reports name a death outcome, 1,107 reportsRuxolitinib (Prerenal / Hemodynamic AKI): AKI ROR 0.58, 13.6% of reports name a death outcome, 73,257 reportsNintedanib (Hypertension): AKI ROR 0.57, 19.8% of reports name a death outcome, 32,818 reportsZongertinib (Pseudo-AKI): AKI ROR 0.56, 13.8% of reports name a death outcome, 167 reportsRadium-223 dichloride (Prerenal / Hemodynamic AKI): AKI ROR 0.54, 20.5% of reports name a death outcome, 5,055 reportsAmivantamab (Electrolyte Disturbance): AKI ROR 0.53, 7.6% of reports name a death outcome, 3,576 reportsErlotinib (Glomerular Injury / Proteinuria): AKI ROR 0.53, 29.5% of reports name a death outcome, 22,936 reportsSotorasib (Prerenal / Hemodynamic AKI): AKI ROR 0.52, 23.7% of reports name a death outcome, 3,470 reportsLomustine (CCNU) (Chronic Interstitial Nephropathy): AKI ROR 0.51, 22.6% of reports name a death outcome, 2,597 reportsToripalimab (Acute Interstitial Nephritis): AKI ROR 0.50, 6% of reports name a death outcome, 1,928 reportsAcalabrutinib (Hypertension): AKI ROR 0.49, 21.2% of reports name a death outcome, 12,744 reportsCabozantinib (Hypertension): AKI ROR 0.49, 11.3% of reports name a death outcome, 48,250 reportsFruquintinib (Hypertension): AKI ROR 0.48, 32.2% of reports name a death outcome, 3,941 reportsTivozanib (Hypertension): AKI ROR 0.47, 9.9% of reports name a death outcome, 1,588 reportsBrigatinib (Pseudo-AKI): AKI ROR 0.46, 21.6% of reports name a death outcome, 3,655 reportsTrastuzumab deruxtecan (Acute Tubular Necrosis): AKI ROR 0.46, 25.6% of reports name a death outcome, 10,910 reportsTrastuzumab emtansine (T-DM1) (Thrombotic Microangiopathy): AKI ROR 0.44, 13.8% of reports name a death outcome, 8,459 reportsNilotinib (Prerenal / Hemodynamic AKI): AKI ROR 0.43, 19.1% of reports name a death outcome, 29,571 reportsEnzalutamide (Hypertension): AKI ROR 0.42, 19.4% of reports name a death outcome, 58,866 reportsCladribine (Crystal / Obstructive Nephropathy): AKI ROR 0.40, 7.2% of reports name a death outcome, 9,967 reportsDenosumab (Electrolyte Disturbance): AKI ROR 0.40, 12.8% of reports name a death outcome, 203,750 reportsLanreotide (Electrolyte Disturbance): AKI ROR 0.39, 18.7% of reports name a death outcome, 7,953 reportsOsimertinib (SIADH / Hyponatremia): AKI ROR 0.39, 42.8% of reports name a death outcome, 33,803 reportsZiv-aflibercept (Hypertension): AKI ROR 0.37, 27.8% of reports name a death outcome, 32,703 reportsPalbociclib (Pseudo-AKI): AKI ROR 0.36, 11.2% of reports name a death outcome, 95,562 reportsLeuprolide (Hypertension): AKI ROR 0.35, 15.6% of reports name a death outcome, 79,718 reportsLorlatinib (Pseudo-AKI): AKI ROR 0.35, 27.8% of reports name a death outcome, 7,455 reportsAlectinib (Pseudo-AKI): AKI ROR 0.34, 12.9% of reports name a death outcome, 7,388 reportsSelumetinib (Prerenal / Hemodynamic AKI): AKI ROR 0.33, 6.1% of reports name a death outcome, 1,684 reportsFotemustine (Chronic Interstitial Nephropathy): AKI ROR 0.32, 17.8% of reports name a death outcome, 331 reportsLutetium-177 PSMA-617 (vipivotide) (Chronic Interstitial Nephropathy): AKI ROR 0.30, 12.1% of reports name a death outcome, 13,841 reportsOlaparib (Pseudo-AKI): AKI ROR 0.26, 28.3% of reports name a death outcome, 21,443 reportsVismodegib (SIADH / Hyponatremia): AKI ROR 0.25, 11.2% of reports name a death outcome, 8,927 reportsNiraparib (Hypertension): AKI ROR 0.22, 6.6% of reports name a death outcome, 22,237 reportsPacritinib (Prerenal / Hemodynamic AKI): AKI ROR 0.21, 11.4% of reports name a death outcome, 3,069 reportsPralsetinib (Hypertension): AKI ROR 0.21, 14.2% of reports name a death outcome, 1,824 reportsEnasidenib (Prerenal / Hemodynamic AKI): AKI ROR 0.19, 24.9% of reports name a death outcome, 3,369 reportsTazemetostat (Prerenal / Hemodynamic AKI): AKI ROR 0.17, 13.3% of reports name a death outcome, 1,622 reportsVorasidenib (Pseudo-AKI): AKI ROR 0.17, 2% of reports name a death outcome, 612 reportsRipretinib (Hypertension): AKI ROR 0.16, 9.5% of reports name a death outcome, 5,243 reportsPexidartinib (Prerenal / Hemodynamic AKI): AKI ROR 0.13, 2% of reports name a death outcome, 717 reportsQuizartinib (Prerenal / Hemodynamic AKI): AKI ROR 0.13, 15.2% of reports name a death outcome, 702 reportsDatopotamab deruxtecan (Dato-DXd) (Acute Tubular Necrosis): AKI ROR 0.11, 20.1% of reports name a death outcome, 859 reportsMirvetuximab soravtansine (Prerenal / Hemodynamic AKI): AKI ROR 0.10, 13% of reports name a death outcome, 1,814 reportsAvapritinib (Prerenal / Hemodynamic AKI): AKI ROR 0.09, 3% of reports name a death outcome, 12,654 reportsRevumenib (Prerenal / Hemodynamic AKI): AKI ROR 0.09, 13.3% of reports name a death outcome, 1,031 reportsAvutometinib (Electrolyte Disturbance): AKI ROR 0.08, 3.3% of reports name a death outcome, 1,125 reportsElacestrant (Prerenal / Hemodynamic AKI): AKI ROR 0.07, 7.7% of reports name a death outcome, 7,181 reportsMechlorethamine (Electrolyte Disturbance): AKI ROR 0.04, 6.9% of reports name a death outcome, 2,247 reports

245 agents plotted — both an AKI ROR and FAERS outcomes on at least 50 reports · filled = significant renal signal (CI lower bound > 1) · faint = no signal · size = total FAERS reports · color = signature injury. Reporting shares, not incidence or case fatality. FAERS snapshot 2026-11-15.

Acute Tubular NecrosisAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceFanconi SyndromeCrystal / Obstructive NephropathyHypertensionPrerenal / Hemodynamic AKISIADH / HyponatremiaHemorrhagic CystitisPseudo-AKIRenal CystsChronic Interstitial Nephropathy
  • Clofarabine (Prerenal / Hemodynamic AKI): AKI ROR 5.51 — signal, 39.6% of reports name a death outcome, 2,287 reports
  • Lifileucel (Prerenal / Hemodynamic AKI): AKI ROR 8.22 — signal, 20.4% of reports name a death outcome, 285 reports
  • Tagraxofusp (Prerenal / Hemodynamic AKI): AKI ROR 4.37 — signal, 29.9% of reports name a death outcome, 538 reports
  • Adagrasib (Prerenal / Hemodynamic AKI): AKI ROR 3.48 — signal, 30.8% of reports name a death outcome, 1,134 reports
  • Streptozocin (Fanconi Syndrome): AKI ROR 4.04 — signal, 25.3% of reports name a death outcome, 245 reports
  • Trabectedin (Acute Tubular Necrosis): AKI ROR 4.69 — signal, 19.7% of reports name a death outcome, 2,350 reports
  • Interleukin-2 (high-dose) (Prerenal / Hemodynamic AKI): AKI ROR 5.41 — signal, 16.8% of reports name a death outcome, 1,263 reports
  • Gemtuzumab ozogamicin (Prerenal / Hemodynamic AKI): AKI ROR 2.82 — signal, 30.9% of reports name a death outcome, 3,665 reports
  • Fludarabine (Crystal / Obstructive Nephropathy): AKI ROR 2.66 — signal, 30.5% of reports name a death outcome, 39,838 reports
  • Pemetrexed (Chronic Interstitial Nephropathy): AKI ROR 3.88 — signal, 18.8% of reports name a death outcome, 39,105 reports
  • Retifanlimab (Acute Interstitial Nephritis): AKI ROR 3.40 — signal, 21.2% of reports name a death outcome, 193 reports
  • Melphalan (SIADH / Hyponatremia): AKI ROR 2.94 — signal, 23.7% of reports name a death outcome, 25,290 reports
  • Lurbinectedin (Acute Tubular Necrosis): AKI ROR 2.78 — signal, 24.6% of reports name a death outcome, 1,175 reports
  • Inotuzumab ozogamicin (Prerenal / Hemodynamic AKI): AKI ROR 1.98 — signal, 34% of reports name a death outcome, 2,992 reports
  • Amsacrine (Electrolyte Disturbance): AKI ROR 1.80, 37% of reports name a death outcome, 538 reports
  • Cisplatin (Acute Tubular Necrosis): AKI ROR 3.43 — signal, 19.1% of reports name a death outcome, 79,025 reports
  • Thiotepa (Hemorrhagic Cystitis): AKI ROR 2.27 — signal, 28% of reports name a death outcome, 9,762 reports
  • Carmustine (BCNU) (Chronic Interstitial Nephropathy): AKI ROR 2.38 — signal, 25.8% of reports name a death outcome, 4,718 reports
  • Busulfan (Thrombotic Microangiopathy): AKI ROR 2.09 — signal, 29.3% of reports name a death outcome, 15,927 reports
  • Epcoritamab (Prerenal / Hemodynamic AKI): AKI ROR 2.27 — signal, 26.5% of reports name a death outcome, 3,771 reports
  • Cytarabine (Crystal / Obstructive Nephropathy): AKI ROR 2.57 — signal, 23.1% of reports name a death outcome, 63,055 reports
  • Sirolimus (Glomerular Injury / Proteinuria): AKI ROR 3.65 — signal, 15.9% of reports name a death outcome, 13,673 reports
  • Glasdegib (Prerenal / Hemodynamic AKI): AKI ROR 1.40, 40.7% of reports name a death outcome, 474 reports
  • Etoposide (Crystal / Obstructive Nephropathy): AKI ROR 2.33 — signal, 24.1% of reports name a death outcome, 74,949 reports
  • Avelumab (Acute Interstitial Nephritis): AKI ROR 2.42 — signal, 22.9% of reports name a death outcome, 4,169 reports
  • Idecabtagene vicleucel (Prerenal / Hemodynamic AKI): AKI ROR 3.77 — signal, 14.2% of reports name a death outcome, 1,241 reports
  • Mobocertinib (Prerenal / Hemodynamic AKI): AKI ROR 1.17, 44.8% of reports name a death outcome, 735 reports
  • Atezolizumab (Acute Interstitial Nephritis): AKI ROR 2.03 — signal, 25.3% of reports name a death outcome, 40,046 reports
  • Belantamab mafodotin (Glomerular Injury / Proteinuria): AKI ROR 1.52 — signal, 33.5% of reports name a death outcome, 3,110 reports
  • Ifosfamide (Fanconi Syndrome): AKI ROR 2.50 — signal, 20.1% of reports name a death outcome, 21,470 reports
  • Azacitidine (Fanconi Syndrome): AKI ROR 1.37 — signal, 36.3% of reports name a death outcome, 30,141 reports
  • Ibritumomab tiuxetan (Prerenal / Hemodynamic AKI): AKI ROR 1.37, 36.2% of reports name a death outcome, 1,524 reports
  • Pirtobrutinib (Crystal / Obstructive Nephropathy): AKI ROR 2.09 — signal, 23.6% of reports name a death outcome, 981 reports
  • Pamidronate (Glomerular Injury / Proteinuria): AKI ROR 3.16 — signal, 15.5% of reports name a death outcome, 4,390 reports
  • Pentostatin (Acute Tubular Necrosis): AKI ROR 1.94 — signal, 25.2% of reports name a death outcome, 555 reports
  • Carfilzomib (Thrombotic Microangiopathy): AKI ROR 3.11 — signal, 15.6% of reports name a death outcome, 28,379 reports
  • Denileukin diftitox (Prerenal / Hemodynamic AKI): AKI ROR 1.80, 26.7% of reports name a death outcome, 60 reports
  • Nivolumab (Acute Interstitial Nephritis): AKI ROR 1.88 — signal, 25.5% of reports name a death outcome, 98,547 reports
  • Gilteritinib (Prerenal / Hemodynamic AKI): AKI ROR 1.77 — signal, 26.6% of reports name a death outcome, 4,738 reports
  • Ipilimumab (Acute Interstitial Nephritis): AKI ROR 2.08 — signal, 22.4% of reports name a death outcome, 43,846 reports
  • Pembrolizumab (Acute Interstitial Nephritis): AKI ROR 2.59 — signal, 17.8% of reports name a death outcome, 109,044 reports
  • Bendamustine (Crystal / Obstructive Nephropathy): AKI ROR 2.19 — signal, 20.5% of reports name a death outcome, 24,082 reports
  • Temsirolimus (Glomerular Injury / Proteinuria): AKI ROR 2.08 — signal, 21.5% of reports name a death outcome, 4,507 reports
  • Gemcitabine (Thrombotic Microangiopathy): AKI ROR 2.36 — signal, 18.8% of reports name a death outcome, 54,066 reports
  • Tafasitamab (Prerenal / Hemodynamic AKI): AKI ROR 1.65 — signal, 26.5% of reports name a death outcome, 2,675 reports
  • Vinorelbine (SIADH / Hyponatremia): AKI ROR 2.05 — signal, 21.2% of reports name a death outcome, 6,966 reports
  • Nelarabine (Crystal / Obstructive Nephropathy): AKI ROR 1.96 — signal, 21.9% of reports name a death outcome, 974 reports
  • Relacorilant (Electrolyte Disturbance): AKI ROR 1.93, 22.2% of reports name a death outcome, 99 reports
  • Mitoxantrone (Crystal / Obstructive Nephropathy): AKI ROR 1.60 — signal, 26.6% of reports name a death outcome, 6,289 reports
  • Idelalisib (Prerenal / Hemodynamic AKI): AKI ROR 1.87 — signal, 22.7% of reports name a death outcome, 7,144 reports
  • Obecabtagene autoleucel (Obe-cel) (Prerenal / Hemodynamic AKI): AKI ROR 1.34, 31% of reports name a death outcome, 71 reports
  • Enfortumab vedotin (Acute Tubular Necrosis): AKI ROR 2.07 — signal, 19.9% of reports name a death outcome, 7,851 reports
  • Cobimetinib (Acute Tubular Necrosis): AKI ROR 3.05 — signal, 13.3% of reports name a death outcome, 4,436 reports
  • Decitabine (Crystal / Obstructive Nephropathy): AKI ROR 1.57 — signal, 25.4% of reports name a death outcome, 5,334 reports
  • Mogamulizumab (Prerenal / Hemodynamic AKI): AKI ROR 2.10 — signal, 18.1% of reports name a death outcome, 1,908 reports
  • Carboplatin (Acute Tubular Necrosis): AKI ROR 2.41 — signal, 15.7% of reports name a death outcome, 130,075 reports
  • Capivasertib (Prerenal / Hemodynamic AKI): AKI ROR 1.94 — signal, 19.3% of reports name a death outcome, 3,064 reports
  • Encorafenib (Acute Tubular Necrosis): AKI ROR 2.23 — signal, 16.7% of reports name a death outcome, 10,191 reports
  • Ceritinib (Prerenal / Hemodynamic AKI): AKI ROR 1.31, 28% of reports name a death outcome, 2,947 reports
  • Brentuximab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.91 — signal, 19.2% of reports name a death outcome, 10,402 reports
  • Everolimus (Glomerular Injury / Proteinuria): AKI ROR 1.69 — signal, 21.6% of reports name a death outcome, 49,667 reports
  • Cyclophosphamide (SIADH / Hyponatremia): AKI ROR 1.80 — signal, 20.2% of reports name a death outcome, 179,391 reports
  • Binimetinib (Acute Tubular Necrosis): AKI ROR 2.23 — signal, 15.7% of reports name a death outcome, 7,953 reports
  • Vemurafenib (Acute Tubular Necrosis): AKI ROR 2.01 — signal, 17.3% of reports name a death outcome, 11,991 reports
  • Vincristine (SIADH / Hyponatremia): AKI ROR 1.90 — signal, 18.3% of reports name a death outcome, 29,521 reports
  • Relatlimab (Acute Interstitial Nephritis): AKI ROR 1.66, 20.8% of reports name a death outcome, 515 reports
  • Isatuximab (Prerenal / Hemodynamic AKI): AKI ROR 2.58 — signal, 13.2% of reports name a death outcome, 5,853 reports
  • Elotuzumab (Prerenal / Hemodynamic AKI): AKI ROR 1.90 — signal, 17.8% of reports name a death outcome, 5,171 reports
  • Cabazitaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.68 — signal, 20% of reports name a death outcome, 3,517 reports
  • Loncastuximab tesirine (Prerenal / Hemodynamic AKI): AKI ROR 0.92, 35.6% of reports name a death outcome, 410 reports
  • Bleomycin (Prerenal / Hemodynamic AKI): AKI ROR 1.42 — signal, 23% of reports name a death outcome, 10,369 reports
  • Afatinib (Prerenal / Hemodynamic AKI): AKI ROR 1.45 — signal, 22.3% of reports name a death outcome, 6,622 reports
  • Crizotinib (Renal Cysts): AKI ROR 1.02, 31.7% of reports name a death outcome, 10,760 reports
  • Glofitamab (Prerenal / Hemodynamic AKI): AKI ROR 1.12, 28.8% of reports name a death outcome, 2,709 reports
  • Ponatinib (Hypertension): AKI ROR 1.12, 28.4% of reports name a death outcome, 11,399 reports
  • Cemiplimab (Acute Interstitial Nephritis): AKI ROR 1.51 — signal, 21% of reports name a death outcome, 2,083 reports
  • Doxorubicin (Glomerular Injury / Proteinuria): AKI ROR 1.68 — signal, 18.7% of reports name a death outcome, 97,231 reports
  • Trifluridine/tipiracil (Prerenal / Hemodynamic AKI): AKI ROR 0.81, 38.2% of reports name a death outcome, 11,253 reports
  • Lisocabtagene maraleucel (Prerenal / Hemodynamic AKI): AKI ROR 1.74 — signal, 17.6% of reports name a death outcome, 876 reports
  • Irinotecan (Prerenal / Hemodynamic AKI): AKI ROR 1.48 — signal, 20.6% of reports name a death outcome, 13,147 reports
  • Durvalumab (Acute Interstitial Nephritis): AKI ROR 0.96, 31.7% of reports name a death outcome, 21,581 reports
  • Bicalutamide (Acute Interstitial Nephritis): AKI ROR 1.69 — signal, 18% of reports name a death outcome, 15,311 reports
  • Oxaliplatin (Thrombotic Microangiopathy): AKI ROR 2.00 — signal, 14.4% of reports name a death outcome, 75,953 reports
  • Zoledronic acid (Acute Tubular Necrosis): AKI ROR 2.13 — signal, 13.5% of reports name a death outcome, 66,922 reports
  • Imatinib (Electrolyte Disturbance): AKI ROR 0.92, 31.1% of reports name a death outcome, 47,183 reports
  • Bortezomib (Thrombotic Microangiopathy): AKI ROR 1.78 — signal, 15.8% of reports name a death outcome, 89,993 reports
  • Raltitrexed (Acute Tubular Necrosis): AKI ROR 1.93 — signal, 14.4% of reports name a death outcome, 672 reports
  • Neratinib (Prerenal / Hemodynamic AKI): AKI ROR 1.77 — signal, 15.7% of reports name a death outcome, 2,319 reports
  • Chlorambucil (SIADH / Hyponatremia): AKI ROR 1.16, 23.7% of reports name a death outcome, 3,932 reports
  • 5-Fluorouracil (Thrombotic Microangiopathy): AKI ROR 1.96 — signal, 14% of reports name a death outcome, 78,755 reports
  • Necitumumab (Electrolyte Disturbance): AKI ROR 1.43, 18.9% of reports name a death outcome, 450 reports
  • Dinutuximab (Prerenal / Hemodynamic AKI): AKI ROR 1.33, 20.1% of reports name a death outcome, 859 reports
  • Temozolomide (SIADH / Hyponatremia): AKI ROR 1.26 — signal, 21.1% of reports name a death outcome, 21,320 reports
  • Abiraterone (Electrolyte Disturbance): AKI ROR 1.29 — signal, 20.5% of reports name a death outcome, 41,137 reports
  • Sunitinib (Hypertension): AKI ROR 0.87, 29.9% of reports name a death outcome, 39,148 reports
  • Tepotinib (Pseudo-AKI): AKI ROR 1.10, 23.6% of reports name a death outcome, 691 reports
  • Bevacizumab (Glomerular Injury / Proteinuria): AKI ROR 1.18 — signal, 22% of reports name a death outcome, 130,956 reports
  • Pegaspargase (Prerenal / Hemodynamic AKI): AKI ROR 1.99 — signal, 12.9% of reports name a death outcome, 12,377 reports
  • Infigratinib (Electrolyte Disturbance): AKI ROR 1.58, 16.2% of reports name a death outcome, 68 reports
  • Procarbazine (Acute Tubular Necrosis): AKI ROR 1.92 — signal, 13.2% of reports name a death outcome, 7,315 reports
  • Sorafenib (Hypertension): AKI ROR 1.02, 24.6% of reports name a death outcome, 20,700 reports
  • Paclitaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.52 — signal, 16.4% of reports name a death outcome, 101,259 reports
  • Idarubicin (Crystal / Obstructive Nephropathy): AKI ROR 1.14, 21.8% of reports name a death outcome, 1,159 reports
  • Rituximab (Crystal / Obstructive Nephropathy): AKI ROR 1.38 — signal, 17.5% of reports name a death outcome, 218,782 reports
  • Melphalan flufenamide (melflufen) (Acute Tubular Necrosis): AKI ROR 0.91, 26.5% of reports name a death outcome, 117 reports
  • Polatuzumab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.14, 21.1% of reports name a death outcome, 10,202 reports
  • Topotecan (Prerenal / Hemodynamic AKI): AKI ROR 1.01, 23.8% of reports name a death outcome, 6,940 reports
  • Elranatamab (Prerenal / Hemodynamic AKI): AKI ROR 0.98, 24.2% of reports name a death outcome, 2,391 reports
  • Ramucirumab (Hypertension): AKI ROR 0.88, 26.8% of reports name a death outcome, 6,320 reports
  • Hydroxyurea (Crystal / Obstructive Nephropathy): AKI ROR 1.58 — signal, 14.9% of reports name a death outcome, 21,340 reports
  • Venetoclax (Crystal / Obstructive Nephropathy): AKI ROR 0.83, 28.1% of reports name a death outcome, 62,878 reports
  • Vinblastine (SIADH / Hyponatremia): AKI ROR 1.65 — signal, 14.1% of reports name a death outcome, 1,961 reports
  • Momelotinib (Pseudo-AKI): AKI ROR 1.48, 15.5% of reports name a death outcome, 1,481 reports
  • Zanidatamab (Prerenal / Hemodynamic AKI): AKI ROR 2.34, 9.8% of reports name a death outcome, 82 reports
  • Entrectinib (Pseudo-AKI): AKI ROR 1.40, 16.3% of reports name a death outcome, 1,691 reports
  • Lenvatinib (Hypertension): AKI ROR 1.69 — signal, 13.5% of reports name a death outcome, 39,694 reports
  • Dabrafenib (Acute Interstitial Nephritis): AKI ROR 1.08, 20.9% of reports name a death outcome, 21,157 reports
  • Axitinib (Hypertension): AKI ROR 1.07, 20.2% of reports name a death outcome, 19,550 reports
  • Ixazomib (Thrombotic Microangiopathy): AKI ROR 1.17 — signal, 18.4% of reports name a death outcome, 28,726 reports
  • Erdafitinib (Electrolyte Disturbance): AKI ROR 0.76, 28% of reports name a death outcome, 1,247 reports
  • Duvelisib (Prerenal / Hemodynamic AKI): AKI ROR 1.00, 21.2% of reports name a death outcome, 853 reports
  • Panitumumab (Electrolyte Disturbance): AKI ROR 1.24 — signal, 17% of reports name a death outcome, 16,107 reports
  • Capecitabine (Prerenal / Hemodynamic AKI): AKI ROR 1.03, 20% of reports name a death outcome, 92,086 reports
  • Pralatrexate (Crystal / Obstructive Nephropathy): AKI ROR 0.81, 25.1% of reports name a death outcome, 529 reports
  • Estramustine (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 27.5% of reports name a death outcome, 437 reports
  • Trametinib (Prerenal / Hemodynamic AKI): AKI ROR 0.94, 21.3% of reports name a death outcome, 24,319 reports
  • Pazopanib (Glomerular Injury / Proteinuria): AKI ROR 0.75, 25.8% of reports name a death outcome, 26,971 reports
  • Regorafenib (Hypertension): AKI ROR 0.93, 20.4% of reports name a death outcome, 11,611 reports
  • Dactinomycin (actinomycin D) (Electrolyte Disturbance): AKI ROR 1.07, 17.7% of reports name a death outcome, 2,211 reports
  • Dacarbazine (Prerenal / Hemodynamic AKI): AKI ROR 1.08, 17.4% of reports name a death outcome, 7,561 reports
  • Daratumumab (Prerenal / Hemodynamic AKI): AKI ROR 1.57 — signal, 11.9% of reports name a death outcome, 44,998 reports
  • Thalidomide (Prerenal / Hemodynamic AKI): AKI ROR 1.05, 17.6% of reports name a death outcome, 19,824 reports
  • Capmatinib (Pseudo-AKI): AKI ROR 0.74, 24.9% of reports name a death outcome, 2,444 reports
  • Selinexor (SIADH / Hyponatremia): AKI ROR 1.08, 17% of reports name a death outcome, 8,763 reports
  • Cetuximab (Electrolyte Disturbance): AKI ROR 1.32 — signal, 13.4% of reports name a death outcome, 31,704 reports
  • Midostaurin (Prerenal / Hemodynamic AKI): AKI ROR 0.72, 24.1% of reports name a death outcome, 1,957 reports
  • Teniposide (Electrolyte Disturbance): AKI ROR 0.79, 21.7% of reports name a death outcome, 405 reports
  • Selpercatinib (Hypertension): AKI ROR 1.15, 14.8% of reports name a death outcome, 1,396 reports
  • Octreotide (Electrolyte Disturbance): AKI ROR 0.85, 19.8% of reports name a death outcome, 31,000 reports
  • Sacituzumab govitecan (Prerenal / Hemodynamic AKI): AKI ROR 0.80, 21% of reports name a death outcome, 4,834 reports
  • Osimertinib (SIADH / Hyponatremia): AKI ROR 0.39, 42.8% of reports name a death outcome, 33,803 reports
  • Obinutuzumab (Crystal / Obstructive Nephropathy): AKI ROR 1.24 — signal, 13.1% of reports name a death outcome, 17,772 reports
  • Copanlisib (Hypertension): AKI ROR 1.33, 12.2% of reports name a death outcome, 403 reports
  • Futibatinib (Electrolyte Disturbance): AKI ROR 0.85, 18.9% of reports name a death outcome, 222 reports
  • Docetaxel (Prerenal / Hemodynamic AKI): AKI ROR 1.19 — signal, 13.2% of reports name a death outcome, 68,125 reports
  • Erlotinib (Glomerular Injury / Proteinuria): AKI ROR 0.53, 29.5% of reports name a death outcome, 22,936 reports
  • Eribulin (Prerenal / Hemodynamic AKI): AKI ROR 0.88, 17.7% of reports name a death outcome, 3,739 reports
  • Fruquintinib (Hypertension): AKI ROR 0.48, 32.2% of reports name a death outcome, 3,941 reports
  • Linvoseltamab (Prerenal / Hemodynamic AKI): AKI ROR 2.04, 7.5% of reports name a death outcome, 53 reports
  • Gefitinib (Glomerular Injury / Proteinuria): AKI ROR 0.70, 21.7% of reports name a death outcome, 8,990 reports
  • Talquetamab (Prerenal / Hemodynamic AKI): AKI ROR 1.31, 11.4% of reports name a death outcome, 2,290 reports
  • Ribociclib (Pseudo-AKI): AKI ROR 1.04, 14.3% of reports name a death outcome, 32,716 reports
  • Tisotumab vedotin (Prerenal / Hemodynamic AKI): AKI ROR 1.78 — signal, 8.3% of reports name a death outcome, 971 reports
  • Inavolisib (Electrolyte Disturbance): AKI ROR 3.03 — signal, 4.8% of reports name a death outcome, 670 reports
  • Zolbetuximab (Prerenal / Hemodynamic AKI): AKI ROR 1.24, 11.7% of reports name a death outcome, 1,525 reports
  • Blinatumomab (Prerenal / Hemodynamic AKI): AKI ROR 0.79, 18% of reports name a death outcome, 10,722 reports
  • Tucatinib (Pseudo-AKI): AKI ROR 1.37 — signal, 10.3% of reports name a death outcome, 7,112 reports
  • Teclistamab (Prerenal / Hemodynamic AKI): AKI ROR 0.75, 18.7% of reports name a death outcome, 2,379 reports
  • Tebentafusp (Prerenal / Hemodynamic AKI): AKI ROR 0.78, 17.8% of reports name a death outcome, 602 reports
  • Larotrectinib (Pseudo-AKI): AKI ROR 0.74, 18.2% of reports name a death outcome, 896 reports
  • Dostarlimab (Acute Interstitial Nephritis): AKI ROR 1.11, 11.9% of reports name a death outcome, 2,502 reports
  • Fedratinib (Electrolyte Disturbance): AKI ROR 0.91, 14.2% of reports name a death outcome, 1,349 reports
  • Mitotane (Electrolyte Disturbance): AKI ROR 0.98, 13% of reports name a death outcome, 1,830 reports
  • Asparaginase (Prerenal / Hemodynamic AKI): AKI ROR 1.47, 8.4% of reports name a death outcome, 1,533 reports
  • Sotorasib (Prerenal / Hemodynamic AKI): AKI ROR 0.52, 23.7% of reports name a death outcome, 3,470 reports
  • Ibrutinib (Hypertension): AKI ROR 0.70, 17.1% of reports name a death outcome, 80,997 reports
  • Tretinoin (ATRA) (Prerenal / Hemodynamic AKI): AKI ROR 1.18, 10% of reports name a death outcome, 8,951 reports
  • Trastuzumab deruxtecan (Acute Tubular Necrosis): AKI ROR 0.46, 25.6% of reports name a death outcome, 10,910 reports
  • Vandetanib (Hypertension): AKI ROR 1.50, 7.8% of reports name a death outcome, 1,286 reports
  • Pemigatinib (Electrolyte Disturbance): AKI ROR 0.66, 17.6% of reports name a death outcome, 853 reports
  • Abemaciclib (Pseudo-AKI): AKI ROR 1.63 — signal, 7.1% of reports name a death outcome, 21,412 reports
  • Lomustine (CCNU) (Chronic Interstitial Nephropathy): AKI ROR 0.51, 22.6% of reports name a death outcome, 2,597 reports
  • Nintedanib (Hypertension): AKI ROR 0.57, 19.8% of reports name a death outcome, 32,818 reports
  • Talazoparib (Pseudo-AKI): AKI ROR 0.61, 18.5% of reports name a death outcome, 1,853 reports
  • Arsenic trioxide (Prerenal / Hemodynamic AKI): AKI ROR 1.70 — signal, 6.6% of reports name a death outcome, 4,043 reports
  • Taletrectinib (Pseudo-AKI): AKI ROR 0.89, 12.5% of reports name a death outcome, 120 reports
  • Radium-223 dichloride (Prerenal / Hemodynamic AKI): AKI ROR 0.54, 20.5% of reports name a death outcome, 5,055 reports
  • Alpelisib (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 14.6% of reports name a death outcome, 9,106 reports
  • Acalabrutinib (Hypertension): AKI ROR 0.49, 21.2% of reports name a death outcome, 12,744 reports
  • Iberdomide (Prerenal / Hemodynamic AKI): AKI ROR 1.27, 8.1% of reports name a death outcome, 149 reports
  • Ziv-aflibercept (Hypertension): AKI ROR 0.37, 27.8% of reports name a death outcome, 32,703 reports
  • Tarlatamab (Prerenal / Hemodynamic AKI): AKI ROR 0.72, 13.9% of reports name a death outcome, 1,917 reports
  • Brigatinib (Pseudo-AKI): AKI ROR 0.46, 21.6% of reports name a death outcome, 3,655 reports
  • Lorlatinib (Pseudo-AKI): AKI ROR 0.35, 27.8% of reports name a death outcome, 7,455 reports
  • Belzutifan (Prerenal / Hemodynamic AKI): AKI ROR 1.02, 9.4% of reports name a death outcome, 1,777 reports
  • Ciltacabtagene autoleucel (Prerenal / Hemodynamic AKI): AKI ROR 0.73, 13.1% of reports name a death outcome, 6,566 reports
  • Zanubrutinib (Prerenal / Hemodynamic AKI): AKI ROR 0.86, 11.1% of reports name a death outcome, 4,598 reports
  • Nedaplatin (Acute Tubular Necrosis): AKI ROR 0.78, 11.6% of reports name a death outcome, 1,100 reports
  • Mitomycin C (Thrombotic Microangiopathy): AKI ROR 0.83, 10.9% of reports name a death outcome, 3,659 reports
  • Pomalidomide (Prerenal / Hemodynamic AKI): AKI ROR 0.66, 13.7% of reports name a death outcome, 103,640 reports
  • Repotrectinib (Pseudo-AKI): AKI ROR 0.69, 13.1% of reports name a death outcome, 274 reports
  • Tamoxifen (SIADH / Hyponatremia): AKI ROR 1.08, 8.2% of reports name a death outcome, 5,782 reports
  • Lenalidomide (Acute Tubular Necrosis): AKI ROR 0.69, 12.7% of reports name a death outcome, 425,916 reports
  • Mosunetuzumab (Prerenal / Hemodynamic AKI): AKI ROR 0.60, 14.1% of reports name a death outcome, 1,107 reports
  • Methotrexate (high-dose) (Crystal / Obstructive Nephropathy): AKI ROR 1.07 — signal, 7.8% of reports name a death outcome, 494,382 reports
  • Nilotinib (Prerenal / Hemodynamic AKI): AKI ROR 0.43, 19.1% of reports name a death outcome, 29,571 reports
  • Asciminib (Hypertension): AKI ROR 0.73, 11.2% of reports name a death outcome, 3,514 reports
  • Enzalutamide (Hypertension): AKI ROR 0.42, 19.4% of reports name a death outcome, 58,866 reports
  • Ruxolitinib (Prerenal / Hemodynamic AKI): AKI ROR 0.58, 13.6% of reports name a death outcome, 73,257 reports
  • Ivosidenib (Prerenal / Hemodynamic AKI): AKI ROR 0.74, 10.5% of reports name a death outcome, 2,178 reports
  • Bosutinib (Pseudo-AKI): AKI ROR 0.87, 8.9% of reports name a death outcome, 8,981 reports
  • Zongertinib (Pseudo-AKI): AKI ROR 0.56, 13.8% of reports name a death outcome, 167 reports
  • Lutetium-177 Dotatate (Chronic Interstitial Nephropathy): AKI ROR 0.62, 12.2% of reports name a death outcome, 5,819 reports
  • Sonidegib (Acute Tubular Necrosis): AKI ROR 0.79, 9.4% of reports name a death outcome, 1,679 reports
  • Olaparib (Pseudo-AKI): AKI ROR 0.26, 28.3% of reports name a death outcome, 21,443 reports
  • Darolutamide (Electrolyte Disturbance): AKI ROR 0.61, 12% of reports name a death outcome, 5,924 reports
  • Lanreotide (Electrolyte Disturbance): AKI ROR 0.39, 18.7% of reports name a death outcome, 7,953 reports
  • Trastuzumab emtansine (T-DM1) (Thrombotic Microangiopathy): AKI ROR 0.44, 13.8% of reports name a death outcome, 8,459 reports
  • Dasatinib (Glomerular Injury / Proteinuria): AKI ROR 0.62, 9.2% of reports name a death outcome, 32,694 reports
  • Fotemustine (Chronic Interstitial Nephropathy): AKI ROR 0.32, 17.8% of reports name a death outcome, 331 reports
  • Cabozantinib (Hypertension): AKI ROR 0.49, 11.3% of reports name a death outcome, 48,250 reports
  • Leuprolide (Hypertension): AKI ROR 0.35, 15.6% of reports name a death outcome, 79,718 reports
  • Denosumab (Electrolyte Disturbance): AKI ROR 0.40, 12.8% of reports name a death outcome, 203,750 reports
  • Enasidenib (Prerenal / Hemodynamic AKI): AKI ROR 0.19, 24.9% of reports name a death outcome, 3,369 reports
  • Tivozanib (Hypertension): AKI ROR 0.47, 9.9% of reports name a death outcome, 1,588 reports
  • Alectinib (Pseudo-AKI): AKI ROR 0.34, 12.9% of reports name a death outcome, 7,388 reports
  • Rucaparib (Pseudo-AKI): AKI ROR 0.74, 5.9% of reports name a death outcome, 8,832 reports
  • Palbociclib (Pseudo-AKI): AKI ROR 0.36, 11.2% of reports name a death outcome, 95,562 reports
  • Amivantamab (Electrolyte Disturbance): AKI ROR 0.53, 7.6% of reports name a death outcome, 3,576 reports
  • Imlunestrant (Pseudo-AKI): AKI ROR 1.16, 3.3% of reports name a death outcome, 92 reports
  • Lutetium-177 PSMA-617 (vipivotide) (Chronic Interstitial Nephropathy): AKI ROR 0.30, 12.1% of reports name a death outcome, 13,841 reports
  • Lazertinib (SIADH / Hyponatremia): AKI ROR 0.87, 4% of reports name a death outcome, 865 reports
  • Naxitamab (Prerenal / Hemodynamic AKI): AKI ROR 0.75, 4.4% of reports name a death outcome, 250 reports
  • Toripalimab (Acute Interstitial Nephritis): AKI ROR 0.50, 6% of reports name a death outcome, 1,928 reports
  • Pralsetinib (Hypertension): AKI ROR 0.21, 14.2% of reports name a death outcome, 1,824 reports
  • Cladribine (Crystal / Obstructive Nephropathy): AKI ROR 0.40, 7.2% of reports name a death outcome, 9,967 reports
  • Vismodegib (SIADH / Hyponatremia): AKI ROR 0.25, 11.2% of reports name a death outcome, 8,927 reports
  • Ibandronate (Acute Tubular Necrosis): AKI ROR 0.66, 4% of reports name a death outcome, 14,757 reports
  • Pacritinib (Prerenal / Hemodynamic AKI): AKI ROR 0.21, 11.4% of reports name a death outcome, 3,069 reports
  • Tazemetostat (Prerenal / Hemodynamic AKI): AKI ROR 0.17, 13.3% of reports name a death outcome, 1,622 reports
  • Datopotamab deruxtecan (Dato-DXd) (Acute Tubular Necrosis): AKI ROR 0.11, 20.1% of reports name a death outcome, 859 reports
  • Selumetinib (Prerenal / Hemodynamic AKI): AKI ROR 0.33, 6.1% of reports name a death outcome, 1,684 reports
  • Quizartinib (Prerenal / Hemodynamic AKI): AKI ROR 0.13, 15.2% of reports name a death outcome, 702 reports
  • Ripretinib (Hypertension): AKI ROR 0.16, 9.5% of reports name a death outcome, 5,243 reports
  • Niraparib (Hypertension): AKI ROR 0.22, 6.6% of reports name a death outcome, 22,237 reports
  • Tislelizumab (Acute Interstitial Nephritis): AKI ROR 0.61, 2.2% of reports name a death outcome, 8,853 reports
  • Mirvetuximab soravtansine (Prerenal / Hemodynamic AKI): AKI ROR 0.10, 13% of reports name a death outcome, 1,814 reports
  • Revumenib (Prerenal / Hemodynamic AKI): AKI ROR 0.09, 13.3% of reports name a death outcome, 1,031 reports
  • Nirogacestat (Electrolyte Disturbance): AKI ROR 0.61, 0.9% of reports name a death outcome, 923 reports
  • Elacestrant (Prerenal / Hemodynamic AKI): AKI ROR 0.07, 7.7% of reports name a death outcome, 7,181 reports
  • Vorasidenib (Pseudo-AKI): AKI ROR 0.17, 2% of reports name a death outcome, 612 reports
  • Mechlorethamine (Electrolyte Disturbance): AKI ROR 0.04, 6.9% of reports name a death outcome, 2,247 reports
  • Avapritinib (Prerenal / Hemodynamic AKI): AKI ROR 0.09, 3% of reports name a death outcome, 12,654 reports
  • Avutometinib (Electrolyte Disturbance): AKI ROR 0.08, 3.3% of reports name a death outcome, 1,125 reports
  • Pexidartinib (Prerenal / Hemodynamic AKI): AKI ROR 0.13, 2% of reports name a death outcome, 717 reports
Figure 19·FAERS acute-kidney-injury reporting odds ratio (x, log) against the share of reports filed with a death outcome (y). The upper-right quadrant — right of ROR = 1, above the cohort median death share — is loudest on both axes; solid dots also clear the renal-signal significance bar, faint ones do not. Both axes are reporting signals, not incidence or case fatality.
Severity:

Horizontal = citation staleness (years behind the freshest-cited agent); vertical = FAERS AKI reporting odds ratio (log). Color = the atlas's severity grade, size = evidence depth. The upper-right — stale & high-ROR — is the neglected-signal corner.

ROR = 1now5y10y15y20y25y0.125×0.25×0.5×1×2×4×8×Citation staleness — years behind the freshest agent (0–25)AKI reporting odds ratio (log)Lifileucel: ROR 8.22 (95% CI 5.37–12.58), 1 y behind the freshest-cited agent, 6 citations, Moderate — signalClofarabine: ROR 5.51 (95% CI 4.60–6.58), 6 y behind the freshest-cited agent, 10 citations, Moderate — signalInterleukin-2 (high-dose): ROR 5.41 (95% CI 4.24–6.90), 15 y behind the freshest-cited agent, 10 citations, Moderate — signalTrabectedin: ROR 4.69 (95% CI 3.88–5.67), 7 y behind the freshest-cited agent, 10 citations, Moderate — signalTagraxofusp: ROR 4.37 (95% CI 2.90–6.58), 0 y behind the freshest-cited agent, 7 citations, Moderate — signalStreptozocin: ROR 4.04 (95% CI 2.08–7.87), 0 y behind the freshest-cited agent, 10 citations, Severe — signalPemetrexed: ROR 3.88 (95% CI 3.69–4.08), 0 y behind the freshest-cited agent, 10 citations, Moderate — signalIdecabtagene vicleucel: ROR 3.77 (95% CI 2.82–5.03), 0 y behind the freshest-cited agent, 9 citations, Moderate — signalSirolimus: ROR 3.65 (95% CI 3.34–3.98), 7 y behind the freshest-cited agent, 13 citations, Moderate — signalAdagrasib: ROR 3.48 (95% CI 2.49–4.84), 1 y behind the freshest-cited agent, 6 citations, Mild — signalCisplatin: ROR 3.43 (95% CI 3.30–3.56), 1 y behind the freshest-cited agent, 21 citations, Severe — signalRetifanlimab: ROR 3.40 (95% CI 1.51–7.67), 1 y behind the freshest-cited agent, 6 citations, Moderate — signalPamidronate: ROR 3.16 (95% CI 2.65–3.77), 15 y behind the freshest-cited agent, 6 citations, Severe — signalCarfilzomib: ROR 3.11 (95% CI 2.91–3.32), 1 y behind the freshest-cited agent, 13 citations, Severe — signalCobimetinib: ROR 3.05 (95% CI 2.58–3.61), 4 y behind the freshest-cited agent, 7 citations, Mild — signalInavolisib: ROR 3.03 (95% CI 1.96–4.68), 2 y behind the freshest-cited agent, 4 citations, Moderate — signalMelphalan: ROR 2.94 (95% CI 2.73–3.16), 1 y behind the freshest-cited agent, 8 citations, Mild — signalGemtuzumab ozogamicin: ROR 2.82 (95% CI 2.32–3.41), 6 y behind the freshest-cited agent, 4 citations, Moderate — signalLurbinectedin: ROR 2.78 (95% CI 1.93–3.99), 1 y behind the freshest-cited agent, 8 citations, Mild — signalFludarabine: ROR 2.66 (95% CI 2.51–2.83), 9 y behind the freshest-cited agent, 11 citations, Moderate — signalPembrolizumab: ROR 2.59 (95% CI 2.49–2.69), 0 y behind the freshest-cited agent, 15 citations, Moderate — signalIsatuximab: ROR 2.58 (95% CI 2.20–3.02), 1 y behind the freshest-cited agent, 7 citations, Mild — signalCytarabine: ROR 2.57 (95% CI 2.45–2.70), 3 y behind the freshest-cited agent, 9 citations, Moderate — signalIfosfamide: ROR 2.50 (95% CI 2.29–2.72), 0 y behind the freshest-cited agent, 16 citations, Severe — signalAvelumab: ROR 2.42 (95% CI 1.97–2.97), 0 y behind the freshest-cited agent, 9 citations, Moderate — signalCarboplatin: ROR 2.41 (95% CI 2.33–2.50), 2 y behind the freshest-cited agent, 12 citations, Mild — signalCarmustine (BCNU): ROR 2.38 (95% CI 1.98–2.86), 14 y behind the freshest-cited agent, 7 citations, Moderate — signalGemcitabine: ROR 2.36 (95% CI 2.24–2.50), 0 y behind the freshest-cited agent, 14 citations, Severe — signalZanidatamab: ROR 2.34 (95% CI 0.57–9.52), 1 y behind the freshest-cited agent, 5 citations, MildEtoposide: ROR 2.33 (95% CI 2.23–2.45), 5 y behind the freshest-cited agent, 9 citations, Mild — signalEpcoritamab: ROR 2.27 (95% CI 1.81–2.83), 0 y behind the freshest-cited agent, 9 citations, Moderate — signalThiotepa: ROR 2.27 (95% CI 1.99–2.59), 2 y behind the freshest-cited agent, 8 citations, Mild — signalBinimetinib: ROR 2.23 (95% CI 1.93–2.58), 4 y behind the freshest-cited agent, 9 citations, Mild — signalEncorafenib: ROR 2.23 (95% CI 1.96–2.54), 4 y behind the freshest-cited agent, 9 citations, Mild — signalBendamustine: ROR 2.19 (95% CI 2.01–2.38), 0 y behind the freshest-cited agent, 10 citations, Moderate — signalZoledronic acid: ROR 2.13 (95% CI 2.02–2.25), 0 y behind the freshest-cited agent, 11 citations, Moderate — signalMogamulizumab: ROR 2.10 (95% CI 1.51–2.90), 5 y behind the freshest-cited agent, 6 citations, Mild — signalBusulfan: ROR 2.09 (95% CI 1.88–2.32), 7 y behind the freshest-cited agent, 8 citations, Moderate — signalPirtobrutinib: ROR 2.09 (95% CI 1.33–3.30), 2 y behind the freshest-cited agent, 6 citations, Mild — signalIpilimumab: ROR 2.08 (95% CI 1.95–2.22), 0 y behind the freshest-cited agent, 13 citations, Severe — signalTemsirolimus: ROR 2.08 (95% CI 1.70–2.54), 10 y behind the freshest-cited agent, 10 citations, Mild — signalEnfortumab vedotin: ROR 2.07 (95% CI 1.78–2.41), 1 y behind the freshest-cited agent, 10 citations, Moderate — signalVinorelbine: ROR 2.05 (95% CI 1.74–2.41), 2 y behind the freshest-cited agent, 7 citations, Mild — signalLinvoseltamab: ROR 2.04 (95% CI 0.28–14.74), 1 y behind the freshest-cited agent, 6 citations, MildAtezolizumab: ROR 2.03 (95% CI 1.89–2.19), 1 y behind the freshest-cited agent, 15 citations, Moderate — signalVemurafenib: ROR 2.01 (95% CI 1.77–2.28), 5 y behind the freshest-cited agent, 9 citations, Moderate — signalOxaliplatin: ROR 2.00 (95% CI 1.90–2.10), 0 y behind the freshest-cited agent, 10 citations, Mild — signalPegaspargase: ROR 1.99 (95% CI 1.76–2.26), 6 y behind the freshest-cited agent, 8 citations, Mild — signalInotuzumab ozogamicin: ROR 1.98 (95% CI 1.54–2.55), 3 y behind the freshest-cited agent, 4 citations, Moderate — signal5-Fluorouracil: ROR 1.96 (95% CI 1.86–2.06), 2 y behind the freshest-cited agent, 9 citations, Mild — signalNelarabine: ROR 1.96 (95% CI 1.26–3.06), 6 y behind the freshest-cited agent, 6 citations, Mild — signalCapivasertib: ROR 1.94 (95% CI 1.48–2.53), 0 y behind the freshest-cited agent, 8 citations, Moderate — signalPentostatin: ROR 1.94 (95% CI 1.04–3.63), 13 y behind the freshest-cited agent, 11 citations, Moderate — signalRaltitrexed: ROR 1.93 (95% CI 1.09–3.41), 5 y behind the freshest-cited agent, 4 citations, Moderate — signalRelacorilant: ROR 1.93 (95% CI 0.48–7.83), 1 y behind the freshest-cited agent, 3 citations, MildProcarbazine: ROR 1.92 (95% CI 1.61–2.28), 5 y behind the freshest-cited agent, 4 citations, Moderate — signalBrentuximab vedotin: ROR 1.91 (95% CI 1.67–2.19), 2 y behind the freshest-cited agent, 5 citations, Mild — signalElotuzumab: ROR 1.90 (95% CI 1.56–2.31), 9 y behind the freshest-cited agent, 4 citations, Mild — signalVincristine: ROR 1.90 (95% CI 1.75–2.07), 2 y behind the freshest-cited agent, 9 citations, Mild — signalNivolumab: ROR 1.88 (95% CI 1.80–1.97), 0 y behind the freshest-cited agent, 10 citations, Moderate — signalIdelalisib: ROR 1.87 (95% CI 1.57–2.24), 5 y behind the freshest-cited agent, 6 citations, Mild — signalAmsacrine: ROR 1.80 (95% CI 0.93–3.48), 9 y behind the freshest-cited agent, 4 citations, ModerateCyclophosphamide: ROR 1.80 (95% CI 1.74–1.87), 3 y behind the freshest-cited agent, 8 citations, Mild — signalDenileukin diftitox: ROR 1.80 (95% CI 0.25–12.96), 1 y behind the freshest-cited agent, 8 citations, ModerateBortezomib: ROR 1.78 (95% CI 1.69–1.86), 1 y behind the freshest-cited agent, 7 citations, Moderate — signalTisotumab vedotin: ROR 1.78 (95% CI 1.08–2.91), 2 y behind the freshest-cited agent, 4 citations, Mild — signalGilteritinib: ROR 1.77 (95% CI 1.42–2.22), 0 y behind the freshest-cited agent, 7 citations, Moderate — signalNeratinib: ROR 1.77 (95% CI 1.31–2.39), 4 y behind the freshest-cited agent, 6 citations, Moderate — signalLisocabtagene maraleucel: ROR 1.74 (95% CI 1.06–2.85), 1 y behind the freshest-cited agent, 8 citations, Moderate — signalArsenic trioxide: ROR 1.70 (95% CI 1.34–2.14), 1 y behind the freshest-cited agent, 9 citations, Moderate — signalBicalutamide: ROR 1.69 (95% CI 1.50–1.90), 6 y behind the freshest-cited agent, 4 citations, Mild — signalEverolimus: ROR 1.69 (95% CI 1.58–1.81), 1 y behind the freshest-cited agent, 12 citations, Moderate — signalLenvatinib: ROR 1.69 (95% CI 1.56–1.83), 0 y behind the freshest-cited agent, 13 citations, Moderate — signalCabazitaxel: ROR 1.68 (95% CI 1.31–2.16), 1 y behind the freshest-cited agent, 9 citations, Mild — signalDoxorubicin: ROR 1.68 (95% CI 1.60–1.76), 0 y behind the freshest-cited agent, 12 citations, Mild — signalRelatlimab: ROR 1.66 (95% CI 0.86–3.22), 0 y behind the freshest-cited agent, 7 citations, ModerateTafasitamab: ROR 1.65 (95% CI 1.21–2.25), 2 y behind the freshest-cited agent, 6 citations, Mild — signalVinblastine: ROR 1.65 (95% CI 1.18–2.32), 2 y behind the freshest-cited agent, 8 citations, Mild — signalAbemaciclib: ROR 1.63 (95% CI 1.47–1.82), 0 y behind the freshest-cited agent, 8 citations, Mild — signalMitoxantrone: ROR 1.60 (95% CI 1.32–1.95), 10 y behind the freshest-cited agent, 9 citations, Mild — signalHydroxyurea: ROR 1.58 (95% CI 1.42–1.75), 6 y behind the freshest-cited agent, 7 citations, Mild — signalInfigratinib: ROR 1.58 (95% CI 0.22–11.39), 1 y behind the freshest-cited agent, 7 citations, ModerateDaratumumab: ROR 1.57 (95% CI 1.45–1.69), 1 y behind the freshest-cited agent, 9 citations, Mild — signalDecitabine: ROR 1.57 (95% CI 1.27–1.94), 3 y behind the freshest-cited agent, 6 citations, Mild — signalBelantamab mafodotin: ROR 1.52 (95% CI 1.13–2.05), 0 y behind the freshest-cited agent, 6 citations, Mild — signalPaclitaxel: ROR 1.52 (95% CI 1.45–1.60), 2 y behind the freshest-cited agent, 9 citations, Mild — signalCemiplimab: ROR 1.51 (95% CI 1.07–2.13), 0 y behind the freshest-cited agent, 11 citations, Moderate — signalVandetanib: ROR 1.50 (95% CI 0.94–2.40), 3 y behind the freshest-cited agent, 6 citations, ModerateIrinotecan: ROR 1.48 (95% CI 1.29–1.70), 2 y behind the freshest-cited agent, 5 citations, Mild — signalMomelotinib: ROR 1.48 (95% CI 0.98–2.23), 0 y behind the freshest-cited agent, 7 citations, MildAsparaginase: ROR 1.47 (95% CI 0.96–2.26), 1 y behind the freshest-cited agent, 6 citations, MildAfatinib: ROR 1.45 (95% CI 1.19–1.76), 2 y behind the freshest-cited agent, 8 citations, Mild — signalNecitumumab: ROR 1.43 (95% CI 0.64–3.21), 5 y behind the freshest-cited agent, 9 citations, ModerateBleomycin: ROR 1.42 (95% CI 1.21–1.67), 5 y behind the freshest-cited agent, 7 citations, Mild — signalEntrectinib: ROR 1.40 (95% CI 0.92–2.13), 2 y behind the freshest-cited agent, 7 citations, MildGlasdegib: ROR 1.40 (95% CI 0.67–2.96), 3 y behind the freshest-cited agent, 6 citations, MildRituximab: ROR 1.38 (95% CI 1.34–1.43), 2 y behind the freshest-cited agent, 8 citations, Moderate — signalAzacitidine: ROR 1.37 (95% CI 1.25–1.51), 2 y behind the freshest-cited agent, 8 citations, Moderate — signalIbritumomab tiuxetan: ROR 1.37 (95% CI 0.90–2.09), 22 y behind the freshest-cited agent, 6 citations, MildTucatinib: ROR 1.37 (95% CI 1.12–1.69), 2 y behind the freshest-cited agent, 4 citations, Mild — signalObecabtagene autoleucel (Obe-cel): ROR 1.34 (95% CI 0.19–9.63), 1 y behind the freshest-cited agent, 5 citations, ModerateCopanlisib: ROR 1.33 (95% CI 0.55–3.22), 5 y behind the freshest-cited agent, 6 citations, ModerateDinutuximab: ROR 1.33 (95% CI 0.75–2.34), 1 y behind the freshest-cited agent, 7 citations, ModerateCetuximab: ROR 1.32 (95% CI 1.20–1.45), 4 y behind the freshest-cited agent, 13 citations, Mild — signalCeritinib: ROR 1.31 (95% CI 0.94–1.82), 1 y behind the freshest-cited agent, 6 citations, MildTalquetamab: ROR 1.31 (95% CI 0.90–1.90), 0 y behind the freshest-cited agent, 7 citations, ModerateAbiraterone: ROR 1.29 (95% CI 1.19–1.40), 1 y behind the freshest-cited agent, 11 citations, Moderate — signalIberdomide: ROR 1.27 (95% CI 0.32–5.14), 1 y behind the freshest-cited agent, 7 citations, MildTemozolomide: ROR 1.26 (95% CI 1.12–1.42), 1 y behind the freshest-cited agent, 9 citations, Mild — signalObinutuzumab: ROR 1.24 (95% CI 1.08–1.43), 1 y behind the freshest-cited agent, 8 citations, Moderate — signalPanitumumab: ROR 1.24 (95% CI 1.08–1.42), 0 y behind the freshest-cited agent, 10 citations, Mild — signalZolbetuximab: ROR 1.24 (95% CI 0.80–1.93), 1 y behind the freshest-cited agent, 4 citations, ModerateDocetaxel: ROR 1.19 (95% CI 1.12–1.28), 1 y behind the freshest-cited agent, 10 citations, Mild — signalTretinoin (ATRA): ROR 1.18 (95% CI 0.97–1.42), 1 y behind the freshest-cited agent, 10 citations, ModerateBevacizumab: ROR 1.18 (95% CI 1.13–1.24), 7 y behind the freshest-cited agent, 9 citations, Moderate — signalIxazomib: ROR 1.17 (95% CI 1.05–1.30), 1 y behind the freshest-cited agent, 8 citations, Moderate — signalMobocertinib: ROR 1.17 (95% CI 0.58–2.34), 1 y behind the freshest-cited agent, 7 citations, MildChlorambucil: ROR 1.16 (95% CI 0.87–1.54), 5 y behind the freshest-cited agent, 3 citations, MildImlunestrant: ROR 1.16 (95% CI 0.16–8.36), 1 y behind the freshest-cited agent, 2 citations, MildSelpercatinib: ROR 1.15 (95% CI 0.69–1.92), 0 y behind the freshest-cited agent, 11 citations, ModerateIdarubicin: ROR 1.14 (95% CI 0.68–1.94), 3 y behind the freshest-cited agent, 8 citations, MildPolatuzumab vedotin: ROR 1.14 (95% CI 0.96–1.36), 2 y behind the freshest-cited agent, 4 citations, MildGlofitamab: ROR 1.12 (95% CI 0.79–1.58), 2 y behind the freshest-cited agent, 6 citations, ModeratePonatinib: ROR 1.12 (95% CI 0.93–1.34), 1 y behind the freshest-cited agent, 9 citations, ModerateDostarlimab: ROR 1.11 (95% CI 0.76–1.64), 1 y behind the freshest-cited agent, 9 citations, ModerateTepotinib: ROR 1.10 (95% CI 0.55–2.20), 1 y behind the freshest-cited agent, 8 citations, MildDabrafenib: ROR 1.08 (95% CI 0.95–1.23), 4 y behind the freshest-cited agent, 9 citations, MildDacarbazine: ROR 1.08 (95% CI 0.87–1.33), 25 y behind the freshest-cited agent, 2 citations, MildSelinexor: ROR 1.08 (95% CI 0.89–1.32), 2 y behind the freshest-cited agent, 10 citations, ModerateTamoxifen: ROR 1.08 (95% CI 0.85–1.38), 3 y behind the freshest-cited agent, 6 citations, MildAxitinib: ROR 1.07 (95% CI 0.94–1.22), 3 y behind the freshest-cited agent, 7 citations, ModerateDactinomycin (actinomycin D): ROR 1.07 (95% CI 0.72–1.59), 9 y behind the freshest-cited agent, 4 citations, ModerateMethotrexate (high-dose): ROR 1.07 (95% CI 1.04–1.10), 1 y behind the freshest-cited agent, 10 citations, Moderate — signalThalidomide: ROR 1.05 (95% CI 0.91–1.21), 9 y behind the freshest-cited agent, 6 citations, MildRibociclib: ROR 1.04 (95% CI 0.94–1.15), 0 y behind the freshest-cited agent, 9 citations, MildCapecitabine: ROR 1.03 (95% CI 0.96–1.09), 1 y behind the freshest-cited agent, 9 citations, MildBelzutifan: ROR 1.02 (95% CI 0.64–1.65), 1 y behind the freshest-cited agent, 7 citations, MildCrizotinib: ROR 1.02 (95% CI 0.84–1.24), 1 y behind the freshest-cited agent, 10 citations, MildSorafenib: ROR 1.02 (95% CI 0.89–1.16), 5 y behind the freshest-cited agent, 11 citations, ModerateTopotecan: ROR 1.01 (95% CI 0.80–1.27), 4 y behind the freshest-cited agent, 4 citations, MildDuvelisib: ROR 1.00 (95% CI 0.52–1.93), 1 y behind the freshest-cited agent, 7 citations, MildElranatamab: ROR 0.98 (95% CI 0.65–1.50), 0 y behind the freshest-cited agent, 10 citations, ModerateMitotane: ROR 0.98 (95% CI 0.63–1.54), 1 y behind the freshest-cited agent, 6 citations, ModerateDurvalumab: ROR 0.96 (95% CI 0.84–1.10), 0 y behind the freshest-cited agent, 11 citations, ModerateTrametinib: ROR 0.94 (95% CI 0.83–1.07), 2 y behind the freshest-cited agent, 10 citations, ModerateRegorafenib: ROR 0.93 (95% CI 0.77–1.12), 1 y behind the freshest-cited agent, 10 citations, ModerateImatinib: ROR 0.92 (95% CI 0.84–1.02), 2 y behind the freshest-cited agent, 9 citations, MildLoncastuximab tesirine: ROR 0.92 (95% CI 0.34–2.47), 2 y behind the freshest-cited agent, 5 citations, ModerateFedratinib: ROR 0.91 (95% CI 0.53–1.57), 6 y behind the freshest-cited agent, 7 citations, MildMelphalan flufenamide (melflufen): ROR 0.91 (95% CI 0.13–6.54), 0 y behind the freshest-cited agent, 4 citations, ModerateTaletrectinib: ROR 0.89 (95% CI 0.12–6.38), 0 y behind the freshest-cited agent, 4 citations, MildEribulin: ROR 0.88 (95% CI 0.63–1.23), 4 y behind the freshest-cited agent, 6 citations, MildRamucirumab: ROR 0.88 (95% CI 0.68–1.14), 1 y behind the freshest-cited agent, 11 citations, ModerateBosutinib: ROR 0.87 (95% CI 0.70–1.08), 1 y behind the freshest-cited agent, 9 citations, MildLazertinib: ROR 0.87 (95% CI 0.43–1.75), 2 y behind the freshest-cited agent, 6 citations, MildSunitinib: ROR 0.87 (95% CI 0.78–0.96), 0 y behind the freshest-cited agent, 8 citations, ModerateZanubrutinib: ROR 0.86 (95% CI 0.62–1.19), 2 y behind the freshest-cited agent, 7 citations, MildFutibatinib: ROR 0.85 (95% CI 0.21–3.42), 2 y behind the freshest-cited agent, 6 citations, ModerateOctreotide: ROR 0.85 (95% CI 0.76–0.96), 2 y behind the freshest-cited agent, 7 citations, MildMitomycin C: ROR 0.83 (95% CI 0.58–1.17), 1 y behind the freshest-cited agent, 13 citations, SevereVenetoclax: ROR 0.83 (95% CI 0.76–0.90), 1 y behind the freshest-cited agent, 12 citations, SeverePralatrexate: ROR 0.81 (95% CI 0.30–2.16), 4 y behind the freshest-cited agent, 8 citations, ModerateTrifluridine/tipiracil: ROR 0.81 (95% CI 0.67–0.99), 1 y behind the freshest-cited agent, 7 citations, ModerateSacituzumab govitecan: ROR 0.80 (95% CI 0.59–1.09), 0 y behind the freshest-cited agent, 5 citations, ModerateBlinatumomab: ROR 0.79 (95% CI 0.64–0.97), 4 y behind the freshest-cited agent, 8 citations, ModerateSonidegib: ROR 0.79 (95% CI 0.47–1.33), 3 y behind the freshest-cited agent, 6 citations, MildTeniposide: ROR 0.79 (95% CI 0.25–2.46), 5 y behind the freshest-cited agent, 5 citations, MildNedaplatin: ROR 0.78 (95% CI 0.39–1.56), 3 y behind the freshest-cited agent, 11 citations, ModerateTebentafusp: ROR 0.78 (95% CI 0.33–1.89), 3 y behind the freshest-cited agent, 4 citations, ModerateErdafitinib: ROR 0.76 (95% CI 0.41–1.41), 2 y behind the freshest-cited agent, 7 citations, ModerateNaxitamab: ROR 0.75 (95% CI 0.19–3.04), 1 y behind the freshest-cited agent, 8 citations, ModeratePazopanib: ROR 0.75 (95% CI 0.66–0.86), 2 y behind the freshest-cited agent, 9 citations, ModerateTeclistamab: ROR 0.75 (95% CI 0.48–1.18), 0 y behind the freshest-cited agent, 9 citations, ModerateCapmatinib: ROR 0.74 (95% CI 0.46–1.20), 1 y behind the freshest-cited agent, 8 citations, MildIvosidenib: ROR 0.74 (95% CI 0.46–1.19), 2 y behind the freshest-cited agent, 6 citations, ModerateLarotrectinib: ROR 0.74 (95% CI 0.35–1.55), 6 y behind the freshest-cited agent, 7 citations, MildRucaparib: ROR 0.74 (95% CI 0.57–0.95), 0 y behind the freshest-cited agent, 7 citations, MildAlpelisib: ROR 0.73 (95% CI 0.57–0.93), 2 y behind the freshest-cited agent, 7 citations, ModerateAsciminib: ROR 0.73 (95% CI 0.49–1.09), 0 y behind the freshest-cited agent, 7 citations, MildCiltacabtagene autoleucel: ROR 0.73 (95% CI 0.56–0.96), 0 y behind the freshest-cited agent, 10 citations, ModerateEstramustine: ROR 0.73 (95% CI 0.23–2.28), 11 y behind the freshest-cited agent, 7 citations, MildMidostaurin: ROR 0.72 (95% CI 0.43–1.20), 3 y behind the freshest-cited agent, 7 citations, MildTarlatamab: ROR 0.72 (95% CI 0.42–1.25), 0 y behind the freshest-cited agent, 8 citations, ModerateGefitinib: ROR 0.70 (95% CI 0.55–0.89), 8 y behind the freshest-cited agent, 12 citations, MildIbrutinib: ROR 0.70 (95% CI 0.65–0.76), 1 y behind the freshest-cited agent, 9 citations, ModerateLenalidomide: ROR 0.69 (95% CI 0.67–0.72), 1 y behind the freshest-cited agent, 9 citations, ModerateRepotrectinib: ROR 0.69 (95% CI 0.17–2.77), 1 y behind the freshest-cited agent, 6 citations, MildIbandronate: ROR 0.66 (95% CI 0.54–0.82), 2 y behind the freshest-cited agent, 9 citations, MildPemigatinib: ROR 0.66 (95% CI 0.30–1.48), 1 y behind the freshest-cited agent, 9 citations, ModeratePomalidomide: ROR 0.66 (95% CI 0.61–0.71), 1 y behind the freshest-cited agent, 7 citations, MildDasatinib: ROR 0.62 (95% CI 0.54–0.72), 1 y behind the freshest-cited agent, 9 citations, ModerateLutetium-177 Dotatate: ROR 0.62 (95% CI 0.45–0.85), 1 y behind the freshest-cited agent, 19 citations, ModerateDarolutamide: ROR 0.61 (95% CI 0.44–0.86), 1 y behind the freshest-cited agent, 5 citations, MildNirogacestat: ROR 0.61 (95% CI 0.27–1.37), 2 y behind the freshest-cited agent, 7 citations, MildTalazoparib: ROR 0.61 (95% CI 0.35–1.08), 0 y behind the freshest-cited agent, 6 citations, MildTislelizumab: ROR 0.61 (95% CI 0.47–0.81), 0 y behind the freshest-cited agent, 8 citations, ModerateMosunetuzumab: ROR 0.60 (95% CI 0.28–1.25), 2 y behind the freshest-cited agent, 8 citations, ModerateRuxolitinib: ROR 0.58 (95% CI 0.53–0.63), 0 y behind the freshest-cited agent, 7 citations, MildNintedanib: ROR 0.57 (95% CI 0.50–0.66), 0 y behind the freshest-cited agent, 9 citations, MildZongertinib: ROR 0.56 (95% CI 0.08–4.03), 1 y behind the freshest-cited agent, 4 citations, MildRadium-223 dichloride: ROR 0.54 (95% CI 0.38–0.78), 4 y behind the freshest-cited agent, 8 citations, MildAmivantamab: ROR 0.53 (95% CI 0.34–0.82), 1 y behind the freshest-cited agent, 7 citations, ModerateErlotinib: ROR 0.53 (95% CI 0.44–0.64), 2 y behind the freshest-cited agent, 9 citations, MildSotorasib: ROR 0.52 (95% CI 0.33–0.81), 1 y behind the freshest-cited agent, 6 citations, MildLomustine (CCNU): ROR 0.51 (95% CI 0.30–0.86), 7 y behind the freshest-cited agent, 9 citations, ModerateToripalimab: ROR 0.50 (95% CI 0.26–0.96), 2 y behind the freshest-cited agent, 7 citations, ModerateAcalabrutinib: ROR 0.49 (95% CI 0.38–0.62), 1 y behind the freshest-cited agent, 8 citations, MildCabozantinib: ROR 0.49 (95% CI 0.43–0.55), 0 y behind the freshest-cited agent, 10 citations, ModerateFruquintinib: ROR 0.48 (95% CI 0.31–0.74), 1 y behind the freshest-cited agent, 10 citations, ModerateTivozanib: ROR 0.47 (95% CI 0.22–0.99), 5 y behind the freshest-cited agent, 5 citations, ModerateBrigatinib: ROR 0.46 (95% CI 0.29–0.74), 1 y behind the freshest-cited agent, 9 citations, MildTrastuzumab deruxtecan: ROR 0.46 (95% CI 0.35–0.60), 0 y behind the freshest-cited agent, 6 citations, ModerateTrastuzumab emtansine (T-DM1): ROR 0.44 (95% CI 0.33–0.61), 0 y behind the freshest-cited agent, 7 citations, ModerateNilotinib: ROR 0.43 (95% CI 0.36–0.50), 1 y behind the freshest-cited agent, 8 citations, MildEnzalutamide: ROR 0.42 (95% CI 0.37–0.47), 2 y behind the freshest-cited agent, 9 citations, MildCladribine: ROR 0.40 (95% CI 0.29–0.54), 3 y behind the freshest-cited agent, 10 citations, MildDenosumab: ROR 0.40 (95% CI 0.37–0.42), 1 y behind the freshest-cited agent, 10 citations, ModerateLanreotide: ROR 0.39 (95% CI 0.28–0.55), 8 y behind the freshest-cited agent, 6 citations, MildOsimertinib: ROR 0.39 (95% CI 0.33–0.47), 0 y behind the freshest-cited agent, 9 citations, MildZiv-aflibercept: ROR 0.37 (95% CI 0.31–0.44), 4 y behind the freshest-cited agent, 8 citations, ModeratePalbociclib: ROR 0.36 (95% CI 0.33–0.40), 0 y behind the freshest-cited agent, 8 citations, MildLeuprolide: ROR 0.35 (95% CI 0.32–0.40), 2 y behind the freshest-cited agent, 8 citations, MildLorlatinib: ROR 0.35 (95% CI 0.24–0.51), 1 y behind the freshest-cited agent, 8 citations, MildAlectinib: ROR 0.34 (95% CI 0.23–0.50), 0 y behind the freshest-cited agent, 9 citations, MildSelumetinib: ROR 0.33 (95% CI 0.15–0.75), 3 y behind the freshest-cited agent, 6 citations, MildFotemustine: ROR 0.32 (95% CI 0.04–2.29), 11 y behind the freshest-cited agent, 4 citations, ModerateLutetium-177 PSMA-617 (vipivotide): ROR 0.30 (95% CI 0.22–0.40), 0 y behind the freshest-cited agent, 12 citations, ModerateOlaparib: ROR 0.26 (95% CI 0.20–0.34), 0 y behind the freshest-cited agent, 8 citations, MildVismodegib: ROR 0.25 (95% CI 0.17–0.38), 3 y behind the freshest-cited agent, 6 citations, MildNiraparib: ROR 0.22 (95% CI 0.17–0.29), 0 y behind the freshest-cited agent, 8 citations, MildPacritinib: ROR 0.21 (95% CI 0.10–0.45), 1 y behind the freshest-cited agent, 7 citations, ModeratePralsetinib: ROR 0.21 (95% CI 0.08–0.55), 1 y behind the freshest-cited agent, 6 citations, MildEnasidenib: ROR 0.19 (95% CI 0.09–0.41), 1 y behind the freshest-cited agent, 8 citations, ModerateTazemetostat: ROR 0.17 (95% CI 0.06–0.54), 4 y behind the freshest-cited agent, 7 citations, MildVorasidenib: ROR 0.17 (95% CI 0.02–1.23), 0 y behind the freshest-cited agent, 4 citations, MildRipretinib: ROR 0.16 (95% CI 0.08–0.31), 0 y behind the freshest-cited agent, 7 citations, MildPexidartinib: ROR 0.13 (95% CI 0.02–0.93), 3 y behind the freshest-cited agent, 5 citations, MildQuizartinib: ROR 0.13 (95% CI 0.02–0.95), 1 y behind the freshest-cited agent, 6 citations, MildDatopotamab deruxtecan (Dato-DXd): ROR 0.11 (95% CI 0.01–0.78), 1 y behind the freshest-cited agent, 6 citations, ModerateMirvetuximab soravtansine: ROR 0.10 (95% CI 0.03–0.41), 2 y behind the freshest-cited agent, 4 citations, MildAvapritinib: ROR 0.09 (95% CI 0.05–0.17), 5 y behind the freshest-cited agent, 5 citations, MildRevumenib: ROR 0.09 (95% CI 0.01–0.65), 2 y behind the freshest-cited agent, 6 citations, ModerateAvutometinib: ROR 0.08 (95% CI 0.01–0.59), 1 y behind the freshest-cited agent, 7 citations, ModerateElacestrant: ROR 0.07 (95% CI 0.03–0.16), 2 y behind the freshest-cited agent, 4 citations, MildMechlorethamine: ROR 0.04 (95% CI 0.01–0.30), 5 y behind the freshest-cited agent, 4 citations, Moderate

245 of 245 agents shown · filled = significant renal signal (CI lower bound > 1) · faint = no signal · color = severity grade · size = citation count. Reporting, not incidence. FAERS snapshot 2026-11-15.

  • Lifileucel: ROR 8.22 (95% CI 5.37–12.58), 1 y behind the freshest-cited agent, 6 citations, Moderate — signal
  • Clofarabine: ROR 5.51 (95% CI 4.60–6.58), 6 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Interleukin-2 (high-dose): ROR 5.41 (95% CI 4.24–6.90), 15 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Trabectedin: ROR 4.69 (95% CI 3.88–5.67), 7 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Tagraxofusp: ROR 4.37 (95% CI 2.90–6.58), 0 y behind the freshest-cited agent, 7 citations, Moderate — signal
  • Streptozocin: ROR 4.04 (95% CI 2.08–7.87), 0 y behind the freshest-cited agent, 10 citations, Severe — signal
  • Pemetrexed: ROR 3.88 (95% CI 3.69–4.08), 0 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Idecabtagene vicleucel: ROR 3.77 (95% CI 2.82–5.03), 0 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Sirolimus: ROR 3.65 (95% CI 3.34–3.98), 7 y behind the freshest-cited agent, 13 citations, Moderate — signal
  • Adagrasib: ROR 3.48 (95% CI 2.49–4.84), 1 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Cisplatin: ROR 3.43 (95% CI 3.30–3.56), 1 y behind the freshest-cited agent, 21 citations, Severe — signal
  • Retifanlimab: ROR 3.40 (95% CI 1.51–7.67), 1 y behind the freshest-cited agent, 6 citations, Moderate — signal
  • Pamidronate: ROR 3.16 (95% CI 2.65–3.77), 15 y behind the freshest-cited agent, 6 citations, Severe — signal
  • Carfilzomib: ROR 3.11 (95% CI 2.91–3.32), 1 y behind the freshest-cited agent, 13 citations, Severe — signal
  • Cobimetinib: ROR 3.05 (95% CI 2.58–3.61), 4 y behind the freshest-cited agent, 7 citations, Mild — signal
  • Inavolisib: ROR 3.03 (95% CI 1.96–4.68), 2 y behind the freshest-cited agent, 4 citations, Moderate — signal
  • Melphalan: ROR 2.94 (95% CI 2.73–3.16), 1 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Gemtuzumab ozogamicin: ROR 2.82 (95% CI 2.32–3.41), 6 y behind the freshest-cited agent, 4 citations, Moderate — signal
  • Lurbinectedin: ROR 2.78 (95% CI 1.93–3.99), 1 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Fludarabine: ROR 2.66 (95% CI 2.51–2.83), 9 y behind the freshest-cited agent, 11 citations, Moderate — signal
  • Pembrolizumab: ROR 2.59 (95% CI 2.49–2.69), 0 y behind the freshest-cited agent, 15 citations, Moderate — signal
  • Isatuximab: ROR 2.58 (95% CI 2.20–3.02), 1 y behind the freshest-cited agent, 7 citations, Mild — signal
  • Cytarabine: ROR 2.57 (95% CI 2.45–2.70), 3 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Ifosfamide: ROR 2.50 (95% CI 2.29–2.72), 0 y behind the freshest-cited agent, 16 citations, Severe — signal
  • Avelumab: ROR 2.42 (95% CI 1.97–2.97), 0 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Carboplatin: ROR 2.41 (95% CI 2.33–2.50), 2 y behind the freshest-cited agent, 12 citations, Mild — signal
  • Carmustine (BCNU): ROR 2.38 (95% CI 1.98–2.86), 14 y behind the freshest-cited agent, 7 citations, Moderate — signal
  • Gemcitabine: ROR 2.36 (95% CI 2.24–2.50), 0 y behind the freshest-cited agent, 14 citations, Severe — signal
  • Zanidatamab: ROR 2.34 (95% CI 0.57–9.52), 1 y behind the freshest-cited agent, 5 citations, Mild
  • Etoposide: ROR 2.33 (95% CI 2.23–2.45), 5 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Epcoritamab: ROR 2.27 (95% CI 1.81–2.83), 0 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Thiotepa: ROR 2.27 (95% CI 1.99–2.59), 2 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Binimetinib: ROR 2.23 (95% CI 1.93–2.58), 4 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Encorafenib: ROR 2.23 (95% CI 1.96–2.54), 4 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Bendamustine: ROR 2.19 (95% CI 2.01–2.38), 0 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Zoledronic acid: ROR 2.13 (95% CI 2.02–2.25), 0 y behind the freshest-cited agent, 11 citations, Moderate — signal
  • Mogamulizumab: ROR 2.10 (95% CI 1.51–2.90), 5 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Busulfan: ROR 2.09 (95% CI 1.88–2.32), 7 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Pirtobrutinib: ROR 2.09 (95% CI 1.33–3.30), 2 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Ipilimumab: ROR 2.08 (95% CI 1.95–2.22), 0 y behind the freshest-cited agent, 13 citations, Severe — signal
  • Temsirolimus: ROR 2.08 (95% CI 1.70–2.54), 10 y behind the freshest-cited agent, 10 citations, Mild — signal
  • Enfortumab vedotin: ROR 2.07 (95% CI 1.78–2.41), 1 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Vinorelbine: ROR 2.05 (95% CI 1.74–2.41), 2 y behind the freshest-cited agent, 7 citations, Mild — signal
  • Linvoseltamab: ROR 2.04 (95% CI 0.28–14.74), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Atezolizumab: ROR 2.03 (95% CI 1.89–2.19), 1 y behind the freshest-cited agent, 15 citations, Moderate — signal
  • Vemurafenib: ROR 2.01 (95% CI 1.77–2.28), 5 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Oxaliplatin: ROR 2.00 (95% CI 1.90–2.10), 0 y behind the freshest-cited agent, 10 citations, Mild — signal
  • Pegaspargase: ROR 1.99 (95% CI 1.76–2.26), 6 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Inotuzumab ozogamicin: ROR 1.98 (95% CI 1.54–2.55), 3 y behind the freshest-cited agent, 4 citations, Moderate — signal
  • 5-Fluorouracil: ROR 1.96 (95% CI 1.86–2.06), 2 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Nelarabine: ROR 1.96 (95% CI 1.26–3.06), 6 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Capivasertib: ROR 1.94 (95% CI 1.48–2.53), 0 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Pentostatin: ROR 1.94 (95% CI 1.04–3.63), 13 y behind the freshest-cited agent, 11 citations, Moderate — signal
  • Raltitrexed: ROR 1.93 (95% CI 1.09–3.41), 5 y behind the freshest-cited agent, 4 citations, Moderate — signal
  • Relacorilant: ROR 1.93 (95% CI 0.48–7.83), 1 y behind the freshest-cited agent, 3 citations, Mild
  • Procarbazine: ROR 1.92 (95% CI 1.61–2.28), 5 y behind the freshest-cited agent, 4 citations, Moderate — signal
  • Brentuximab vedotin: ROR 1.91 (95% CI 1.67–2.19), 2 y behind the freshest-cited agent, 5 citations, Mild — signal
  • Elotuzumab: ROR 1.90 (95% CI 1.56–2.31), 9 y behind the freshest-cited agent, 4 citations, Mild — signal
  • Vincristine: ROR 1.90 (95% CI 1.75–2.07), 2 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Nivolumab: ROR 1.88 (95% CI 1.80–1.97), 0 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Idelalisib: ROR 1.87 (95% CI 1.57–2.24), 5 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Amsacrine: ROR 1.80 (95% CI 0.93–3.48), 9 y behind the freshest-cited agent, 4 citations, Moderate
  • Cyclophosphamide: ROR 1.80 (95% CI 1.74–1.87), 3 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Denileukin diftitox: ROR 1.80 (95% CI 0.25–12.96), 1 y behind the freshest-cited agent, 8 citations, Moderate
  • Bortezomib: ROR 1.78 (95% CI 1.69–1.86), 1 y behind the freshest-cited agent, 7 citations, Moderate — signal
  • Tisotumab vedotin: ROR 1.78 (95% CI 1.08–2.91), 2 y behind the freshest-cited agent, 4 citations, Mild — signal
  • Gilteritinib: ROR 1.77 (95% CI 1.42–2.22), 0 y behind the freshest-cited agent, 7 citations, Moderate — signal
  • Neratinib: ROR 1.77 (95% CI 1.31–2.39), 4 y behind the freshest-cited agent, 6 citations, Moderate — signal
  • Lisocabtagene maraleucel: ROR 1.74 (95% CI 1.06–2.85), 1 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Arsenic trioxide: ROR 1.70 (95% CI 1.34–2.14), 1 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Bicalutamide: ROR 1.69 (95% CI 1.50–1.90), 6 y behind the freshest-cited agent, 4 citations, Mild — signal
  • Everolimus: ROR 1.69 (95% CI 1.58–1.81), 1 y behind the freshest-cited agent, 12 citations, Moderate — signal
  • Lenvatinib: ROR 1.69 (95% CI 1.56–1.83), 0 y behind the freshest-cited agent, 13 citations, Moderate — signal
  • Cabazitaxel: ROR 1.68 (95% CI 1.31–2.16), 1 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Doxorubicin: ROR 1.68 (95% CI 1.60–1.76), 0 y behind the freshest-cited agent, 12 citations, Mild — signal
  • Relatlimab: ROR 1.66 (95% CI 0.86–3.22), 0 y behind the freshest-cited agent, 7 citations, Moderate
  • Tafasitamab: ROR 1.65 (95% CI 1.21–2.25), 2 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Vinblastine: ROR 1.65 (95% CI 1.18–2.32), 2 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Abemaciclib: ROR 1.63 (95% CI 1.47–1.82), 0 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Mitoxantrone: ROR 1.60 (95% CI 1.32–1.95), 10 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Hydroxyurea: ROR 1.58 (95% CI 1.42–1.75), 6 y behind the freshest-cited agent, 7 citations, Mild — signal
  • Infigratinib: ROR 1.58 (95% CI 0.22–11.39), 1 y behind the freshest-cited agent, 7 citations, Moderate
  • Daratumumab: ROR 1.57 (95% CI 1.45–1.69), 1 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Decitabine: ROR 1.57 (95% CI 1.27–1.94), 3 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Belantamab mafodotin: ROR 1.52 (95% CI 1.13–2.05), 0 y behind the freshest-cited agent, 6 citations, Mild — signal
  • Paclitaxel: ROR 1.52 (95% CI 1.45–1.60), 2 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Cemiplimab: ROR 1.51 (95% CI 1.07–2.13), 0 y behind the freshest-cited agent, 11 citations, Moderate — signal
  • Vandetanib: ROR 1.50 (95% CI 0.94–2.40), 3 y behind the freshest-cited agent, 6 citations, Moderate
  • Irinotecan: ROR 1.48 (95% CI 1.29–1.70), 2 y behind the freshest-cited agent, 5 citations, Mild — signal
  • Momelotinib: ROR 1.48 (95% CI 0.98–2.23), 0 y behind the freshest-cited agent, 7 citations, Mild
  • Asparaginase: ROR 1.47 (95% CI 0.96–2.26), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Afatinib: ROR 1.45 (95% CI 1.19–1.76), 2 y behind the freshest-cited agent, 8 citations, Mild — signal
  • Necitumumab: ROR 1.43 (95% CI 0.64–3.21), 5 y behind the freshest-cited agent, 9 citations, Moderate
  • Bleomycin: ROR 1.42 (95% CI 1.21–1.67), 5 y behind the freshest-cited agent, 7 citations, Mild — signal
  • Entrectinib: ROR 1.40 (95% CI 0.92–2.13), 2 y behind the freshest-cited agent, 7 citations, Mild
  • Glasdegib: ROR 1.40 (95% CI 0.67–2.96), 3 y behind the freshest-cited agent, 6 citations, Mild
  • Rituximab: ROR 1.38 (95% CI 1.34–1.43), 2 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Azacitidine: ROR 1.37 (95% CI 1.25–1.51), 2 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Ibritumomab tiuxetan: ROR 1.37 (95% CI 0.90–2.09), 22 y behind the freshest-cited agent, 6 citations, Mild
  • Tucatinib: ROR 1.37 (95% CI 1.12–1.69), 2 y behind the freshest-cited agent, 4 citations, Mild — signal
  • Obecabtagene autoleucel (Obe-cel): ROR 1.34 (95% CI 0.19–9.63), 1 y behind the freshest-cited agent, 5 citations, Moderate
  • Copanlisib: ROR 1.33 (95% CI 0.55–3.22), 5 y behind the freshest-cited agent, 6 citations, Moderate
  • Dinutuximab: ROR 1.33 (95% CI 0.75–2.34), 1 y behind the freshest-cited agent, 7 citations, Moderate
  • Cetuximab: ROR 1.32 (95% CI 1.20–1.45), 4 y behind the freshest-cited agent, 13 citations, Mild — signal
  • Ceritinib: ROR 1.31 (95% CI 0.94–1.82), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Talquetamab: ROR 1.31 (95% CI 0.90–1.90), 0 y behind the freshest-cited agent, 7 citations, Moderate
  • Abiraterone: ROR 1.29 (95% CI 1.19–1.40), 1 y behind the freshest-cited agent, 11 citations, Moderate — signal
  • Iberdomide: ROR 1.27 (95% CI 0.32–5.14), 1 y behind the freshest-cited agent, 7 citations, Mild
  • Temozolomide: ROR 1.26 (95% CI 1.12–1.42), 1 y behind the freshest-cited agent, 9 citations, Mild — signal
  • Obinutuzumab: ROR 1.24 (95% CI 1.08–1.43), 1 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Panitumumab: ROR 1.24 (95% CI 1.08–1.42), 0 y behind the freshest-cited agent, 10 citations, Mild — signal
  • Zolbetuximab: ROR 1.24 (95% CI 0.80–1.93), 1 y behind the freshest-cited agent, 4 citations, Moderate
  • Docetaxel: ROR 1.19 (95% CI 1.12–1.28), 1 y behind the freshest-cited agent, 10 citations, Mild — signal
  • Tretinoin (ATRA): ROR 1.18 (95% CI 0.97–1.42), 1 y behind the freshest-cited agent, 10 citations, Moderate
  • Bevacizumab: ROR 1.18 (95% CI 1.13–1.24), 7 y behind the freshest-cited agent, 9 citations, Moderate — signal
  • Ixazomib: ROR 1.17 (95% CI 1.05–1.30), 1 y behind the freshest-cited agent, 8 citations, Moderate — signal
  • Mobocertinib: ROR 1.17 (95% CI 0.58–2.34), 1 y behind the freshest-cited agent, 7 citations, Mild
  • Chlorambucil: ROR 1.16 (95% CI 0.87–1.54), 5 y behind the freshest-cited agent, 3 citations, Mild
  • Imlunestrant: ROR 1.16 (95% CI 0.16–8.36), 1 y behind the freshest-cited agent, 2 citations, Mild
  • Selpercatinib: ROR 1.15 (95% CI 0.69–1.92), 0 y behind the freshest-cited agent, 11 citations, Moderate
  • Idarubicin: ROR 1.14 (95% CI 0.68–1.94), 3 y behind the freshest-cited agent, 8 citations, Mild
  • Polatuzumab vedotin: ROR 1.14 (95% CI 0.96–1.36), 2 y behind the freshest-cited agent, 4 citations, Mild
  • Glofitamab: ROR 1.12 (95% CI 0.79–1.58), 2 y behind the freshest-cited agent, 6 citations, Moderate
  • Ponatinib: ROR 1.12 (95% CI 0.93–1.34), 1 y behind the freshest-cited agent, 9 citations, Moderate
  • Dostarlimab: ROR 1.11 (95% CI 0.76–1.64), 1 y behind the freshest-cited agent, 9 citations, Moderate
  • Tepotinib: ROR 1.10 (95% CI 0.55–2.20), 1 y behind the freshest-cited agent, 8 citations, Mild
  • Dabrafenib: ROR 1.08 (95% CI 0.95–1.23), 4 y behind the freshest-cited agent, 9 citations, Mild
  • Dacarbazine: ROR 1.08 (95% CI 0.87–1.33), 25 y behind the freshest-cited agent, 2 citations, Mild
  • Selinexor: ROR 1.08 (95% CI 0.89–1.32), 2 y behind the freshest-cited agent, 10 citations, Moderate
  • Tamoxifen: ROR 1.08 (95% CI 0.85–1.38), 3 y behind the freshest-cited agent, 6 citations, Mild
  • Axitinib: ROR 1.07 (95% CI 0.94–1.22), 3 y behind the freshest-cited agent, 7 citations, Moderate
  • Dactinomycin (actinomycin D): ROR 1.07 (95% CI 0.72–1.59), 9 y behind the freshest-cited agent, 4 citations, Moderate
  • Methotrexate (high-dose): ROR 1.07 (95% CI 1.04–1.10), 1 y behind the freshest-cited agent, 10 citations, Moderate — signal
  • Thalidomide: ROR 1.05 (95% CI 0.91–1.21), 9 y behind the freshest-cited agent, 6 citations, Mild
  • Ribociclib: ROR 1.04 (95% CI 0.94–1.15), 0 y behind the freshest-cited agent, 9 citations, Mild
  • Capecitabine: ROR 1.03 (95% CI 0.96–1.09), 1 y behind the freshest-cited agent, 9 citations, Mild
  • Belzutifan: ROR 1.02 (95% CI 0.64–1.65), 1 y behind the freshest-cited agent, 7 citations, Mild
  • Crizotinib: ROR 1.02 (95% CI 0.84–1.24), 1 y behind the freshest-cited agent, 10 citations, Mild
  • Sorafenib: ROR 1.02 (95% CI 0.89–1.16), 5 y behind the freshest-cited agent, 11 citations, Moderate
  • Topotecan: ROR 1.01 (95% CI 0.80–1.27), 4 y behind the freshest-cited agent, 4 citations, Mild
  • Duvelisib: ROR 1.00 (95% CI 0.52–1.93), 1 y behind the freshest-cited agent, 7 citations, Mild
  • Elranatamab: ROR 0.98 (95% CI 0.65–1.50), 0 y behind the freshest-cited agent, 10 citations, Moderate
  • Mitotane: ROR 0.98 (95% CI 0.63–1.54), 1 y behind the freshest-cited agent, 6 citations, Moderate
  • Durvalumab: ROR 0.96 (95% CI 0.84–1.10), 0 y behind the freshest-cited agent, 11 citations, Moderate
  • Trametinib: ROR 0.94 (95% CI 0.83–1.07), 2 y behind the freshest-cited agent, 10 citations, Moderate
  • Regorafenib: ROR 0.93 (95% CI 0.77–1.12), 1 y behind the freshest-cited agent, 10 citations, Moderate
  • Imatinib: ROR 0.92 (95% CI 0.84–1.02), 2 y behind the freshest-cited agent, 9 citations, Mild
  • Loncastuximab tesirine: ROR 0.92 (95% CI 0.34–2.47), 2 y behind the freshest-cited agent, 5 citations, Moderate
  • Fedratinib: ROR 0.91 (95% CI 0.53–1.57), 6 y behind the freshest-cited agent, 7 citations, Mild
  • Melphalan flufenamide (melflufen): ROR 0.91 (95% CI 0.13–6.54), 0 y behind the freshest-cited agent, 4 citations, Moderate
  • Taletrectinib: ROR 0.89 (95% CI 0.12–6.38), 0 y behind the freshest-cited agent, 4 citations, Mild
  • Eribulin: ROR 0.88 (95% CI 0.63–1.23), 4 y behind the freshest-cited agent, 6 citations, Mild
  • Ramucirumab: ROR 0.88 (95% CI 0.68–1.14), 1 y behind the freshest-cited agent, 11 citations, Moderate
  • Bosutinib: ROR 0.87 (95% CI 0.70–1.08), 1 y behind the freshest-cited agent, 9 citations, Mild
  • Lazertinib: ROR 0.87 (95% CI 0.43–1.75), 2 y behind the freshest-cited agent, 6 citations, Mild
  • Sunitinib: ROR 0.87 (95% CI 0.78–0.96), 0 y behind the freshest-cited agent, 8 citations, Moderate
  • Zanubrutinib: ROR 0.86 (95% CI 0.62–1.19), 2 y behind the freshest-cited agent, 7 citations, Mild
  • Futibatinib: ROR 0.85 (95% CI 0.21–3.42), 2 y behind the freshest-cited agent, 6 citations, Moderate
  • Octreotide: ROR 0.85 (95% CI 0.76–0.96), 2 y behind the freshest-cited agent, 7 citations, Mild
  • Mitomycin C: ROR 0.83 (95% CI 0.58–1.17), 1 y behind the freshest-cited agent, 13 citations, Severe
  • Venetoclax: ROR 0.83 (95% CI 0.76–0.90), 1 y behind the freshest-cited agent, 12 citations, Severe
  • Pralatrexate: ROR 0.81 (95% CI 0.30–2.16), 4 y behind the freshest-cited agent, 8 citations, Moderate
  • Trifluridine/tipiracil: ROR 0.81 (95% CI 0.67–0.99), 1 y behind the freshest-cited agent, 7 citations, Moderate
  • Sacituzumab govitecan: ROR 0.80 (95% CI 0.59–1.09), 0 y behind the freshest-cited agent, 5 citations, Moderate
  • Blinatumomab: ROR 0.79 (95% CI 0.64–0.97), 4 y behind the freshest-cited agent, 8 citations, Moderate
  • Sonidegib: ROR 0.79 (95% CI 0.47–1.33), 3 y behind the freshest-cited agent, 6 citations, Mild
  • Teniposide: ROR 0.79 (95% CI 0.25–2.46), 5 y behind the freshest-cited agent, 5 citations, Mild
  • Nedaplatin: ROR 0.78 (95% CI 0.39–1.56), 3 y behind the freshest-cited agent, 11 citations, Moderate
  • Tebentafusp: ROR 0.78 (95% CI 0.33–1.89), 3 y behind the freshest-cited agent, 4 citations, Moderate
  • Erdafitinib: ROR 0.76 (95% CI 0.41–1.41), 2 y behind the freshest-cited agent, 7 citations, Moderate
  • Naxitamab: ROR 0.75 (95% CI 0.19–3.04), 1 y behind the freshest-cited agent, 8 citations, Moderate
  • Pazopanib: ROR 0.75 (95% CI 0.66–0.86), 2 y behind the freshest-cited agent, 9 citations, Moderate
  • Teclistamab: ROR 0.75 (95% CI 0.48–1.18), 0 y behind the freshest-cited agent, 9 citations, Moderate
  • Capmatinib: ROR 0.74 (95% CI 0.46–1.20), 1 y behind the freshest-cited agent, 8 citations, Mild
  • Ivosidenib: ROR 0.74 (95% CI 0.46–1.19), 2 y behind the freshest-cited agent, 6 citations, Moderate
  • Larotrectinib: ROR 0.74 (95% CI 0.35–1.55), 6 y behind the freshest-cited agent, 7 citations, Mild
  • Rucaparib: ROR 0.74 (95% CI 0.57–0.95), 0 y behind the freshest-cited agent, 7 citations, Mild
  • Alpelisib: ROR 0.73 (95% CI 0.57–0.93), 2 y behind the freshest-cited agent, 7 citations, Moderate
  • Asciminib: ROR 0.73 (95% CI 0.49–1.09), 0 y behind the freshest-cited agent, 7 citations, Mild
  • Ciltacabtagene autoleucel: ROR 0.73 (95% CI 0.56–0.96), 0 y behind the freshest-cited agent, 10 citations, Moderate
  • Estramustine: ROR 0.73 (95% CI 0.23–2.28), 11 y behind the freshest-cited agent, 7 citations, Mild
  • Midostaurin: ROR 0.72 (95% CI 0.43–1.20), 3 y behind the freshest-cited agent, 7 citations, Mild
  • Tarlatamab: ROR 0.72 (95% CI 0.42–1.25), 0 y behind the freshest-cited agent, 8 citations, Moderate
  • Gefitinib: ROR 0.70 (95% CI 0.55–0.89), 8 y behind the freshest-cited agent, 12 citations, Mild
  • Ibrutinib: ROR 0.70 (95% CI 0.65–0.76), 1 y behind the freshest-cited agent, 9 citations, Moderate
  • Lenalidomide: ROR 0.69 (95% CI 0.67–0.72), 1 y behind the freshest-cited agent, 9 citations, Moderate
  • Repotrectinib: ROR 0.69 (95% CI 0.17–2.77), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Ibandronate: ROR 0.66 (95% CI 0.54–0.82), 2 y behind the freshest-cited agent, 9 citations, Mild
  • Pemigatinib: ROR 0.66 (95% CI 0.30–1.48), 1 y behind the freshest-cited agent, 9 citations, Moderate
  • Pomalidomide: ROR 0.66 (95% CI 0.61–0.71), 1 y behind the freshest-cited agent, 7 citations, Mild
  • Dasatinib: ROR 0.62 (95% CI 0.54–0.72), 1 y behind the freshest-cited agent, 9 citations, Moderate
  • Lutetium-177 Dotatate: ROR 0.62 (95% CI 0.45–0.85), 1 y behind the freshest-cited agent, 19 citations, Moderate
  • Darolutamide: ROR 0.61 (95% CI 0.44–0.86), 1 y behind the freshest-cited agent, 5 citations, Mild
  • Nirogacestat: ROR 0.61 (95% CI 0.27–1.37), 2 y behind the freshest-cited agent, 7 citations, Mild
  • Talazoparib: ROR 0.61 (95% CI 0.35–1.08), 0 y behind the freshest-cited agent, 6 citations, Mild
  • Tislelizumab: ROR 0.61 (95% CI 0.47–0.81), 0 y behind the freshest-cited agent, 8 citations, Moderate
  • Mosunetuzumab: ROR 0.60 (95% CI 0.28–1.25), 2 y behind the freshest-cited agent, 8 citations, Moderate
  • Ruxolitinib: ROR 0.58 (95% CI 0.53–0.63), 0 y behind the freshest-cited agent, 7 citations, Mild
  • Nintedanib: ROR 0.57 (95% CI 0.50–0.66), 0 y behind the freshest-cited agent, 9 citations, Mild
  • Zongertinib: ROR 0.56 (95% CI 0.08–4.03), 1 y behind the freshest-cited agent, 4 citations, Mild
  • Radium-223 dichloride: ROR 0.54 (95% CI 0.38–0.78), 4 y behind the freshest-cited agent, 8 citations, Mild
  • Amivantamab: ROR 0.53 (95% CI 0.34–0.82), 1 y behind the freshest-cited agent, 7 citations, Moderate
  • Erlotinib: ROR 0.53 (95% CI 0.44–0.64), 2 y behind the freshest-cited agent, 9 citations, Mild
  • Sotorasib: ROR 0.52 (95% CI 0.33–0.81), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Lomustine (CCNU): ROR 0.51 (95% CI 0.30–0.86), 7 y behind the freshest-cited agent, 9 citations, Moderate
  • Toripalimab: ROR 0.50 (95% CI 0.26–0.96), 2 y behind the freshest-cited agent, 7 citations, Moderate
  • Acalabrutinib: ROR 0.49 (95% CI 0.38–0.62), 1 y behind the freshest-cited agent, 8 citations, Mild
  • Cabozantinib: ROR 0.49 (95% CI 0.43–0.55), 0 y behind the freshest-cited agent, 10 citations, Moderate
  • Fruquintinib: ROR 0.48 (95% CI 0.31–0.74), 1 y behind the freshest-cited agent, 10 citations, Moderate
  • Tivozanib: ROR 0.47 (95% CI 0.22–0.99), 5 y behind the freshest-cited agent, 5 citations, Moderate
  • Brigatinib: ROR 0.46 (95% CI 0.29–0.74), 1 y behind the freshest-cited agent, 9 citations, Mild
  • Trastuzumab deruxtecan: ROR 0.46 (95% CI 0.35–0.60), 0 y behind the freshest-cited agent, 6 citations, Moderate
  • Trastuzumab emtansine (T-DM1): ROR 0.44 (95% CI 0.33–0.61), 0 y behind the freshest-cited agent, 7 citations, Moderate
  • Nilotinib: ROR 0.43 (95% CI 0.36–0.50), 1 y behind the freshest-cited agent, 8 citations, Mild
  • Enzalutamide: ROR 0.42 (95% CI 0.37–0.47), 2 y behind the freshest-cited agent, 9 citations, Mild
  • Cladribine: ROR 0.40 (95% CI 0.29–0.54), 3 y behind the freshest-cited agent, 10 citations, Mild
  • Denosumab: ROR 0.40 (95% CI 0.37–0.42), 1 y behind the freshest-cited agent, 10 citations, Moderate
  • Lanreotide: ROR 0.39 (95% CI 0.28–0.55), 8 y behind the freshest-cited agent, 6 citations, Mild
  • Osimertinib: ROR 0.39 (95% CI 0.33–0.47), 0 y behind the freshest-cited agent, 9 citations, Mild
  • Ziv-aflibercept: ROR 0.37 (95% CI 0.31–0.44), 4 y behind the freshest-cited agent, 8 citations, Moderate
  • Palbociclib: ROR 0.36 (95% CI 0.33–0.40), 0 y behind the freshest-cited agent, 8 citations, Mild
  • Leuprolide: ROR 0.35 (95% CI 0.32–0.40), 2 y behind the freshest-cited agent, 8 citations, Mild
  • Lorlatinib: ROR 0.35 (95% CI 0.24–0.51), 1 y behind the freshest-cited agent, 8 citations, Mild
  • Alectinib: ROR 0.34 (95% CI 0.23–0.50), 0 y behind the freshest-cited agent, 9 citations, Mild
  • Selumetinib: ROR 0.33 (95% CI 0.15–0.75), 3 y behind the freshest-cited agent, 6 citations, Mild
  • Fotemustine: ROR 0.32 (95% CI 0.04–2.29), 11 y behind the freshest-cited agent, 4 citations, Moderate
  • Lutetium-177 PSMA-617 (vipivotide): ROR 0.30 (95% CI 0.22–0.40), 0 y behind the freshest-cited agent, 12 citations, Moderate
  • Olaparib: ROR 0.26 (95% CI 0.20–0.34), 0 y behind the freshest-cited agent, 8 citations, Mild
  • Vismodegib: ROR 0.25 (95% CI 0.17–0.38), 3 y behind the freshest-cited agent, 6 citations, Mild
  • Niraparib: ROR 0.22 (95% CI 0.17–0.29), 0 y behind the freshest-cited agent, 8 citations, Mild
  • Pacritinib: ROR 0.21 (95% CI 0.10–0.45), 1 y behind the freshest-cited agent, 7 citations, Moderate
  • Pralsetinib: ROR 0.21 (95% CI 0.08–0.55), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Enasidenib: ROR 0.19 (95% CI 0.09–0.41), 1 y behind the freshest-cited agent, 8 citations, Moderate
  • Tazemetostat: ROR 0.17 (95% CI 0.06–0.54), 4 y behind the freshest-cited agent, 7 citations, Mild
  • Vorasidenib: ROR 0.17 (95% CI 0.02–1.23), 0 y behind the freshest-cited agent, 4 citations, Mild
  • Ripretinib: ROR 0.16 (95% CI 0.08–0.31), 0 y behind the freshest-cited agent, 7 citations, Mild
  • Pexidartinib: ROR 0.13 (95% CI 0.02–0.93), 3 y behind the freshest-cited agent, 5 citations, Mild
  • Quizartinib: ROR 0.13 (95% CI 0.02–0.95), 1 y behind the freshest-cited agent, 6 citations, Mild
  • Datopotamab deruxtecan (Dato-DXd): ROR 0.11 (95% CI 0.01–0.78), 1 y behind the freshest-cited agent, 6 citations, Moderate
  • Mirvetuximab soravtansine: ROR 0.10 (95% CI 0.03–0.41), 2 y behind the freshest-cited agent, 4 citations, Mild
  • Avapritinib: ROR 0.09 (95% CI 0.05–0.17), 5 y behind the freshest-cited agent, 5 citations, Mild
  • Revumenib: ROR 0.09 (95% CI 0.01–0.65), 2 y behind the freshest-cited agent, 6 citations, Moderate
  • Avutometinib: ROR 0.08 (95% CI 0.01–0.59), 1 y behind the freshest-cited agent, 7 citations, Moderate
  • Elacestrant: ROR 0.07 (95% CI 0.03–0.16), 2 y behind the freshest-cited agent, 4 citations, Mild
  • Mechlorethamine: ROR 0.04 (95% CI 0.01–0.30), 5 y behind the freshest-cited agent, 4 citations, Moderate
Figure 20·Citation staleness (how far each agent's newest reference trails the freshest-cited agent) against its FAERS AKI reporting odds ratio (log); color is the editorial severity grade, size is citation depth.

Timing, regimen & era

When injury declares, how combinations compound it, and how the phenotype shifted by drug generation.

When each agent's kidney injury tends to surface, on a log time axis from one hour to two years. A solid bar with end-caps marks an explicit reported earliest→latest range; a lighter cap-less bar is a window estimate only (no dated range); a dot is a single reported day (a dashed tail marks a lone bound — onset can fall later → or earlier ←); and a faint dashed band is a genuinely variable course. Colored by signature injury and grouped beneath it — distilled from each drug's own cited onset prose.

  • Prerenal / Hemodynamic AKI — Naxitamab: Hyperacute (<24 h), from about day 0
  • Prerenal / Hemodynamic AKI — Paclitaxel: Hyperacute (<24 h), no explicit day range
  • Prerenal / Hemodynamic AKI — Catumaxomab: Acute (~1–7 days), from about day 0
  • Prerenal / Hemodynamic AKI — Ibritumomab tiuxetan: Acute (~1–7 days), from about day 0
  • Prerenal / Hemodynamic AKI — Lifileucel: Acute (~1–7 days), from about day 0
  • Prerenal / Hemodynamic AKI — Afamitresgene autoleucel (Afami-cel): Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Blinatumomab: Acute (~1–7 days), from about day 1
  • Prerenal / Hemodynamic AKI — CAR-T Cell Therapy: Acute (~1–7 days), from about day 1
  • Prerenal / Hemodynamic AKI — Ciltacabtagene autoleucel: Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Idecabtagene vicleucel: Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Linvoseltamab: Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Mosunetuzumab: Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Obecabtagene autoleucel (Obe-cel): Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Pivekimab sunirine: Acute (~1–7 days), day 1–21
  • Prerenal / Hemodynamic AKI — Pomalidomide: Acute (~1–7 days), from about day 1
  • Prerenal / Hemodynamic AKI — Tagraxofusp: Acute (~1–7 days), from about day 1
  • Prerenal / Hemodynamic AKI — Tasonermin: Acute (~1–7 days), day 1–2
  • Prerenal / Hemodynamic AKI — Tebentafusp: Acute (~1–7 days), day 1–21
  • Prerenal / Hemodynamic AKI — Teclistamab: Acute (~1–7 days), day 1–14
  • Prerenal / Hemodynamic AKI — Lisocabtagene maraleucel: Acute (~1–7 days), around day 10
  • Prerenal / Hemodynamic AKI — Afatinib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Brentuximab vedotin: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Capecitabine: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Capivasertib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Clofarabine: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Denileukin diftitox: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Dinutuximab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Elranatamab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Epcoritamab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Gemtuzumab ozogamicin: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Gilteritinib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Glofitamab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Imetelstat: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Inotuzumab ozogamicin: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Interleukin-2 (high-dose): Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Irinotecan: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Midostaurin: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Mobocertinib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Mogamulizumab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Olutasidenib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Pegaspargase: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Polatuzumab vedotin: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Quizartinib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Revumenib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Sevabertinib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Tafasitamab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Talquetamab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Tarlatamab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Tazemetostat: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Thalidomide: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Tisotumab vedotin: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Zanubrutinib: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Zenocutuzumab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Zolbetuximab: Acute (~1–7 days), no explicit day range
  • Prerenal / Hemodynamic AKI — Enasidenib: Subacute (~1–6 weeks), day 1–150
  • Prerenal / Hemodynamic AKI — Tretinoin (ATRA): Subacute (~1–6 weeks), by about day 21
  • Prerenal / Hemodynamic AKI — Pacritinib: Subacute (~1–6 weeks), by about day 56
  • Prerenal / Hemodynamic AKI — Estramustine: Subacute (~1–6 weeks), by about day 60
  • Prerenal / Hemodynamic AKI — Adagrasib: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Alpelisib: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Arsenic trioxide: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Belzutifan: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Ivosidenib: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Loncastuximab tesirine: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Neratinib: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Sotorasib: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Trifluridine/tipiracil: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Ziftomenib: Subacute (~1–6 weeks), no explicit day range
  • Prerenal / Hemodynamic AKI — Docetaxel: Delayed (>6 weeks / cumulative), no explicit day range
  • Prerenal / Hemodynamic AKI — Duvelisib: Delayed (>6 weeks / cumulative), no explicit day range
  • Prerenal / Hemodynamic AKI — Idelalisib: Delayed (>6 weeks / cumulative), no explicit day range
  • Prerenal / Hemodynamic AKI — Nilotinib: Delayed (>6 weeks / cumulative), no explicit day range
  • Prerenal / Hemodynamic AKI — Bleomycin: Variable / unpredictable, from about day 0
  • Prerenal / Hemodynamic AKI — Elotuzumab: Variable / unpredictable, around day 0
  • Prerenal / Hemodynamic AKI — Altretamine (hexamethylmelamine): Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Asparaginase: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Avapritinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Cabazitaxel: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Casdatifan: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Ceritinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Dacarbazine: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Daratumumab: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Elacestrant: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Eribulin: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Glasdegib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Isatuximab: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Mirdametinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Mirvetuximab soravtansine: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Pexidartinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Radium-223 dichloride: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Ruxolitinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Sacituzumab govitecan: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Selumetinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Topotecan: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Tovorafenib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Trametinib: Variable / unpredictable, no explicit day range
  • Prerenal / Hemodynamic AKI — Zanidatamab: Variable / unpredictable, no explicit day range
  • Electrolyte Disturbance — Inavolisib: Hyperacute (<24 h), around day 0
  • Electrolyte Disturbance — Amsacrine: Acute (~1–7 days), from about day 0
  • Electrolyte Disturbance — Dactinomycin (actinomycin D): Acute (~1–7 days), from about day 0
  • Electrolyte Disturbance — Mechlorethamine: Acute (~1–7 days), from about day 0
  • Electrolyte Disturbance — Strontium-89 chloride: Acute (~1–7 days), from about day 0
  • Electrolyte Disturbance — Vinflunine: Acute (~1–7 days), no explicit day range
  • Electrolyte Disturbance — Avutometinib: Subacute (~1–6 weeks), by about day 90
  • Electrolyte Disturbance — Abiraterone: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Amivantamab: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Cetuximab: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Denosumab: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Erdafitinib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Fedratinib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Futibatinib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Gedatolisib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Infigratinib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Mitotane: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Necitumumab: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Panitumumab: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Pemigatinib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Sunvozertinib: Subacute (~1–6 weeks), no explicit day range
  • Electrolyte Disturbance — Imatinib: Delayed (>6 weeks / cumulative), no explicit day range
  • Electrolyte Disturbance — Relacorilant: Delayed (>6 weeks / cumulative), no explicit day range
  • Electrolyte Disturbance — Darolutamide: Variable / unpredictable, day 0–2
  • Electrolyte Disturbance — Lanreotide: Variable / unpredictable, no explicit day range
  • Electrolyte Disturbance — Nirogacestat: Variable / unpredictable, no explicit day range
  • Electrolyte Disturbance — Octreotide: Variable / unpredictable, no explicit day range
  • Electrolyte Disturbance — Teniposide: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Cisplatin: Acute (~1–7 days), by about day 7
  • Acute Tubular Necrosis — Gallium nitrate: Acute (~1–7 days), by about day 7
  • Acute Tubular Necrosis — BRAF / MEK Inhibitors: Acute (~1–7 days), no explicit day range
  • Acute Tubular Necrosis — Carboplatin: Acute (~1–7 days), no explicit day range
  • Acute Tubular Necrosis — Ibandronate: Acute (~1–7 days), no explicit day range
  • Acute Tubular Necrosis — Nedaplatin: Acute (~1–7 days), no explicit day range
  • Acute Tubular Necrosis — Zoledronic acid: Acute (~1–7 days), no explicit day range
  • Acute Tubular Necrosis — Vemurafenib: Subacute (~1–6 weeks), by about day 90
  • Acute Tubular Necrosis — Binimetinib: Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Cobimetinib: Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Datopotamab deruxtecan (Dato-DXd): Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Encorafenib: Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Melphalan flufenamide (melflufen): Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Plicamycin (mithramycin): Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Raltitrexed: Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Sonidegib: Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Telisotuzumab vedotin (Teliso-V): Subacute (~1–6 weeks), no explicit day range
  • Acute Tubular Necrosis — Iobenguane I-131: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Tubular Necrosis — Trabectedin: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Tubular Necrosis — Enfortumab vedotin: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Lenalidomide: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Lurbinectedin: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Pentostatin: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Procarbazine: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Samarium-153 lexidronam: Variable / unpredictable, no explicit day range
  • Acute Tubular Necrosis — Trastuzumab deruxtecan: Variable / unpredictable, no explicit day range
  • Hypertension — Copanlisib: Hyperacute (<24 h), from about day 0
  • Hypertension — Acalabrutinib: Acute (~1–7 days), no explicit day range
  • Hypertension — Axitinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Cabozantinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Enzalutamide: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Fruquintinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Lenvatinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Niraparib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Pralsetinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Ramucirumab: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Regorafenib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Ripretinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Selpercatinib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Sorafenib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Tivozanib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Vandetanib: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — VEGFR Tyrosine Kinase Inhibitors: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Ziv-aflibercept: Subacute (~1–6 weeks), no explicit day range
  • Hypertension — Leuprolide: Delayed (>6 weeks / cumulative), no explicit day range
  • Hypertension — Nintedanib: Delayed (>6 weeks / cumulative), no explicit day range
  • Hypertension — Asciminib: Variable / unpredictable, no explicit day range
  • Hypertension — Ibrutinib: Variable / unpredictable, no explicit day range
  • Hypertension — Ponatinib: Variable / unpredictable, no explicit day range
  • Hypertension — Sunitinib: Variable / unpredictable, no explicit day range
  • Pseudo-AKI — Repotrectinib: Acute (~1–7 days), no explicit day range
  • Pseudo-AKI — Taletrectinib: Acute (~1–7 days), no explicit day range
  • Pseudo-AKI — Vimseltinib: Subacute (~1–6 weeks), day 1–56
  • Pseudo-AKI — Abemaciclib: Subacute (~1–6 weeks), around day 21
  • Pseudo-AKI — Palbociclib: Subacute (~1–6 weeks), around day 32
  • Pseudo-AKI — Ribociclib: Subacute (~1–6 weeks), around day 42
  • Pseudo-AKI — Alectinib: Subacute (~1–6 weeks), by about day 90
  • Pseudo-AKI — Brigatinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Capmatinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Entrectinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Larotrectinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Lorlatinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Olaparib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Rucaparib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Tepotinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Tucatinib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Vorasidenib: Subacute (~1–6 weeks), no explicit day range
  • Pseudo-AKI — Bosutinib: Delayed (>6 weeks / cumulative), no explicit day range
  • Pseudo-AKI — Ensartinib: Variable / unpredictable, no explicit day range
  • Pseudo-AKI — Momelotinib: Variable / unpredictable, no explicit day range
  • Pseudo-AKI — Talazoparib: Variable / unpredictable, no explicit day range
  • Pseudo-AKI — Zongertinib: Variable / unpredictable, no explicit day range
  • Acute Interstitial Nephritis — Bicalutamide: Subacute (~1–6 weeks), no explicit day range
  • Acute Interstitial Nephritis — Retifanlimab: Delayed (>6 weeks / cumulative), around day 90
  • Acute Interstitial Nephritis — Immune Checkpoint Inhibitors: Delayed (>6 weeks / cumulative), around day 98
  • Acute Interstitial Nephritis — Nivolumab: Delayed (>6 weeks / cumulative), around day 98
  • Acute Interstitial Nephritis — Sugemalimab: Delayed (>6 weeks / cumulative), around day 98
  • Acute Interstitial Nephritis — Pembrolizumab: Delayed (>6 weeks / cumulative), around day 105
  • Acute Interstitial Nephritis — Penpulimab: Delayed (>6 weeks / cumulative), around day 105
  • Acute Interstitial Nephritis — Cosibelimab: Delayed (>6 weeks / cumulative), around day 108
  • Acute Interstitial Nephritis — Atezolizumab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Avelumab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Cemiplimab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Dostarlimab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Durvalumab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Relatlimab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Tislelizumab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Toripalimab: Delayed (>6 weeks / cumulative), no explicit day range
  • Acute Interstitial Nephritis — Ipilimumab: Variable / unpredictable, around day 91
  • Acute Interstitial Nephritis — Dabrafenib: Variable / unpredictable, no explicit day range
  • Crystal / Obstructive Nephropathy — Hydroxyurea: Hyperacute (<24 h), day 0–1
  • Crystal / Obstructive Nephropathy — Bendamustine: Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Cytarabine: Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Etoposide: Acute (~1–7 days), day 0–3
  • Crystal / Obstructive Nephropathy — Idarubicin: Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Methotrexate (high-dose): Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Mitoxantrone: Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Obinutuzumab: Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Rituximab: Acute (~1–7 days), day 0–3
  • Crystal / Obstructive Nephropathy — Venetoclax: Acute (~1–7 days), from about day 0
  • Crystal / Obstructive Nephropathy — Cladribine: Acute (~1–7 days), day 1–3
  • Crystal / Obstructive Nephropathy — Odronextamab: Acute (~1–7 days), day 1–14
  • Crystal / Obstructive Nephropathy — Sonrotoclax: Acute (~1–7 days), day 1–3
  • Crystal / Obstructive Nephropathy — Fludarabine: Acute (~1–7 days), no explicit day range
  • Crystal / Obstructive Nephropathy — Nelarabine: Acute (~1–7 days), no explicit day range
  • Crystal / Obstructive Nephropathy — Pirtobrutinib: Acute (~1–7 days), no explicit day range
  • Crystal / Obstructive Nephropathy — Decitabine: Variable / unpredictable, no explicit day range
  • Crystal / Obstructive Nephropathy — Pralatrexate: Variable / unpredictable, no explicit day range
  • Glomerular Injury / Proteinuria — Bevacizumab: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Dasatinib: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Doxorubicin: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Erlotinib: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Everolimus: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Gefitinib: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Interferon-α: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — mTOR Inhibitors: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Pazopanib: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Temsirolimus: Subacute (~1–6 weeks), no explicit day range
  • Glomerular Injury / Proteinuria — Pamidronate: Delayed (>6 weeks / cumulative), day 450–1,440
  • Glomerular Injury / Proteinuria — Belantamab mafodotin: Variable / unpredictable, no explicit day range
  • Glomerular Injury / Proteinuria — Ivonescimab: Variable / unpredictable, no explicit day range
  • Glomerular Injury / Proteinuria — Olverembatinib: Variable / unpredictable, no explicit day range
  • Glomerular Injury / Proteinuria — Sirolimus: Variable / unpredictable, no explicit day range
  • Thrombotic Microangiopathy — Oxaliplatin: Acute (~1–7 days), no explicit day range
  • Thrombotic Microangiopathy — Busulfan: Subacute (~1–6 weeks), no explicit day range
  • Thrombotic Microangiopathy — 5-Fluorouracil: Delayed (>6 weeks / cumulative), no explicit day range
  • Thrombotic Microangiopathy — Doxifluridine: Delayed (>6 weeks / cumulative), no explicit day range
  • Thrombotic Microangiopathy — Gemcitabine: Delayed (>6 weeks / cumulative), no explicit day range
  • Thrombotic Microangiopathy — Mitomycin C: Delayed (>6 weeks / cumulative), no explicit day range
  • Thrombotic Microangiopathy — Tegafur-uracil (UFT): Delayed (>6 weeks / cumulative), no explicit day range
  • Thrombotic Microangiopathy — Bortezomib: Variable / unpredictable, no explicit day range
  • Thrombotic Microangiopathy — Carfilzomib: Variable / unpredictable, no explicit day range
  • Thrombotic Microangiopathy — Carmofur (HCFU): Variable / unpredictable, no explicit day range
  • Thrombotic Microangiopathy — Ixazomib: Variable / unpredictable, no explicit day range
  • Thrombotic Microangiopathy — Moxetumomab pasudotox: Variable / unpredictable, no explicit day range
  • Thrombotic Microangiopathy — Trastuzumab emtansine (T-DM1): Variable / unpredictable, no explicit day range
  • SIADH / Hyponatremia — Cyclophosphamide: Hyperacute (<24 h), from about day 0
  • SIADH / Hyponatremia — Melphalan: Acute (~1–7 days), no explicit day range
  • SIADH / Hyponatremia — Vinblastine: Acute (~1–7 days), no explicit day range
  • SIADH / Hyponatremia — Vincristine: Acute (~1–7 days), no explicit day range
  • SIADH / Hyponatremia — Selinexor: Subacute (~1–6 weeks), no explicit day range
  • SIADH / Hyponatremia — Osimertinib: Delayed (>6 weeks / cumulative), around day 60
  • SIADH / Hyponatremia — Chlorambucil: Variable / unpredictable, no explicit day range
  • SIADH / Hyponatremia — Lazertinib: Variable / unpredictable, no explicit day range
  • SIADH / Hyponatremia — Tamoxifen: Variable / unpredictable, no explicit day range
  • SIADH / Hyponatremia — Temozolomide: Variable / unpredictable, no explicit day range
  • SIADH / Hyponatremia — Vinorelbine: Variable / unpredictable, no explicit day range
  • SIADH / Hyponatremia — Vismodegib: Variable / unpredictable, no explicit day range
  • Chronic Interstitial Nephropathy — Carmustine (BCNU): Delayed (>6 weeks / cumulative), no explicit day range
  • Chronic Interstitial Nephropathy — Fotemustine: Delayed (>6 weeks / cumulative), no explicit day range
  • Chronic Interstitial Nephropathy — Lomustine (CCNU): Delayed (>6 weeks / cumulative), no explicit day range
  • Chronic Interstitial Nephropathy — Lutetium-177 Dotatate: Delayed (>6 weeks / cumulative), no explicit day range
  • Chronic Interstitial Nephropathy — Lutetium-177 PSMA-617 (vipivotide): Delayed (>6 weeks / cumulative), no explicit day range
  • Chronic Interstitial Nephropathy — Nimustine (ACNU): Delayed (>6 weeks / cumulative), no explicit day range
  • Chronic Interstitial Nephropathy — Pemetrexed: Delayed (>6 weeks / cumulative), no explicit day range
  • Fanconi Syndrome — Azacitidine: Acute (~1–7 days), no explicit day range
  • Fanconi Syndrome — Streptozocin: Subacute (~1–6 weeks), no explicit day range
  • Fanconi Syndrome — Ifosfamide: Variable / unpredictable, no explicit day range
  • Hemorrhagic Cystitis — Thiotepa: Variable / unpredictable, no explicit day range
  • Renal Cysts — Crizotinib: Delayed (>6 weeks / cumulative), no explicit day range

Background bands mark the named onset windows on the log time axis: hyperacute (under 24 hours), acute (about 1–7 days), subacute (about 1–6 weeks), and delayed (beyond 6 weeks).

1 h1 d1 wk1 mo1 yrPrerenal / Hemodynamic AKIPrerenal / Hemody…97 · 23 variableNaxitamabNaxitamab: Hyperacute (<24 h), from about day 0PaclitaxelPaclitaxel: Hyperacute (<24 h), no explicit day rangeCatumaxomabCatumaxomab: Acute (~1–7 days), from about day 0Ibritumomab tiuxetanIbritumomab tiuxetan: Acute (~1–7 days), from about day 0LifileucelLifileucel: Acute (~1–7 days), from about day 0Afamitresgene autole…Afamitresgene autoleucel (Afami-cel)Afamitresgene autoleucel (Afami-cel): Acute (~1–7 days), day 1–14BlinatumomabBlinatumomab: Acute (~1–7 days), from about day 1CAR-T Cell TherapyCAR-T Cell Therapy: Acute (~1–7 days), from about day 1Ciltacabtagene autol…Ciltacabtagene autoleucelCiltacabtagene autoleucel: Acute (~1–7 days), day 1–14Idecabtagene vicleuc…Idecabtagene vicleucelIdecabtagene vicleucel: Acute (~1–7 days), day 1–14LinvoseltamabLinvoseltamab: Acute (~1–7 days), day 1–14MosunetuzumabMosunetuzumab: Acute (~1–7 days), day 1–14Obecabtagene autoleu…Obecabtagene autoleucel (Obe-cel)Obecabtagene autoleucel (Obe-cel): Acute (~1–7 days), day 1–14Pivekimab sunirinePivekimab sunirine: Acute (~1–7 days), day 1–21PomalidomidePomalidomide: Acute (~1–7 days), from about day 1TagraxofuspTagraxofusp: Acute (~1–7 days), from about day 1TasonerminTasonermin: Acute (~1–7 days), day 1–2TebentafuspTebentafusp: Acute (~1–7 days), day 1–21TeclistamabTeclistamab: Acute (~1–7 days), day 1–14Lisocabtagene marale…Lisocabtagene maraleucelLisocabtagene maraleucel: Acute (~1–7 days), around day 10AfatinibAfatinib: Acute (~1–7 days), no explicit day rangeBrentuximab vedotinBrentuximab vedotin: Acute (~1–7 days), no explicit day rangeCapecitabineCapecitabine: Acute (~1–7 days), no explicit day rangeCapivasertibCapivasertib: Acute (~1–7 days), no explicit day rangeClofarabineClofarabine: Acute (~1–7 days), no explicit day rangeDenileukin diftitoxDenileukin diftitox: Acute (~1–7 days), no explicit day rangeDinutuximabDinutuximab: Acute (~1–7 days), no explicit day rangeElranatamabElranatamab: Acute (~1–7 days), no explicit day rangeEpcoritamabEpcoritamab: Acute (~1–7 days), no explicit day rangeGemtuzumab ozogamicinGemtuzumab ozogamicin: Acute (~1–7 days), no explicit day rangeGilteritinibGilteritinib: Acute (~1–7 days), no explicit day rangeGlofitamabGlofitamab: Acute (~1–7 days), no explicit day rangeImetelstatImetelstat: Acute (~1–7 days), no explicit day rangeInotuzumab ozogamicinInotuzumab ozogamicin: Acute (~1–7 days), no explicit day rangeInterleukin-2 (high-…Interleukin-2 (high-dose)Interleukin-2 (high-dose): Acute (~1–7 days), no explicit day rangeIrinotecanIrinotecan: Acute (~1–7 days), no explicit day rangeMidostaurinMidostaurin: Acute (~1–7 days), no explicit day rangeMobocertinibMobocertinib: Acute (~1–7 days), no explicit day rangeMogamulizumabMogamulizumab: Acute (~1–7 days), no explicit day rangeOlutasidenibOlutasidenib: Acute (~1–7 days), no explicit day rangePegaspargasePegaspargase: Acute (~1–7 days), no explicit day rangePolatuzumab vedotinPolatuzumab vedotin: Acute (~1–7 days), no explicit day rangeQuizartinibQuizartinib: Acute (~1–7 days), no explicit day rangeRevumenibRevumenib: Acute (~1–7 days), no explicit day rangeSevabertinibSevabertinib: Acute (~1–7 days), no explicit day rangeTafasitamabTafasitamab: Acute (~1–7 days), no explicit day rangeTalquetamabTalquetamab: Acute (~1–7 days), no explicit day rangeTarlatamabTarlatamab: Acute (~1–7 days), no explicit day rangeTazemetostatTazemetostat: Acute (~1–7 days), no explicit day rangeThalidomideThalidomide: Acute (~1–7 days), no explicit day rangeTisotumab vedotinTisotumab vedotin: Acute (~1–7 days), no explicit day rangeZanubrutinibZanubrutinib: Acute (~1–7 days), no explicit day rangeZenocutuzumabZenocutuzumab: Acute (~1–7 days), no explicit day rangeZolbetuximabZolbetuximab: Acute (~1–7 days), no explicit day rangeEnasidenibEnasidenib: Subacute (~1–6 weeks), day 1–150Tretinoin (ATRA)Tretinoin (ATRA): Subacute (~1–6 weeks), by about day 21PacritinibPacritinib: Subacute (~1–6 weeks), by about day 56EstramustineEstramustine: Subacute (~1–6 weeks), by about day 60AdagrasibAdagrasib: Subacute (~1–6 weeks), no explicit day rangeAlpelisibAlpelisib: Subacute (~1–6 weeks), no explicit day rangeArsenic trioxideArsenic trioxide: Subacute (~1–6 weeks), no explicit day rangeBelzutifanBelzutifan: Subacute (~1–6 weeks), no explicit day rangeIvosidenibIvosidenib: Subacute (~1–6 weeks), no explicit day rangeLoncastuximab tesiri…Loncastuximab tesirineLoncastuximab tesirine: Subacute (~1–6 weeks), no explicit day rangeNeratinibNeratinib: Subacute (~1–6 weeks), no explicit day rangeSotorasibSotorasib: Subacute (~1–6 weeks), no explicit day rangeTrifluridine/tipirac…Trifluridine/tipiracilTrifluridine/tipiracil: Subacute (~1–6 weeks), no explicit day rangeZiftomenibZiftomenib: Subacute (~1–6 weeks), no explicit day rangeDocetaxelDocetaxel: Delayed (>6 weeks / cumulative), no explicit day rangeDuvelisibDuvelisib: Delayed (>6 weeks / cumulative), no explicit day rangeIdelalisibIdelalisib: Delayed (>6 weeks / cumulative), no explicit day rangeNilotinibNilotinib: Delayed (>6 weeks / cumulative), no explicit day rangeBleomycinBleomycin: Variable / unpredictable, from about day 0ElotuzumabElotuzumab: Variable / unpredictable, around day 0Altretamine (hexamet…Altretamine (hexamethylmelamine)Altretamine (hexamethylmelamine): Variable / unpredictable, no explicit day rangeAsparaginaseAsparaginase: Variable / unpredictable, no explicit day rangeAvapritinibAvapritinib: Variable / unpredictable, no explicit day rangeCabazitaxelCabazitaxel: Variable / unpredictable, no explicit day rangeCasdatifanCasdatifan: Variable / unpredictable, no explicit day rangeCeritinibCeritinib: Variable / unpredictable, no explicit day rangeDacarbazineDacarbazine: Variable / unpredictable, no explicit day rangeDaratumumabDaratumumab: Variable / unpredictable, no explicit day rangeElacestrantElacestrant: Variable / unpredictable, no explicit day rangeEribulinEribulin: Variable / unpredictable, no explicit day rangeGlasdegibGlasdegib: Variable / unpredictable, no explicit day rangeIsatuximabIsatuximab: Variable / unpredictable, no explicit day rangeMirdametinibMirdametinib: Variable / unpredictable, no explicit day rangeMirvetuximab soravta…Mirvetuximab soravtansineMirvetuximab soravtansine: Variable / unpredictable, no explicit day rangePexidartinibPexidartinib: Variable / unpredictable, no explicit day rangeRadium-223 dichlorideRadium-223 dichloride: Variable / unpredictable, no explicit day rangeRuxolitinibRuxolitinib: Variable / unpredictable, no explicit day rangeSacituzumab govitecanSacituzumab govitecan: Variable / unpredictable, no explicit day rangeSelumetinibSelumetinib: Variable / unpredictable, no explicit day rangeTopotecanTopotecan: Variable / unpredictable, no explicit day rangeTovorafenibTovorafenib: Variable / unpredictable, no explicit day rangeTrametinibTrametinib: Variable / unpredictable, no explicit day rangeZanidatamabZanidatamab: Variable / unpredictable, no explicit day rangeElectrolyte DisturbanceElectrolyte Distu…28 · 4 variableInavolisibInavolisib: Hyperacute (<24 h), around day 0AmsacrineAmsacrine: Acute (~1–7 days), from about day 0Dactinomycin (actino…Dactinomycin (actinomycin D)Dactinomycin (actinomycin D): Acute (~1–7 days), from about day 0MechlorethamineMechlorethamine: Acute (~1–7 days), from about day 0Strontium-89 chlorideStrontium-89 chloride: Acute (~1–7 days), from about day 0VinflunineVinflunine: Acute (~1–7 days), no explicit day rangeAvutometinibAvutometinib: Subacute (~1–6 weeks), by about day 90AbirateroneAbiraterone: Subacute (~1–6 weeks), no explicit day rangeAmivantamabAmivantamab: Subacute (~1–6 weeks), no explicit day rangeCetuximabCetuximab: Subacute (~1–6 weeks), no explicit day rangeDenosumabDenosumab: Subacute (~1–6 weeks), no explicit day rangeErdafitinibErdafitinib: Subacute (~1–6 weeks), no explicit day rangeFedratinibFedratinib: Subacute (~1–6 weeks), no explicit day rangeFutibatinibFutibatinib: Subacute (~1–6 weeks), no explicit day rangeGedatolisibGedatolisib: Subacute (~1–6 weeks), no explicit day rangeInfigratinibInfigratinib: Subacute (~1–6 weeks), no explicit day rangeMitotaneMitotane: Subacute (~1–6 weeks), no explicit day rangeNecitumumabNecitumumab: Subacute (~1–6 weeks), no explicit day rangePanitumumabPanitumumab: Subacute (~1–6 weeks), no explicit day rangePemigatinibPemigatinib: Subacute (~1–6 weeks), no explicit day rangeSunvozertinibSunvozertinib: Subacute (~1–6 weeks), no explicit day rangeImatinibImatinib: Delayed (>6 weeks / cumulative), no explicit day rangeRelacorilantRelacorilant: Delayed (>6 weeks / cumulative), no explicit day rangeDarolutamideDarolutamide: Variable / unpredictable, day 0–2LanreotideLanreotide: Variable / unpredictable, no explicit day rangeNirogacestatNirogacestat: Variable / unpredictable, no explicit day rangeOctreotideOctreotide: Variable / unpredictable, no explicit day rangeTeniposideTeniposide: Variable / unpredictable, no explicit day rangeAcute Tubular NecrosisAcute Tubular Nec…26 · 7 variableCisplatinCisplatin: Acute (~1–7 days), by about day 7Gallium nitrateGallium nitrate: Acute (~1–7 days), by about day 7BRAF / MEK InhibitorsBRAF / MEK Inhibitors: Acute (~1–7 days), no explicit day rangeCarboplatinCarboplatin: Acute (~1–7 days), no explicit day rangeIbandronateIbandronate: Acute (~1–7 days), no explicit day rangeNedaplatinNedaplatin: Acute (~1–7 days), no explicit day rangeZoledronic acidZoledronic acid: Acute (~1–7 days), no explicit day rangeVemurafenibVemurafenib: Subacute (~1–6 weeks), by about day 90BinimetinibBinimetinib: Subacute (~1–6 weeks), no explicit day rangeCobimetinibCobimetinib: Subacute (~1–6 weeks), no explicit day rangeDatopotamab deruxtec…Datopotamab deruxtecan (Dato-DXd)Datopotamab deruxtecan (Dato-DXd): Subacute (~1–6 weeks), no explicit day rangeEncorafenibEncorafenib: Subacute (~1–6 weeks), no explicit day rangeMelphalan flufenamid…Melphalan flufenamide (melflufen)Melphalan flufenamide (melflufen): Subacute (~1–6 weeks), no explicit day rangePlicamycin (mithramy…Plicamycin (mithramycin)Plicamycin (mithramycin): Subacute (~1–6 weeks), no explicit day rangeRaltitrexedRaltitrexed: Subacute (~1–6 weeks), no explicit day rangeSonidegibSonidegib: Subacute (~1–6 weeks), no explicit day rangeTelisotuzumab vedoti…Telisotuzumab vedotin (Teliso-V)Telisotuzumab vedotin (Teliso-V): Subacute (~1–6 weeks), no explicit day rangeIobenguane I-131Iobenguane I-131: Delayed (>6 weeks / cumulative), no explicit day rangeTrabectedinTrabectedin: Delayed (>6 weeks / cumulative), no explicit day rangeEnfortumab vedotinEnfortumab vedotin: Variable / unpredictable, no explicit day rangeLenalidomideLenalidomide: Variable / unpredictable, no explicit day rangeLurbinectedinLurbinectedin: Variable / unpredictable, no explicit day rangePentostatinPentostatin: Variable / unpredictable, no explicit day rangeProcarbazineProcarbazine: Variable / unpredictable, no explicit day rangeSamarium-153 lexidro…Samarium-153 lexidronamSamarium-153 lexidronam: Variable / unpredictable, no explicit day rangeTrastuzumab deruxtec…Trastuzumab deruxtecanTrastuzumab deruxtecan: Variable / unpredictable, no explicit day rangeHypertensionHypertension24 · 4 variableCopanlisibCopanlisib: Hyperacute (<24 h), from about day 0AcalabrutinibAcalabrutinib: Acute (~1–7 days), no explicit day rangeAxitinibAxitinib: Subacute (~1–6 weeks), no explicit day rangeCabozantinibCabozantinib: Subacute (~1–6 weeks), no explicit day rangeEnzalutamideEnzalutamide: Subacute (~1–6 weeks), no explicit day rangeFruquintinibFruquintinib: Subacute (~1–6 weeks), no explicit day rangeLenvatinibLenvatinib: Subacute (~1–6 weeks), no explicit day rangeNiraparibNiraparib: Subacute (~1–6 weeks), no explicit day rangePralsetinibPralsetinib: Subacute (~1–6 weeks), no explicit day rangeRamucirumabRamucirumab: Subacute (~1–6 weeks), no explicit day rangeRegorafenibRegorafenib: Subacute (~1–6 weeks), no explicit day rangeRipretinibRipretinib: Subacute (~1–6 weeks), no explicit day rangeSelpercatinibSelpercatinib: Subacute (~1–6 weeks), no explicit day rangeSorafenibSorafenib: Subacute (~1–6 weeks), no explicit day rangeTivozanibTivozanib: Subacute (~1–6 weeks), no explicit day rangeVandetanibVandetanib: Subacute (~1–6 weeks), no explicit day rangeVEGFR Tyrosine Kinas…VEGFR Tyrosine Kinase InhibitorsVEGFR Tyrosine Kinase Inhibitors: Subacute (~1–6 weeks), no explicit day rangeZiv-afliberceptZiv-aflibercept: Subacute (~1–6 weeks), no explicit day rangeLeuprolideLeuprolide: Delayed (>6 weeks / cumulative), no explicit day rangeNintedanibNintedanib: Delayed (>6 weeks / cumulative), no explicit day rangeAsciminibAsciminib: Variable / unpredictable, no explicit day rangeIbrutinibIbrutinib: Variable / unpredictable, no explicit day rangePonatinibPonatinib: Variable / unpredictable, no explicit day rangeSunitinibSunitinib: Variable / unpredictable, no explicit day rangePseudo-AKIPseudo-AKI22 · 4 variableRepotrectinibRepotrectinib: Acute (~1–7 days), no explicit day rangeTaletrectinibTaletrectinib: Acute (~1–7 days), no explicit day rangeVimseltinibVimseltinib: Subacute (~1–6 weeks), day 1–56AbemaciclibAbemaciclib: Subacute (~1–6 weeks), around day 21PalbociclibPalbociclib: Subacute (~1–6 weeks), around day 32RibociclibRibociclib: Subacute (~1–6 weeks), around day 42AlectinibAlectinib: Subacute (~1–6 weeks), by about day 90BrigatinibBrigatinib: Subacute (~1–6 weeks), no explicit day rangeCapmatinibCapmatinib: Subacute (~1–6 weeks), no explicit day rangeEntrectinibEntrectinib: Subacute (~1–6 weeks), no explicit day rangeLarotrectinibLarotrectinib: Subacute (~1–6 weeks), no explicit day rangeLorlatinibLorlatinib: Subacute (~1–6 weeks), no explicit day rangeOlaparibOlaparib: Subacute (~1–6 weeks), no explicit day rangeRucaparibRucaparib: Subacute (~1–6 weeks), no explicit day rangeTepotinibTepotinib: Subacute (~1–6 weeks), no explicit day rangeTucatinibTucatinib: Subacute (~1–6 weeks), no explicit day rangeVorasidenibVorasidenib: Subacute (~1–6 weeks), no explicit day rangeBosutinibBosutinib: Delayed (>6 weeks / cumulative), no explicit day rangeEnsartinibEnsartinib: Variable / unpredictable, no explicit day rangeMomelotinibMomelotinib: Variable / unpredictable, no explicit day rangeTalazoparibTalazoparib: Variable / unpredictable, no explicit day rangeZongertinibZongertinib: Variable / unpredictable, no explicit day rangeAcute Interstitial NephritisAcute Interstitia…18 · 1 variableBicalutamideBicalutamide: Subacute (~1–6 weeks), no explicit day rangeRetifanlimabRetifanlimab: Delayed (>6 weeks / cumulative), around day 90Immune Checkpoint In…Immune Checkpoint InhibitorsImmune Checkpoint Inhibitors: Delayed (>6 weeks / cumulative), around day 98NivolumabNivolumab: Delayed (>6 weeks / cumulative), around day 98SugemalimabSugemalimab: Delayed (>6 weeks / cumulative), around day 98PembrolizumabPembrolizumab: Delayed (>6 weeks / cumulative), around day 105PenpulimabPenpulimab: Delayed (>6 weeks / cumulative), around day 105CosibelimabCosibelimab: Delayed (>6 weeks / cumulative), around day 108AtezolizumabAtezolizumab: Delayed (>6 weeks / cumulative), no explicit day rangeAvelumabAvelumab: Delayed (>6 weeks / cumulative), no explicit day rangeCemiplimabCemiplimab: Delayed (>6 weeks / cumulative), no explicit day rangeDostarlimabDostarlimab: Delayed (>6 weeks / cumulative), no explicit day rangeDurvalumabDurvalumab: Delayed (>6 weeks / cumulative), no explicit day rangeRelatlimabRelatlimab: Delayed (>6 weeks / cumulative), no explicit day rangeTislelizumabTislelizumab: Delayed (>6 weeks / cumulative), no explicit day rangeToripalimabToripalimab: Delayed (>6 weeks / cumulative), no explicit day rangeIpilimumabIpilimumab: Variable / unpredictable, around day 91DabrafenibDabrafenib: Variable / unpredictable, no explicit day rangeCrystal / Obstructive NephropathyCrystal / Obstruc…18 · 2 variableHydroxyureaHydroxyurea: Hyperacute (<24 h), day 0–1BendamustineBendamustine: Acute (~1–7 days), from about day 0CytarabineCytarabine: Acute (~1–7 days), from about day 0EtoposideEtoposide: Acute (~1–7 days), day 0–3IdarubicinIdarubicin: Acute (~1–7 days), from about day 0Methotrexate (high-d…Methotrexate (high-dose)Methotrexate (high-dose): Acute (~1–7 days), from about day 0MitoxantroneMitoxantrone: Acute (~1–7 days), from about day 0ObinutuzumabObinutuzumab: Acute (~1–7 days), from about day 0RituximabRituximab: Acute (~1–7 days), day 0–3VenetoclaxVenetoclax: Acute (~1–7 days), from about day 0CladribineCladribine: Acute (~1–7 days), day 1–3OdronextamabOdronextamab: Acute (~1–7 days), day 1–14SonrotoclaxSonrotoclax: Acute (~1–7 days), day 1–3FludarabineFludarabine: Acute (~1–7 days), no explicit day rangeNelarabineNelarabine: Acute (~1–7 days), no explicit day rangePirtobrutinibPirtobrutinib: Acute (~1–7 days), no explicit day rangeDecitabineDecitabine: Variable / unpredictable, no explicit day rangePralatrexatePralatrexate: Variable / unpredictable, no explicit day rangeGlomerular Injury / ProteinuriaGlomerular Injury…15 · 4 variableBevacizumabBevacizumab: Subacute (~1–6 weeks), no explicit day rangeDasatinibDasatinib: Subacute (~1–6 weeks), no explicit day rangeDoxorubicinDoxorubicin: Subacute (~1–6 weeks), no explicit day rangeErlotinibErlotinib: Subacute (~1–6 weeks), no explicit day rangeEverolimusEverolimus: Subacute (~1–6 weeks), no explicit day rangeGefitinibGefitinib: Subacute (~1–6 weeks), no explicit day rangeInterferon-αInterferon-α: Subacute (~1–6 weeks), no explicit day rangemTOR InhibitorsmTOR Inhibitors: Subacute (~1–6 weeks), no explicit day rangePazopanibPazopanib: Subacute (~1–6 weeks), no explicit day rangeTemsirolimusTemsirolimus: Subacute (~1–6 weeks), no explicit day rangePamidronate›Pamidronate: Delayed (>6 weeks / cumulative), day 450–1,440Belantamab mafodotinBelantamab mafodotin: Variable / unpredictable, no explicit day rangeIvonescimabIvonescimab: Variable / unpredictable, no explicit day rangeOlverembatinibOlverembatinib: Variable / unpredictable, no explicit day rangeSirolimusSirolimus: Variable / unpredictable, no explicit day rangeThrombotic MicroangiopathyThrombotic Microa…13 · 6 variableOxaliplatinOxaliplatin: Acute (~1–7 days), no explicit day rangeBusulfanBusulfan: Subacute (~1–6 weeks), no explicit day range5-Fluorouracil5-Fluorouracil: Delayed (>6 weeks / cumulative), no explicit day rangeDoxifluridineDoxifluridine: Delayed (>6 weeks / cumulative), no explicit day rangeGemcitabineGemcitabine: Delayed (>6 weeks / cumulative), no explicit day rangeMitomycin CMitomycin C: Delayed (>6 weeks / cumulative), no explicit day rangeTegafur-uracil (UFT)Tegafur-uracil (UFT): Delayed (>6 weeks / cumulative), no explicit day rangeBortezomibBortezomib: Variable / unpredictable, no explicit day rangeCarfilzomibCarfilzomib: Variable / unpredictable, no explicit day rangeCarmofur (HCFU)Carmofur (HCFU): Variable / unpredictable, no explicit day rangeIxazomibIxazomib: Variable / unpredictable, no explicit day rangeMoxetumomab pasudotoxMoxetumomab pasudotox: Variable / unpredictable, no explicit day rangeTrastuzumab emtansin…Trastuzumab emtansine (T-DM1)Trastuzumab emtansine (T-DM1): Variable / unpredictable, no explicit day rangeSIADH / HyponatremiaSIADH / Hyponatre…12 · 6 variableCyclophosphamideCyclophosphamide: Hyperacute (<24 h), from about day 0MelphalanMelphalan: Acute (~1–7 days), no explicit day rangeVinblastineVinblastine: Acute (~1–7 days), no explicit day rangeVincristineVincristine: Acute (~1–7 days), no explicit day rangeSelinexorSelinexor: Subacute (~1–6 weeks), no explicit day rangeOsimertinibOsimertinib: Delayed (>6 weeks / cumulative), around day 60ChlorambucilChlorambucil: Variable / unpredictable, no explicit day rangeLazertinibLazertinib: Variable / unpredictable, no explicit day rangeTamoxifenTamoxifen: Variable / unpredictable, no explicit day rangeTemozolomideTemozolomide: Variable / unpredictable, no explicit day rangeVinorelbineVinorelbine: Variable / unpredictable, no explicit day rangeVismodegibVismodegib: Variable / unpredictable, no explicit day rangeChronic Interstitial NephropathyChronic Interstit…7Carmustine (BCNU)Carmustine (BCNU): Delayed (>6 weeks / cumulative), no explicit day rangeFotemustineFotemustine: Delayed (>6 weeks / cumulative), no explicit day rangeLomustine (CCNU)Lomustine (CCNU): Delayed (>6 weeks / cumulative), no explicit day rangeLutetium-177 DotatateLutetium-177 Dotatate: Delayed (>6 weeks / cumulative), no explicit day rangeLutetium-177 PSMA-61…Lutetium-177 PSMA-617 (vipivotide)Lutetium-177 PSMA-617 (vipivotide): Delayed (>6 weeks / cumulative), no explicit day rangeNimustine (ACNU)Nimustine (ACNU): Delayed (>6 weeks / cumulative), no explicit day rangePemetrexedPemetrexed: Delayed (>6 weeks / cumulative), no explicit day rangeFanconi SyndromeFanconi Syndrome3 · 1 variableAzacitidineAzacitidine: Acute (~1–7 days), no explicit day rangeStreptozocinStreptozocin: Subacute (~1–6 weeks), no explicit day rangeIfosfamideIfosfamide: Variable / unpredictable, no explicit day rangeHemorrhagic CystitisHemorrhagic Cysti…1 · 1 variableThiotepaThiotepa: Variable / unpredictable, no explicit day rangeRenal CystsRenal Cysts1CrizotinibCrizotinib: Delayed (>6 weeks / cumulative), no explicit day range
Prerenal / Hemodynamic AKIElectrolyte DisturbanceAcute Tubular NecrosisHypertensionPseudo-AKIAcute Interstitial NephritisCrystal / Obstructive NephropathyGlomerular Injury / ProteinuriaThrombotic MicroangiopathySIADH / HyponatremiaChronic Interstitial NephropathyFanconi SyndromeHemorrhagic CystitisRenal Cysts

285 agents carrying a structured onset overlay, 65 with explicit day numbers · solid capped bar = reported earliest→latest days · light cap-less bar = window estimate only (no dated range) · dot = single reported day (dashed tail = a lone earliest/latest bound) · hollow dot = typical within a range · dashed band = variable course · › = extends beyond the 2-year axis · faint background bands mark the named onset windows (hyperacute / acute / subacute / delayed). Log time axis (1 h → 2 yr). Distilled from each drug's own cited onset prose — clinical timing, not a guarantee.

Figure 21·For each agent carrying a structured onset overlay, when its signature kidney injury tends to declare after dosing — on a log time axis from one hour to two years, grouped by injury and filterable by signature injury (compare two or three onset profiles side by side). The hub's first clinical-time figure (the streamgraph and approval-to-signal lag are calendar time); distilled from each drug's own cited onset prose.

How soon after dosing each drug-class family's kidney injury tends to declare. Read across a row for a family's onset spread, down a column for the classes that share a tempo.

Show:
raw agent counts, shaded across the whole grid
Number of agents in each drug-class family (rows) whose signature injury declares in each onset window (columns).
Drug-class family
Hyperacute<24 hcolumn total: 6
Acute1–7 dcolumn total: 87
Subacute1–6 wkcolumn total: 84
Delayed>6 wkcolumn total: 41
Variablespreadcolumn total: 67
Other targeted agents, row total 38
Other targeted agents, Hyperacute: 0 agents (0% of row)
Other targeted agents, Acute: 13 agents (34% of row)
Other targeted agents, Subacute: 14 agents (37% of row)
Other targeted agents, Delayed: 1 agent (3% of row)
Other targeted agents, Variable: 10 agents (26% of row)
Alkylating agents, row total 21
Alkylating agents, Hyperacute: 1 agent (5% of row)
Alkylating agents, Acute: 3 agents (14% of row)
Alkylating agents, Subacute: 4 agents (19% of row)
Alkylating agents, Delayed: 5 agents (24% of row)
Alkylating agents, Variable: 8 agents (38% of row)
Antimetabolites, row total 20
Antimetabolites, Hyperacute: 1 agent (5% of row)
Antimetabolites, Acute: 8 agents (40% of row)
Antimetabolites, Subacute: 2 agents (10% of row)
Antimetabolites, Delayed: 5 agents (25% of row)
Antimetabolites, Variable: 4 agents (20% of row)
Checkpoint inhibitors, row total 17
Checkpoint inhibitors, Hyperacute: 0 agents (0% of row)
Checkpoint inhibitors, Acute: 0 agents (0% of row)
Checkpoint inhibitors, Subacute: 0 agents (0% of row)
Checkpoint inhibitors, Delayed: 15 agents (88% of row)
Checkpoint inhibitors, Variable: 2 agents (12% of row)
Monoclonal antibodies (other), row total 16
Monoclonal antibodies (other), Hyperacute: 1 agent (6% of row)
Monoclonal antibodies (other), Acute: 7 agents (44% of row)
Monoclonal antibodies (other), Subacute: 4 agents (25% of row)
Monoclonal antibodies (other), Delayed: 0 agents (0% of row)
Monoclonal antibodies (other), Variable: 4 agents (25% of row)
Anti-angiogenic (VEGF), row total 15
Anti-angiogenic (VEGF), Hyperacute: 0 agents (0% of row)
Anti-angiogenic (VEGF), Acute: 0 agents (0% of row)
Anti-angiogenic (VEGF), Subacute: 13 agents (87% of row)
Anti-angiogenic (VEGF), Delayed: 1 agent (7% of row)
Anti-angiogenic (VEGF), Variable: 1 agent (7% of row)
Antibody-drug conjugates, row total 15
Antibody-drug conjugates, Hyperacute: 0 agents (0% of row)
Antibody-drug conjugates, Acute: 6 agents (40% of row)
Antibody-drug conjugates, Subacute: 3 agents (20% of row)
Antibody-drug conjugates, Delayed: 0 agents (0% of row)
Antibody-drug conjugates, Variable: 6 agents (40% of row)
Other kinase inhibitors, row total 13
Other kinase inhibitors, Hyperacute: 0 agents (0% of row)
Other kinase inhibitors, Acute: 3 agents (23% of row)
Other kinase inhibitors, Subacute: 6 agents (46% of row)
Other kinase inhibitors, Delayed: 0 agents (0% of row)
Other kinase inhibitors, Variable: 4 agents (31% of row)
ALK / ROS1 / MET / TRK inhibitors, row total 12
ALK / ROS1 / MET / TRK inhibitors, Hyperacute: 0 agents (0% of row)
ALK / ROS1 / MET / TRK inhibitors, Acute: 2 agents (17% of row)
ALK / ROS1 / MET / TRK inhibitors, Subacute: 7 agents (58% of row)
ALK / ROS1 / MET / TRK inhibitors, Delayed: 1 agent (8% of row)
ALK / ROS1 / MET / TRK inhibitors, Variable: 2 agents (17% of row)
Bispecifics / T-cell engagers, row total 12
Bispecifics / T-cell engagers, Hyperacute: 0 agents (0% of row)
Bispecifics / T-cell engagers, Acute: 12 agents (100% of row)
Bispecifics / T-cell engagers, Subacute: 0 agents (0% of row)
Bispecifics / T-cell engagers, Delayed: 0 agents (0% of row)
Bispecifics / T-cell engagers, Variable: 0 agents (0% of row)
BRAF / MEK inhibitors, row total 11
BRAF / MEK inhibitors, Hyperacute: 0 agents (0% of row)
BRAF / MEK inhibitors, Acute: 1 agent (9% of row)
BRAF / MEK inhibitors, Subacute: 5 agents (45% of row)
BRAF / MEK inhibitors, Delayed: 0 agents (0% of row)
BRAF / MEK inhibitors, Variable: 5 agents (45% of row)
EGFR / HER2 inhibitors, row total 11
EGFR / HER2 inhibitors, Hyperacute: 0 agents (0% of row)
EGFR / HER2 inhibitors, Acute: 3 agents (27% of row)
EGFR / HER2 inhibitors, Subacute: 5 agents (45% of row)
EGFR / HER2 inhibitors, Delayed: 1 agent (9% of row)
EGFR / HER2 inhibitors, Variable: 2 agents (18% of row)
Hormonal / endocrine, row total 10
Hormonal / endocrine, Hyperacute: 0 agents (0% of row)
Hormonal / endocrine, Acute: 0 agents (0% of row)
Hormonal / endocrine, Subacute: 4 agents (40% of row)
Hormonal / endocrine, Delayed: 1 agent (10% of row)
Hormonal / endocrine, Variable: 5 agents (50% of row)
Microtubule inhibitors, row total 8
Microtubule inhibitors, Hyperacute: 1 agent (13% of row)
Microtubule inhibitors, Acute: 3 agents (38% of row)
Microtubule inhibitors, Subacute: 0 agents (0% of row)
Microtubule inhibitors, Delayed: 1 agent (13% of row)
Microtubule inhibitors, Variable: 3 agents (38% of row)
Antitumor antibiotics, row total 7
Antitumor antibiotics, Hyperacute: 0 agents (0% of row)
Antitumor antibiotics, Acute: 3 agents (43% of row)
Antitumor antibiotics, Subacute: 2 agents (29% of row)
Antitumor antibiotics, Delayed: 1 agent (14% of row)
Antitumor antibiotics, Variable: 1 agent (14% of row)
BCR-ABL inhibitors, row total 7
BCR-ABL inhibitors, Hyperacute: 0 agents (0% of row)
BCR-ABL inhibitors, Acute: 0 agents (0% of row)
BCR-ABL inhibitors, Subacute: 1 agent (14% of row)
BCR-ABL inhibitors, Delayed: 3 agents (43% of row)
BCR-ABL inhibitors, Variable: 3 agents (43% of row)
PI3K / AKT inhibitors, row total 7
PI3K / AKT inhibitors, Hyperacute: 2 agents (29% of row)
PI3K / AKT inhibitors, Acute: 1 agent (14% of row)
PI3K / AKT inhibitors, Subacute: 2 agents (29% of row)
PI3K / AKT inhibitors, Delayed: 2 agents (29% of row)
PI3K / AKT inhibitors, Variable: 0 agents (0% of row)
Radiopharmaceuticals, row total 7
Radiopharmaceuticals, Hyperacute: 0 agents (0% of row)
Radiopharmaceuticals, Acute: 2 agents (29% of row)
Radiopharmaceuticals, Subacute: 0 agents (0% of row)
Radiopharmaceuticals, Delayed: 3 agents (43% of row)
Radiopharmaceuticals, Variable: 2 agents (29% of row)
CAR-T cell therapy, row total 5
CAR-T cell therapy, Hyperacute: 0 agents (0% of row)
CAR-T cell therapy, Acute: 5 agents (100% of row)
CAR-T cell therapy, Subacute: 0 agents (0% of row)
CAR-T cell therapy, Delayed: 0 agents (0% of row)
CAR-T cell therapy, Variable: 0 agents (0% of row)
Cytokines & enzymes, row total 5
Cytokines & enzymes, Hyperacute: 0 agents (0% of row)
Cytokines & enzymes, Acute: 3 agents (60% of row)
Cytokines & enzymes, Subacute: 1 agent (20% of row)
Cytokines & enzymes, Delayed: 0 agents (0% of row)
Cytokines & enzymes, Variable: 1 agent (20% of row)
Topoisomerase inhibitors, row total 5
Topoisomerase inhibitors, Hyperacute: 0 agents (0% of row)
Topoisomerase inhibitors, Acute: 3 agents (60% of row)
Topoisomerase inhibitors, Subacute: 0 agents (0% of row)
Topoisomerase inhibitors, Delayed: 0 agents (0% of row)
Topoisomerase inhibitors, Variable: 2 agents (40% of row)
Bisphosphonates & bone, row total 4
Bisphosphonates & bone, Hyperacute: 0 agents (0% of row)
Bisphosphonates & bone, Acute: 2 agents (50% of row)
Bisphosphonates & bone, Subacute: 1 agent (25% of row)
Bisphosphonates & bone, Delayed: 1 agent (25% of row)
Bisphosphonates & bone, Variable: 0 agents (0% of row)
BTK inhibitors, row total 4
BTK inhibitors, Hyperacute: 0 agents (0% of row)
BTK inhibitors, Acute: 3 agents (75% of row)
BTK inhibitors, Subacute: 0 agents (0% of row)
BTK inhibitors, Delayed: 0 agents (0% of row)
BTK inhibitors, Variable: 1 agent (25% of row)
FGFR inhibitors, row total 4
FGFR inhibitors, Hyperacute: 0 agents (0% of row)
FGFR inhibitors, Acute: 0 agents (0% of row)
FGFR inhibitors, Subacute: 4 agents (100% of row)
FGFR inhibitors, Delayed: 0 agents (0% of row)
FGFR inhibitors, Variable: 0 agents (0% of row)
mTOR inhibitors, row total 4
mTOR inhibitors, Hyperacute: 0 agents (0% of row)
mTOR inhibitors, Acute: 0 agents (0% of row)
mTOR inhibitors, Subacute: 3 agents (75% of row)
mTOR inhibitors, Delayed: 0 agents (0% of row)
mTOR inhibitors, Variable: 1 agent (25% of row)
Platinum agents, row total 4
Platinum agents, Hyperacute: 0 agents (0% of row)
Platinum agents, Acute: 4 agents (100% of row)
Platinum agents, Subacute: 0 agents (0% of row)
Platinum agents, Delayed: 0 agents (0% of row)
Platinum agents, Variable: 0 agents (0% of row)
CDK4/6 inhibitors, row total 3
CDK4/6 inhibitors, Hyperacute: 0 agents (0% of row)
CDK4/6 inhibitors, Acute: 0 agents (0% of row)
CDK4/6 inhibitors, Subacute: 3 agents (100% of row)
CDK4/6 inhibitors, Delayed: 0 agents (0% of row)
CDK4/6 inhibitors, Variable: 0 agents (0% of row)

Agent counts per class family × onset window · color depth scales within the grid · column totals above each window.

Figure 22·Each drug-class family by how fast its signature kidney injury tends to declare — from hyperacute (<24 h) to a genuinely variable course. Fast-declaring families cluster on the left, slow-burn/cumulative ones on the right; distilled from each agent's cited onset prose.

How the count of agents per drug generation distributes across kidney injuries — a composition view by era (left), not calendar year. Each ribbon's width is the number of agents from that era carrying that signature injury (right). What the ribbons actually show: the established generation spreads across the structural lesions — tubular necrosis, thrombotic microangiopathy, crystal and chronic interstitial disease — while the frontier concentrates into prerenal/hemodynamic AKI above all, with electrolyte disturbance and pseudo-AKI its next-widest ribbons, and carries no TMA agent at all. Hover or tap a node to isolate its flows.

  • Established era → Acute Tubular Necrosis: 6 agents
  • Established era → Acute Interstitial Nephritis: 5 agents
  • Established era → Thrombotic Microangiopathy: 3 agents
  • Established era → Glomerular Injury / Proteinuria: 3 agents
  • Established era → Electrolyte Disturbance: 9 agents
  • Established era → Crystal / Obstructive Nephropathy: 3 agents
  • Established era → Hypertension: 3 agents
  • Established era → Prerenal / Hemodynamic AKI: 13 agents
  • Established era → SIADH / Hyponatremia: 2 agents
  • Established era → Chronic Interstitial Nephropathy: 2 agents
  • Recent era → Acute Tubular Necrosis: 7 agents
  • Recent era → Acute Interstitial Nephritis: 7 agents
  • Recent era → Thrombotic Microangiopathy: 2 agents
  • Recent era → Glomerular Injury / Proteinuria: 1 agents
  • Recent era → Electrolyte Disturbance: 6 agents
  • Recent era → Crystal / Obstructive Nephropathy: 1 agents
  • Recent era → Hypertension: 4 agents
  • Recent era → Prerenal / Hemodynamic AKI: 21 agents
  • Recent era → SIADH / Hyponatremia: 1 agents
  • Recent era → Pseudo-AKI: 8 agents
  • Recent era → Chronic Interstitial Nephropathy: 1 agents
  • Frontier era → Acute Tubular Necrosis: 2 agents
  • Frontier era → Acute Interstitial Nephritis: 1 agents
  • Frontier era → Glomerular Injury / Proteinuria: 1 agents
  • Frontier era → Electrolyte Disturbance: 6 agents
  • Frontier era → Crystal / Obstructive Nephropathy: 2 agents
  • Frontier era → Prerenal / Hemodynamic AKI: 27 agents
  • Frontier era → SIADH / Hyponatremia: 1 agents
  • Frontier era → Pseudo-AKI: 4 agents
  • Frontier era → Chronic Interstitial Nephropathy: 1 agents
  • Investigational era → Prerenal / Hemodynamic AKI: 1 agents
Frontier → Acute Tubular Necrosis: 2 agentsRecent → Acute Tubular Necrosis: 7 agentsEstablished → Acute Tubular Necrosis: 6 agentsFrontier → Acute Interstitial Nephritis: 1 agentsEstablished → Acute Interstitial Nephritis: 5 agentsRecent → Acute Interstitial Nephritis: 7 agentsRecent → Thrombotic Microangiopathy: 2 agentsEstablished → Thrombotic Microangiopathy: 3 agentsFrontier → Glomerular Injury / Proteinuria: 1 agentsRecent → Glomerular Injury / Proteinuria: 1 agentsEstablished → Glomerular Injury / Proteinuria: 3 agentsFrontier → Electrolyte Disturbance: 6 agentsRecent → Electrolyte Disturbance: 6 agentsEstablished → Electrolyte Disturbance: 9 agentsFrontier → Crystal / Obstructive Nephropathy: 2 agentsRecent → Crystal / Obstructive Nephropathy: 1 agentsEstablished → Crystal / Obstructive Nephropathy: 3 agentsRecent → Hypertension: 4 agentsEstablished → Hypertension: 3 agentsRecent → Prerenal / Hemodynamic AKI: 21 agentsFrontier → Prerenal / Hemodynamic AKI: 27 agentsInvestigational → Prerenal / Hemodynamic AKI: 1 agentsEstablished → Prerenal / Hemodynamic AKI: 13 agentsFrontier → SIADH / Hyponatremia: 1 agentsRecent → SIADH / Hyponatremia: 1 agentsEstablished → SIADH / Hyponatremia: 2 agentsFrontier → Pseudo-AKI: 4 agentsRecent → Pseudo-AKI: 8 agentsRecent → Chronic Interstitial Nephropathy: 1 agentsFrontier → Chronic Interstitial Nephropathy: 1 agentsEstablished → Chronic Interstitial Nephropathy: 2 agentsEstablished 49Recent 59Frontier 45Investigational 1Acute Tubular NecrosisAcute Interstitial NephritisThrombotic MicroangiopathyGlomerular Injury / ProteinuriaElectrolyte DisturbanceCrystal / Obstructive NephropathyHypertensionPrerenal / Hemodynamic AKISIADH / HyponatremiaPseudo-AKIChronic Interstitial Nephropathy

Ribbon width = agents flowing from each era to their signature injury · numbers = agents per era. A further 146 catalog agents carry no recorded era and are not in this figure — the ribbons total 154 agents, not the full catalog.

Figure 23·Composition by DRUG ERA, not calendar year: how many AGENTS from each generation (established → frontier) carry each signature injury. Where the streamgraph counts citations over time, this counts drugs per era — read the established generation's spread across the structural lesions against the frontier's concentration in prerenal/hemodynamic injury above all, with electrolyte disturbance and pseudo-AKI its next-widest ribbons.

Assemble a regimen and see where kidney risk compounds. Each bar is a kidney injury; its length is how many of the chosen agents carry it, at any tier. Injuries two or more drugs carry, at least one above the rare tier, are the additive hazards to watch (⚠).

Hemorrhagic Cystitis
Cisplatin: Hemorrhagic Cystitis, rare injury
Gemcitabine: Hemorrhagic Cystitis, rare injury
Cisplatin, Gemcitabine
2
Acute Tubular Necrosis
Cisplatin: Acute Tubular Necrosis, primary injury
Cisplatin
1
Thrombotic Microangiopathy
Gemcitabine: Thrombotic Microangiopathy, primary injury
Gemcitabine
1
Glomerular Injury / Proteinuria
Gemcitabine: Glomerular Injury / Proteinuria, rare injury
Gemcitabine
1
Electrolyte Disturbance
Cisplatin: Electrolyte Disturbance, secondary injury
Cisplatin
1
Fanconi Syndrome
Cisplatin: Fanconi Syndrome, rare injury
Cisplatin
1
Hypertension
Gemcitabine: Hypertension, secondary injury
Gemcitabine
1
Prerenal / Hemodynamic AKI
Cisplatin: Prerenal / Hemodynamic AKI, rare injury
Cisplatin
1
SIADH / Hyponatremia
Cisplatin: SIADH / Hyponatremia, rare injury
Cisplatin
1

2 agents selected · bar segments = contributing drugs (opacity = injury tier: primary / secondary / rare) · ⚠ marks injuries two or more agents carry, at least one above the rare tier (compounding risk). Educational — not a dosing tool.

Figure 24·An interactive regimen builder: for each kidney injury, how many chosen agents carry it — surfacing where combined risk compounds.

The documented anti-cancer combinations whose kidney risk compounds beyond either drug alone. Each arc joins two agents whose co-administration drives a kidney injury — colored by that phenotype — and a node grows with the number of combinations it anchors. Read the hubs that recur across regimens and the phenotype that dominates the synergies. Hover, tap, or focus a node for its combinations; the complementary agent-count view is the regimen injury-stacking figure above.

  • Cisplatin + gemcitabine — synergistic thrombotic microangiopathy (PMID 33980166)
  • Mitomycin C + 5-fluorouracil — carcinoma-associated TMA/HUS (PMID 36706238)
  • Ipilimumab + nivolumab — dual checkpoint blockade, higher immune AIN (PMID 31896554)
  • Cisplatin + ifosfamide — potentiated proximal-tubular injury / Fanconi (PMID 8232077)
  • Cisplatin + pemetrexed — additive proximal-tubular ATN (PMID 32505078)
  • Cisplatin + high-dose methotrexate — platinum tubular injury delays MTX clearance (PMID 31169759)
  • Sunitinib + bevacizumab — dual VEGF blockade, MAHA/TMA plus hypertension & proteinuria (PMID 19402058)
Cisplatin + gemcitabine — synergistic thrombotic microangiopathy (PMID 33980166)Gemcitabine + bevacizumab — VEGF-blockade-potentiated TMA (PMID 36706238)Mitomycin C + 5-fluorouracil — carcinoma-associated TMA/HUS (PMID 36706238)Ipilimumab + nivolumab — dual checkpoint blockade, higher immune AIN (PMID 31896554)Cisplatin + ifosfamide — potentiated proximal-tubular injury / Fanconi (PMID 8232077)Cisplatin + pemetrexed — additive proximal-tubular ATN (PMID 32505078)Cisplatin + high-dose methotrexate — platinum tubular injury delays MTX clearance (PMID 31169759)Sunitinib + bevacizumab — dual VEGF blockade, MAHA/TMA plus hypertension & proteinuria (PMID 19402058)CisplatinCisplatinGemcitabineGemcitabineBevacizumabBevacizumabSunitinibSunitinibIfosfamideIfosfamideMethotrexate (high-dose)Methotrexate (high-dose)PemetrexedPemetrexed5-Fluorouracil5-FluorouracilMitomycin CMitomycin CIpilimumabIpilimumabNivolumabNivolumab
  • Acute Tubular Necrosis
  • Acute Interstitial Nephritis
  • Thrombotic Microangiopathy
  • Fanconi Syndrome

7 verified combinations across 11 agents, thrombotic microangiopathy the most common synergy phenotype (3). Hover, tap, or focus a node to trace its combinations.

Node size = combinations anchored · arc color = the compounded kidney injury · every edge is PMID-grounded. Documented additive/synergistic risk, not a per-patient prediction.

Figure 25·The documented anti-cancer combinations whose kidney risk compounds beyond either agent alone, drawn as a network: nodes are agents (sized by how many combinations they anchor), arcs are verified synergistic pairs colored by the injury they drive. Cisplatin is the recurring hub and thrombotic microangiopathy the dominant synergy phenotype; every edge is PMID-grounded. The regimen-level companion to the injury-stacking figure above.

Data Studio

Build your own view of the whole nephrotoxicity dataset. Pick a chart, choose the axes, color and group by any dimension, and filter to a slice — then read what falls out. Every field comes from the same citation-grounded catalog behind the rest of the atlas.

Chart
r = 0.18Cisplatin · Citations 21, FAERS AKI ROR 3.43Carboplatin · Citations 12, FAERS AKI ROR 2.41Oxaliplatin · Citations 10, FAERS AKI ROR 2Nedaplatin · Citations 11, FAERS AKI ROR 0.78Ifosfamide · Citations 16, FAERS AKI ROR 2.5Cyclophosphamide · Citations 8, FAERS AKI ROR 1.8Streptozocin · Citations 10, FAERS AKI ROR 4.04Carmustine (BCNU) · Citations 7, FAERS AKI ROR 2.38Lomustine (CCNU) · Citations 9, FAERS AKI ROR 0.51Bendamustine · Citations 10, FAERS AKI ROR 2.19Melphalan · Citations 8, FAERS AKI ROR 2.94Busulfan · Citations 8, FAERS AKI ROR 2.09Temozolomide · Citations 9, FAERS AKI ROR 1.26Dacarbazine · Citations 2, FAERS AKI ROR 1.08Thiotepa · Citations 8, FAERS AKI ROR 2.27Methotrexate (high-dose) · Citations 10, FAERS AKI ROR 1.07Pemetrexed · Citations 10, FAERS AKI ROR 3.88Gemcitabine · Citations 14, FAERS AKI ROR 2.36Pralatrexate · Citations 8, FAERS AKI ROR 0.815-Fluorouracil · Citations 9, FAERS AKI ROR 1.96Capecitabine · Citations 9, FAERS AKI ROR 1.03Cytarabine · Citations 9, FAERS AKI ROR 2.57Fludarabine · Citations 11, FAERS AKI ROR 2.66Clofarabine · Citations 10, FAERS AKI ROR 5.51Azacitidine · Citations 8, FAERS AKI ROR 1.37Decitabine · Citations 6, FAERS AKI ROR 1.57Hydroxyurea · Citations 7, FAERS AKI ROR 1.58Nelarabine · Citations 6, FAERS AKI ROR 1.96Mitomycin C · Citations 13, FAERS AKI ROR 0.83Doxorubicin · Citations 12, FAERS AKI ROR 1.68Bevacizumab · Citations 9, FAERS AKI ROR 1.18Ramucirumab · Citations 11, FAERS AKI ROR 0.88Ziv-aflibercept · Citations 8, FAERS AKI ROR 0.37Lenvatinib · Citations 13, FAERS AKI ROR 1.69Cabozantinib · Citations 10, FAERS AKI ROR 0.49Regorafenib · Citations 10, FAERS AKI ROR 0.93Vandetanib · Citations 6, FAERS AKI ROR 1.5Tivozanib · Citations 5, FAERS AKI ROR 0.47Nintedanib · Citations 9, FAERS AKI ROR 0.57Sirolimus · Citations 13, FAERS AKI ROR 3.65Cetuximab · Citations 13, FAERS AKI ROR 1.32Panitumumab · Citations 10, FAERS AKI ROR 1.24Necitumumab · Citations 9, FAERS AKI ROR 1.43Osimertinib · Citations 9, FAERS AKI ROR 0.39Erlotinib · Citations 9, FAERS AKI ROR 0.53Gefitinib · Citations 12, FAERS AKI ROR 0.7Afatinib · Citations 8, FAERS AKI ROR 1.45Atezolizumab · Citations 15, FAERS AKI ROR 2.03Durvalumab · Citations 11, FAERS AKI ROR 0.96Avelumab · Citations 9, FAERS AKI ROR 2.42Cemiplimab · Citations 11, FAERS AKI ROR 1.51Dostarlimab · Citations 9, FAERS AKI ROR 1.11Blinatumomab · Citations 8, FAERS AKI ROR 0.79Teclistamab · Citations 9, FAERS AKI ROR 0.75Talquetamab · Citations 7, FAERS AKI ROR 1.31Elranatamab · Citations 10, FAERS AKI ROR 0.98Mosunetuzumab · Citations 8, FAERS AKI ROR 0.6Epcoritamab · Citations 9, FAERS AKI ROR 2.27Glofitamab · Citations 6, FAERS AKI ROR 1.12Enfortumab vedotin · Citations 10, FAERS AKI ROR 2.07Sacituzumab govitecan · Citations 5, FAERS AKI ROR 0.8Trastuzumab deruxtecan · Citations 6, FAERS AKI ROR 0.46Trastuzumab emtansine (T-DM1) · Citations 7, FAERS AKI ROR 0.44Brentuximab vedotin · Citations 5, FAERS AKI ROR 1.91Polatuzumab vedotin · Citations 4, FAERS AKI ROR 1.14Belantamab mafodotin · Citations 6, FAERS AKI ROR 1.52Mirvetuximab soravtansine · Citations 4, FAERS AKI ROR 0.1Tisotumab vedotin · Citations 4, FAERS AKI ROR 1.78Tebentafusp · Citations 4, FAERS AKI ROR 0.78Zolbetuximab · Citations 4, FAERS AKI ROR 1.24Elacestrant · Citations 4, FAERS AKI ROR 0.07Imlunestrant · Citations 2, FAERS AKI ROR 1.16Relatlimab · Citations 7, FAERS AKI ROR 1.66Gemtuzumab ozogamicin · Citations 4, FAERS AKI ROR 2.82Inotuzumab ozogamicin · Citations 4, FAERS AKI ROR 1.98Carfilzomib · Citations 13, FAERS AKI ROR 3.11Bortezomib · Citations 7, FAERS AKI ROR 1.78Ixazomib · Citations 8, FAERS AKI ROR 1.17Lenalidomide · Citations 9, FAERS AKI ROR 0.69Pomalidomide · Citations 7, FAERS AKI ROR 0.66Thalidomide · Citations 6, FAERS AKI ROR 1.05Iberdomide · Citations 7, FAERS AKI ROR 1.27Imatinib · Citations 9, FAERS AKI ROR 0.92Dasatinib · Citations 9, FAERS AKI ROR 0.62Nilotinib · Citations 8, FAERS AKI ROR 0.43Ponatinib · Citations 9, FAERS AKI ROR 1.12Bosutinib · Citations 9, FAERS AKI ROR 0.87Crizotinib · Citations 10, FAERS AKI ROR 1.02Alectinib · Citations 9, FAERS AKI ROR 0.34Brigatinib · Citations 9, FAERS AKI ROR 0.46Lorlatinib · Citations 8, FAERS AKI ROR 0.35Ceritinib · Citations 6, FAERS AKI ROR 1.31Olaparib · Citations 8, FAERS AKI ROR 0.26Niraparib · Citations 8, FAERS AKI ROR 0.22Rucaparib · Citations 7, FAERS AKI ROR 0.74Talazoparib · Citations 6, FAERS AKI ROR 0.61Encorafenib · Citations 9, FAERS AKI ROR 2.23Cobimetinib · Citations 7, FAERS AKI ROR 3.05Binimetinib · Citations 9, FAERS AKI ROR 2.23Selumetinib · Citations 6, FAERS AKI ROR 0.33Erdafitinib · Citations 7, FAERS AKI ROR 0.76Pemigatinib · Citations 9, FAERS AKI ROR 0.66Futibatinib · Citations 6, FAERS AKI ROR 0.85Selpercatinib · Citations 11, FAERS AKI ROR 1.15Pralsetinib · Citations 6, FAERS AKI ROR 0.21Capmatinib · Citations 8, FAERS AKI ROR 0.74Tepotinib · Citations 8, FAERS AKI ROR 1.1Ivosidenib · Citations 6, FAERS AKI ROR 0.74Enasidenib · Citations 8, FAERS AKI ROR 0.19Sotorasib · Citations 6, FAERS AKI ROR 0.52Adagrasib · Citations 6, FAERS AKI ROR 3.48Belzutifan · Citations 7, FAERS AKI ROR 1.02Ibrutinib · Citations 9, FAERS AKI ROR 0.7Acalabrutinib · Citations 8, FAERS AKI ROR 0.49Zanubrutinib · Citations 7, FAERS AKI ROR 0.86Venetoclax · Citations 12, FAERS AKI ROR 0.83Tretinoin (ATRA) · Citations 10, FAERS AKI ROR 1.18Arsenic trioxide · Citations 9, FAERS AKI ROR 1.7Rituximab · Citations 8, FAERS AKI ROR 1.38Obinutuzumab · Citations 8, FAERS AKI ROR 1.24Daratumumab · Citations 9, FAERS AKI ROR 1.57Isatuximab · Citations 7, FAERS AKI ROR 2.58Abemaciclib · Citations 8, FAERS AKI ROR 1.63Palbociclib · Citations 8, FAERS AKI ROR 0.36Ribociclib · Citations 9, FAERS AKI ROR 1.04Tagraxofusp · Citations 7, FAERS AKI ROR 4.37Irinotecan · Citations 5, FAERS AKI ROR 1.48Topotecan · Citations 4, FAERS AKI ROR 1.01Etoposide · Citations 9, FAERS AKI ROR 2.33Vincristine · Citations 9, FAERS AKI ROR 1.9Vinblastine · Citations 8, FAERS AKI ROR 1.65Vinorelbine · Citations 7, FAERS AKI ROR 2.05Paclitaxel · Citations 9, FAERS AKI ROR 1.52Docetaxel · Citations 10, FAERS AKI ROR 1.19Cabazitaxel · Citations 9, FAERS AKI ROR 1.68Eribulin · Citations 6, FAERS AKI ROR 0.88Asparaginase · Citations 6, FAERS AKI ROR 1.47Interleukin-2 (high-dose) · Citations 10, FAERS AKI ROR 5.41Zoledronic acid · Citations 11, FAERS AKI ROR 2.13Pamidronate · Citations 6, FAERS AKI ROR 3.16Denosumab · Citations 10, FAERS AKI ROR 0.4Ibandronate · Citations 9, FAERS AKI ROR 0.66Abiraterone · Citations 11, FAERS AKI ROR 1.29Enzalutamide · Citations 9, FAERS AKI ROR 0.42Relacorilant · Citations 3, FAERS AKI ROR 1.93Tamoxifen · Citations 6, FAERS AKI ROR 1.08Leuprolide · Citations 8, FAERS AKI ROR 0.35Amivantamab · Citations 7, FAERS AKI ROR 0.53Datopotamab deruxtecan (Dato-DXd) · Citations 6, FAERS AKI ROR 0.11Tarlatamab · Citations 8, FAERS AKI ROR 0.72Revumenib · Citations 6, FAERS AKI ROR 0.09Fruquintinib · Citations 10, FAERS AKI ROR 0.48Pirtobrutinib · Citations 6, FAERS AKI ROR 2.09Capivasertib · Citations 8, FAERS AKI ROR 1.94Nirogacestat · Citations 7, FAERS AKI ROR 0.61Lazertinib · Citations 6, FAERS AKI ROR 0.87Repotrectinib · Citations 6, FAERS AKI ROR 0.69Zanidatamab · Citations 5, FAERS AKI ROR 2.34Lifileucel · Citations 6, FAERS AKI ROR 8.22Tucatinib · Citations 4, FAERS AKI ROR 1.37Ruxolitinib · Citations 7, FAERS AKI ROR 0.58Momelotinib · Citations 7, FAERS AKI ROR 1.48Entrectinib · Citations 7, FAERS AKI ROR 1.4Quizartinib · Citations 6, FAERS AKI ROR 0.13Zongertinib · Citations 4, FAERS AKI ROR 0.56Lutetium-177 Dotatate · Citations 19, FAERS AKI ROR 0.62Lutetium-177 PSMA-617 (vipivotide) · Citations 12, FAERS AKI ROR 0.3Ibritumomab tiuxetan · Citations 6, FAERS AKI ROR 1.37Radium-223 dichloride · Citations 8, FAERS AKI ROR 0.54Trabectedin · Citations 10, FAERS AKI ROR 4.69Lurbinectedin · Citations 8, FAERS AKI ROR 2.78Denileukin diftitox · Citations 8, FAERS AKI ROR 1.8Selinexor · Citations 10, FAERS AKI ROR 1.08Cladribine · Citations 10, FAERS AKI ROR 0.4Pentostatin · Citations 11, FAERS AKI ROR 1.94Pegaspargase · Citations 8, FAERS AKI ROR 1.99Infigratinib · Citations 7, FAERS AKI ROR 1.58Mobocertinib · Citations 7, FAERS AKI ROR 1.17Larotrectinib · Citations 7, FAERS AKI ROR 0.74Idecabtagene vicleucel · Citations 9, FAERS AKI ROR 3.77Ciltacabtagene autoleucel · Citations 10, FAERS AKI ROR 0.73Mitoxantrone · Citations 9, FAERS AKI ROR 1.6Idarubicin · Citations 8, FAERS AKI ROR 1.14Estramustine · Citations 7, FAERS AKI ROR 0.73Alpelisib · Citations 7, FAERS AKI ROR 0.73Idelalisib · Citations 6, FAERS AKI ROR 1.87Duvelisib · Citations 7, FAERS AKI ROR 1Copanlisib · Citations 6, FAERS AKI ROR 1.33Vismodegib · Citations 6, FAERS AKI ROR 0.25Sonidegib · Citations 6, FAERS AKI ROR 0.79Glasdegib · Citations 6, FAERS AKI ROR 1.4Gilteritinib · Citations 7, FAERS AKI ROR 1.77Midostaurin · Citations 7, FAERS AKI ROR 0.72Asciminib · Citations 7, FAERS AKI ROR 0.73Avapritinib · Citations 5, FAERS AKI ROR 0.09Ripretinib · Citations 7, FAERS AKI ROR 0.16Pexidartinib · Citations 5, FAERS AKI ROR 0.13Tazemetostat · Citations 7, FAERS AKI ROR 0.17Neratinib · Citations 6, FAERS AKI ROR 1.77Loncastuximab tesirine · Citations 5, FAERS AKI ROR 0.92Tafasitamab · Citations 6, FAERS AKI ROR 1.65Mogamulizumab · Citations 6, FAERS AKI ROR 2.1Dinutuximab · Citations 7, FAERS AKI ROR 1.33Raltitrexed · Citations 4, FAERS AKI ROR 1.93Trifluridine/tipiracil · Citations 7, FAERS AKI ROR 0.81Elotuzumab · Citations 4, FAERS AKI ROR 1.9Melphalan flufenamide (melflufen) · Citations 4, FAERS AKI ROR 0.91Procarbazine · Citations 4, FAERS AKI ROR 1.92Bleomycin · Citations 7, FAERS AKI ROR 1.42Fotemustine · Citations 4, FAERS AKI ROR 0.32Teniposide · Citations 5, FAERS AKI ROR 0.79Dactinomycin (actinomycin D) · Citations 4, FAERS AKI ROR 1.07Mechlorethamine · Citations 4, FAERS AKI ROR 0.04Chlorambucil · Citations 3, FAERS AKI ROR 1.16Amsacrine · Citations 4, FAERS AKI ROR 1.8Bicalutamide · Citations 4, FAERS AKI ROR 1.69Octreotide · Citations 7, FAERS AKI ROR 0.85Lanreotide · Citations 6, FAERS AKI ROR 0.39Mitotane · Citations 6, FAERS AKI ROR 0.98Darolutamide · Citations 5, FAERS AKI ROR 0.61Tislelizumab · Citations 8, FAERS AKI ROR 0.61Toripalimab · Citations 7, FAERS AKI ROR 0.5Retifanlimab · Citations 6, FAERS AKI ROR 3.4Linvoseltamab · Citations 6, FAERS AKI ROR 2.04Vorasidenib · Citations 4, FAERS AKI ROR 0.17Taletrectinib · Citations 4, FAERS AKI ROR 0.89Inavolisib · Citations 4, FAERS AKI ROR 3.03Obecabtagene autoleucel (Obe-cel) · Citations 5, FAERS AKI ROR 1.34Sunitinib · Citations 8, FAERS AKI ROR 0.87Axitinib · Citations 7, FAERS AKI ROR 1.07Pazopanib · Citations 9, FAERS AKI ROR 0.75Ipilimumab · Citations 13, FAERS AKI ROR 2.08Nivolumab · Citations 10, FAERS AKI ROR 1.88Pembrolizumab · Citations 15, FAERS AKI ROR 2.59Vemurafenib · Citations 9, FAERS AKI ROR 2.01Dabrafenib · Citations 9, FAERS AKI ROR 1.08Trametinib · Citations 10, FAERS AKI ROR 0.94Everolimus · Citations 12, FAERS AKI ROR 1.69Temsirolimus · Citations 10, FAERS AKI ROR 2.08Sorafenib · Citations 11, FAERS AKI ROR 1.02Pacritinib · Citations 7, FAERS AKI ROR 0.21Avutometinib · Citations 7, FAERS AKI ROR 0.08Fedratinib · Citations 7, FAERS AKI ROR 0.91Naxitamab · Citations 8, FAERS AKI ROR 0.75Lisocabtagene maraleucel · Citations 8, FAERS AKI ROR 1.74CitationsFAERS AKI ROR221
ALK / ROS1 / MET / TRK inhibitorsAlkylating agentsAnti-angiogenic (VEGF)Antibody-drug conjugatesAntimetabolitesAntitumor antibioticsBCR-ABL inhibitorsBRAF / MEK inhibitorsBTK inhibitorsBispecifics / T-cell engagersBisphosphonates & boneCAR-T cell therapyCDK4/6 inhibitorsCheckpoint inhibitorsCytokines & enzymesEGFR / HER2 inhibitorsFGFR inhibitorsHormonal / endocrineMicrotubule inhibitorsMonoclonal antibodies (other)Other kinase inhibitorsOther targeted agentsPI3K / AKT inhibitorsPlatinum agentsRadiopharmaceuticalsTopoisomerase inhibitorsmTOR inhibitors

292 of 292 agents; charts omit any agent missing the plotted value. Exploratory view of documented data — not a statistical model or a clinical recommendation.

Covers the 292 cataloged agents. Exploratory teaching tool — read the shape, not a statistical model.

Go deeper

Figures are derived from the static, citation-grounded catalog. FAERS is a spontaneous-reporting system — reporting odds ratios reflect disproportionate reporting, not incidence or proven causation. Medical-education content only — not medical advice.